A mixed methods investigation of trial design for measuring glaucoma medication adherence by Cate, Heidi
  
 
 
 
 
A mixed methods investigation of 
trial design for measuring 
glaucoma medication adherence 
 
 
Heidi Cate MSc 
Submitted for the degree of Doctor of Philosophy 
 
University of East Anglia 
School of Pharmacy 
 
Submitted in June 2016 
 
This copy of the thesis has been supplied on condition that anyone who consults it 
is understood to recognise that its copyright rests with the author and that use of 
any information derived there from must in accordance with current UK Copyright 
Law.  In addition, any quotation or extract must include attribution. 
©2016  
 ii 
Abstract 
Sub-optimal adherence to glaucoma therapy has negative health and financial 
implications.  The Norwich Adherence Glaucoma Study (NAGS) adopted gold-
standard methods including randomisation and objective outcome measurement to 
investigate an adherence intervention.  Patients were randomised to standard care 
alone (control group) or additional glaucoma and medication related information 
provision using Behaviour Change Counselling.  A Travalert Dosing Aid® (TDA) 
was used to collect 8 months of adherence data.  For the 208 patients 
randomised, adherence was higher than expected in the control group and there 
was no significant difference in adherence between intervention and control. 
Two qualitative studies collected user experiences from NAGS and established 
patient experiences of administering eye drops using the TDA.  Potential NAGS 
experimental design errors were identified that might have inadvertently introduced 
changes in patient behaviour, causing bias in the observed study outcomes; a 
phenomenon known as a reactivity effect.  Thus, the React study was designed to 
quantify the magnitude of reactivity effects on observed adherence behaviour, but 
the study required the use of a modified consent method.  Focus groups informed 
the content of a questionnaire that was piloted using cognitive interviewing 
methods.  The subsequent questionnaire was distributed to 400 members of the 
public attending an out-patient NHS hospital.  From the 208 questionnaires 
returned, the majority of respondents felt that the proposed React study used an 
acceptable consent method in order to investigate reactivity effects. 
Work continues with the React study to recruit the target sample size.   
Participants with lower measured adherence were less likely to participate and this 
self-selecting bias compromised estimates of the true magnitude of reactivity 
effects.  However, the evidence collected to date confirmed the presence of 
reactivity effects.   
This research suggests that objective measures coupled with modified consent 
procedures may be an appropriate methodological strategy to minimise reactivity 
effects in trials designed to change behaviour.  
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Section 1. Introduction 
 
Publications developed from this section: 
Broadway D C and Cate H. Pharmacotherapy and Adherence Issues 
in Treating Elderly Patients with Glaucoma. Drugs and Aging. 2015, 
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 Glaucoma and Adherence to 
Medication 
1.1 Introduction to glaucoma 
Glaucoma is the leading cause of irreversible blindness worldwide and the second 
cause of blind registration in the UK.1, 2  There are an estimated 500,000 people 
with glaucoma in England and Wales alone and more than 70 million people are 
affected worldwide.3  Sight loss resulting from glaucoma causes problems with 
restricted mobility,4 motor vehicle accidents,5 and other such problems that effect 
everyday activities and lifestyle, which can also have prominent psychological 
effects for those with the disease.6, 7  Studies in western developed countries have 
shown that approximately half of the people with glaucoma remained 
undiagnosed.8-10  Together with a rapidly aging population, the prevalence of 
glaucoma is set to rise.3  Once diagnosed, patients with glaucoma require lifelong 
treatment and careful monitoring; the costs associated with the management of 
such a disease are therefore high and these increase as the disease worsens.11  
The Cost of Blindness Report in 2003 estimated that as a chronic illness, an 
individual lifetime cost for a patient with glaucoma was as high as £40,000 in the 
UK12 and the direct cost estimates for approximately 2 million US citizens were 
$2.9 billion.13  Glaucoma has thus been described as ‘an important global public 
health concern’.14  
Glaucoma is a disease of the optic nerve, the most common forms of which are 
classified into two different types, each with specific risk factors and therapeutic 
treatments; primary open angle glaucoma (POAG) and primary angle closure 
glaucoma (PACG).  In PACG the iris blocks the drainage angle in the eye 
preventing the fluid (aqueous) draining from the eye.  The decrease of aqueous 
drainage in turn leads to increased intraocular pressure (IOP), potentially causing 
permanent damage to the optic nerve.  Without medical intervention elevated IOP 
can lead to a chronic and slowly progressive disease.  However, in some cases 
the drainage angle can become completely closed and during a period of a few 
hours can cause an acute elevation of IOP associated with severe pain and rapid 
visual loss requiring urgent medical attention.  Conversely, POAG is always 
chronic and slowly progressive in nature with no warning signs of the permanent 
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loss of vision that can be occurring.  The drainage angle remains grossly 
unaffected in POAG, but compromised drainage of aqueous within the drainage 
angle tissue (trabecular meshwork) causes a rise in outflow resistance, elevation 
in IOP and subsequent damage to the optic nerve.  The issue relating to IOP is 
complicated by the fact that certain individuals develop elevation of IOP without 
optic nerve damage (Ocular Hypertension; OH) whereas others develop optic 
nerve damage in the apparent absence of IOP elevation (Normal Tension 
Glaucoma; NTG).  Although much less common, there are many types of 
secondary glaucoma where other ocular disorders result in elevation of IOP.  
The main risk factor for all types of glaucomatous optic neuropathy is IOP and 
currently available treatment for glaucoma is aimed at reducing IOP, either by 
inhibiting the production and/or increasing drainage of aqueous. 
There are fundamental risk factors that link race with the severity, prevalence and 
type of glaucoma.  For example, the rate of blindness is higher in those of black 
race than white, and generally this is believed to be unrelated to socio-economic 
factors15 (which are thought to exist when comparing black and white populations).  
Ethnic origin can play a role with respect to glaucoma risk and PACG, for example, 
it is relatively less common compared with POAG in European regions but is more 
prevalent in Asia where it is almost equal to that of POAG.16  An anatomical 
precursor of PACG is a shallow anterior chamber, which can create a 
predisposition to PACG, this being more prevalent in Asia.  Surveys also suggest 
that a greater proportion of people affected by PACG are bilaterally blind (10% for 
POAG and 25% for PACG).17  
The most significant risk factor for glaucoma blindness is advanced loss of vision 
when the condition is first detected.18  Thus, it is essential to detect glaucoma early 
to prevent significant sight loss.  POAG is particularly difficult to detect and treat 
due to its slow progressive nature, lack of patient symptoms until significant 
damage has occurred, together with the lack of screening programmes.  Thus, for 
all the types of glaucoma, POAG holds a particular challenge in terms of 
diagnosis, treatment and patient education.   
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1.1.1 Primary open angle glaucoma  
Primary open angle glaucoma is characterised by progressive loss of retinal 
ganglion cells, reduction of retinal nerve fibre layer thickness and characteristic 
thinning of the neuroretinal rim at the optic nerve head (Figure 1.1 and 1.2).19  No 
single factor has been identified to cause POAG.  The damage done to the optic 
nerve is triggered in most cases by excessive pressure on the optic nerve that, 
over time, causes damage.  The pressure is exerted by an increase of aqueous 
production (a watery liquid that fills the space between the lens and the cornea).  
POAG is usually bilateral, but often asymmetric.  Although often asymptomatic at 
presentation, untreated POAG results in characteristic visual field loss (usually 
peripheral) and only later in the disease is central vision affected, this frequently 
being associated with symptoms.  In the UK, total blindness from glaucoma is 
uncommon, but it remains the most common reason for an individual being 
registered blind in England and Wales, and the leading cause of irreversible, but 
preventable, blindness in the UK.20  
 
 
 
 
 
 
 
Adapted from A.D.A.M 21 
 
 
 
 
 
 Figure 1.1 Cross section of the eye showing pressure on the optic nerve 
head 
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Figure 1.2 Front view of optic nerve head showing progressive 
glaucomatous damage 
 
 
 
 
 
 
 
 
 
 
 
Artwork by Tarrant T.R.22  
 
 
1.1.2 Diagnosis and follow-up care 
The visual field test remains the most important functional test for assessing 
glaucoma.  Visual field testing is aimed at detecting any loss of visual field 
(peripheral and central) and provides a map of that loss which is helpful in the 
diagnosis and future monitoring of disease progression.  With automated 
Humphrey visual field analyses, the darker areas or black areas of the visual field 
print-outs indicate the areas of vision that have lost sensitivity to light relative to 
age-matched normal control eyes.  An example of a Humphrey visual field print-
out can be seen in figure 1.3a.  Figure 1.3b shows how damage to the optic nerve 
seen by slit-lamp examination directly correlates to a loss of visual field shown on 
a visual field test as a black ‘arc’.  However, not all optic nerve damage will be 
detected using a visual field test and thus optic nerve assessment using slit-lamp 
biomicroscopy or imaging is essential, particularly in the earlier stages of the 
disease.  
Normal optic nerve 
Severe glaucoma 
Moderate glaucoma 
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The damage 
b. Photograph of optic disc 
The effect 
a. Visual field test results 
 
a. Visual field test results showing the visual field loss ‘arc’ and b. 
photograph of the optic nerve head showing the point of maximum nerve 
damage. 
 
The relative risk for POAG appears to rise continuously with the level of IOP and 
there is no evidence of a threshold IOP for the onset of the condition.23  Despite 
previous beliefs, elevated pressure is not always apparent in eyes with manifest 
glaucoma and thus an eye with an IOP lower than the mean for the population (16 
mmHg) may still show evidence of glaucomatous damage.   
POAG has been subdivided into high pressure and normal pressure categories to 
reflect the fact that elevation of IOP is not always a feature of POAG.  The benefits 
of lowering IOP, even if the pressure is within normal limits at the time of 
diagnosis, have been proven.24  The main risk factors for POAG are, level of IOP, 
age, African descent and family history.15, 25  It has also been suggested that 
diabetes, hypertension and migraine are associated risk factors.26  
Normal tension glaucoma (NTG) is now considered to be a sub-group of POAG.  
Glaucomatous damage is detected whilst the mean diurnal IOP remains within the 
normal range (rarely above 21 mmHg, taken to be the statistical upper limit of the 
Figure 1.3 An illustration of nerve damage and corresponding visual field 
loss for the left eye of a patient with POAG 
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normal range),27 thus making elevated IOP a significant risk factor, but not the only 
causal factor of glaucoma.  Fluctuation of IOP could also play an important role in 
the progression of optic neuropathy.28  Drance29 was one of the first to study 
diurnal IOP variation in patients with glaucoma.  Drance pointed out that a single 
pressure reading on a patient may not necessarily be representative of what the 
pressure is most of the time, and certainly not indicative of highest value during 
the day.30  However, finding the true diurnal and nocturnal IOP variation is 
problematic, the influence of body position on IOP over a 24-hour period and 
practicalities for the patient, all hindering assessment.  Furthermore, the Early 
Manifest Glaucoma Treatment Study23 found that IOP fluctuation was not an 
independent factor of glaucomatous progression.  Thus, the available evidence for 
the role of IOP fluctuation in the progression of glaucoma is controversial28 and as 
various IOP independent risk factors have been identified, it is assumed that these 
play a more significant role in the NTG sub-type of POAG.  
For the purposes of further discussion, glaucoma refers to both POAG and NTG.  
Although glaucoma is not currently curable, with early detection and appropriate 
therapy the majority of glaucoma damage is preventable and those diagnosed 
early can expect to retain vision for the duration of their lives.   
 
1.1.3 Ocular hypertension  
Patients with an elevated IOP without detectable glaucomatous damage on 
standard clinical tests have ocular hypertension (OH).  The decision as to whether 
or not to treat OH is problematic, since although a risk factor for glaucoma, only a 
minority of patients from this group will actually develop glaucomatous damage.  
Patients with mild/moderate OH can be left without treatment until the detection of 
early glaucomatous damage occurs.25  It is reasoned that observation still allows 
timely intervention if damage begins before visual loss of consequence to the 
patient occurs.  Conversely, it is argued that up to 20-50% of optic nerve fibres 
may be lost focally before damage is recognised by conventional perimetry and 
that once damage occurs this makes the remaining optic nerve fibres more 
susceptible to further damage.25  The current recommendation from the National 
Institute for Health and Care Excellence (NICE) is to ensure that patients with 
significant risk of developing POAG should have treatment initiated before visual 
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loss occurs, whilst patients with low risk of developing POAG should not be given 
unnecessary long-term therapy.27  Much research and debate continues in 
unravelling the complexity of detecting and treating glaucoma and its risk factors 
appropriately.   
 
1.1.4 Long-term management of glaucoma and ocular hypertension 
The European Glaucoma Society Guidelines31 and The NICE Glaucoma 
Guidelines27 sets out clear standards for the diagnosis and treatment of patients.   
A typical care pathway in the UK involves referral to a specialist glaucoma clinic 
for diagnosis by standard glaucoma examination followed by long-term monitoring, 
with treatment if indicated, according to risk of disease progression.  Currently, 
provision of information for patients, carers and family members is usually 
provided by the diagnosing clinician.   
In spite of treatment, most glaucoma will continue to progress,27 albeit in a minor 
way when IOP is adequately controlled.  Measures of progression are essential to 
ensure that the treatment reduced IOP is achieving the goal of reducing damage 
to the optic nerve.  Progression may be considered to have occurred when there is 
evidence that visual field or optic disc damage has worsened.27  As more 
technology becomes available, more sensitive and measurable progression 
markers have been established to assess optic disc appearance and visual field 
sensitivity.  
There have been several large scale glaucoma studies investigating the efficacy of 
medical treatment in delaying or preventing the onset of POAG.  The Ocular 
Hypertension Treatment Study (OHTS; n=1636) randomised patients with OH 
(with no evidence of glaucomatous damage) to either observation or treatment 
(topical ocular anti-hypertensive medication).  The primary outcome of OHTS was 
the development of a visual field defect or optic disc deterioration attributed to 
conversion from OH to POAG.  The OHTS study demonstrated that the probability 
of developing glaucoma over a 6-year period was reduced from 9.5% to 4.4% with 
medication (hazard ratio, 0.4; 95% confidence interval, 0.27-0.59; p<0.0001).  The 
study concluded that maintaining IOP at a desirable range was effective in 
delaying the onset of POAG in patients with elevated IOP and thus an effective 
means of reducing glaucomatous progression.32 
 9 
The Collaborative Normal Tension Glaucoma Study (CNTGS) found that in 
patients with NTG, a reduction in IOP from 16 mmHg to 11 mmHg resulted in a 
reduction risk of progression from 60% to 20%.33  In the Advanced Glaucoma 
Intervention Study (AGIS), patients with POAG and moderate to severe visual field 
loss with low IOP below 18 mmHg, had no net progression of visual field loss 
detected during 8 years of follow-up.34  The results of the OHTS, CNTGS and 
AGIS studies have demonstrated the importance of long-term follow-up of 
glaucoma and OH patients to ensure that target IOP is maintained and this 
pressure has controlled the progression of optic nerve damage and/or visual field 
defects.  Although the correct diagnosis is an essential component in the 
management of glaucoma appropriate treatment is of equal importance.   
 
1.1.5 Treatment goals for glaucoma and ocular hypertension 
Treatment in its many forms, aims to decrease aqueous production and/or 
increase aqueous outflow to lower IOP and settle the fluctuations in IOP over a 24-
hour period.  The general therapeutic goal is a reduction in IOP by 20% - 30% 
from the initial pressure at which damage occurs and below 21 mmHg for cases of 
OH.24, 27  Studies have shown that treatment regimens that achieve this IOP 
reduction may play a role in halting the progression of visual field loss in 
glaucoma.23, 35, 36  The Early Manifest Glaucoma Treatment Study randomised 
POAG patients (n=255) to treatment (argon laser trabeculoplasty plus topical 
betaxolol; n=129) or no treatment (controls, n=126) and these patients were 
followed-up every 3 months for 6 years.  The magnitude of initial IOP reduction 
was a major factor that influenced outcome, but each 1mmHg rise of IOP at follow-
up was associated with an approximate 10% increased risk of progression.23  
More recently, the UK Glaucoma Treatment Study used a masked treatment 
allocation randomised controlled trial (RCT) to compare latanoprost (n=231) to a 
placebo (n=230).  After 24 months, the mean reduction in IOP was 3.8 mmHg (SD 
4.0) in the latanoprost group compared with 0.9 mmHg (3.8) in the placebo group 
and the preservation of the visual field with latanoprost was significantly longer 
than the placebo group (HR 0.44, 95% CI, 0.28-0.69; p=0.003).36 
In addition to this, consideration to the reduction of IOP fluctuation must be given 
particularly in the case of patients with NTG.  Case studies have shown where a 
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30% reduction from peak IOP has been achieved, but the magnitude of fluctuation 
has remained unchanged, glaucomatous progression has been detected.28  
However, disease progression is difficult to predict and can still be difficult to 
detect when mild.37 
Choice of treatment is made on an individual patient basis.  Consideration is given 
to the perceived threat to sight during lifetime, status of the fellow eye, likelihood of 
using treatment as directed, likelihood of surgical success and patient preferences 
regarding treatment options.38   
Target IOP is an estimate of the IOP below which the IOP should be maintained to 
prevent progressive loss of vision.  Numerous factors are considered in making 
the estimate of target IOP, including initial peak/mean IOP, degree of visual field 
loss, amount of optic nerve damage, age, gender past/present medical history and 
predicted life expectancy.38  Frequent follow-up is required to ensure that target 
IOP is maintained and the risk of progressive field loss minimised.  At follow-up 
visits patients need assessment of IOP, visual fields and their optic nerves.  If the 
target IOP is achieved but progression continues, further pressure lowering 
intervention is warranted and a new target IOP should be set.28  
 
1.1.6 Treatment options 
Topical ocular hypotensive medications are recommended by the NICE glaucoma 
guidelines27 for initial treatment; there are various types, which can be used alone 
or in combination.  Other options include laser and filtration surgery procedures 
that can be employed to lower IOP by increasing aqueous outflow or reducing 
aqueous production.  Currently, lowering IOP is the only proven form of 
management for preserving vision in eyes with glaucoma, although there is current 
interest in developing neuroprotective agents and drugs that improve ocular blood 
flow, which may aid the preservation of optic nerve function.26 
 
1.1.6.1 Medical therapy 
There are many factors to consider when prescribing eye drops.  There are 
several medical contraindications to the use of certain medications such as beta-
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blockers (eg. broncho-pulmonary disease or cardiac arrhythmia) since systemic 
absorption of beta-blocker drugs may cause adverse effects.  Further aspects 
include cost and quality of life balance and whether the patient has the manual 
dexterity required to administer the drops to one or both eyes.39  All topical 
medications carry a risk of local ocular side effects such as irritation, lacrimation, 
hyperaemia, dry eye, toxic or allergic conjunctivitis and/or keratopathy39 and thus 
for asymptomatic patients, the side effects of topical therapy could be worse than 
the perceived effects of glaucoma itself. 
There is a wide choice of topical agents available for treating glaucoma.  Current 
ocular hypotensive agents in common use include prostaglandin analogues, beta-
blockers, alpha-agonists, and carbonic anhydrase inhibitors.  Prostaglandin 
analogues are often used as first line therapy and if only partly efficacious 
additional therapies are added to the therapeutic regimen.  When initial or 
additional therapies are ineffective or side effects are experienced, alternative 
medications can be tried.  Effective therapy regimens are pursued until the ‘target 
pressure’ is reached and the rate of progression is under control.  Thereafter, 
patients are reviewed, often on an annual basis, for the duration of their lives to 
ensure the ‘target pressure’ is minimising progression with review of the treatment 
regimen at each follow-up visit.38   
 
1.1.6.2  Laser therapy 
When there is a failure of medical therapy either due to sub-optimal effect or use 
of eye drops, laser or surgical management may be indicated.  Occasionally laser 
or surgical management is utilised as a primary option.  There are several types of 
laser therapy, including Argon Laser Trabeculoplasty (ALT), Selective Laser 
Trabeculoplasty (SLT) and cyclodiode laser therapy.  ALT improves the drainage 
of the aqueous fluid although the exact mode of action remaining unknown.  SLT 
is a relatively new technology that uses laser to target specific cells within the 
trabecular meshwork as in ALT but it creates less thermal damage than ALT.  As a 
new therapy the long-term outcomes of SLT have not yet been determined but 
efficacy studies are currently in progress.  However, it is thought that since SLT 
uses low power and causes less damage to the trabecular meshwork than ALT, 
the former is safer to repeat than the latter, should the effects of the original 
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treatment begin to wear off.40  Cyclodiode laser reduces the production of the 
aqueous fluid by partial destruction of the ciliary processes that produce aqueous 
humour.  Cyclodiode laser, because of its destructive nature, is generally reserved 
for treatment of severe glaucoma where all other therapies have failed, although 
the threshold for using cyclodiode laser is falling as clinicians become more 
familiar with it.  Cyclodiode laser is often used when an eye has become blind but 
because of elevated pressure remains painful.   
 
1.1.6.3  Surgical therapy 
The generally accepted gold standard surgical technique used in the management 
of POAG is a form of glaucoma filtration surgery called trabeculectomy.  
Trabeculectomy is generally very effective in achieving low IOPs but, as with all 
surgery, carries the risk of complications, failure and potentially total loss of vision 
should there be significant haemorrhage or infection associated with the surgery.  
Figure 1.4 shows a simplified step-by-step diagram of the procedure.  The 
procedure site is just above the iris through the sclera as shown in Figure 1.4.  A 
partial thickness scleral flap is formed, which is sewn loosely back in place 
overlying a small penetration into the anterior chamber.  In successful cases, the 
fistula between the anterior chamber and the sub-conjunctival space allows 
continual outflow of aqueous through the created opening.  In the early days 
following surgery, by using releasable sutures, the flap can be adjusted to achieve 
the right amount of aqueous outflow to try and achieve optimal IOP.  Post-
operatively the continual effectiveness of the procedure must be monitored to 
ensure that the IOP remains low and the features of glaucoma stable.  
Supplementary eye drops can be used to lower IOP further if IOP starts to rise or 
progression of the glaucoma occurs and the surgery appears to be only a partial 
success.  Other surgical procedures can be performed to lower IOP and these 
include non-penetrating filtration surgery or the insertion of drainage tube devices.  
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Artwork by Tarrant T.R. 41 
Figure 1.4 Diagram of a trabeculectomy procedure 
  
 14 
1.2 Adherence to glaucoma medication 
Although current standard glaucoma treatments range from the use of topical 
medications, laser procedures to surgery, use of medication remains the most 
accessible, viable and effective option for the majority of patients with glaucoma.  
However, correct use of topical medication is still a major obstacle42 and not all 
glaucoma patients use their therapy all of the time.  Appropriate treatment is, 
however, of equal if not greater importance in the management of glaucoma than 
the diagnosis itself; the results from AGIS suggest that greater long-term 
fluctuation in IOP, determined by variation in IOP measures at each follow-up 
clinic visit, may be associated with greater visual field loss over time.34  Several 
other studies have also noted that the rate and extent of visual field loss are worse 
with higher mean and peak IOP measures.43, 44  The growing evidence suggests 
that worse control of IOP, greater fluctuations in IOP and worsening of visual field 
defects correlates with failure of use of medical therapy as directed.45-48  A study 
carried out by Stewart et al. in patients with advanced POAG (n=72) found a 
significantly lower mean (15.4 ± 2.7mmHg) and peak (24.5 ± 6.9mmHg) IOP in 
patients whose vision remained stable for five years compared to higher mean 
(21.3 ± 3.2) and peak (39.2 ± 11.0mmHg) IOP, for those with decreased 
vision(p<0.001).  Furthermore, patients who lost visual function were significantly 
less likely to use medical and surgical intervention as recommended in 
comparison with patients whose vision remained stable (p<0.001).45  
Glaucomatous progression was seen in 50% of all patients noted to have poor use 
of medication and remained stable in 90% of patients who did use medication as 
directed; however, the method for assessing adherence was not described by 
Stewart et al. 45 
There is a wealth of literature which has attempted to measure and explain the 
complex phenomenon of medication-taking behaviour.  The terminology used to 
describe medication-taking behaviour has evolved over time and has been 
controversial, many different terms are still used interchangeably, and no ‘official’ 
definition exists.49  Each term has a different connotation and subtleties that need 
further explanation.  
Traditionally practitioners have used the term ‘compliance’ to describe the extent 
of conformity to prescribed treatment regimens and patients’ actual dosing 
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history.50  More recently, ‘compliance’ has become less widely used since it 
implies a negative relationship between the prescriber as ‘the instructor’ and 
patient as a passive follower of doctors’ orders.  Thus, ‘adherence’ is preferred 
since it accepts that there is an alliance between the patient and provider; the 
patient has the freedom to decide whether or not to adhere to the providers 
recommendations and therefore, adherence is a factual statement and is non-
judgemental.51, 52  The term ‘concordance’ is used to describe the interaction 
between the healthcare professional and patient at the point of prescribing to 
reach agreement on the therapeutic options even when there may be conflicting 
views.51  Whereas, ‘adherence’ refers to the extent of conforming to the 
recommendations in terms of timing, dosage and frequency, the term ‘persistence’ 
is used to describe the duration of medication use from initiation to 
discontinuation.53   
The therapeutic benefit from glaucoma medication is only maximized when 
administered correctly.  In short, medication will not be effective if not 
administered.  Yet, effective adherence is a health behaviour that involves a 
complex set of actions with four basic steps: obtain the medication, successfully 
instil the drop into the eye, use of the medication at the right time and remember to 
do so each day.54 
In order to investigate the issues that are central to the topic of adherence with 
glaucoma medication, a review of previous research and existing opinions and 
theories was necessary.  Personal knowledge gained from research undertaken in 
2008 to understand the barriers that prevent good adherence42 formed the basis of 
the initial literature review.  Topics such as the magnitude of non-adherence, 
predictive factors, economic burden of non-adherence and how to measure 
adherence was largely informed by the body of work undertaken by Olthoff et al.55 
in which the evidence of non-compliance with ocular hypotensive treatment was 
published in 2005.  Subsequent to Olthoff and Lacey’s work on non-adherence 
with glaucoma medication, in 2008 Haynes et al.56 published a Cochrane review of 
interventions to enhance medication adherence.  Although Haynes et al. included 
a range of both oral and inhaled drugs in their review, adherence to eye drops 
specifically were not included.  Thus in 2009, Gray et al.57 reviewed the 
interventions for improving adherence to ocular hypotensive therapy which was 
later updated by Waterman et al. in 2013.58  Collectively the four reviews by 
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Olthoff, Haynes, and Gray were essential in informing the breadth of the topic and 
identifying the published literature which expands on these topics.  Literature 
searches were also performed using Pubmed (from 1949), conference 
presentations and relevant RSS feeds to keep up to date with new and emerging 
work on the relevant topic areas.   
 
1.2.1 Magnitude of non-adherence to medication 
In 2003, The World Health Organisation (WHO) adherence project group found 
that poor adherence to treatment regimens was a commonly reported problem 
with an estimated 50% adherence rate for long term treatment of chronic illnesses 
in developed countries.59  A meta-analysis of studies from 1948 to 1998 reporting 
adherence to medical treatment was published in 2004 by DiMatteo et al. with 
reported adherence being highest in Human Immunodeficiency Virus (HIV) 
disease, arthritis, gastrointestinal disorders or cancer and lowest in pulmonary 
disease, diabetes or sleep.  The average non-adherence rate was only 24.8%.60   
Studies specific to glaucoma treatment report similar high rates of non-adherence; 
a systematic review of glaucoma studies found that percentages of patients who 
deviated from their prescribed medication regimen ranged from 5 - 80%,55 the 
disparity in reported adherence due to the varying definitions of non-adherence 
and assessments methods used.  Studies using the Travalert Dosing Aid® an 
electronic eye drop monitoring device for use with travoprost (a prostaglandin 
analogue requiring once daily dosing), have reported adherence rates in the order 
of 75%.61   
 
1.2.2 Barriers to use of glaucoma medication 
Adherence to the use of medication is a multi-faceted process with numerous 
stages where a patient might deviate from their agreed regimen with more than 
200 variables described over the years.62  Various qualitative studies have also 
examined adherence behaviours among patients with glaucoma one of these 
being the study by Tsai et al. in which a four category classification of 71 identified 
barriers of significant obstacles to adherence with glaucoma medication were 
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created; regimen factors, individual patient factors, medical provider factors and 
situational (i.e. social/environmental) factors.63   
More recently Newman-Casey and co-workers evaluated 11 commonly cited 
reasons for poor glaucoma medication adherence; scepticism that glaucoma 
medications are effective, poor knowledge about glaucoma, poor self-efficacy, 
forgetfulness, cost, difficulties with the medication schedule, side effects, difficulty 
with eye drop administration, mistrust in the physician, and perceived life stress.64  
Of these 11 reasons, poor self-efficacy, forgetfulness and difficulty with drop 
administration and the medication schedule were found to be the most significant 
barriers associated with poor adherence, when measured by patient self-report of 
medication use.64   
 
1.2.2.1 Successful installation  
The application of eye drops is a significant barrier to adherence for some patients 
with glaucoma.65, 66  Eye drops are difficult to self-administer and require co-
ordination, manual dexterity and good central vision.67  Most patients with 
glaucoma are older adults who can be challenged by taking any medications; 
reasons include hearing difficulty, low health literacy, physical or cognitive 
disability and limited social and financial resources.68  Research has shown that 
even when patients do adhere to their medication regimen, drop application 
technique can be poor.  Only 60% of patients instilled the correct number of drops 
in a study observing 140 experienced patients with glaucoma.65  In a cross 
sectional observational study of patients with glaucoma, nine out of ten glaucoma 
patients were not able to correctly instil eye drops into the eye.69  Problems 
encountered included the wrong number of drops squeezed out from the bottle, 
eye drops falling on eyelids or cheek, the dropper tip touching the eye.69 A 
questionnaire survey given to 253 consecutive patients with glaucoma in order to 
evaluate techniques for instillation of eye drops found that 25% of patients who 
self-administered their drops reported touching the dropper tip on their eye; 
furthermore, 17% relied on others to administer their drops for them.70  In a study 
of 324 patients the most commonly self-reported problems with administration of 
eye drops included difficulty with: drop administration (44%), reading the print on 
the bottle (18%), side effects (16%), bottle squeezing (14%), seal removal (14%) 
and remembering to take medication (12%).71 
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1.2.2.2 Dosing regimens  
As previously discussed, if fluctuation in IOP is harmful, then patients missing 
doses of medication for treatment of glaucoma, cause gaps in therapy that could 
increase fluctuation in IOP and varying adherence is thus an essential 
consideration.  Furthermore, some glaucoma medication has a short half-life, thus 
successful adherence to therapy is not just dependent on administering eye drops 
on a daily basis but also at the correct time of day.54  A study using an electronic 
monitoring device to measure time of administration of eye drops found that whilst 
all patients stated they were adherent, they did not take their medication at the 
correct time of day.72   
Complex dosing regimens involve both the number of drugs prescribed, and the 
number of doses that have to be administered each day.  In a qualitative study 
using 100 interviews with patients using eye drops for glaucoma, dose timing and 
frequency was listed as the third most common reason for non-adherence, the 
number of missed doses increasing with the number of doses required per day.73  
A study in the USA using a retrospective review of patient records found that the 
addition of a second drug in 1784 participants using latanoprost showed an 
increase in the time between renewed prescriptions by a mean of 6.7+/-25.6 days 
and 23% of study participants increased the interval by more than 2 weeks (p 
<0.0001) compared with 3146 participants who continued on monotherapy.74    
Whilst the evidence suggests that people on simpler drug regimens are more likely 
to adhere and persist with their ocular hypertensive therapy, the systematic review 
conducted by Waterman et al. found the evidence was weak as studies were of 
variable quality and only short term.58 
 
1.2.2.3 Remembering to administer doses  
Diabetes and hypertension are similar to glaucoma in their asymptomatic nature in 
the early stages and as such, can be associated with increased levels of non-
adherence.75  When patients are without symptoms they may not understand the 
importance of daily adherence76 in contrast with diseases where patients are 
symptomatic if non-adherent with their medication, such as those used for pain 
relief or allergies.  Forgetfulness is one of the most widely reported reasons for 
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non-adherence.55, 63  However, it could be argued that forgetfulness is reported 
more often because it is considered to be a more socially acceptable barrier and 
easier for patients to say that they forgot to take their medication than discuss the 
real issues.64  An internet survey of patients enrolled in the ‘Medicare’ social 
insurance programme in the USA (n=1220), found that patients who had multiple 
concerns about their medication were more likely to report forgetting to take their 
medications.77  Thus, ‘forgetfulness’ may disguise other underlying reasons which 
may not be disclosed to health professionals or researchers, such as concerns 
about whether the medication is helping their condition. 
Feedback from patients suggests that when using tablets from a ‘blister pack’, the 
empty ‘blister’ can act as a visual reminder that the intended dose has been 
administered.  To overcome memory issues, tablets can be transferred into dosing 
boxes, which can be an important resource for elderly patients.78  Visual cues from 
blister packs or dosing boxes and other similar practical reminders are not so 
easily possible with a bottle of drops.79  Administering eye drops from a bottle may 
not only be difficult for patients to achieve but also restricts the use of the 
packaging as a reminder to use drops.  Memory problems have the potential to 
result in either under-dosing or overdosing of therapy, the latter being important 
with respect to potential adverse side effects.   
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1.2.2.4 Disease severity  
Non-adherence to follow-up visit schedules has been significantly associated with 
less severe disease; patients diagnosed as ‘glaucoma suspect’ had greater non-
compliance to follow-up than those with manifest glaucoma.80  In a retrospective 
cohort study of health insurance claims data, newly treated patients diagnosed 
with glaucoma (n=3623) were compared to patients diagnosed with suspected 
glaucoma (n=1677).  Persistence with medication was marginally higher in those 
diagnosed with glaucoma than those with suspected glaucoma (RR 1.11; 95% 
confidence interval, 1.05-1.18).81  A focused summary of the available literature by 
Tsai et al. also advocated that adherence could be proportional to disease 
severity.82 
 
1.2.2.5 Access to medication 
The cost of medication may be an important factor for some patients.  However 
determining if this is a consistent barrier which significantly affects adherence with 
glaucoma medication is difficult to establish due to the different healthcare 
structures and payment practices between countries for the provision of care and 
medication. In a cross-sectional survey in the USA in 2006 (n=324), where 
individuals are responsible for their own cost of care via healthcare insurance 
providers, 41% of patients with glaucoma found that they had difficulty in paying 
for their medications.71  However, in a previous interview study in the USA (1995, 
n=100), of individuals who paid fully for their medications only 11.5% stated that 
the expense of the medication on occasion had prevented them from obtaining 
their prescription.73  Thus, comparing data over different time periods or data 
extraction methods could prevent the comparison of available data.  However, 
both studies suggested that patients who have to meet full/partial medication costs 
personally may face restricted access to medication.  Such a theory could be 
relevant to UK residents under the age of 60 and who do not meet the National 
Health Service (NHS) exemption criteria, who must pay a fixed prescription cost 
per item, although this hypothesis has not been systematically investigated.  
Further consideration also needs to be given to the fact that cost of medication as 
a barrier to adherence is likely to be under reported; in a survey of older adults 
with chronic illness, 66% of respondents did not inform their clinician that they 
intended not to buy their medication.83  
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Failure to reorder drops, or problems in obtaining new bottles can also lead to 
periods of missed doses.42, 84  Unlike tablets in a ‘blister pack’ where the number of 
remaining pills can be counted and diarised collection of new prescription 
calculated, bottles containing liquid cannot easily be examined to determine how 
many doses remain; often the view of the liquid is either obstructed because the 
plastic bottle is too opaque or labels cover the majority of the small bottle.39   
 
1.2.3 Predictive factors  
Identifying predictors of adherence is an important consideration as a tool to 
improve patient long-term care and has the potential to reduce healthcare 
expenditure by identifying specific causes of non-adherence or distinguishing ‘at-
risk’ patients, to enable specific ‘targeting strategies’.  Several studies have 
identified race and socioeconomic status as risk factors for non-adherence to eye 
drops;85-88  African descent, lower income and increased number of eye diseases 
were found to be predictive of partial treatment adherence85 as was age less than 
50 or more than 80 years, African-American race and lower income88 and non-
white patients.86  At present, there is no consistent evidence to suggest that other 
variables such as gender, time since diagnosis, number of medications used, 
health status, vision, education attainment, or living alone have any significant 
effect on adherence to medication.58, 64 
However, a review of the literature which classified determinants into four different 
demographic aspects, knowledge, duration and severity of disease and complexity 
of treatment regimen, have failed to identify any consistent variables.55 
 
1.2.4 The economic burden of non-adherence 
Non-adherence increases the burden of healthcare required and increases the 
cost of healthcare.  In a study describing the patterns and economics of glaucoma 
treatment, published by Denis et al., 88 ophthalmologists examined 5 years of the 
medical item consumption data of 337 patients with OH and POAG.89  Lower costs 
were positively associated in patients with less visual field defects.  Higher 
expenses were always related to a greater severity of optic nerve damage and 
additional costs were always seen as the disease worsened.  Although Denis et al. 
did not carry out a cost analysis of poor adherence, the number of medical 
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therapies tried contributed independently, in an additive way, to the total cost of 
glaucoma treatment in their study.89  Furthermore, non-adherence can be 
mistaken for low medical efficacy of treatment.  If a patient fails to respond to 
therapy, a change in therapy is often tried or additional topical agents added; this 
may only lead to further problems since adherence with therapy appears to decline 
with increasingly complex regimens.66  Winfield et al. found that, even if asked, 
69% of patients taking glaucoma medication would not tell their clinician that they 
were having problems with adherence and approximately 50% of the individuals 
started on glaucoma medications reported to discontinue them within 6 months.66  
Thus, non-adherence can lead to unnecessary additional prescribing, wastage of 
unfinished pharmaceutical supplies, more frequent hospital appointments and/or 
diagnostic tests, this leading to increased healthcare expenditure.  If surgical 
treatment is required because all avenues of medical treatment have been 
explored, this not only increases the cost of glaucoma care significantly, but adds 
surgical risk to the patient.89   
 
1.2.5 Measuring adherence  
The method of measuring adherence utilised usually determines how adherence is 
reported; adherence can either be expressed as the percentage of doses taken by 
an individual or as the percentage of non-adherent subjects,90 although this 
assumes that the definition of adherence has first been established.  By 
convention, an 80% adherence rate is widely recognised as ‘acceptable’.91  But, 
an ‘adherence rate’ is just an arbitrary figure if it has no relevance to the effect on 
clinical outcome.  Thus, classification of ‘adherent’ and ‘non-adherent’ parameters 
should be established in relation to the disease specific target at which a beneficial 
clinical outcome would expect to be achieved.55  The desired ‘adherence rate’ for 
topical ocular hypotensive medication used in the management of glaucoma has 
yet to be quantified.  Failure to establish a desired ‘adherence rate’ for ocular 
hypotensive medication has resulted from the inconsistency between patients in 
achieving their target IOP measure, the variance of drop efficacy between patients 
and the different treatment regimens used to control glaucoma on an individual 
basis.  Without supporting evidence to suggest otherwise and due to the adverse 
consequences of non-administration ophthalmologists at the Norfolk & Norwich 
University Hospital aim for 100% adherence, this being supported by the Royal 
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Manchester Eye Hospital opinion.92  Knowing that ocular hypotensive medication 
not only lowers mean IOP, but also minimises IOP fluctuations, strengthens the 
perceived requirement for 100% adherence.  As already discussed, patients who 
stop and start treatment on a regular basis are thought to increase IOP fluctuation; 
on adherent days the IOP will be lower, on non-adherent days the IOP will be 
higher, causing peaks and troughs in IOP.  Thus, although no conclusive evidence 
exists, the non-adherent patient may inadvertently increase the risk of developing 
progressive glaucomatous visual loss.  Unfortunately, the complexity and ethical 
implications associated with such a theory prevents the collection of empirical 
evidence.    
In addition to the nuances of defining adherence, the numerous methods of 
measuring adherence and reporting outcomes can also be problematic with 
respect to gathering good scientific evidence for studies of adherence.58  
Subjective measures such as patient self-report are generally cheap and easy to 
administer but in comparison with objective measures, can yield higher adherence 
estimates.93, 94  Whilst objective measures remain the gold standard of clinical 
trials they have several drawbacks.   
 
1.2.6 Objective measures of adherence to medication 
1.2.6.1 Electronic monitoring systems 
Studies using electronic monitoring methods have become increasingly more 
common in recent years.  The Medication Event Monitoring System (MEMS) 
contains a microelectronic circuit that registers the exact date and time of 
medication events, such as ‘Track Caps’ which record each time the bottle is 
opened to retrieve medication from within the bottle.  Such a method can provide 
more detailed information about the timing of doses than can be obtained through 
most other methods and is considered to be an accurate method for assessing 
adherence.  However use of the MEMS with eye drops would entail the user to 
unscrew the MEMS cap to retrieve the bottle of eye drops, subsequently 
unscrewing the eye drop cap before administering the dose.  Thus, a “bottle within 
a bottle” method requires multiple extra steps that deviates from the usual 
administration procedure.  Currently, no RCT has reported using the MEMS to 
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measure adherence to ocular hypertensive medication.58  Electronic drug 
monitoring is a particularly attractive method employed to measure adherence with 
eye drops for glaucoma treatment, firstly because ‘pill counting methods’ cannot 
be employed when dealing with liquids and electronic monitors that can report the 
time that patients use their treatment is an important factor for glaucoma patients 
who must maintain a constant time of drop administration to avoid peaks and 
troughs in IOP.72  Electronic dosing monitors may also be useful in identifying 
dosing habits and may give a better understanding of actual medication-
adherence behaviour which cannot be derived by calculation of an ‘adherence 
rate’.79, 94-96  The studies by Norell and Granstrom were the first to use electronic 
monitors to obtain an objective measure of adherence with topical ocular 
hypotensive medication.97, 98  More recently, Alcon® has introduced the Travatan 
Dosing Aid (Travalert®,TDA) which electronically stores data on the time, date and 
number of drops administered.  The TDA can only be used in conjunction with 
Travatan® (travoprost) and Duotrav® (travoprost/timolol combination) eye drops 
due to the TDA’s aperture size restricting other shaped bottles from fitting the 
device.  Three studies using the TDA have reported that it accurately records drop 
administration.93, 99, 100    
However, there is a potential drawback to the use of electronic devices because 
the monitoring device can be so obvious to the user that adherence behaviour is 
consequently modified.94, 101  When research assessment prepares people to be 
more receptive to the study intervention or causes a modification in expected 
behaviour, a reactivity bias can occur which may either strengthen or weaken the 
true intervention effect size.102, 103  When they occur, the effects of a reactivity bias 
can threaten the validity of any conclusions that are drawn from research studies 
and are therefore important to eradicate from studies.  Electronic bottle monitoring, 
pill counting or bottle weighing may suggest to patients that they are not being 
trusted, resulting in resentment and a possible reduction in adherence or an 
undermining of any intervention that may be the object of the study using this 
measure of adherence.104  However, a pilot study established that the TDA had no 
demonstrable impact on modifying adherence behaviour by emphasising the 
monitoring itself.105  and a study carried out by Cramer et al. found that reactivity 
bias to medication monitoring devices was short lived and patients quickly 
returned to their self-medication behaviour patterns.106   
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Electronic devices are also expensive to fund, often more difficult to operate and 
cumbersome than the bottle itself, and their use thus leads to a predetermined 
selection of participants who would be able to operate such devices rather than 
being usable by the greater patient population.  In addition, bottle openings do not 
always correspond to an applied dose. 
The first studies reported by Norell and Granstrom.97, 98 indicated that adherence 
could be improved significantly with an educational intervention, however, 
adherence was only monitored using the devices for a 20-day period following the 
educational intervention.  As suggested by Cramer et al.106, the 20-day period may 
not have been long enough to overcome the reactivity bias associated with the 
monitoring device itself and therefore longer term follow-up should have been 
used to allow patients to revert to their usual medication behaviour pattern.  
Longer term follow-up studies are needed to determine how long the effects of 
adherence interventions can persist.   
 
1.2.6.2 Therapeutic outcome 
In some diseases, objective observations can be made which are directly 
attributable to the use of medication such as hypertension where adherence can 
be assessed by taking blood pressure readings and diabetes by glucose or 
HbA1C monitoring which give an indication of the effectiveness of therapy.  When 
the desired target of blood pressure/glucose/HbA1C control is reached, it can be 
considered that the patient is adherent to medication in order to have achieved 
therapeutic control.  Due to the slow progressive damage to the optic nerve, 
determination of the effectiveness of therapy in patients with glaucoma, requires 
long term follow-up, possibly over many years, and or multiple repeat testing to 
establish true deterioration rather than fluctuation in test variation.  An alternative 
would be to measure IOP control but as previously discussed, it is well 
documented that IOP is not constant and varies considerably throughout the day, 
particularly in eyes with glaucoma.  Therefore, utilising IOP thresholds or IOP 
reduction by comparing one IOP measurement at a random time point against 
another is relatively futile with respect to assessing adherence.  Likewise, 
whatever the target IOP, there is no guarantee that apparent achievement of that 
target IOP will halt progression of the glaucoma due to the variation of individual 
progression rates, often determined by other IOP independent risk factors such as 
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family history, co-morbidity and degree of glaucomatous damage already 
sustained. 
Strategies to accommodate diurnal IOP fluctuations include the use of multiple 
daily readings to obtain peak and trough readings enabling calculation of a daily 
average or integrating IOP measures collected at several time points during the 
study period as utilised in the Ocular Hypertension Treatment Study.32  However, 
the method of obtaining multiple IOP readings is time consuming, inconvenient 
and can also increase participant awareness that they are being monitored.   
There have been six studies that have assessed non-adherence in relation to IOP 
or the progression of visual field loss.107-112  A relationship would be expected 
because it is known that ocular hypotensive treatment is effective and adherence 
should result in a lower IOP.  However, only the study by Konstas et al.107 found 
non-adherent participants to have a higher mean IOP than adherent participants 
(n=100) (22.9 vs 18.5 mmHg; p>0.001).  Adherence in this study was determined 
by participant self-report of missed doses per month and this correlated with level 
of IOP.  However, this was a study of relatively small size and it relied upon 
participant self-report of adherence, which is known to underestimate adherence.  
A failure to consistently demonstrate a relationship between adherence and IOP 
control,55 could be explained by the lack of a quantified correlation or that the 
methodological quality of the studies performed has been poor, but more likely that 
the complexities of assessing the level of IOP due to individual differences, 
different types of glaucoma and effect of the diurnal variance lead to ‘noisy data’. 
Furthermore, studies have demonstrated that adherence with medication improves 
in the five days before and after appointments with a clinician.93, 113  Thus patients 
could be persistent with medication but not adherent to their treatment regimen 
and could inadvertently produce false positive clinical outcomes.  In summary, with 
so many variables to control, assessing adherence rates based on rate of 
glaucomatous progression or IOP control is neither straightforward nor practicable.  
When adherence does not easily correlate with immediate clinical benefits ideally 
both adherence and clinical endpoints should be measured.56  
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1.2.6.3 Blood and serum samples  
Many reviews have suggested that biologic assays are the most accurate measure 
of adherence.114  Body fluid can be used for analysis to enable the concentration 
of the therapeutic drug to be measured.  However, it is not always possible to 
detect the concentration of the therapeutic drug under investigation and therefore 
a marker drug, which has no therapeutic benefit other than its ability to be 
accurately measured, can be formulated and used to assess adherence with the 
medication.  Such methodology, although objective, does have limitations.  Some 
drug concentrations are highly variable due to individual variability of absorption 
and elimination.  Development of pharmacokinetic models to support such 
methodology is costly and not always possible.  Assessment of drug concentration 
has not yet been used to assess adherence with ocular hypotensive medications. 
 
1.2.6.4 Prescription databases 
Prescription databases provide prescribing data that can be used to estimate the 
level of adherence based on how many new prescriptions have been issued.  
However, while collection of a prescription suggests intention to use medication, it 
does not ensure its administration.115   
Choo et al. in the United States, evaluated patient self-report, pharmacy 
dispensing records and pill counts using electronic monitoring as a validation 
standard for adherence with systemic antihypertensive treatment.116  In the 
patients using an antihypertensive (n=286) it was revealed that refill prescription 
patterns were moderately correlated with electronic monitoring and it was 
suggested that pharmacy dispensing records could be used with predictive 
validity; by using gaps in the medication supply as indications of non-
adherence.116 
Prescription claim databases as described in the study by Choo et al.116 are 
particularly common place in the US as their healthcare system relies heavily upon 
insurance claims for healthcare costs.  Prescription claims data are particularly 
useful for identification of non-adherence due to discontinuation or changes in 
treatment.  However, if patients do not collect prescriptions from the same source 
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each time or within the same pharmacy networks, the recording process can be 
unreliable.117 
 
1.2.7 Subjective measures of adherence to medication 
1.2.7.1 Physician estimated adherence 
It has been reported that ophthalmologists do a poor job of detecting non-
adherence in their patients.118  In a study published in 1986, eye drop medication 
monitoring data were compared with ophthalmologist predictions of adherence119 
and it was found that ophthalmologists were unable to identify which of their 
patients were adhering correctly to prescribed therapy.  More recently, in an 
observational cohort study (n= 196) using the TDA, virtually no correlation 
between physician predictions of adherence and electronic monitor recordings 
(r=0.09; 95% confidence interval, 0.00 – 0.19) was identified.93  
Furthermore, another study found that 69% of patients when interviewed would not 
tell a doctor of their problems using eye drops; this was reflected in the lack of 
awareness among the medical staff of the problems experienced by these 
patients.66  Thus, physician estimation of adherence does not appear to be a 
reliable measure of adherence.  
 
1.2.7.2 Self-report of adherence 
Patient self-report is used frequently as a measure of indirect adherence levels 
and involves questionnaires, diaries and/or interviews.  Self-report tools are 
generally cheap and simple to carry out and specific to non-adherence.  However, 
self-report measures can yield higher adherence estimates in comparison with 
objective measures.93, 94  The discrepancy between self-report and objective 
measures of adherence is attributed both to the social desirability to be adherent 
to medication regimens as prescribed by clinicians and memory bias; if non-
adherence is due to forgetfulness, how can a missed dose be remembered for the 
purposes of self-report?  In addition, if patients have misinterpreted their 
prescribed regimen, they may not realise that they are not adhering and therefore 
self-reported adherence at a fixed point in time is not necessarily representative of 
adherence over a period of time.   
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Adherence is not a dichotomous variable, although it is usually described and 
presented in this way “are you adherent?  Yes/no”.  For the patient there may be 
many ‘shades of grey’ in the adherence pattern and a variety of factors that affect 
the use of medication on a given day.  The visual analogue scale (VAS) is a 
commonly used picture-graphic tool used in questionnaires to assess subjective 
attitude to characteristics that cannot be measured, such as “how much pain do 
you feel”.  As a measure of adherence, patients are asked to put a line on the 
scale indicating how much of the time they consider that they use their medication 
as directed.  It has been proposed that VAS scales may be particularly useful in 
assessing medication adherence in lower-literacy populations.120 
The missed-dose method for assessment of adherence is simple and involves 
asking patients to confirm whether they ever miss taking their medications and if 
so how often they do: once a day, once a week, once a month, rarely, never.121  
The missed-dose method can also be used in open-ended face-to-face interviews 
leaving the patient free to quantify their level of adherence if no suggested time 
has been given.   
A recent glaucoma adherence study reported by Ajit et al 61 used the self-report of 
missed dose method to compare patient estimate of adherence with that of the 
TDA (n=34).  Ajit et al. found that patient reported adherence was below that of the 
TDA in the majority of cases.  In some cases, patients reported 100% adherence 
when their TDA indicated <40% adherence.  Similar reports have been published 
by Okeke et al. 93 and Kass et al. 122 Therefore, relying on patient reports of 
adherence in glaucoma studies would appear to be prone to error. 
 Brief Medication Questionnaire (BMQ) 
Svarstad et al 123 developed the Brief Medication Questionnaire (BMQ), a self-
report instrument for measuring and monitoring adherence from the patient 
perspective.  The BMQ questionnaire has three parts; the regimen screen, belief 
screen, and recall screen, to increase the sensitivity and positive predictive value 
and specificity level of the questionnaire.  The frequency of missed-dose screen 
uses neutral, open ended-questions and a short recall period of a week.  The 
questionnaire was validated (n=20) using MEMS and the BMQ achieved a 
sensitivity level of 80-100% and accuracy of 95%.123 
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 The Morisky Medication Adherence Scale (MMAS) 
The Morisky Medication Adherence Scale (MMAS) is a structured four-item self-
report adherence measure validated for use in hypertensive patients. Results 
showed that 75% of the patients who scored high on the four-item scale at year 2 
had their blood pressure under adequate control at year 5, compared with 47% 
under control at year 5 with a low score (p<0.001).124  Although not validated for 
use in patients with glaucoma, MMAS has been used in hypertension studies 
which has a similar asymptomatic characteristic to that of glaucoma and thus has 
the potential to be useful for the latter condition.     
Using questionnaires that attempt not only to measure adherence but also to 
provide information about medication behaviour helps to implement appropriate 
adherence interventions.  There is a lack of literature comparing the different 
methods used to elicit which tools are preferred by patients, which take into 
account ease of use along with their reliability and usefulness as an adherence 
screening mechanism.  It is interesting to find evidence of VAS specifically 
designed to function as an easily administered assessment tool suggesting that 
other tools are not accessible to all patients regardless of literacy, although this 
has not been described in the reviewed literature. 
Clinicians and researchers struggle to determine the best way to measure 
adherence.  Comparison of measurement techniques only add to the controversy 
as to whether measures really provide complementary information. 
 
1.2.8 Further considerations when measuring adherence to glaucoma 
medication 
It is plausible that the treatment options available for every different health 
condition will carry their own set of difficulties when measuring adherence.  
Measuring adherence in glaucoma patients has its own set of intricacies.  Olthoff 
et al.55 reviewed intervention protocols for glaucoma adherence studies and found 
the strictest definition of non-adherence to be taking less than 100% of prescribed 
eyed drops.  Studies that reported patients who were not strictly compliant 
generally reported higher prevalence rates of non-adherence.  In reality a number 
of definitions and cut offs are reported for each published study.  Therefore, direct 
comparison of study results was not plausible or relevant. 
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Olthoff et al.55 concluded that whilst all interventional studies reported a significant 
improvement in adherence the majority of studies had a poor research design.  
Only the studies of Norell and Granstrom97, 98 were considered by Olthoff et al. to 
be demonstrative of acceptable trial design due to their use of an objective 
outcome measure: a medication monitor recording the day and time of opening the 
bottle.  Other factors included a lack of adjustments made for confounding 
variables.  The study by Konstas et al.107 used a cross-sectional assessment of 
patients using various different eye drops for treatment of their glaucoma.  No 
adjustment was made for patients who were required to use more complicated 
dosing regimens with multiple dosing of different medications a factor which has 
previously been reported to reduce adherence.74  Length of the monitoring period, 
whether researchers were blind to the control and intervention groups, patients 
changing their adherence behaviour due to the fact they are being monitored 
(particularly just before clinic visits if IOP measure is the determinant of 
adherence), use of language in questionnaires which could introduce socially 
desirable answers and selection bias, are all areas for potential methodological 
failure.55  Studies that lack a comprehensive methodological design have been 
compared under one umbrella when ideally, only comparisons of studies using the 
same methodology should be compared, particularly in a complex topic areas 
such as adherence; only then will we begin to understand true trends and 
adherence rates to guide future research.   
Consideration of inter-country healthcare system differences are also required 
since elements of cultural disparity and structural diversity between healthcare 
systems can affect health beliefs and attitudes which, in turn, may affect 
adherence.  Patients paying for medication may also be less likely to adhere when 
a condition is asymptomatic.42   
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 Improving adherence to glaucoma 
medication 
 
Chapter 1 highlighted that medication non-adherence leads to poor clinical 
outcome for patients with glaucoma and increases the economic burden of 
healthcare costs.  Estimating the magnitude of non-adherence and establishing 
the effectiveness of interventions designed to improve adherence is important for 
the advancement of ophthalmic care for patients with glaucoma.  However, 
defining, measuring and reporting adherence is challenging.  Chapter 2 looks at 
the health behaviour models that have underpinned our understanding of 
adherence behaviour.  Knowledge, beliefs, motivation and planning abilities are 
the core explanatory frameworks from which interventions can be developed to 
improve the use of medication to ensure that patients with glaucoma receive the 
very best care in the future. 
 
2.1 Behaviour change interventions 
Behaviour change interventions aim to change behavior that is damaging to 
people’s health.  Interventions can range from a single intervention to high 
intensity interventions that can be delivered over a number of sessions.  Behaviour 
change interventions are used in a wide range of health areas, such as alcohol 
misuse, eating disorders, lack of physical activity, unsafe sexual behavior and 
smoking.  The common link is that the intervention aims to change behavior in 
order to improve an individual’s health and wellbeing.125 
Identifying facilitators and barriers to adherence as discussed in chapter 1.2.2 are 
helpful in isolating the practical assistance that patients require, but they cannot in 
themselves be used as preparatory work for developing behavior change 
interventions, since we must first understand the health education need.92  There 
are many reasons for non-adherence to medical regimens and historically non-
adherence has been categorised as being due to either intentional or unintentional 
forms of behaviour.  Unintentional non-adherence is a passive process that 
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prevents use of medication, such as poor comprehension of dosing regimen, lack 
of education delivery by the clinician, or physical inability to self-administer 
medication.  Intentional non-adherence has been described as a deliberate 
decision by the patient to deviate from the prescribed recommendations by not 
taking medication, reducing the dosing frequency or prematurely discontinuing the 
medication.  However, the manifest behaviour is often an amalgam of a range of 
these factors and therefore the categories overlap.126  Furthermore, forgetting is 
often categorised as unintentional behaviour, but forgetting use of drops can be 
influenced by intentional or motivational factors, such as lack of perceived need for 
treatment.127  The overlap in categorisation of unintentional and intentional 
behaviour renders this inadequate as a framework to design adherence 
interventions. 
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2.2  Behavioural models 
There has been a move to maximise the impact that interventions have on 
adherence by using multi-component designs grounded in behaviour models.  
Thus, identification of the beliefs and cognitions that determine an individual’s 
behaviour have become key in psychology and health-related disciplines.  The 
Health Belief Model (HBM) was first described in 1966 by Rosenstock128 and 
summarised by Dunbar et al. in 1979.129  According to the HBM model, an 
individual will follow the directions given to them by their health practitioner 
providing they believe that they have a susceptibility to the illness, that the 
consequences of that illness are considered to be serious and the costs of the 
required action do not exceed the benefits; therefore the health practitioner’s 
directions will be beneficial in reducing risk or severity of the disease.  The 
application of health promotion is key in providing the individual with adequate 
knowledge of their condition to enable them to recognise the importance of these 
elements.  However, whilst the HBM focuses on patient behaviour related to 
illness prevention, the model does not explore medication taking behaviour in 
relation to chronic illness.   
The Theory of Reasoned Action (TRA) is a general model of behaviour, 
determining behaviour to be led by an individual’s intention to perform a behaviour 
as described in Figure 2.1.130-132  The intention is governed by two factors; firstly, 
attitude toward the behaviour is informed by beliefs about the outcomes of the 
behaviour combined with the perceived value of these outcomes and secondly, the 
influence of the social environment and subjective norm surrounding that person 
which is informed by the beliefs of what other people think and motivation to 
comply with the opinions of others.  Thus, in a healthcare setting, TRA suggests 
that patients will evaluate the benefits, drawbacks or barriers of adhering to 
medication, before forming their own intention.  Therefore, TRA predicts 
adherence behaviour is based upon pre-existing attitudes and intentions.   
The Theory of Planned Behaviour (TPB) supplements the elements of the TRA by 
adding a third concept of perceived control as shown in Figure 2.2.  If the 
individual believes they have control over their opportunities, resources and skills 
necessary to perform a particular behaviour they will be able to overcome the 
potential barriers.131, 133  Thus, in a healthcare setting TPB expects that in addition, 
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the pressure of social norms the individual must feel able and confident to perform 
and control the behaviour required to remain adherent to medication.134   
  
 Adapted from Horne and Weinman 135 
Figure 2.1        Theory of Reasoned Action 
  Adapted from Horne and Weinman 135 
Figure 2.2 Theory of Planned Behaviour   
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Social Cognitive Theory (SCT) suggests that optimal adherence will be achieved if 
the individual believes in his or her capability to perform the appropriate behaviour, 
known as self-efficacy.136  Thus, the behaviour outcome relates to whether the 
individual believes that certain behaviour will have a positive impact on their health 
condition and if they value the outcomes or consequences that will occur as a 
result of performing that specific behaviour or action.  Self-efficacy can be 
improved by providing clear instructions and giving opportunities for training and 
modelling the desired behaviour.131  Patients that have a stronger belief in the 
necessity for eye drops are more adherent137 and studies that have targeted 
patient beliefs have been effective in improving adherence.138, 139   
Unlike most other theoretical models, SCT has been applied to measure self-
efficacy and outcome expectation scales in glaucoma patients using eye drops.  
Sleath et al. developed two specific instruments, one to measure self-efficacy and 
the other to measure outcome expectation.140  To assess validity, two self-report 
measures of adherence (the MMAS 124 and a VAS measure) was distributed to 60 
patients with glaucoma.  The self-efficacy scales had a significant association with 
the patient self-report of adherence.  Whilst patients with higher self-efficacy were 
significantly more likely to be adherent with their glaucoma medications, the 
outcome expectations scale did not correlate significantly with either adherence 
measure.140  Such findings are important since they help to explain adherence 
behaviour and have the potential to be used in clinical practice.  Patients could be 
screened to detect those who have low self-efficacy or confidence in using their 
glaucoma medications so that health providers can target education specifically for 
those individuals.  However, more recent findings from a study using a different 
patient population with more patients newly prescribed treatment suggest that the 
self-efficacy questionnaire was not correlated with a MEMS adherence measure94 
and highlights the complexity of patient behaviour. 
More recently, the methods that have been used to change different health-related 
behaviours have been brought together and integrated as part of an over-arching 
taxonomy of behaviour change techniques.141, 142  The development of the 
taxonomy has led to new ways of conceptualising the factors which determine 
individual health-related behaviours.  The COM-B142 captures the range of 
mechanisms that may be involved with change by referencing the existing theories 
of behaviour.  Interaction between three components: Capability, Opportunity and 
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Motivation (COM) cause the performance of Behaviour (B).  The COM-B is 
recommended as a starting point to choose interventions that are most likely to be 
effective and address each identified component which can influence behaviour 
and is a useful new tool for research aimed at designing new interventions that 
involve behaviour change. 
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2.3 Intervention approaches   
The findings from previous studies reveal that individuals often report more than 
one reason for non-adherence.64  Thus, the causes of non-adherence are 
complex42, 143 and a single intervention may not be enough to produce a sustained 
change in adherence behaviour.144  A Cochrane review of adherence interventions 
concluded that effective adherence interventions were complex in nature and 
labour intensive with those using personal contact remaining the most effective.145  
Studies using multifaceted intervention components including education and 
discussing strategies for incorporating medication administration into their daily 
activities have detected a significant improvement in adherence.97, 146 
A study designed to improve adherence to glaucoma medication using a 30 
minute education and tailoring program (n=73), found a positive, significant 
improvement in adherence.97  Norell’s educational component was similar to other 
reported studies, however, the additional ‘one to one’ tailoring program allowed the 
patient to consider and discuss strategies for incorporating the medication 
administration into daily activities.   
However, the evidence to support interventions to improve adherence with 
glaucoma medications remains weak.57, 145  A systematic review of adherence 
intervention studies found that only 46% had enough power to detect clinically 
important effects to determine efficacy of the intervention.145  Many studies have 
used self-report of adherence which is known to over-estimate adherence and 
thus may not adequately represent the differences between control and 
intervention groups.  Thus, objective measures of adherence such as MEMS or 
pharmacy refill records should be employed.57, 145   
 
2.3.1 Education  
The NICE glaucoma treatment guidelines27 launched in 2009 recommended that 
patient information should be improved to avoid the potential harm patients face 
due to uncertainty surrounding the disease.  When information is withheld, this can 
lead to low adherence with medication and follow-up care which effects the 
positive clinical outcomes expected for patients with glaucoma and ocular 
hypertension and may also increase the anxiety felt by patients that may impact 
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upon quality of life.  The HBM suggests that an individual with adequate 
knowledge of their condition is likely to acknowledge the importance of their 
diagnoses and act accordingly.  However, whilst poor glaucoma education has 
been cited as an explanation for non-adherence to therapy,42, 143, 147 the magnitude 
and nature of any association is unclear.  Studies related to oral anti-hypertensives 
have found that education alone is ineffective in improving adherence148, 149 and 
similar outcomes have been reported with glaucoma.148, 150, 151   
The systematic review by waterman et al.58 reported adherence interventions by 
Gray139, Norell 97 and Okeke146 which used education and/or patient education 
combined with other behavioural change interventions, all found improved 
adherence.  However, four studies did not find any differences between their 
control and intervention groups.  The semi-structured educational session reported 
by Sheppard et al.150 identified an improvement in participant knowledge but no 
significant difference in adherence between intervention and control groups.  
Sheppard’s findings may, in part, be attributable to the small sample size (n=73), 
short follow-up (12 weeks) and failure to ascertain the fidelity of intervention 
delivery by nurses.  
Thus, the influence of both intentional and unintentional factors that lead to non-
adherence and the complexity of human behaviour may explain the failure of 
purely educational interventions alone to achieve significant improvement in 
adherence to medication. 
Traditionally, interventions have been delivered to single patients58 but group-
based educational interventions in patients with glaucoma have previously been 
investigated.152  Group education has been found to be of equal value in 
comparison with individual education in diabetes.153  There is only one previous 
glaucoma intervention study clearly set in a health education context which used a 
group based intervention using a health promotion approach investigated by 
Waterman et al.154  The results from Waterman et al.58 suggested that this 
approach would be appealing to certain individuals but not all patients and it still 
needs to be tested for equivalence to one-to-one delivery of education.  
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2.3.2 Patient-centred care 
Patient-centred therapy was first developed by Carl Rogers in the 1950s and later 
introduced to the medical world by Michael Balint termed “patient-centred 
medicine”.155  Evidence suggests that patient-centred medicine improves patient 
satisfaction with care received, reduces symptom severity, reduces health care 
costs and increases adherence to medication.156, 157  Using patient-centred 
therapy in consultations to elicit a behaviour change is used in many health care 
settings to prevent and manage a wide range of conditions, for example, diabetes, 
asthma and heart disease.158  Achieving greater adherence to medications uses 
communication that can engage the patient in shared decision making about 
medication in order to address the barriers to adherence.159   
Thus, the goal of patient-centred communication in order to elicit a change in 
behaviour is to help the patient weigh up the perceived benefits of the change in 
behaviour with the perceived disadvantages.  It has been illustrated as a seesaw 
reaction; when the perceived disadvantage is low and perceived benefit is high, 
then a decision and change in behaviour is easily achieved.  However, when the 
costs outweigh the perceived benefits, the balance tips, and ambivalence to 
change occurs.  Ambivalence in itself is a natural phase in the process of change, 
but ambivalence must be overcome in order to help a person move towards a 
change which is of benefit to them.  As such, in some cases a brief intervention to 
explain the risks and benefits of a change in behaviour is enough to resolve the 
issues involved and for a change to be willingly accepted.  However, where the 
benefits are unclear and the costs are high, a person may need additional help to 
move through their ambivalence and the magnitude of the help required to achieve 
this will be founded upon the type of behavioural change required, and resistance 
to change displayed by the patient.160  
A qualitative study of factors influencing glaucoma treatment adherence reported 
that non-adherent participants were less likely to believe that the healthcare team 
devoted sufficient time to them, were less likely to ask questions and know of the 
benefits of the medication and were more likely to report problems with 
remembering to use their medication.161  Clinical consultations are often didactic in 
nature147 and thus providing a more relaxed environment to allow patients to 
discuss their concerns and ask questions may encourage better exchange of 
patient education and medication concerns.   
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2.3.3 Motivational interviewing and Behaviour Change Counselling 
Motivational Interviewing (MI) has been suggested as an important area of 
research for use in interventions to improve adherence to glaucoma medication147, 
162 and more widely in other chronic conditions.163-165  Motivational Interviewing 
and more recently Behaviour Change Counselling (BCC) have been developed in 
order to identify ambivalence and guide patients in adopting behavioural change160 
and is used today in many different health care related settings, such as smoking 
cessation, HIV prevention, management of disease, diet and physical activity and 
medication adherence, but its roots were first founded in addiction counselling.  
The theory and practice of MI differs when applied to both addictive or non-
addictive behaviours and chronic diseases.  For example, changing patient 
behaviour to adhere to medication does not have the same resistance and depth 
of psychological meaning as stopping alcohol, and thus non-addictive behaviours 
will need less time to overcome ambivalence.163 
Miller and Rollnick (2002) define MI as “a client-centred, directive method for 
enhancing intrinsic motivation to change by exploring and resolving 
ambivalence”.166  In this sense, MI focuses on the concerns and perspectives of 
the individual and is wholly centred on the resolution of ambivalence in a particular 
direction of change.  MI extracts the central motivation for change rather than 
imposing pressure, punishment or force.  Thus, the interviewer prompts change 
talk and then responds to resistance by intending to diminish it.  Miller and 
Rollnick, in particular advocate that MI is not a technique, rather a method of 
communication that evokes natural change.167   
MI in its original format consists of multiple sessions of 30-60 minute duration.  
However, in a medical setting particularly in primary care, patient encounters 
typically range from 10-15 minutes and patients often do not see the same 
clinician at follow-up visits which limits the use of MI.  When the duration and 
frequency of client contact is limited, it does not allow motivational interviewing to 
be used in its pure form as the depth of rapport is not present to maximise the 
effect.  In addition, in medical and public health settings, there is often a multi-
component approach to care such as the provision of educational materials and 
the communication of information.163  Thus, BCC, an adaption of MI, is suitable for 
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brief consultations and was developed for use in healthcare settings by 
practitioners.  Whereas MI uses open questions and reflective listening, often 
found in generic counselling,168 BCC can be used to exchange information but 
also use listening skills to understand the patient perspective and then build 
motivation for change.  BCC is often used as an opportunistic tool for patients 
rather than with clients deliberately seeking help and can be of brief duration or 
extended to a longer time if required, typically between 5-30 minutes.169 
Training public health practitioners to use BCC can be problematic.  Practitioners 
inherently learn a practitioner-centred technique since they deliver information to 
their patients in a prescriptive way.  Thus changing to the motivational interviewing 
approach can be difficult.  In addition the time frame for training practitioners tends 
to be limited.163  However, the behaviour change counselling index (BECCI) was 
developed in order to evaluate the skills of practitioners using BCC and ensure 
that they meet the core skills required and can be used in research to evaluate 
practitioner competence using a BCC intervention in controlled trials.158 
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2.4  Conclusions 
Improving adherence with anti-glaucoma therapy is an important objective in 
achieving adequate patient adherence with glaucoma medication since evidence 
suggests that any degree of non-adherence with glaucoma treatment could be a 
risk factor for the progression of glaucoma.  It would appear that by increasing 
patient adherence there should be improvement in treatment effect and an 
associated reduction in overall health costs.  Reduction in surgical management 
would be of particular benefit since any invasive eye surgery is both costly, carries 
a risk of failure, can lead to sight-threatening complications and is rarely a patient 
preference. 
However, there is an ongoing challenge in the education and counselling of 
glaucoma patients, particularly in the area of disease awareness and the issues 
specific to non-adherence with topical medication.  Due to the lack of quality 
evidence, governing bodies such as NICE are unable to provide clear evidence-
based guidelines on how to improve knowledge and promote adherence.  The 
NICE Guideline Development Group conclude by simply recommending that 
“patients are offered the opportunity to discuss their diagnosis, prognosis and 
treatment by providing relevant information in an accessible format at initial and 
subsequent visits… and that further research is required in order to make 
recommendations”.27 
The literature has revealed how an understanding of health behaviour models 
could be used to improve adherence.  The NICE guidelines encourage the use of 
behaviour change interventions to encourage practitioners to help patients to 
adopt a healthier lifestyle.125  Interventions should be prioritised based on the 
evidence of efficacy and cost-effectiveness, tailored to tackle individual attitudes, 
knowledge and skills associated with the target behaviour and can specify the 
theoretical link between the intervention and the outcome.   
Previous multi-component interventions used to improve adherence to glaucoma 
medication have lacked grounding in approaches and models that focus on 
patients’ beliefs, motivation and planning abilities, resulting in ineffective 
components.  It was therefore proposed necessary to develop and trial an 
intervention that targets the factors elucidated in theoretical models to determine 
their impact on adherence.  As such a BCC intervention as discussed in section 
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2.3.3 offered all the elements required of a reasonable and cost-effective 
intervention and would influence the body of work undertaken to achieve a 
successful intervention which is described in Chapter 3.  
Understanding the methodological principles of measuring adherence also needed 
further development, the literature reviewed revealing where past research studies 
had failed.  A discreet and effective way of measuring adherence and impact of an 
intervention was required.  
Self-report methodology is easy to administer and analyse and is used frequently 
in adherence studies.  Discerning the agreement between self-report measures 
and an objective measure of adherence will help our understanding for the use of 
these methodologies.  It has been well documented that the effects of monitoring 
individuals to assess their level of adherence will affect their level of self-reported 
adherence but the degree of this effect remains unknown. 
Clear predictors of non-adherence or reduced adherence have not yet been 
established for patients prescribed topical ocular hypotensive medications.  
Sociodemographic variables have been investigated previously but have not been 
shown to be accurate enough to ensure that patients at risk can be selected 
without the possibility of missing at-risk individuals.  In addition, the evidence 
suggests that different degrees of non-adherence will lead to varying degrees of 
glaucoma progression.  With tools that measure adherence with an adequate 
degree of accuracy, reliability and repeatability, then high quality studies can be 
performed to determine interventions that can improve adherence.  
.    
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Section 2. Helping Adherence with 
Glaucoma Therapy; the Norwich 
Adherence Glaucoma Study 
This section presents independent research funded by the National 
Institute for Health Research (NIHR) under its Research for Patient 
Benefit (RfPB) Programme (Grant Reference Number PB-PG-1207-
14119). The views expressed are those of the author and not 
necessarily those of the NHS, the NIHR or the Department of Health. 
Neither the sponsor nor funding organization had any role in the 
design or conduct of this research. 
 
Chief Investigator:  Professor David Broadway 
Co-applicants:   Mrs Heidi Cate, Trial Manager 
    Dr D Bhattacharya, Project Advisor 
    Dr A Clark, Statistician 
    Dr R. Holland, Clinical Trialist  
    Dr R. Fordham, Health Economist 
 
Heidi Cate was one of the co-applicants on the NIHR grant before 
becoming a PhD student.  The NIHR granted permission for Heidi to 
use this study as an educational project for her PhD.   
Heidi was integral to the planning and design of the study and was 
Vice-chair to David Broadway on the Steering Committee.  
Heidi was trial manager for the project and was also one of the key 
Glaucoma Support Assistants delivering the intervention to 
participants.  
Heidi undertook the analysis under the guidance of Allan Clark the 
Statistician also a co-applicant.    
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 The Norwich Adherence Glaucoma 
Study 
3.1  Introduction  
As discussed in Section 1, the majority of glaucoma damage is preventable with 
appropriate therapy23, 32, 45 and the mainstay of treatment involves the daily 
administration of topical medications to reduce IOP.27  Non-adherence to 
therapeutic regimens is associated with a reduction in treatment benefit170 
resulting in additional health service costs through changes to prescribed 
medication requiring additional follow-up to assess efficacy, wastage of unfinished 
pharmaceutical supplies, or the costs of surgery that may have been 
unnecessary.89  If surgical treatment is required, there is also the increased risk of 
associated adverse effects and the costs of managing these. 
According to UK national guidance,27 a typical care pathway involves referral to a 
specialist glaucoma clinic for diagnosis by standard glaucoma examination, 
followed by long-term monitoring, with treatment if indicated, according to risk of 
disease progression.  Provision of information for patients, carers and family 
members is usually provided by the diagnosing clinician.  However, previous 
research in a UK eye clinic found that there was unsatisfactory hospital-led 
education where “doctors appeared too busy clinically to have time to provide 
adequate education … and poor communication” which had become a barrier to 
good adherence with glaucoma medication.42 
The aim of the Norwich Adherence Glaucoma Study (NAGS) was to determine 
whether an intervention designed to both target beliefs and provide tailored 
education using a similar approach to Norell et al.97 described in Section 1 could 
be beneficial in improving adherence with topical therapy.  There is little evidence 
to suggest that adherence interventions can consistently improve adherence with 
medication within the resources available in clinical settings.  Interventions are 
generally led by research teams which cannot easily be translated into routine 
clinical practice.56  Thus, the NAGS study was also specifically designed to be led 
by specialist nurses and technicians working within the local hospital to provide a 
more realistic consideration of use of the intervention at a local level.   
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3.2 Intervention development 
A successful behaviour change intervention should be underpinned by relevant 
evidence and theory identified in the early stages of development.171  Previous 
qualitative work undertaken by the researcher and the wider research team led to 
the creation of the Glaucoma Medication Adherence Model (GMAM), 42 which is 
Illustrated in Figure 3.1.  The GMAM elicits the barriers that prevent adherence 
with eye drop therapy, identifying positive and negative influences and provides 
the evidence base for development of the intervention.  Because the GMAM was 
drawn from data collected from participants attending the Norfolk and Norwich 
University Hospital (NNUH) (the same patient population whom the intervention 
was being developed) we were confident that the identified factors that affect 
adherence were relevant to our target study population.   
There is evidence to suggest that delivery of an intervention should be early in the 
patients trajectory of care.92  Specifically, at least two studies have reported that 
patients need support and education when first placed on treatment,42, 172 a theory 
mirrored by the GMAM; initial education about glaucoma and the advantages of 
using eye drops to prevent progression of glaucoma is likely to encourage use of 
eye drops from the outset of diagnosis.  Therefore, paramount to the design of the 
intervention was the feasibility of delivering the intervention at the point of 
treatment initiation incorporating information provision as one of the main goals.   
Information provision was aimed to be manifold; information about glaucoma/OH, 
treatment/medication and drop taking techniques.  Information provided to patients 
about their glaucoma/OH was guided by current literature and patient information 
leaflets, and expert opinion from a glaucoma consultant at NNUH.  The chronic, 
asymptomatic and slowly progressive nature of glaucoma must be communicated 
to patients so they understand the need for long-term follow-up to establish a 
maintained therapeutic regimen.  Gaining an appreciation of how treatment 
efficacy is obtained is also problematic for patients using anti-hypertensive therapy 
since the benefits of persisting with the prescribed medication cannot be perceived 
until IOP is measured at each clinic consultation.  Research has shown that the 
requirement for information about medication to ensure that medicines are taken 
appropriately varies widely amongst individuals.  Thus, the quality of the 
information given to patients needs to be measured in relation to the extent in 
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which an individuals perceived needs for information have been met.173, 174  To 
that end, SIMS offers a valid and reliable method of assessing patient satisfaction 
with medication information175 by way of a questionnaire comprising of 17 items 
derived from published recommendations of the Association of the British 
Pharmaceutical Industry to enable safe self-management of medication.176  Thus, 
the SIMS scale was used to guide the selection of information provided to patients 
about their travoprost eye drops.  For example, ‘how does your medication work?’, 
and ‘can you drink alcohol whilst using your medication?’ appear on the SIMS 
scale and therefore such information was included in the intervention.  
When basic information about glaucoma and treatment have been imparted, the 
GMAM indicates that patients will become motivated to use their eye drops but will 
require information about techniques to help administer eye drops to promote 
confidence in their use.  Those patients who lack confidence in eye drop 
application and efficacy may cease to be adherent.  Thus, providing information 
about good and safe application techniques was also paramount to the information 
provision part of the intervention.  
The next barrier highlighted by the GMAM was the problems patients have with 
remembering to use their medication.  Whist patients can be aided by good routine 
and memory aids, it is important to remember that adherence is easily disrupted 
by broken routines, busy periods and complex dosing regimens.  Equally, there 
may be patients who are extremely motivated to use their eye drops, but for 
practical reasons beyond their control cannot become or remain adherent; 
examples such as poor dexterity prohibiting correct use of eye drops, poor 
memory which cannot be aided by daily dosing boxes, poor mobility which 
prevents collection of medication from the pharmacy or residing in a rural location 
to name but a few.  Of course, personal states do not remain static and any 
sudden or unforeseen change in social or medical circumstances can also bring 
about practical barriers to using medication.  Accordingly, motivating patients’ use 
of eye drops and assessing ambivalence to maintaining use of drops is important 
for the long-term attainability of adherent behaviour.  Consequently, building self-
efficacy136 is key to obtaining ongoing motivation and the skills necessary to 
overcome barriers which arise to the use of eye drops.  Whilst information 
provision was an important aspect of the intervention, using a combination of 
teaching skills to brainstorm solutions to perceived barriers and exploration of 
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resistance to change and motivation was also necessary.  A Motivational 
Interviewing approach, as discussed in Section 1, Chapter 2.3.3 had the essential 
elements required for this intervention.   
As the GMAM concludes its 6-item chain of potential barriers, long-term 
adherence requires continuous feedback and education from clinicians to maintain 
motivation to use eye drops.  Furthermore, the model advises that individuals 
experience a range of difficulties in managing their medications and each patient 
has a unique profile of needs.  As such, a standardised intervention may not 
accommodate for these variances and the design of the intervention must be 
responsive to the needs of the individual175 and address the unique challenges 
that adherence with glaucoma medication requires using a tailored, patient centred 
approach.82  An intervention that could be used within the existing hospital 
healthcare setting to successfully overcome ambivalence to use of glaucoma 
medication, provide education about glaucoma and use of eye drops was felt to be 
a reasonable foundation from which a tailored intervention to improve adherence 
to glaucoma medication could be developed.  A Behaviour Change Counselling 
(BCC) intervention was ultimately chosen as this offered the flexibility of use as a 
‘brief intervention’ and could be developed to enable the healthcare providers to 
support medication adherence in a patient-centred way whilst also incorporating 
practical assistance such as teaching eye drop installation technique.  In order to 
standardise the delivery of the information, the ‘Behaviour Change Counselling 
Template’ demonstrated in Figure 3.2 was used as the main structure of the BCC 
intervention.   
At the time of designing this intervention for the NAGS study, the COM-B142 
discussed in Section 1, Chapter 2.2, had not been described as a new tool for 
designing interventions involving behaviour change and there was limited previous 
high quality research in medication adherence on which to build our novel 
intervention.   
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Diagnosis
Initial 
Education
Motivation
Correct 
Application
Remembering
Practical 
Problems
ADHERENCE
  
  
 Communication issues 
 Busy service 
Negative 
Effects on 
Adherence 
Positive 
Effects on 
Adherence 
 Self-education 
 Lack of confidence 
 Technique issues 
 Perceived drop 
efficacy 
 Broken routine 
 Busy times 
 Complex dosing 
regimes 
 Good routine 
 Memory aids 
 Good clinician 
communication skills 
 Poor clinician 
communication skills 
Older participants (60 and over) 
Application of drops and 
remembering drops – effects of 
aging and conditions associated 
with older age make adherence 
more difficult 
Education – some older 
participants had problems with 
access to self-education 
(particularly using internet 
resources)  
 
Older participants (60 and over) 
Application of drops and 
remembering drops – effects of 
aging and conditions associated 
with older age make adherence 
more difficult 
Education – some older 
participants had problems with 
Younger participants (60 and under) 
Anxiety increased due to longer life 
expectancy  
Treated differently by Eye Clinic 
Staff – either more/less attentive  
Face different issues because they 
are at a different stage in life, are 
still working as opposed to retired 
and therefore desire to meet other 
patients in “young exclusive” 
support groups  
 
 
Younger participants (60 and under) 
Anxiety increased due to longer life 
expectancy  
Treated differently by Eye Clinic 
Staff – either more/less attentive  
Face different issues because they 
Age Differences 
 
Age Differ nces 
Initial education and long-term 
feedback – level of satisfaction, level of 
information required and delivery 
Correct application – degree of initial 
problems, ongoing application problems 
Remembering – frequency of forgetting, 
feelings about forgetting, cues used 
other than routine  
Practical problems – evident across all 
identified areas according to individual 
lifestyle 
 
 
Initial education and long-term 
feedback – level of satisfaction, level of 
information required and delivery 
Correct application – degree of initial 
problems, ongoing application problems 
Remembering – frequency of forgetting, 
feelings about forgetting, cues used 
Individual Differences 
 
Individual Differ nces 
Age and Individual Differences for Consideration within Each Barrier 
Figure 3.1 The Glaucoma Medication Adherence Model  
 
Figure 3.1 The Glaucoma Medication Adherence Model  
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One criticism of the Norell et al97 work using a ‘one to one’ tailored program to 
provide education was the short follow-up time of 20 days, which meant there was 
no estimate of sustainability of intervention effect and no estimate of intervention 
cost.  The design of the NAGs intervention needed to address these issues with 
an appropriate follow-up period to establish the longevity of any intervention effect 
on adherence and health economic analyses.  The sample of participants was also 
not restricted to those who were known to be non-adherent as other studies have 
done, because there is no widely accepted level at which non-adherence is 
deemed unsafe, and adherence behaviour is not a stable phenomenon and known 
to decline over time.177 
 
3.2.1 Evaluation of the Behaviour Change Counselling intervention  
Measurement of intervention fidelity is required to ensure the reliability and validity 
of the behavioural programme.178  There is often no evidence of any skill 
assessment undertaken for the practitioners delivering the intervention or 
measures of patient-centeredness158 or the extent to which a person delivers the 
essential content.  
There are a multitude of adaptations to the original form of MI used in RCTs.  
Miller and Rollnick179 consider that as long as the intervention is primarily 
implementing the principles of MI rather than the principles of another approach, 
such as Cognitive Behavioural Therapy, and is delivered on a one-to-one and 
face-to-face basis, it is considered to be an ‘Adaption of Motivational Interviewing’ 
(AMI).  Thus, when there is uncertainty about how MI has been adapted, there is a 
need to ensure that the intervention is fully described and that practitioner skills 
are assessed and measured to ensure patient-centeredness is achieved.  
There have been a number of instruments used to measure patient-centeredness 
in its pure form as reviewed by Hudon et al in 2011 using the conceptual 
framework of patient-centred care;155 however, these are not specific to health 
behaviour change techniques.  The Motivational Interviewing Skill Code (MISC) 
and Behavioural Change Counselling Index (BECCI) are specific measures of 
motivational interviewing techniques used for behaviour change counselling.  
MISC applies three phases of analysis be means of direct observation of a 
recorded clinical encounter.  The first phase uses a Likert-type scale in order to 
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observe the encounter in terms of the interaction between the client and therapist.  
In the second phase, specific behaviours of the client and therapist are coded and 
counted and the third phase calculates the talk time of the client and therapist.  
The scores from each section are computed which produces an overall summary 
score which can be compared to the benchmarks which depict proficiency in MI.180  
Lane et al. suggest that that although MISC provides counts of actual behaviours, 
it does not provide an assessment of the overall strength of the behaviour.158  
Even though the MISC has been revised in 2008 to an altogether more 
streamlined process which no longer includes the third part of timing the talk 
time,181 there are a number of subsections that are not essential for users of BCC 
to assess, such as reflective listening strategy.158 
Choosing the most appropriate health professional to deliver a behaviour change 
intervention for patients newly diagnosed with glaucoma within the secondary care 
setting had to be considered carefully.  Whilst clinicians may appear a natural 
choice as they are well placed to deliver the intervention as an extension to the 
patient consultation, staffing costs are expensive in comparison to nursing and 
health care assistants, and their time is limited in clinical practice as well as in 
training.  Training health practitioners to use BCC can be problematic since 
practitioners inherently learn a practitioner-centred technique as they deliver 
information to their patients in a prescriptive way.  Thus, changing to the 
motivational interviewing approach can be difficult.  In addition the time frame for 
training practitioners tends to be limited.163  For this reason, pharmacists, nursing 
staff, and health care assistants are potentially better assigned to deliver patient-
centred services as part of their existing roles and time given to learning MI 
techniques.  BECCI was developed in order to evaluate the skills and competence 
of practitioners using BCC in particular.158   
BECCI focuses on the practitioner consulting behaviour rather than the response 
of the patient.  A one-phase analysis is employed using Likert-type scales to 
indicate either frequency or strength of practitioner behaviour on 11 themes.158  An 
overall BECCI score can be calculated using the mean of all the scored items.  
Thus, the BECCI may be an appropriate method evaluating practitioner skills and 
patient-centeredness within a study.  
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Figure 3.2 Behaviour Change Counselling Template  
  
A) Agenda and time setting 
B) Establish patient’s initial thoughts / attitude towards the prescribed 
medication 
C) Establish patient’s baseline knowledge and therefore information needs – 
confirm type of glaucoma 
D) Agree agenda incorporating patient needs; address all of the information 
outlined in discussion topics below but tailored to patient knowledge 
level as reported at stage C.  
Discussion topics:  
What is glaucoma? 
What causes glaucoma? 
What creates the pressure? 
How will this affect me? 
Treatment with eye drops 
Drop Application Techniques 
E) Establish patient’s thoughts / attitude towards the prescribed medication. 
Tailor further information and discuss:  
 Side effects  
F) Determine patient’s optimism for treatment and address any 
ambivalence. 
G) Discuss patient’s self-efficacy and develop strategies to enhance self. 
Tailor further information and discuss:  
 Drop taking regimen 
H) Discuss patient’s outcome expectancy, if ambivalence identified, return to 
decisional balance and then key question. 
 
A) Agenda and time setting 
B) Establish patient’s initial thoughts / attitude towards the prescribed 
medication 
C) Establish patient’s baseline knowledge and therefore information needs – 
confirm type of glaucoma 
D) Agree agenda incorporating patient needs; address all of the information 
outlined in discussion topics below but tailored to patient knowledge 
level as reported at stage C.  
Discussion topics:  
What is glaucoma? 
What causes glaucoma? 
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3.3 Method 
 
3.3.1 Study aim and objectives  
The purpose of the study was to determine whether additional education and 
advice about glaucoma using a BCC intervention, improved adherence with topical 
anti-glaucoma therapy when compared to standard care.  The duration of the 
study was 8 months in order to assess the longevity of the intervention effect on 
adherence.  The objectives were to: 
 Determine the effect of the intervention on adherence compared to 
standard care alone 
 Establish the pattern of adherence over an 8-month period to determine if 
there is a longevity of effect on adherence 
 Report any predictors of non-adherence based upon social, demographic, 
medical and family history information 
 Establish if IOP could be used as a surrogate marker of adherence 
 Examine different methods of adherence measurement 
 Describe user experiences of the educational intervention and self 
perception of adherence in order to gain a better understanding of the 
components of the intervention that might improve adherence.  
 
3.3.2 Study design 
The study was a randomised controlled intervention study.  A flow-chart of the 
study design is shown in Figure 3.3.  The duration of the study was eight months 
in order to cover a longer period of follow-up than previously reported glaucoma 
intervention studies; standard practice care at NNUH at the time of the study 
conception was to assess response to treatment at two months and then 6-months 
post treatment initiation.  Follow-up study visits were planned to coincide with the 
routine treatment plans.  The study received ethical approval from the Norfolk 
Research Ethics Committee, (appendix1) and research governance approvals 
from the East Norfolk and Waveney Research Governance Committee (appendix 
2).  The study was registered on a public database; Current Controlled Trials, 
ISRCTN89683704.    
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3.3.2.1 Setting, recruitment and treatment allocation 
The study was conducted in the Glaucoma Clinic at NNUH.  Patients newly 
diagnosed, or previously untreated, with either glaucoma or OH requiring 
treatment with travoprost, (using established standard criteria as documented in 
the European Glaucoma Society Guidelines),31 were invited to participate.  
Patients were 18 years of age or older, able to give informed consent, and had 
adequate ability to read and understand English.  Patients requiring care-home 
staff or home-help (not provided by a co-habiting partner or family member) to 
apply eye drops were excluded.  Patients were made aware that they would be 
randomised to either the standard care or the intervention group, and that their 
adherence to travoprost would be monitored for the duration of the study. 
Potential participants were identified at the time of clinic consultation by their 
clinician and referred to a research assistant to explain the nature of the research 
and obtain consent following standard consent procedures. 
Eligible patients were randomised using an automated telephone randomisation 
system to ensure allocation concealment.  Randomisation was stratified by 
diagnosis (either glaucoma, or OH / glaucoma suspect) and experience of the 
glaucoma service (new or follow-up patient advised to use medication).  
Stratification controlled for possible variances, since previous studies have shown 
that patients with suspected glaucoma or OH without the presence of manifest 
glaucomatous disease are less adherent than those with evidence of manifest 
glaucoma.80, 81  Also, patients previously reviewed as out-patients but not started 
on anti-glaucoma treatment, had an increased opportunity to ask questions or self-
educate before therapy initiation and becoming eligible to participate in the study.  
Patients declining study participation, following consent, had demographic 
information collected or determined (age, gender and index of multiple deprivation, 
(IMD)).  
 
3.3.2.2 The control group  
Patients attended a specialist glaucoma clinic for treatment initiation.  Initiation 
included undergoing appropriate tests and a consultation of approximately 10 
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minutes with a specialist glaucoma clinician.  The consultation consisted of the 
following: 
 A brief explanation about glaucoma or OH 
 A summary of the proposed future management 
 Guidance regarding drop administration 
 The relevance of glaucoma with respect to driving and future vision 
The Control group received what was accepted as ‘standard care’ for the NNUH 
ophthalmic glaucoma service including a patient information leaflet providing 
information about glaucoma.  
 
3.3.2.3 The intervention group 
Following the standard care consultation at NNUH, the intervention group received 
a BCC intervention provided by the Glaucoma Support Assistants (GSAs).  GSAs 
are described in Chapter 3.3.3.  A telephone advice-line for patients and their 
carers to respond to glaucoma related queries was also provided.  
 
3.3.2.4 The Travalert® Dosing Aid (TDA) 
The TDA (Alcon Laboratories, Inc., Forth Worth, TX, USA) 
electronically stores the time, date and number of drops 
administered.  The TDA can only be used in conjunction with 
Travatan® (travoprost) and Duotrav® (travoprost/timolol 
combination) eye drops due to aperture size restricting other 
shaped bottles from fitting the aid.  Three studies using the 
TDA have reported that it accurately records drop 
administration.93, 99, 100  An additional feature of the TDA is the 
alarm and digital visual reminder window which informs participants when it is time 
to use their eye drops.  For the purposes of the study, the alarm feature was 
disabled during the study period and the visual reminder was covered over by a 
sticker to prevent participants using this visual cue as a reminder to use their eye 
drops.  Participants were given a demonstration of the TDA and provided with 
written operating instructions (appendix 3).105  Participants were asked to use the 
TDA to admister their travoprost eye drops for the duration of the study.  
 
60 
 
 
Figure 3.3. Illustration of the participant study pathway 
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3.3.2.5 Intraocular pressure (IOP) measurements  
All patients attending the Eye Department at NNUH have their IOP measured by 
their clinician using Goldmann applanation tonometry at each visit.27  The IOP 
value for each eye at each visit was obtained from the participants’ medical 
records.  Clinicians were masked to patients participating in the study, and 
participants were encouraged not to report their participation to clinicians involved 
with their care. 
 
3.3.2.6 Social demographics and medical history 
A researcher lead questionnaire was used to collect patient demographics; age, 
IMD, type of housing, educational qualifications, family history of glaucoma 
(appendix 4). Co-morbidity was classified using the Charlson Co-morbidity 
Index182 from information available in participant medical records to characterise 
demographics.  
 
3.3.2.7 Questionnaires 
A participant self-administered questionnaire was completed after the baseline 
visit/visit 1 (appendix 5), Visit 2 and Final Visit (appendix 6) and returned by post 
to capture the following information:  
Self-reported adherence: Two self-report adherence measures were utilised, (i) a 
modified MMAS124 and (ii) the Frequency of Missed Dose (FMD).  The MMAS is a 
four-item measure described in Chapter 1.2.7.2 (see appendix 8) that was 
modified in order that the final question incorporated multiple response options 
from which participants could report any other reasons for non-adherence using a 
7-item list of suggested reasons; forgot ran out of drops, side effects of drops, 
difficult to use drops, change in routine, fell asleep, felt unwell and an ‘other’ option 
(as shown in appendix 6, questions 3-6).  The FMD is a quantitative measure of 
eye drop doses missed each month (see appendix 8). 
Satisfaction with information received: SIMS174 was used to quantify satisfaction 
with information received about travoprost (appendix 5, question 1 and appendix 
6, question 7).  Three different analyses can be carried out from SIMS; medicine 
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information profiles, total satisfaction rating and sub-scale scores of action and 
usage of medications and potential problems of medication.  A previous study 
carried out by Gellaitry et al., used SIMS methodology to profile patient satisfaction 
with information received about HAART (Highly Active Anti-Retroviral Therapy) 
among patients attending HIV clinics in Brighton.176  The SIMS showed good 
internal reliability with a Cronbach α- coefficient of 0.92.  Gelliatry et al. were able 
to conclude that individuals faced with treatment decisions varied widely in their 
perception of information they had received.  Furthermore, those individuals who 
acted positively to the offer of HAART were more satisfied with the information 
they had received about treatment than those who declined it.176  
The SIMS tool has been evaluated previously in a variety of clinical settings, both 
for ease of use, internal consistency and test-retest reliability.174  Although not 
validated for use in glaucoma patients, SIMS has been sampled in various disease 
and treatment characteristic groups including other asymptomatic conditions such 
as early diabetes or hypertension.   
Potential predictors of adherence: 
 Use of medications (appendix 5, question 2 and appendix 6, question 9) 
 Problems with use of eye drops (appendix 6, question 1) 
 Previous experience of using eye drops (appendix 5, question 4) 
 If drops are applied by a carer (appendix 5, question 3 and appendix 6, 
question 10) 
 satisfaction with information about glaucoma, effects on vision and driving 
(appendix 5, question 5 and appendix 6, question 11) 
 more information required (appendix 5, question 6 and appendix 6, 
question12) 
 additional information sought about glaucoma (appendix 6, question 8) 
 
In addition, at Visit 2, the intervention group were asked to rate the acceptability of 
the education and support service provided (appendix 7).  A 5-point Likert scale 
(strongly agree, agree, neutral, disagree, strongly disagree) was used to rate their 
satisfaction with the information provided by the GSAs.  Eight questions were 
given, 4 relating to the helpfulness of the information given about glaucoma, how 
to apply eye drops as part of a daily routine and information provided by the 
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telephone helpline service, and 4 questions relating to patient reported outcomes 
of improvement to understanding of glaucoma, better use of drops as part of a 
routine and if they would recommend the service to other patients with glaucoma.  
 
3.3.2.8 Resources Log 
Time spent with each participant by NAGs research staff in the out-patient 
department or on the telephone helpline was recorded. 
 
3.3.2.9 Repeat prescription refills 
In the UK, patient repeat prescription history is maintained by their General 
Practitioner (GP). In order to retrieve this information, with participant consent, the 
researcher wrote to each individual participant’s GP to ask for their repeat 
prescribing records specific for their glaucoma/OH condition including, drug name, 
date of issue, and prescribed days of treatment.  Payment was made for this 
administrative task via an existing research payment contract held by the Primary 
Care Research Network and participating GPs.  From these data a measure of 
expected repeat prescription orders and actual repeat prescription orders were 
used to calculate the Medication Possession Ratio (MPR) as displayed in Figure 
3.4.  The MPR indicates over or under usage of eye drop refills and persistence 
with use of medication. 
 
3.3.3 Glaucoma Support Assistants and training  
Five GSA roles were created specifically for the purpose of this study.  Prior to 
recruitment, the GSAs had worked within within NNUH eye department in standard 
NHS nursing and technician roles (Band 4 glaucoma research technician, Band 5 
ophthalmic nurse, Band 6 glaucoma nurse specialist (x2) and Band 6 glaucoma 
research co-ordinator), all with experience of working with glaucoma patients.  
Five GSAs were utilised to ensure the results of the study were attributable to the 
intervention method rather than the specific context of any one individual 
delivering the intervention.   
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The GSAs participated in BCC training and quality assurance sessions.  Training 
Session 1 was a 4 hour session which introduced to the causes of non-adherence 
and predictors of behaviour and MI theory.  Session 2 was a 2 hour session and 
was role-play facilitated by a qualified MI coach.  Individualised guidance was 
provided in response to any reported or observed problems.  The GSAs practiced 
MI and BCC skills within their usual clinical duties for the following 2 months.   
The GSAs also underwent a training session with the Glaucoma Specialist 
Consultant to ensure competency in the knowledge and skills required to deliver 
education to patients about glaucoma and related issues.   
The GSAs had the freedom to conduct the counselling session in their own BCC 
style.  Education was tailored to individual patients, but followed the BCC template 
(Figure 3.2). 
 
3.3.3.1 Fidelity testing  
Six months after completion of training, the GSAs underwent a formal assessment 
of their BCC skills and information given to participants to fulfil the BCC template 
and assess whether the consultation style meet expectations.  The GSAs were 
each videoed with the same actress who was playing the role of a patient newly 
diagnosed with glaucoma.  The actress’ ‘brief’ was prepared by the Glaucoma 
Specialist Consultant and the MI coach.   
The BECCI instrument is designed for trainers to score practitioners’ use of 
Behaviour Change Counselling in consultations either in real or simulated 
situations.  Each assessor used the BECCI scoring sheet to score each item under 
the four domains as detailed in Table 3.1.  Three assessors were used and their 
scores averaged as detailed in Table 3.1; a low score indicating that the action 
was not carried out up to a higher score indicating it was carried out to a great 
extent.  The videoed role-play sessions were independently reviewed according to 
the BECCI158 criteria by the MI coach and a further 2 MI expert’s independent from 
the research study as described in Chapter 3.2.1.  Table 3.1 summarises the 
BECCI scores by the three assessors.  The mean average BECCI score reveals 
that the GSAs used BCC to some extent during the simulated session.  Feedback 
from the MI coach found that 3 GSAs did not clearly discuss with the patient that 
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there would be no tangible immediate effect from using the eye drops.  Two GSAs 
did not discuss the patient’s expectations of adherence to treatment and for each 
of the following criteria, one GSA did not clearly address the issue during the role-
play: eye drop application technique, patient’s thoughts/attitudes regarding the 
prescribed medication, patient’s optimism and perceived self-efficacy regarding 
adherence to the prescribed travoprost.  Individualised, written feedback was 
provided to each of the GSAs.  
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Table 3.1  Average BECCI scores of role play assessment; 0 (not at all) to 
4 (a great extent) 
BECCI criterion GSA 1 GSA 2 GSA 3 GSA 4 GSA 5 
Domain 1. Agenda setting and permission seeking 
1. The practitioner invites the patient to talk 
about behaviour change 
1.5 2.0 2.0 2.1 1.7 
2. The practitioner demonstrates sensitivity 
to talking about other issues 
2.3 2.0 2.7 3.0 2.0 
Domain 2. The why and how of change in behaviour 
3. Practitioner encourages patient to talk 
about current behaviour or status quo 
2.3 2.3 2.7 2.7 3.0 
4. Practitioner encourages patient to talk 
about behaviour change 
2.0 2.0 2.3 2.7 2.7 
5. Practitioner asks questions to elicit how 
patient thinks and feels about the topic 
2.0 2.3 3.0 3.0 3.0 
6. Practitioner uses empathic listening 
statements when patient talks about the topic 
2.0 3.0 2.7 3.0 2.7 
7. Practitioner uses summaries to bring 
together what the patient says about the 
topic 
2.3 1.0 0.7 2.3 2.0 
Domain 3. The whole consultation 
8. Practitioner acknowledges challenges 
about behaviour change that the patient 
faces 
1.3 2.3 2.7 2.0 1.7 
9. When practitioner provides information, it 
is sensitive to patient concerns and 
understanding 
2.7 2.7 3.0 3.0 2.3 
10. Practitioner actively conveys respect for 
patient choice about behaviour change 
1.3 2.3 2.3 1.7 1.7 
Domain 4. Talk about targets 
11. Practitioner and patient exchange ideas 
about how the patient could change current 
behaviour 
2.3 2.0 2.0 2.3 2.0 
Practitioner BECCI score 
Mean score excluding domain 1 2.1 2.2 2.4 2.6 2.3 
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3.3.4 Rationale for sample size calculations 
Glaucoma intervention studies that had used medication monitors to observe 
adherence found a range of adherence rates; a mean of 76 ± 24% of prescribed 
pilocarpine doses when dosing four times a day,122 and 72 ± 19% when dosing 
twice daily and 62 ± 16% when dosing three times daily with Brimonidine.183  
However, in these studies, adherence behaviour was observed for a shorter 
duration using a more complicated dosing regimen than the proposed study.  The 
absence of an accepted adherence rate with once daily glaucoma medication and 
limited robust research55 to indicate the likely effect of an intervention on 
adherence to glaucoma medication at the time of the study design led to estimates 
being derived from general medicine.  Adherence to treatment for hypertension 
suggested that 40% failed to take a consistent therapeutic dose of medication and 
use of electronic monitoring of adherence found adherence using a MEMS device 
was 58%.184  Therefore, without a like study for comparison, a 20% increase in 
adherence to glaucoma medication was estimated for sample size power 
calculations.  Assuming an adherence rate of 60% in the control group and 80% in 
the intervention group, having 81 people in each group was calculated to provide 
80% power to detect a difference using a Chi-Squared test, at a 5% level of 
significance.  Based on an estimated, approximate 20% drop-out rate, the aim was 
to recruit 200 participants.  
 
3.3.5 Primary outcome measure 
Adherence was determined using the number of adherent doses recorded by the 
TDA, divided by the expected number of doses for the monitoring period using the 
adjusted adherence calculator.105  The adherence calculation and the rules for 
determining an adherent dose are shown in Figure 3.4.  Two adherence scores 
were calculated; the average of the total 8 month study duration and the average 
of the final 2 months of follow-up.  The average adherence score for the final 2 
months of follow-up was also given as a dichotomous classification based on 
‘adherent’ if the average number of TDA recorded doses was 80% of expected 
and ‘non-adherent’ if <80%.  
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Figure 3.4  Calculations used for outcome measures; Adherence 
percentage and Medication Possession Ratios (a and b) 
 
3.3.6 Secondary outcome measures 
Outcome measures were collected at three different time points; Baseline, Visit 2 
and Final Visit: 
 The IOP measurement for each treated eye was recorded from the hospital 
records and the mean of both eyes calculated for each time point.  Two 
values were calculated for two time periods; percentage reduction in IOP 
between baseline to Visit 2, and from Baseline to Final Visit, and the 
absolute reduction in IOP between Baseline to Visit 2 and Baseline to Final 
Visit.    
 Repeat prescription information was used to calculate MPR; MPRa used 
the average travoprost drop count115, 185 and MPRb used the UK general 
prescribing instruction to renew eye drop prescriptions every 28 days 
(Figure 3.4).  An MPR less than 0 indicated not enough medication to meet 
the required dosing regimen.   
 Self-reported adherence using the MMAS score was calculated for each 
participant.  Participants that answered ‘yes’ to a question score 1, thus 
𝐴𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 % =  (
𝑁𝑜. 𝑜𝑓 𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑡 𝑑𝑜𝑠𝑒𝑠 ∗ 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑛𝑜. 𝑑𝑜𝑠𝑒𝑠 𝑓𝑜𝑟 𝑚𝑜𝑛𝑖𝑡𝑜𝑟𝑖𝑛𝑔 𝑝𝑒𝑟𝑖𝑜𝑑
 ) ×100 
* Adherent dose = >one recorded application during the expected dosing time # 
# Expected dosing time = calculated mean average dosing time for duration of study +/- 
2 hours (occuring between 17:00 and 04:59 hours) 
 
𝑀𝑃𝑅𝑎 =
𝑆𝑢𝑚 𝑜𝑓 days supply 𝑜𝑓 𝑎𝑙𝑙 𝑔𝑙𝑎𝑢𝑐𝑜𝑚𝑎 𝑚𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑑𝑢𝑟𝑖𝑛𝑔 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑖𝑜𝑑#
𝑆𝑢𝑚 𝑜𝑓 days of medication required 𝑑𝑢𝑟𝑖𝑛𝑔 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 ∗
 
# Mean no. of days/2.5 ml size bottle (ou dosing)= 51.5 (Fiscilla et al. 2003)  
*Observation period: days from index prescription until end of study, or change of 
treatment 
𝑀𝑃𝑅𝑏 =
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑠𝑢𝑚 𝑜𝑓 𝑑𝑎𝑦𝑠 +/−𝑎 28 𝑑𝑎𝑦 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑟𝑒𝑓𝑖𝑙𝑙 𝑝𝑒𝑟𝑖𝑜𝑑
𝑆𝑢𝑚 𝑜𝑓 days of medication required 𝑑𝑢𝑟𝑖𝑛𝑔 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 ∗
 
*Observation period: days from index prescription until end of study (change of 
treatment inclusive) 
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scores ranged from 0-4.  Participants who scored 0/1 were dichotomised to 
the adherent group, participants scoring 2-4 were dichotomised to the non-
adherent group.  Participants reporting missing their medication more than 
once a month on the FMD scale were dichotomised as non-adherent.   
 Self- reported reasons given for non-adherence using a 7-item list were 
quantified for each participant. 
 SIMS scores ranged from 0 to 17, 0 indicating dissatisfication and 17, 
complete satisfaction.  An overall median SIMS score was calculated for 
each participant and a median score for the two separate domains ‘action 
and usage of travoprost’ and ‘potential problems of travoprost’.   
 Demographic variables were quantified either by classification codes or 
scoring scales for number of prescribed medications (which included 
anything listed in the hospital records), IMD, and the Charlson score.  
 TDA data were used to produce a chronology plot to diplay the days (24-
hours) between each dosing event.   
 Intervention satisfaction scores were reported for using the Likert scale 
(strongly agree, agree, neutral, disagree, strongly disagree) to rate their 
satisfaction with the information provided by the GSAs.   
 
3.3.7 Statistical analysis 
Initially, descriptive statistics were used to characterise the demographics of the 
study population.  All analysis used the Statistical Package for Social Sciences 
(SPSS) version 21.   
Histograms were visually checked to review the distribution of the data before 
deciding on the appropriate statistical analysis method and all analyses were 
based on an intention-to-treat principle. 
 
3.3.7.1 Primary objective 
The mean adherence measured by the TDA were calculated for the control and 
intervention groups.  The sample characteristics of the data were reviewed to 
understand the spread, but with an expected sample greater than 50 participants 
in each group parametric tests still perform well with non-normal data, but medians 
were calculated to better define the measure of central tendency if required.  
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Missing data were imputed using a multivariate normal imputation model after 
suitable transformations, to ensure that the variables were normally distributed.  A 
total of 10 imputed datasets were created, each analysed separately and the 
results averaged using Rubin’s equations.  A sensitivity analysis was carried out to 
assess the effects of missing data.  A comparison of the observed and imputed 
primary outcome data were compared using t-tests and Chi-squared for 
dichotomised data.  If significant differences were present then imputed data 
would be used for the remainder of the planned analysis.  
The primary analysis compared the mean adherence for the total 8-month period 
for the control group with the intervention group using a t-test.  The t-test was 
repeated using the combined month 7 and 8 post-randomisation percentage 
adherence.  The proportion of individuals with ≥80% were compared between 
groups using the Chi-squared test.   
A repeated measures analysis-of-variance was carried out (with time measured in 
months) to assess for any difference between intervention and control groups over 
time.  
Because the TDA adherence data were analysed using three different methods a 
comparison of these measures was undertaken to assess any significant 
differences between them using t-tests for mean adherence and a Chi-squared 
test for dichotomised adherence data. 
 
3.3.7.2 Secondary objectives   
Intraocular pressure:  Mean IOP measure was reported for each time point, 
difference in IOP and percentage difference in IOP for the control and intervention 
groups.  The difference between the control and intervention groups was 
compared using t-tests as the sample was greater than 50 in each group. 
Mean percentage adherence measured by the TDA at month 2 and was correlated 
with absolute IOP reduction and percentage reduction between Baseline and Visit 
2 for the control and intervention groups using a Spearman’s rho to establish if 
there were any initial positive correlations in IOP control and use of medication.  
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The month 7 and 8 combined mean percentage adherence measured by the TDA 
and was correlated with absolute IOP reduction and percentage reduction 
between Baseline and the Final Visit for the control and intervention groups using 
a Spearman’s rho to establish if there were any positive correlations in IOP control 
and use of medication for the duration of the observation period.  Spearman’s rho 
was chosen as the most appropriate test to use with a non-linear relationship and 
non-parametric data.   
Medication possession ratio: The mean MPR was reported for the control and 
intervention groups using two measures, 28-day MPR and bottle contents MPR as 
previously described.  The MPR was compared between the control and 
intervention group using a t-test as there were more than 50 in the sample.   
The measure of variability was reported for both the control and intervention 
groups using the median and interquartile range (IQR).  The sum of the MPR for 
the control and intervention group were also calculated to compare differences in 
overall medication possession between the two groups.  
The month 7 and 8 combined mean percentage adherence measured by the TDA 
was correlated with the MPR for the total period of the study for both the control 
and intervention groups using a Spearman’s rho to establish if there was a positive 
correlation between MPR and TDA measured adherence.  Spearman’s rho was 
chosen as the most appropriate test to use with a non-linear relationship and non-
parametric data.   
Satisfaction with Information about travoprost: The mean SIMS scores were 
reported for control and intervention groups and differences between the two 
groups compared using a Mann-Whitney U test to establish any differences 
between the two groups.  A Mann-Whitney U test was chosen as the data were 
non-parametric, with ordinal data for the dependent variable and an independent 
variable was two independent groups using categorical data. 
The month 7 and 8 combined mean percentage adherence measured by the TDA 
and was correlated with the mean SIMS scores for both the control and 
intervention groups using a Spearman’s rho to establish if there was a positive 
correlation between SIMS and adherence.  The correlation was carried out with 
data from each time point to establish if there were any differences during the 
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course of the study.  Spearman’s rho was chosen as the most appropriate to test 
to use with a non-linear relationship and non-parametric data.   
The specific items that constitute SIMS were reported for both the control and 
intervention groups and mean scores for items that comprised ‘action and usage’ 
and ‘potential problems of travoprost’ to establish differences in satisfaction with 
medication information between the two groups.   
Self-reported adherence: MMAS and FMD scores were used to report the 
percentage of participants that were adherent in the control and intervention 
groups.  The differences between the control and intervention groups were 
compared using a t-test as there were more than 50 in each sample group.    
Agreement between dichotomised mean percentage adherence measured by the 
TDA and MMAS and FMD for both the control and intervention using a Cohen’s 
Kappa test at Visit 2 and Final Visit was used to establish if there was a positive 
association between self-reported and TDA measured adherence.  A Cohen’s 
Kappa test was used because the variables were binary measuring the same 
dependent variable (adherence).   
Reasons for non-adherence:  Percentage of participants reporting their reasons 
for non-adherence using the MMAS four-item scale component and the 7-item list 
were reported and compared between the control and intervention groups using t-
tests. 
Graphical representation of adherence behaviour: The graphical 
representations of adherence chronological plots were used to visualise and 
classify patterns of adherence behaviour.  The methodology and categories 
described by Ajit et al. in a 3 month study61 were used to classify 4 patterns of 
adherence; (i) adherence greater than 80%, (ii) discontinuation of dosing after a 
short time interval, (iii) frequent drug holidays, and (iv) variable with frequent 
missed doses.  The longevity of monitoring for NAGS compared with the Ajit et al. 
study required additional categories at the point of analysis.   
The mean adherence measured by the TDA were reported for each classified 
group and compared between control and intervention groups using t-tests to 
establish any differences between the two groups. 
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Adherence predictors:  A stepwise regression model was used to identify 
possible predictors for adherence to travoprost.  For categorical variables logistic 
regression was used and simple linear regression for scale variables to predict the 
probability.  An unadjusted multivariate model was constructed to identify 
independent predictors of adherence.  Variables that were identified to be more 
statistically significant in the model were selected and entered into the adjusted 
model to establish statistical significance. 
Information provision:  Percentage of participants reporting satisfaction with 
information received about glaucoma, effects on vision and driving at Baseline, 
Visit 2 and the Final Visit.  T-tests were used to compare responses between the 
control and intervention groups at each time point.  
Specific unanswered questions reported by participants were classified and 
quantified. 
Sources of additional information sought independently by participants were 
classified and quantified. 
Problems with eye drops:  reported problems were classified and quantified.  
Intervention evaluation:  Number and type of telephone calls made to the GSA 
service were categorised and quantified.  
Percentage of participants reporting satisfaction with the GSA service were 
reported and additionally comments were described. Satisfaction with the GSA 
service was correlated to adherence using a Spearman’s rho test.   
Comparison of Glaucoma Support Assistant effects:  The mean time that each 
GSA spent with each participant and percentage of adherent participants per GSA 
was reported to establish if there was ‘therapist effect’ in which GSAs were more 
effective in delivering the intervention than others.  Time spent with participants 
compared with TDA measured adherence was analysed using a Spearman’s rho 
to establish if length of therapy caused the intervention to be more effective.  
Individuals who declined participation:  The demographics (age, gender and 
IMD score) of the group who had declined participation were compared to the 
study sample using the Mann Whitney-U for age and IMD, and a Chi-square test 
for gender.   
 
74 
3.4 Results  
3.4.1 Recruitment 
Eligible participants were recruited from mid-November 2009 to mid-December 
2010 (13 months).  Research specific procedures were incorporated into 
participant out-patient appointments, which were commonly standardised on 
initiation of treatment as part of standard care at three time points; appointment 
when treatment initiated (Baseline), 2 months post initiation of treatment (Visit 2), 
and 8 months post initiation of treatment (Final Visit).  The intervention was given 
at the baseline visit following consent and randomisation and collection of baseline 
demographics.  Follow-up data were collected at Visit 2 and Final Visit.   
 
3.4.2 Participants and data collection 
The Consort diagram in Figure 3.5 provides details of the exclusion rate, number 
of patients declining participation, participant treatment allocation and data attrition 
rate.  Whilst a significant amount of TDA data was not collected, an intention to 
treat analysis avoided any potential bias associated with non-random loss of 
participants.  
 
3.4.3 Protocol deviations  
Study follow-up visits were dependent upon patient follow-up appointments 
generated by the NNUH Glaucoma Outpatient Clinic service.  At the time of the 
study standard care appointments would be scheduled for 2 and 8 months post 
commencement of treatment.  In practice, the 2 month and 8 months follow-up 
visits scheduled were not always adhered to, either because there was lack of 
available appointments because of pressures on the Hospital Eye Service or, 
patients did not attend appointments, beyond the control of the Glaucoma 
Outpatient Clinic service.  Protocol deviations arose where participants did not 
attend a follow-up appointment within the target window as shown in Table 3.2. 
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Figure 3.5 The Consolidated Standards of Reporting Trials diagram  
 
When participant out-patient appointments occurred outside of the specified time 
window, the corresponding data collected from the questionnaires and TDA were 
at different time points compared to the rest of the cohort.  Where the deviations 
did occur they were well balanced between the intervention and control group.  
The deviations were felt to have a negligible effect on the data collected from 
questionnaires.  However, when calculating the percentage adherence rate for the 
final two months (months seven and eight) TDA data collected after day 252 after 
Not eligible for inclusion 
n = 13,966 (97%) 
 
Screened to categorise non-eligibility 
n = 6717 (48%) 
1.  Already on treatment  
n = 3496 (52%) 
2. No treatment required n = 2914 
(43%) 
a. OH/GS not requiring treatment  
 n= 1673 (25%) 
b. Non-glaucoma case 
  n = 666 (10%) 
c. Previous use of eye drops but 
currently off treatment 
  n = 435 (7%) 
d.  On waiting list for cataract 
surgery n = 140 (2%) 
3.  Other n = 307 (5%) 
Eligible for inclusion 
n = 379 (3%) 
 
Not approached n = 123 (33%) 
Declined n = 48 (13%) 
 
Demographics of those who 
declined n = 46 
 
Randomised 
n = 208 (55%) 
 
Intervention Group  
n = 102 (49%) 
102 received allocated treatment 
 
Control Group  
n = 106 (51%) 
106 received allocated treatment 
 
Assessed for Eligibility 
n = 14,345 
 
Completed n = 92 
Withdrawn n = 2 
Deceased n = 0 
Treatment changed n = 8 
No further contact n = 0 
 
Completed n = 96  
Withdrawn n = 2  
Deceased n = 1  
Treatment changed n = 6  
No further contact n = 1  
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baseline was ignored, thus ensuring that the final two months adherence score 
was always calculated from data collected between months seven - nine.  Data 
from participants that stopped using the TDA before months seven and eight were 
annotated as ‘missing data’.  There were no protocol deviations that led to loses of 
recruitment or failure to deliver the intervention.  
 
Table 3.2 Protocol deviations 
 
Control 
(range in deviation of days) 
Intervention 
(range in deviation of days) 
Visit 2 target window  
(56 days +/- 42 days) 
n=4 
(+10 to +43) 
n=1 
(+18) 
Final Visit target window 
(224 days +/- 42 days) 
n=3 
(+3 to +9) 
n=3 
(-62 to +43) 
 
 
3.4.4 Missing data 
The reasons for incomplete adherence data are summarised in Table 3.3.  
Questionnaire data provided the most complete datasets over the 8-month period 
relative to data collected from health centres and the TDA.  The reason for the 
failure of the TDA was not always possible to establish.  In some cases the 
internal mechanics of the device appeared to have been tampered with by the 
participant but it was not possible to determine in which cases the device had 
failed due to deliberate tampering or genuine device malfunction.  MPR data were 
missing where health centres refused to provide the prescribing data when 
requested.  
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Table 3.3 Reason for missing data compared between measures  
 
Reason for  
missing data 
Number of participants with missing data 
*MMAS 
Questionnaire  
#FMD  
Questionnaire  
Prescribing  
record 
~TDA 
2     
months 
8  
months 
2    
months 
8  
months 
Total   
period 
2  
months 
8 
months 
Questionnaire or ~TDA 
not returned / used / 
fully completed by 
patient 
17 13 11 8 - 8 12 
Data not provided by 
health centre 
- - - - 49 - - 
Device / battery failure - - - - - 12 32 
Participant withdrawn 
or stopped or changed 
treatment 
1 18 1 18 24 19 48 
Lost to follow-up / 
Deceased 
2 2 2 2 2 2 2 
Total Missing 
20  
(10%) 
33 
(16%) 
14 
(7%) 
28 
(13%) 
75 
(36%) 
41 
(20%) 
94 
(45%) 
*MMAS (Morisky Medication Adherence Score) 
#FMD (Frequency Missed Dose) 
~TDA (Travalert Dosing Aid) 
 
The TDA data was used as the primary outcome measure, thus the data collected 
using this method was further categorised to ensure that the control and 
intervention groups were evenly matched as shown in Figure 3.6.  Missing data 
was evenly matched in both groups, but a greater number of participants stopped 
using travoprost (due to either side effects and/or lack of efficacy) in the 
intervention group than in the control group.  Consequently, the intervention group 
had less complete data than the control group. 
 
 
 
 
78 
 
Figure 3.6  Comparison of missing TDA data for the control and 
intervention groups 
 
3.4.5 Individuals who declined participation 
A total of 46 patients declined to participate in the study.  When age, gender, and 
IMD demographics were compared between those who agreed to participate and 
those who declined, the samples had no statistically significant differences; age 
(Mann Whitney U, p=0.257), gender (Chi-square p=0.253) and IMD (Mann 
Whitney U, p= 0.379).  
 
3.4.6 Baseline data 
The demographic characteristics of the sample population are summarised in 
Table 3.4 and were evenly balanced between groups.  The participants were 
predominantly of white British ethnicity and, at the time of recruitment, largely had 
no family history of glaucoma and had been diagnosed with POAG as opposed to 
having OH or being a glaucoma suspect.  The cohort was evenly matched as to 
whether they were new patients or had been seen previously in the glaucoma 
clinic.    
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Table 3.4 Population characteristics 
       Control Intervention 
 N % N % 
Gender 
Male 58 54.7 47 46.1 
Female 48 45.3 55 53.9 
Ethnicity 
White 104 98.1 102 100 
Other 2 1.9 0 0 
Housing Tenure 
Home owner 92 86.8 82 80.4 
Renter (council) 6 5.7 11 10.8 
Renter (private) 5 4.7 4 3.9 
Other 3 2.8 5 4.9 
Marital Status 
Married/partner 75 70.8 73 71.6 
Divorced/separated 5 4.7 7 6.9 
Widowed 19 17.9 17 16.7 
Single 7 6.6 5 4.9 
Highest Qualification 
GCSE 44 41.5 45 44.1 
A-levels 4 3.8 5 4.9 
Degree 11 10.4 8 7.8 
Post-graduate 8 7.5 2 2 
Other 37 34.9 42 41.2 
Parents with glaucoma 
No 79 74.5 70 68.6 
Yes 22 20.08 24 23.5 
Not known/no contact 5 4.7 8 7.8 
Siblings with glaucoma 
No 93 87.7 85 83.3 
Yes 8 7.5 9 8.8 
Not known/no contact 5 4.7 8 7.8 
Children with glaucoma 
No 102 96.2 95 93.1 
Yes 2 1.9 0 0 
Not known/no contact 2 1.9 7 6.9 
Diagnosis and new/follow-up care 
POAG/NTG new patient 33 31.1 32 31.4 
POAG/NTG follow-up 
patient 
40 37.7 37 36.3 
GS/OH new patient 16 15.1 15 14.7 
GS/OH follow-up patient 17 16.0 18 17.6 
 
Mean SD Mean SD 
Age 70.06 10.9 70.7 11.3 
Intraocular pressure 23.4 10.9 22.2 5.4 
Charlson Score 1.6 2.2 1.4 2.1 
Number of medications 2.8 2.9 2.6 2.9 
IMD 12.7 7.7 15.4 11.2 
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3.4.7 Primary outcome 
The distribution of adherence measured by the TDA for 167 participants with 
complete TDA data had a positive skew in both the control and intervention group 
indicating that the majority of participants had a high percentage adherence rate 
regardless of randomisation.  The mean adherence over the total 8-month 
monitoring period was 77.2% in the control group, but the difference (2.4%; 95% 
CI, -4.2, 9.0) between the two groups was small and not statistically significant 
(p=0.471).  Median adherence for the total period was 80.61% (IQ=63.9, 93.3, 
n=84) for the control group and 80.9% (IQ= 65.3, 93.1, n=83) for the intervention 
group.   
There was also no difference in the mean adherence for the final 2 months of 
monitoring; 79.3% in the control group, the difference (1.6%; 95% CI, -6.8, 10.0) 
between the two groups being minimal (p=0.703).  There was no statistically 
significant difference in the proportion of individuals with ≥80% adherence 
(p=0.631) between the two groups: control group 62.5% and intervention group 
66.7%.  
A repeated measures analysis of percentage adherence rate for each month found 
no difference in adherence between the two groups (p=0.685) or any interaction 
between month and group (p=0.894), the details of which are provided in Figure 
3.7. 
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Figure 3.7 Monthly mean percentage adherence with confidence intervals 
for control and intervention groups 
 
3.4.8 Comparison of primary outcome measures of adherence  
Adherence levels measured by the TDA and calculated using three different 
methods are presented in Table 3.5 using both observed and imputed data.  The 
mean adherence rates calculated for the total period and the final 2 months of 
monitoring were high in both groups and thus the proportion of individuals with 
≥80% adherence was also high in both groups.  There were no statistically 
significant differences in adherence levels measured between the two groups. 
There was no large differences between the results using observed and imputed 
data sets, thus all further analyses were based upon observed data only.  
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 Table 3.5   Comparison of the primary outcome measures of adherence calculated with observed and imputed data 
 Observed data Imputed data 
 
Control Intervention   Control Intervention   
Mean (SD) Mean (SD) P-value 
Mean 
difference 
(95% CI) 
Mean (SD) 
n = 106 
Mean (SD) 
n = 102 
P-value 
Mean 
difference 
Mean average over the 
monitoring period 
77.2 
(19.5) 
n=84 
74.8 
(23.5) 
n=83 
0.471 
2.4 
(-4.2, 9.0) 
77.0 
(19.3) 
75.4 
(22.2) 
0.617 
1.48 
 
Mean average for final 2 
months of monitoring 
79.3 
(21.7) 
n=64 
77.7 
(25.2) 
n=60 
0.703 
1.6 
 (-6.8, 10.0) 
78.0 
(22.2) 
76.9 
(22.8) 
0.997 
0.01 
 
Dichotomised final two 
months 
Proportion 
(%) 
Proportion 
(%) 
P-value % difference 
Proportion 
(%) 
Proportion 
(%) 
P-value % difference 
≥ 80% adherent 
40 
(62.5) 
40 
(66.7) 
0.628 -4.0 
(57.1) (60.8) 
0.654 -3.7  
< 80% adherent 
24  
(37.5) 
20 
(33.3) 
(42.9) (39.2) 
 
 83 
3.4.9 Secondary outcomes 
3.4.9.1 Association between IOP and adherence  
The difference in IOP control was compared between control and intervention 
groups at three time points; initiation of treatment (Baseline), 2 months (Visit 2) 
and 8 months (Final Visit) as presented in Table 3.6.  IOP reduction using two 
different methods of calculating IOP reduction (percentage difference in and 
absolute IOP reduction) and at two different time points is also displayed in Table 
3.6.  There was a small difference between groups but these were not statistically 
different. 
 
Table 3.6 Comparison of measures of intraocular pressure between 
control and intervention groups 
 
Control  
Mean IOP 
(SD) 
Intervention  
Mean IOP 
(SD) 
p-value CI 
Baseline  
23.68 
(5.82) n=105 
22.36 
(5.51)  n=102 
0.096 
1.31 
-0.23, 2.87 
Visit 2  
16.22 
(3.98)  n=105 
15.87 
(3.87)  n=102 
0.520 
0.35 
-0.73, 1.43 
Final Visit 
16.43 
(4.25)  n=84 
16.16 
(3.92)  n=83 
0.675 
0.27 
-0.98, 1.51 
Difference in % IOP 
reduction 
 Baseline – Visit 2 
30.40 
(20.26)  n=105 
26.69 
(18.19)  n=101 
0.168 
3.72 
-1.58, 9.01 
Difference in % IOP 
reduction  
Baseline – Final Visit 
27.58 
(19.18)  n=85 
25.30 
(19.71)  n=83 
0.448 
2.28 
-3.64, 8.21 
Difference in IOP  
Baseline – Visit 2 
7.64 
(5.17) n=104 
6.48 
(5.33) n=101 
0.098 
1.16 
-0.22, 2.53 
Difference in IOP  
Baseline - Final Visit 
7.00 
(5.19)  n=85 
6.28 
(5.33)  n=83 
0.398 
0.69 
-0.91, 2.29 
 
The IOP reduction between Baseline to Visit 2 and Baseline to Final Visit was 
correlated with adherence measured by the TDA, the results for the intervention 
and control groups are displayed in Table 3.7.  Only the IOP reduction at the Final 
Visit in the intervention group showed a small weak positive correlation but this 
was not statistically significant.   
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Table 3.7 Correlation of IOP reduction 
 Control group Intervention group 
 Spearman’s r p-value Spearman’s r p-value 
Correlation with mean % adherence for month 2 
 n=83 n =85 
Difference in IOP  
Baseline – Visit 2 
0.031 0.782 0.004 0.969 
IOP % reduction  
Baseline – Visit 2 
0.030 0.785 0.006 0.958 
(Correlation with mean % adherence for month 7 and 8 ) 
 n=60 n=55 
Difference in IOP  
Baseline - Final Visit 
0.059 0.657 0.237 0.082 
IOP % reduction  
Baseline – Final Visit 
0.048 0.717 0.225 0.099 
† Correlation of two different measures of IOP reduction (absolute and % reduction) 
compared with mean % adherence measured by the TDA.  The data is shown for control 
and intervention groups and for two time points; baseline to month 2, and baseline to 
final two months.  
 
An unplanned analysis was undertaken to establish if IOP could be used as a 
surrogate marker of adherence, the relationship was examined further.  Rather 
than using the average IOP measure of both eyes, the right and left eye data were 
examined separately.  Since the variance between eyes is usually less than 
between groups because of their combined mutual correlation (since they are not 
independent samples), data collected from both eyes could underestimate any 
true variance.186, 187  Figure 3.8 shows the plots for the control and intervention 
groups and the weak positive correlation with small statistical significance with 
right eye data in the intervention group.  
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Control group 
Spearman’s:  Right eye:  r =0.103; p=0.450 (n=56) 
 Left eye  r = -0.014; p=0.923 (n=53) 
 
 
 
Intervention group 
Spearman’s: Right eye:  r=0.258; p=0.067 (n=51) 
 Left eye:  r=0.200; p=0.146 (n=54) 
 
 
Figure 3.8 Relationship between adherence measured by the TDA and 
percentage IOP change between Baseline and Final Visit 
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3.4.9.2 Medication possession ratio 
The mean possession ratio was 1.95 (SD 0.69) for the control group and 1.88 (SD 
0.83) for the intervention group, but this was not statistically different between the 
two groups (p=0.590, mean difference 0.07, CI -0.19 – 0.33). 
The MPR calculation is based upon contents of the bottle, whereas the ‘28 day 
MPR’ is based upon a 28-day prescription re-fill recommendation.  Using a 28 day 
MPR, for both control and intervention groups most participants fall within an MPR 
of 0.00 – 5.00 (21 participants in both groups) as demonstrated in Figure 3.9 which 
suggests that most participants have the correct prescription ratio based upon a 
prescription refill every 28 days.  Comparison of the medians as displayed in Table 
3.8 revealed that the control group had a lower median and interquartile range 
than the intervention group and the sum of the intervention group (116.59) was 
greater than the control group (96.18).  Therefore, the intervention group had more 
medication than required for a 28 day prescription refill, and the control group were 
more likely to run out of medication during the observation period, although this 
difference was not statistically significant when compared between groups 
(p=0.798, mean difference -0.41, CI -3.57 – 2.75). 
 
Table 3.8  Median and interquartile ranges of 28-day refill prescriptions 
 
 
 
 
 
Quartiles 
Control group 
Median 
Intervention group 
Median 
25 -4.73 -3.67 
50 0.75 1.00 
75 5.44 6.00 
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Figure 3.9 Medication possession ratio from retrospective pharmacy 
prescription 28-day re-fill data comparing intervention and control groups 
 
There was no significant correlation between either MPR or 28-day refill MPR with 
adherence as presented in Table 3.9. 
 
Table 3.9 Correlation of month 7 and 8 percentage adherence with 
medication prescription ratios 
 
Control group 
Spearman’s co-efficient 
Intervention group 
Spearman’s co-efficient 
MPR 0.209 (p=0.133) -0.076 (p=0.619) 
28-day refill MPR 0.149 (p=0.283) 0.086 (p=0.571) 
 
 
3.4.9.3  Satisfaction with information about travoprost 
The initial satisfaction with information about travoprost questionnaire was fully 
completed by 182 participants; 94 controls and 88 from the intervention group.  
The median SIMS score for the control and intervention groups at each visit are 
0
5
10
15
20
25
-25 -20 -15 -10 -5 0 5 10 15 20 25 30 35
Fr
eq
u
en
cy
28 day MPR
Intervention
Control
 88 
shown in Table 3.10.  Satisfaction with information about travoprost was higher in 
the intervention group (p<0.001) at all three time points.  Satisfaction with 
information increased over time in the control group.  There was no statistically 
significant positive correlation between satisfaction with information and increased 
adherence to medication at any time point as indicated in Table 3.11. 
 
Table 3.10 Comparison of SIMS scores between intervention and control 
groups at Baseline, Visit 2 and Final Visits 
 
Control Intervention 
Mann-Whitney U 
(Mean Rank) Median (IQ) Median (IQ) 
Baseline 7.5 
(5.0, 11.0) n=94 
15.0 
(13.0, 17.0) n=88 
Z=-8.791 
p<0.001 
(58.46 – 126.79) 
Visit 2 10.0 
(8.0, 14.0) n=92 
15.0 
(13.0, 17.0) n=76 
Z=-5.604 
p<0.001 
(65.55 – 107.43) 
Final Visit 11.0 
(8.0, 14.0) n=85 
16.0 
(11.8, 17.0) n=74 
Z=-4.529 
p<0.001 
(64.81 – 97.45) 
 
 
Table 3.11 Correlation of SIMS scores and month 7 and 8 percentage 
adherence 
 Control Intervention 
Spearman’s 
coefficient 
P-value 
Spearman’s 
coefficient 
P-value 
Baseline -0.083 
(n=57) 
0.539 
0.186 
(n=52) 
0.186 
Visit 2 -0.287 
(n=57) 
0.030 
0.126 
(n=44) 
0.415 
Final Visit -0.257 
(n=58) 
0.052 
0.136 
(n=49) 
0.350 
 
 
3.4.9.3.1  Satisfaction with information about travopost profile 
Figures 3.10 – 3.12 provide a comparative illustration of the specific items of SIMS 
information that intervention and control participants felt they lacked at three 
different time points; Figure 3.10 displays Baseline, Figure 3.11 displays Visit 2 
and Figure 3.12 displays Final Visit.  
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Following the Baseline visit, participants in the intervention group were more 
satisfied with all information items than the control group participants, apart from 
‘how to apply eye drops?’ (97.0%) where the control group satisfaction was 
marginally higher (98.1%).  ‘How to get a further supply of eye drops?’ was also 
the item reported by both groups to have the highest satisfaction with information.  
The lowest satisfaction scores in the control group were reported for ‘if alcohol can 
be consumed whilst using eye drops?’ (12.6%) and in the intervention group ‘how 
you can tell if eye drops are working?’ (59.8%). 
At Visit 2, the control group had a greater satisfaction with ‘if alcohol can be 
consumed whilst using eye drops?’ (41.6%) than at Visit 1, and were least 
satisfied with ‘how you can tell if eye drops are working’ (30.7%) which was also 
the lowest item in the intervention group (56.5%).  The control group were most 
satisfied with ‘how to apply eye drops?’ (99.0%) and ‘how to get a further supply of 
eye drops?’ (99.0%), both higher than the intervention group (97.8% and 98.9% 
respectively).   
At the Final Visit, the control and intervention group were still least satisfied with 
‘how you can tell if eye drops are working?’ (36.3% and 62.4% respectively) which 
remained low at every time point.  The greatest satisfaction for both control and 
intervention groups still remained ‘how to apply eye drops?’ (98.1% and 97.0% 
respectively).   
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Where difference in means were statistically significant: * >0.01 **>0.001 
 
Figure 3.10  Comparison of control and intervention groups SIMS results 
following Basleine visit  
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Where difference in means were statistically significant: * >0.01 **>0.001 
 
Figure 3.11 Comparison of the control and intervention groups SIMS results 
following Visit 2 
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Figure 3.12  Comparison of the control and intervention groups SIMS results 
following the Final Visit 
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3.4.9.3.2  Action/usage and potential problems with travoprost 
Participant responses to the SIMS questionnaire were also categorised into items 
related to ‘action and usage of travoprost’ (items 1-9) or ‘potential problems with 
travoprost’ (items 10-17).174  Table 3.12 provides the comparative data between 
the control and intervention groups.  The control group felt that they had 
significantly more information about the action and usage of travoprost than the 
potential problems of travoprost at all three time points.  The intervention group 
remained completely constant with their satisfaction of action and usage of 
travoprost over the three time points, but become slightly less satisfied with the 
information about the potential problems.   
 
Table 3.12 Mean percentage of participants satisfied with information 
about travoprost for control and intervention groups  
 
Control 
Mean %  
Intervention 
Mean % 
Items 1-9* Items 10-17# Items 1-9* Items 10-17# 
Baseline 65 33 86 80 
Visit 2 70 52 86 78 
Final Visit 75 50 86 75 
*Action and usage of travoprost 
(items 1-9) 
#Potentional problems of travoprost 
(items 10-17) 
1. What eye drops are called 10. Whether the eye drops have 
unwanted side effects  
2. What eye drops are for  11. What are the risks of side effects  
3. What eye drops do  12. What to do if unwanted side effects 
are experienced  
4. How eye drops work  13. If alcohol can be consumed whilst 
using eye drops  
5. How long eye drops take to work  14. Will the eye drops interfere with 
other medicines  
6. How you can tell if eye drops are 
working  
15. Will the eye drops make you feel 
drowsy  
7. How long to use eye drops for  16. Will eye drops affect sex life  
8. How to apply eye drops 17. What to do if a dose is forgotten  
9. How to get a further supply of eye 
drops 
 
 
 94 
3.4.9.4 Self-reported adherence  
Patient self-report of adherence was measured using two different methodologies; 
MMAS and FMD which are presented in Table 3.13 together with a comparison of 
the results between the control and intervention groups.  There was no significant 
difference in self-reported adherence between groups at either Visit 2 or the Final 
Visit using MMAS.  However, the FMD measure did reveal that the intervention 
group had a statistically significant greater report of adherence than the control 
group at Visit 2 but this was not repeated at any other time point.  
 
Table 3.13  Comparison of self-reported adherence using two different 
measures 
  
Control 
% Adherent 
Intervention 
% Adherent 
P-value 
Mean Diff 
(95% CI) 
MMAS Visit 2 
 
71.4 
(n=98) 
74.4 
(n=90) 
0.462 
0.059 
(-0.10, 0.22) 
MMAS Final Visit 
 
55.4 
(n=92) 
65.1 
(n=83) 
0.164 
0.125 
(-0.05, 0.30) 
FMD Visit 2 
 
61.8 
(n=102) 
74.2 
(n=93) 
0.010* 
0.30 
(0.07, 0.54) 
FMD Final Visit 
 
54.8 
(n=93) 
59.8 
(n=87) 
0.318 
0.14 
(-0.13, 0.40) 
*Statistically significant 
 
3.4.9.4.1  Agreement between TDA and self-report 
Table 3.14 shows a cross tabulation of both self-report methodologies (FMD and 
MMAS) compared to the TDA adherence score at two different time points (Visit 2 
and Final Visit) for both control and intervention groups.  A Cohen’s Kappa test 
was used to measure the agreement between self-report measures and TDA 
adherence scores.  There was no agreement between adherence measured by 
the TDA and self-report methods which was statistically significant for the FMD 
measure and the MMAS only in the control group for the Final Visit.   
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Table 3.14   Comparison between TDA identified non-adherence to self-report measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Statistically significant 
Self-report measure 
Control group Intervention group 
TDA 
 
TDA 
Adherent 
(n) 
Non-adherent 
(n) 
Agreement 
(Kappa) 
Adherent 
(n) 
Non-adherent 
(n) 
Agreement 
(Kappa) 
MMAS  
Visit 2 
n=61 
Adherent 14 8 
-0.129 
p=0.177 
11 8 
-0.161 
p=0.108 
Non-adherent 31 8 
29 8 
MMAS  
Final 
Visit 
n=62 
Adherent 8 15 
-0.290 
p=0.015* 
11 8 
-0.090 
p=0.433 
Non-adherent 26 13 
24 11 
FMD 
Visit 2 
n=62 
Adherent 11 13 
-0.314 
p=0.003* 
8 11 
-0.313 
p=0.003* 
Non-adherent 31 7 
31 7 
FMD 
Final 
Visit 
n=63 
Adherent 8 16 
-0.330 
p=0.005* 
7 11 
-0.242 
p=0.036* 
Non-Adherent 27 12 
26 12 
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3.4.9.4.2  Morisky Measure Adherence Score 
There are four component questions of MMAS which can be used to assess the 
reason for non-adherence within the groups as presented in Table 3.15 which 
compares the component questions used to classify non-adherence for each 
group at Visit 2 and the Final Visit.  The biggest reported reason for non-
adherence is forgetting to use eye drops, with the other 3 categories having 
minimal impact on adherence.  There is no statistically significant difference in 
type of self-reported non-adherence between the control and intervention groups 
at either time point.   
 
Table 3.15 Comparison of MMAS component questions for control and 
intervention groups at Visit 2 and the Final Visit 
 Visit 2 Final Visit 
 
Control 
n (%) 
Interven
-tion 
n (%) 
p-
value 
Control 
n (%) 
Interven
-tion 
n (%) 
p-
value 
Are you casual at times 
about using your eye 
drops? 
 
5 (4.9) 4 (4.3) 0.830 8 (8.7) 6 (6.9) 0.656 
When your vision feels 
better do you sometimes 
stop using your eye 
drops? 
1 (1) 0 (0) 0.344 0 (0) 0 (0) - 
If your vision feels worse 
when you use the eye 
drops, do you 
sometimes stop using it? 
2 (2) 2 (2.2) 0.958 0 (0) 0 (0) 0.134 
Do you sometimes 
forget to use your eye 
drops? 
25 (24.3) 20 (21.1) 0.591 39 (41.1) 29 (32.2) 0.215 
 
 
3.4.9.4.3  Reasons for non-adherence 
Participants reporting non-adherence were asked to report reasons from a 7-item 
list as presented in Table 3.16.  The biggest reported reason for non-adherence 
was forgetting to use the eye drops, with the other 6 categories having minimal 
impact on reported non-adherence.  Between the control and intervention groups, 
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running out of drops at Visit 2 was the only statistically significant difference.  
Forgetting to use eye drops was reported more in both the control and intervention 
groups at the Final Visit compared to Visit 2.  
 
Table 3.16 Comparison of reasons for missing drops between control and 
intervention groups at Visit 2 and Final Visit 
 Visit 2 Final Visit 
 
Control 
n (%) 
Interven
-tion 
n (%) 
p-
value 
Control 
n (%) 
Interven
-tion 
n (%) 
p-value 
Forgot  23 (23.5) 22 (22.2) 0.836 37 (40.7) 32 (34.4) 0.384 
Ran out of drops 3 (3.1) 12 (12.1) 0.016 4 (4.4) 6 (6.5) 0.541 
Side effects of drops 4 (4.1) 3 (3.0) 0.692 2 (2.2) 4 (4.3) 0.425 
Difficult to use drops 2 (2.0) 1 (1.0) 0.557 1 (1.1) 0 0.313 
Change in routine  6 (5.7) 5 (5.0) 0.821 6 (5.7) 4 (4.0) 0.571 
Fell asleep  1 (0.9) 2 (2.0) 0.535 0 0 - 
Felt unwell 0 0 - 0 2 (2.0) 0.147 
 
 
3.4.9.5 Graphical representation  
Figure 3.13 displays the TDA recorded adherence behaviour patterns from the 
available data n = 154.  The four patterns of classification described by Ajit et al.95 
were modified to differentiate between two further behaviour patterns.  Not only 
could we depict participants with good adherence defined as >80% (Type 2b) but 
those with excellent adherence ≥97% (Type 2a).  Participants who took ‘drug 
holidays’ (missed doses for 7 or more consecutive days) also fell into two 
categories, those who primarily missed doses during a ‘drug holiday’ (Type 3b) 
and those whose behaviour was mixed between having ‘drug holidays’ and 
variable dosing in between these periods (Type 3a) as illustrated in Figure 3.13.  
Table 3.17 displays the comparison of these magnitude of these behaviour types 
between the control and intervention groups.  There was a small statistically 
significant difference between control and intervention groups in Type 3b which 
may suggest that non-adherence in the intervention group was primarily due to a 
mix of variable dosing combined with drug holidays.  
 98 
Table 3.17 Comparison of adherence behaviour types between control and 
intervention groups 
 Control Intervention  
Mean % 
adherence 
SD 
Mean % 
adherence 
SD 
t-test 
Mean (CI) 
p-value 
G
o
o
d
 a
d
h
e
re
n
c
e
  
<
 8
0
%
 
2a 
 
98.2 0.98 97.5 1.05 
0.67 
(-0.91, 2.25) 
0.328 
2b 
 
86.95 4.98 90.05 4.83 
-3.1 
(-7.03, 0.83) 
0.115 
P
o
o
r 
a
d
h
e
re
n
c
e
  
>
 8
0
%
 
3a 56.73 
10.0
6 
61.64 
14.2
4 
-4.9 
(-15.63, 5.81) 
0.331 
3b 63.67 
14.8
3 
37.50 
21.4
7 
26.17 
(-0.94, 53.27) 
0.056 
4 65.67 
15.2
8 
72.67 3.79 
-7.0 
(-43.08, 
29.08) 
0.492 
2a = Adherence ≥ 97% 
2b = Adherence ≥ 80% <96%. More variable than 2a with variable missed doses. 
3a = Adherence < 80% drug holidays (≥ 7 days without dosing) mixed with variable dosing 
3b = Adherence < 80% drug holidays (≥ 7 days without dosing) with <30 variable missed doses. 
4 = Adherence < 80% with variable and frequent missed doses 
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Dose number 
 
Dose number 
Type 2 
2a Adherence ≥ 97%  
Control=19%   
Intervention=12% 
 
No more than 27 days missed over 
the entire period.  Mean adherence for 
this example is 100%. 
 
2b Adherence ≥ 80% <96% 
Control=32%   
Intervention=45%  
 
More variable than 2a with frequent 
and variable missed doses.  Mean 
adherence for this example is 90%. 
 
Type 3 – Drug Holidays 
(≥ 7 days without dosing) 
 
3a Adherence < 80% drug holidays 
with variable dosing 
Control =18%   
Intervention=24% 
 
Mixed with variable and frequent 
missed doses.  Mean adherence for 
this example is 50%. 
 
*3b Adherence <80% 
Control=10%   
Intervention=14% 
 
With <30 variable missed doses. 
Mean adherence for example is 33%. 
*Note change in vertical axis  
 
Type 4  
 
Adherence < 80% with variable and 
frequent missed doses  
Control=21%   
Intervention=6% 
 
Mean adherence for this example is 
77%. 
 
Type 1 
 
Side effects  
Control = 6% 
Intervention = 10% 
 
 
*No response to treatment 
Control = 11%   
Intervention 6% 
 
*Note difference in horizontal axes 
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3.4.9.6  Predictors of adherence 
Demographic characteristics and other related behaviour characteristics listed in 
Table 3.4 were added to the probabilistic model to determine possible predictors of 
adherent behaviour.  As the measure of adherence was not statistically different 
between the control and intervention groups, the predictive model used the 
combined adherence data from both groups.  
Due to ethnicity of the group being predominantly a British population (1.9%), the 
effect of ethnicity on adherence was not included in the analysis.   
The results are summarised in Table 3.18 and show that marital status, using 
other medication at the same time as travoprost and IMD (index of multiple 
deprivation) may have predicted more adherent behaviour.  These three variables 
were selected and entered into the adjusted model.  Use of medication at the 
same time as travoprost was a predictor of adherence.  
 
3.4.10 Information provision 
Participants in both the control and intervention groups were asked to self-rate 
their satisfaction with the level of information they were given about glaucoma, 
effects on vision and driving.  The questionnaires that ascertained this information 
were given at three different time points during the study; after the Baseline Visit, 
after Visit 2 and after the Final Visit.  As is presented in Table 3.19, the 
intervention group were much more satisfied with the information they received 
and an independent samples t-test between the control and intervention group 
confirmed a statistically significant difference between the level of satisfaction 
between the two groups at all time points. 
After the initial visit 26 participants (24.5%) from the control group and 12 
participants (11.8%) from the intervention reported that they required more 
information.  At the Final Visit this had reduced to 12 participants (11.3%) from the 
control group and 4 participants (3.9%) from the intervention group, which was 
statistically significant; p=0.027 at the Baseline Visit and p=0.044 for the Final 
Visit.  The number of participants that required further information did decrease 
over time in both groups (p=0.002, t-test).  
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Table 3.18  Baseline predictors of adherence, based on more than 80% 
adherence for the whole cohort  
 Adherent Unadjusted Selected* 
Predictor Yes No (%) OR (95%,CI) p-value OR (95%,CI) p-value 
Gender 
Male 41 21 (33.9) 1.15 (0.55, 2.40) 0.707   
Female 39 23 (37.1) 1    
Home Owner 
Yes 67 35 (34.3) 1.33 (0.52, 3.40) 0.558   
No 13 9 (40.9) 1    
Marital Status 
Married/partner 51 33 (39.3) 1 
 
1  
Not married/partner, 
widowed or single 
29 11 (27.5) 1.71 (0.75, 3.88) 0.202 
2.03 (0.58, 
7.05) 
0.267 
Education 
Left school ≤ 16 30 17 (36.2) 1 
 
  
Further education > 16 49 27 (35.5) 1.03 (0.48, 2.20) 0.942   
Positive family history (Parent, sibling or child) 
No 58 32 (35.6) 1 0.978   
Yes 22 12 (35.3) 1.01 (0.44, 2.31)    
Diagnosis  
POAG 57 32 (36.0) 1 
 
  
NTG  23 12 (34.3) 1.08 (0.47, 2.45) 0.861   
First appointment or seen before 
New patient 38 21 (35.6) 1 
 
  
Follow-up patient 42 23 (35.4) 1.01 (0.48, 2.11) 0.981   
Application of drops (Visit 1) 
Self 64 39 (37.9) 1 
 
  
Help 13 5 (27.8) 1.58 (0.52, 4.79) 0.415   
Need more information 
Yes 16 6 (27.3) 1.65 (0.59, 4.62) 0.342   
No 55 34 (38.2) 1    
Other medication used at same time 
Yes 29 10 (25.6) 2.75 (1.05, 7.22) 0.040 
3.81 (1.34, 
10.87) 
0.012 
No 19 18 (48.6) 1  1  
Previous use of eye drops 
Never 52 28 (35.0) 1.14 (0.53, 2.48) 0.735   
Occasional / Frequent 26 16 (38.1) 1    
Mean Age (SD) 
71.47 
(11.7) 
68.82 
(10.48) 
1.02 (0.99, 1.06) 0.212   
Mean Charlson Score (SD) 
1.4 
(2.1) 
1.39 (1.85) 1.00 (0.84, 1.20) 0.971   
Mean Number of 
medications (SD) 
2.56 
(2.8) 
2.64 (2.60) 0.99 (0.86, 1.13) 0.884   
Mean Intraocular pressure 
(SD) 
22.94 
(5.71) 
22.58 (5.14) 1.01 (0.95, 1.08) 0.728   
Mean IMD (SD) 
14.39 
(10.0) 
11.68 (8.39) 1.04 (0.99, 1.08) 0.139 
1.06 (0.99, 
1.13) 
0.107 
Mean SIMS at visit 1 (SD) 
10.93 
(4.77) 
11.68 (4.46) 0.97 (0.89, 1.05) 0.410   
* Using forward selection
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Table 3.19 Satisfaction with information  
 
Glaucoma 
Effect on 
vision 
Effect on 
driving 
Visit 1 / Baseline    
Control n = 105 (%) 74 (70.5) 56 (53.3) 49 (46.2) 
Intervention n = 98 (%) 91(92.9) 82 (83.7) 82 (83.7) 
p-value <0.001 <0.001 <0.001 
Visit 2    
Control n = 102 (%) 72 (70.5) 58 (56.9) 53 (52.0) 
Intervention n = 94 (%) 88 (93.6) 76 (80.9) 72 (76.6) 
p-value <0.001 <0.001 <0.001 
Final Visit    
Control n = 92 (%) 73 (79.3) 64 (69.6) 48 (52.2) 
Intervention n = 88 (%) 82 (92.1) 73 (83.9) 74 (84.1) 
p-value 0.014 0.024 <0.001 
† Satisfaction with information received compared between 
control and intervention groups at three different time points.  
Information received was subdivided into three categories; 
glaucoma, effect on vision and effect on driving. 
  
 
Participants were asked to report unanswered questions they may have had after 
each visit.  The type of questions were analysed qualitatively and their frequency 
shown in Table 3.20.  The topics with greatest number of unanswered questions 
were information about glaucoma (13), effects on driving, swimming and informing 
the DVLA (12), how it will effect long term vision (7) and side effects of drops (13). 
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Table 3.20  Topic areas of unanswered questions following each visit for 
control and intervention groups 
 
Initial 
visit 
Second 
visit 
Final 
Visit 
Topic area of questions 
Control 4 2 5 
More information about glaucoma 
Intervention 1 1 0 
Control 6 3 2 Driving / swimming / watching TV / 
Informing DVLA  Intervention 0 1 0 
Control 3 0 0 
Administration of eye drops 
Intervention 2 0 0 
Control 1 1 1 
Risk to family 
Intervention 0 0 0 
Control 3 0 0 
Vitamins, diet and lifestyle 
Intervention 1 0 1 
Control 3 2 2 
How it will affect long term vision 
Intervention 0 0 1 
Control 5 1 0 Information about how eye drops work 
and if you can tell it is working Intervention 0 0 0 
Control 1 0 0 How will glaucoma in one eye effect the 
other eye Intervention 0 0 0 
Control 1 0 1 
How it will effect use of contact lenses 
Intervention 0 0 0 
Control 3 0 0 
Interaction with other medicines 
Intervention 0 0 0 
Control 2 3 2 
Side effects of drops 
Intervention 1 3 2 
Control 4 0 0 
Alcohol consumption 
Intervention 1 0 0 
Control 2 1 1 
How long to use drops for 
Intervention 0 1 0 
Control 0 1 1 Surgery for glaucoma or laser 
treatments available  Intervention 0 0 0 
Control 0 0 1 Specific information about individual 
prognosis and treatment Intervention 1 0 0 
Control 1 0 0 How to get a further supply of eye 
drops Intervention 0 0 0 
Control 39 14 16 
Total 
Intervention 7 6 4 
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3.4.11 Seeking additional advice and information  
Participants were asked to report if they had sought any additional advice or 
information about glaucoma from other independent sources, such as from leaflets 
or from the internet.  After the second visit, 40 (37.7%) participants in the control 
group reported seeking further information compared to 20 (19.6%) from the 
intervention group.  After the Final Visit, 37 (34.9%) of the control group sought 
further information compared to 22 (21.6%) from the intervention group.  The 
sources of further information are described in Table 3.21, the internet being the 
most popular.  
 
Table 3.21 Where additional information was sought reported following 
Visit 2 and Final Visit  
Visit 2 
Final 
Visit 
Where additional information 
has been sought 
39 35 Internet 
3 8 Leaflets from hospital  
0 3 Leaflets from GP surgery 
10 7 Other leaflets (unspecified) 
0 1 Pharmacy 
2 2 From medication leaflet  
5 5 Medical enclopedia 
1 1 Optician 
1 0 Other glaucoma suffrers 
2 0 GP/Practice nurse 
 
 
3.4.12 Problems with use of eye drops  
Participants were asked to report if they had experienced any problems with their 
eye drops.  After Visit 2, 30 (28.3%) participants in the control group reported 
experiencing a problem compared to 21 (20.6%) of the the intervention group.  
After the Final Visit, 25 (23.6%) had experienced a problem compared to 28 
(27.5%) in the intervention group.  Table 3.22 describes the type of problems 
experienced at each time point between the two groups. 
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Table 3.22 The type of problems experienced with eye drops, reported 
after the Visit 2 and Final Visit 
 Visit 2 
Final 
Visit 
Type of problem 
Control 15 10 
Adverse event relating to eye drop use 
Intervention 7 12 
Control 13 11 
Difficulty in applying eye drops 
Intervention 14 11 
Control 0 0 
Remembering to use eye drops 
Intervention 0 1 
Control 0 1 
Drops not available from pharmacy 
Intervention 0 0 
 
3.4.13 Evaluation of the intervention  
3.4.13.1 Telephone helpline 
There were 100 calls made to the telephone helpline from 64% of participants from 
the intervention group over the course of the study.  Eighteen participants made 
multiple calls (2-5 calls each).  Removing calls made for study related issues (only 
31%), calls were categorised into the following:  
 Enquiries for further information: 16% (n=11) 
 Participants suffering side effects: 81% (n=56) 
 Information about driving and the DVLA: 3% (n=2) 
 
 
3.4.13.2 The Behaviour Change Counselling intervention 
The majority of the intervention group participants found the Glaucoma Education 
and Support Service helpful and improved their understanding of glaucoma and 
use of eye drops as presented in Table 3.23. There was a positive correlation with 
satisfaction of information provided by the Glaucoma Support Assistants and 
adherence (0.243, p=0.022). 
Participants were invited to make any additional comments or suggestions about 
the service.  
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 Twelve comments described the Glaucoma Support Assistants who 
delivered the services.  Comments included that they were helpful, kind, 
friendly, considerate, supportive and gave outstanding care.  
 Twelve comments described the service; Time was given to listen to 
patients and allow them to talk, patients were made to feel welcome 
(important to one participant who did not like hospitals), felt as though they 
were an individual, beneficial to have a service that offers encouragement, 
an essential service. 
 Seven comments related to usefulness of the service; Participants learnt 
more than they would have done, the service could help others, gave 
participants confidence, participants felt included in the treatment decisions, 
the help was comforting, good to be given the opportunity to discuss eye 
drops specifically.  
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Table 3.23 Satisfaction and effects of the Behaviour Change Counselling 
intervention and telephone helpline 
 
Neutral Agree 
Strongly 
Agree 
Disagree 
Strongly 
Disagree 
Not 
used/not 
provided 
Participant satisfaction with the Glaucoma Education and Support Service 
Found information about 
glaucoma helpful.  N= 88 5 
(5.7) 
53 
(60.2) 
28 
(31.8) 
0 0 
2 
(2.3) 
Found information about how to 
apply eye drops helpful.  N= 89 2 
(2.2) 
55 
(61.8) 
30 
(33.7) 
2 
(2.2) 
0 0 
Found discussion about the 
best was to fit my eye drops use 
into my daily routine helpful.  
N=89 
7 
(7.9) 
51 
(57.3) 
30 
(33.7) 
0 0 
1 
(1.1) 
Found the telephone helpline 
helpful.  N=85 6 
(7.1) 
22 
(25.9) 
20 
(23.5) 
1 
(1.2) 
0 
36 
(42.4) 
Recommend the education and 
support service to other 
patients.  N=88 
5 
(5.7) 
45 
(51.1) 
38 
(43.2) 
0 0 0 
Effect of Glaucoma Education and Support Service 
Better understanding of 
glaucoma.  N=86 
11 
(12.8) 
47 
(54.7) 
28 
(32.6) 
0 0 0 
Better able to use my eye 
drops.  N=88 
11 
(12.5) 
51 
(58.0) 
26 
(29.5) 
0 0 0 
Confident about using eye 
drops regularly.  N=88 
11 
(12.5) 
46 
(52.3) 
29 
(33.0) 
2 
(2.0) 
0 0 
 
 
Other comments (28) were made regarding study related issues, such as 
questionnaires, and information about the DVLA.  The DVLA is not connected with 
the NHS health service and patients are asked to contact the DVLA directly for 
concerns about their driving licence.   
The intervention was presented at the initial visit but all participants were given the 
opportunity to ask for further information at their follow-up visit; 47% did not 
request any further information. 
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3.4.14 Comparison of Glaucoma Support Assistants 
Since the intervention was individualised to the patient, the intervention outcomes 
were examined between GSAs.  Table 3.24 presents the number of interventions 
delivered by each GSA and the time taken to deliver the intervention with each 
participant, the number of patients with complete TDA data collected, and the 
number and percentage of adherent cases.  There was no statistically significant 
association between GSA and adherent cases (Fishers Exact p= 0.860).  
Increased time spent with the Glaucoma Support Assistant (GSA) during the 
intervention did not correlate with improved adherence (Spearmans coefficient -
0.083, p=0.528).   
 
Table 3.24 Comparison of therapist effects 
GSA 
Number of BCC 
interventions 
delivered 
Mean time to 
deliver intervention 
(SD) 
No. of 
participants with 
completeTDA 
data (%) 
No. of participants 
with complete TDA 
data that were 
adherent (%) 
1 7 23.25 (13.61) 7 (100) 4 (57) 
2 30 32.93 (7.43) 19 (63) 12 (63) 
3 16 22.12 (10.13) 9 (56) 6 (67) 
4 15 30.47 (5.1) 8 (53) 7 (88) 
5 22 27.41 (6.6) 14 (64) 9 (64) 
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3.5 Discussion 
The intervention used in NAGS failed to achieve greater adherence to newly 
initiated topical glaucoma treatment.  Adherence in the control group was 
considerably higher than previously reported estimates used in general medicine 
which informed the power calculations.56  Thus, improving adherence, in an 
already adherent population, would have been difficult to achieve.   
Previous studies examining interventions to improve adherence to glaucoma 
medication have enrolled patients identified to be poorly adherent in an attempt to 
create the best conditions to measure greater effect sizes188 or have measured 
adherence pre- and post- intervention to make a comparison of individual 
differences.146  However, NAGS examined the potential of an intervention to 
improve adherence at the point of medication initiation in accordance with previous 
research findings.42  Furthermore, outside of the study environment, current 
clinical practice cannot accurately predict patients likely to have poor adherence118 
and measuring such behaviour would have taken several months to achieve such 
that it was neither appropriate nor feasible to target a poorly adherent cohort in the 
study.  Whilst it may be argued that improving adherence in those who are known 
to be non-adherent is more cost effective, the advantages of improving adherence 
in patients with glaucoma is substantial enough to suggest that all patients should 
be included in these intervention strategies. 
NAGS was designed to monitor participants for a longer period than other studies 
of its kind, in attempt to observe adherence over time.  If the length of monitoring 
period does have an effect on adherence behaviour, comparisons between studies 
of different durations should not be made.  Therefore, three outcome measures 
were appropriately reported, median percentage adherence for the study period, a 
monthly mean percentage score, and mean percentage of the final 2 months of 
monitoring to take into account the longevity of the study.  However, there were no 
differences in reported adherence with any of the methods. 
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3.5.1 Secondary Adherence Outcome Measures:  
In addition to the TDA data as the primary method to measure adherence, the 
study used three other methods to measure adherence; the objective measures 
were reduction in intraocular pressure and medication prescription counts, and a 
subjective participant self-report method.  Good correlation between adherence 
measured by the TDA and objective measures and/or self-report methods could 
have indicated these to be useful proxy measures of adherence in clinical practice.  
The following section explores these measures in more detail.  
 
3.5.1.1. Reduction in intraocular pressure 
Reduction of IOP was evaluated using two different methods; absolute and 
percentage reduction.  No differences were found between the absolute and 
percentage reduction methods and there was no significant correlation between 
TDA measured adherence.  There was no differences in IOP control between the 
intervention and control groups most likely due to limitations of the methodological 
approach and the pharmacodynamics of prostaglandin analogues, rather than 
conclusive evidence that the intervention failed to improve IOP control.  Previous 
studies using similar methods also found that IOP reduction had no relationship to 
adherence.95, 146  Assessing IOP due to individual differences (types of glaucoma 
and diurnal variance) together with regression to the mean, led to ‘noisy data’.189, 
190   
 
3.5.1.2 Medication possession ratio 
The calculation of MPRs with eye drops was found to be complex due to 
inaccuracies in the data caused by variation in prescribing conduct.  In addition, 
unlike tablets or syrups, it is not possible to determine the volume of liquid 
correctly instilled in the eye as it relies upon the dexterity of the patient to instil the 
correct amount of liquid into the eye on the first attempt.  If a patient were to miss 
the eye for example, they may need to apply another drop whilst with prolonged 
squeezing excessive liquid flows from the bottle resulting in the administration of 
more than one measured drop.  Thus, absence of a fixed dose measure with 
respect to eye drops and differences in prescribing protocols can easily lead to 
erroneous MPR calculations.  Inaccurate calculation of MPR may have been the 
 111 
reason why the present study failed to identify a strong correlation between TDA 
and MPR measures.  In a previous UK study using MPR calculations, the same 
28-day calculation for refills was used but the authors did not describe any of the 
potential inaccuracies or limitations in collecting the data as described in the 
present study.139  The present study observations are worth further consideration 
since the complexity of repeat prescription administration itself, and variation in 
health care professional practice with respect to prescribing medication, may have 
a role to play in patient attitudes to medication use.115 
 
3.5.1.3 Self-reported adherence 
Self-reported non-adherence remains a popular method to collect adherence 
information in clinical practice and research.  However, there was a discrepancy 
between self-reported non-adherence and TDA measured non-adherence.  Whilst 
self-reported non-adherence was greater at eight months than at two months, TDA 
measured non-adherence did not increase at any time during the eight month 
follow-up period.  If one were to accept that the level of electronic monitoring 
accuracy remained constant over the monitoring period, then participants were 
poor reporters of adherence since their reporting became less accurate over time 
or they were inclined to over-report adherence within the first two months of 
observation.  The social desirability to report adherent behaviour or memory bias 
could be the cause for the discrepancy between self-report and the objective 
measure of non-adherence.79, 95, 119  More recent evidence has shown that 31% of 
patients (n=75) overestimated their adherence when using a VAS to self-report 
compared with MEMS-measured percentage adherence score and those who 
were newly diagnosed with glaucoma were more likely to over report their 
adherence (OR, 3.07, CI, 1.22-7.75).94  
 
3.5.1.4 Graphical representation 
The TDA data provided graphical representations of participant patterns of drop 
usage.79, 95  Comparing patterns of drop usage determined that ‘drug holidays’ 
were the predominate type of non-adherent behaviour in both groups rather than 
just incidental missed doses.  Drug holidays may be indicative of a more 
intentional non-adherent behaviour trait when a patient chooses not to use their 
medication for longer periods of time.42, 127  However, non-adherence in the 
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intervention group was more likely to be due to a mix of drug holidays and 
incidental missed doses. Thus, reviewing medication usage patterns rather than 
average adherence scores may be more useful in establishing the cause(s) of 
observed non-adherence.  Adherence pattern observation in turn can provide 
invaluable information for guiding the selection of intervention(s) most appropriate 
for supporting patients to adhere to their prescribed therapy. 
 
3.5.2 Missing data  
Self-report questionnaires provided the most complete datasets for the eight 
month period of study.  Conversely, almost a quarter of the MPR data were 
missing due to health centres not providing prescribing data for research purposes 
despite being offered payment for this administrative task.  Only one similar UK 
study using prospective collection of prescribing data has been identified from the 
literature139 but in that study the authors did not report any limitations in data 
collection.  Other UK studies using prescribing data have used retrospective data 
collection methods191-194 of which missing or inaccurate data was often noted as a 
possible limitation, although the magnitude of the problem was not quantified. 
Previous studies have reported that the TDA accurately recorded drop 
administration, but the longest of these studies was only for a three month 
period.93, 95, 100  The NAGS study found that the TDA was relatively successful at 
measuring adherence for the initial two month period.  However by eight months of 
follow-up, data attrition was high.  Retrieval of data from the TDA due to device 
failure, which was outside of the control of either patient or researcher, accounted 
for the greatest loss of daily electronic data for the eight month period.  Some 
TDAs were returned and had malfunctioned and this might have been caused by 
participants tampering with the internal batteries and mechanics of the TDA.  The 
stickers used to cover the visual display had often been peeled off so that patients 
could see when the tear drop appeared.  In addition, when treatment was 
changed, it rendered the TDA useless since the TDA aperture only holds Travatan 
shaped bottles.  Therefore, calculating the average adherence score using TDA 
over the total monitoring period was the least successful of the three studied 
methods and was a significant limitation of this study.  
If non-adherent participants had failed to return their TDA devices, thus creating 
more missing TDA data, this could have caused a study bias.  However, a 
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subsequent analysis of the data found that the magnitude of adherence at two 
months was comparable for participants with full eight-month data and those who 
subsequently went on to have missing TDA data.  Therefore, those who had 
missing TDA data but still provided self-reported adherence data were not likely to 
have been a less adherent cohort in comparison with those who had full TDA data.   
 
3.5.3 Reasons for non-adherence  
Participants reported more non-adherence due to forgetfulness than any other 
reason which is in line with previous research.42, 73, 107, 143  Forgetfulness was 
reported as the reason for non-adherence more at the Final Visit in comparison to 
Visit 2.  Conceivably, participants may have felt more confident to report 
forgetfulness when the study had reached its conclusion than at the beginning of 
the study process knowing they would meet a researcher at follow-up visits.  Or, 
as new users of eye drops, participants may not have felt at ease to disclose this 
behaviour to the researcher.  Forgetfulness is a behaviour that arguably could be 
exhibited as a result of either unintentional or intentional non-adherence.  Thus 
interventions based upon BCC might improve non-adherence caused by 
intentional non-adherence, together with the use of dosing aid reminders and 
routine rehearsal more appropriate to unintentional non-adherence.127   
 
3.5.4 Predictors of non-adherence 
In addition to understanding the reasons which may influence non-adherent 
behaviour, identifying factors which may predict patients likely to be non-adherent 
would also enable healthcare professionals to target resources to vulnerable 
individuals requiring additional support.  The NAGS study found that patients were 
more adherent to travoprost if the drop-administration time coincided with the time 
they used ‘other medications’.  Thus, administration of multiple medications may 
be a potential advantage for patients to be adherent to eye drops and 
understanding the reasons may be useful when developing future interventions.  
Participants already in the routine of using their ‘other medications’ at the time of 
starting eye drops may have found that administration of an eye drop to an 
established good routine was easier than for participants who had to learn and 
remember a new routine.  The good routine or medication use may have been 
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established through the longevity of medication use, or, unlike glaucoma which 
until significant damage has occurred has no discernible symptoms, ‘other 
medication’ is indicated for a condition which has symptoms and can in 
themselves act as the motivator to use medication.  
 
3.5.5 Satisfaction with information  
The NAGS intervention group were more satisfied with information received about 
use of their travoprost when compared to the control group, measured by SIMS, 
but this had no measurable effect on adherence.  Responses to individual items of 
the SIMS suggested that the control group lacked information about the potential 
problems of using travoprost; standard care requires greater information provision 
with respect to these aspects, but whether this would improve adherence has not 
been established.  Satisfaction with information about travoprost increased over 
time in the control group and suggests that patients seek/obtain information from 
additional sources post treatment initiation or that the desire for information 
declines over time. 
Although there were no significant results that showed the long-term benefits of 
the intervention for the treatment of glaucoma, the NAGS study found that 
additional information, tailored to the individual, was able to achieve higher 
satisfaction with regards to care and drop taking techniques.  The control group 
reported the need for more information and had many more unanswered questions 
than the intervention group, particularly when newly initiated on treatment, and had 
to seek most of the information they required from the internet.  At month two the 
control group reported missing more doses than the intervention group due to eye 
drops running out, which suggests that information given during the intervention 
did prevent this particular barrier to good adherence which wasn’t addressed by 
standard care alone.  However, adverse events related to use of eye drops and 
problems applying eye drops were still reported to be a problem in both the 
intervention and control groups. 
 
3.5.6 The intervention 
The support and education given by the GSAs was well received by participants 
and those reporting higher levels satisfaction with the service were more adherent.  
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As the majority of the calls to the telephone helpline provided by the GSAs related 
to side effects of using travoprost, a further potential benefit of the intervention 
became evident during the course of the study.  A GSA telephone service may 
have a wider benefit to the NHS and patients, not captured in the analysis of this 
study.  Currently patients’ experiencing side effects with their eye drops will require 
further advice from their prescribing clinician at their hospital eye service/glaucoma 
clinic.  Patients will either contact the consultant’s secretary directly, or will have to 
consult their community General Practitioner who subsequently contacts the 
prescribing consultant on the patients’ behalf.  The patient may then either be 
referred to the Hospital Eye Casualty Service for further examination, or the case 
history reviewed by a clinician or consultant and appropriate advice given.  
Whatever route the side-effect query is presented, resolution involves a 
considerable amount of administrative and clinician time.  Furthermore, this 
system can sometimes leave the patient for days without a satisfactory solution to 
their side-effect query, which is far from adequate.  The helpline enabled a one-to-
one discussion between the patient and GSA with sufficient knowledge to give 
immediate advice and reassurance to the patient.  The GSA had access to the 
patients’ glaucoma related medical records and could discuss an appropriate 
course of action with a specialist clinician immediately and organise either a new 
prescription or emergency appointment if necessary.  The potential cost savings 
and patient satisfaction with a streamlined, ‘one-stop’ advice line for drop side-
effects were not captured in the methodology used for this study, but a wider audit 
could be undertaken of the potential cost benefits.  
More than half of participants in the intervention group asked for further 
information when they attended their follow-up visits with the GSAs, which may 
suggest that the intervention should have been expanded to provide another 
session of tailored information provision at the follow-up appointment at month two 
and month eight post the initial intervention.  A more recent group-based 
education intervention study also concluded that having two intervention sessions 
may have enabled important messages to be reinforced and had a greater impact 
on adherence.92  A group-based education session would also be an interesting 
intervention idea to use for future development of the NAGs intervention, enabling 
an interactive style of learning for patients who prefer this option of self-education. 
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3.5.7 Study Limitations and strengths 
By far the greatest limitation was the TDA data attrition rate as described in 
Section 3.5.2 which led to 45% of the primary outcome measure being missing.  
The TDA was therefore a poor method of collecting adherence data.   
The NAGS intervention was led by specialist nurses and technicians already 
working within the hospital eye service which demonstrated the ease with which 
such an intervention could be incorporated into clinical practice.  However, during 
the study period, ensuring there was no contamination between the GSAs who 
worked on the study part-time and had received enhanced training in motivational 
interviewing skills, and also worked in the standard care clinic part-time was more 
problematic.  Every effort was made to ensure that participants did not come into 
contact with GSAs during their follow-up period, but it was not possible to account 
for any influences these staff and the study itself had on routine practices of all 
clinical staff during the study. 
Whilst there was no demographic bias in those participants who chose participate 
compared to those who declined, for variables that were collected (age, gender 
and IMD), studies of adherence may be intrinsically biased through selection of 
patients who attend appointments and engage in healthcare; thus non-adherent 
patients are more likely to be missing from the sample and those agreeing to 
participate may be more adherent to medication than those who decline.195  The 
results of the NAGS study relate to a relatively affluent, primarily white British 
population prescribed glaucoma mono-therapy, and may not be generalisable to 
other populations that may have different cultural practices.  Mono-therapy is also 
thought to aid adherence, with more complex regimens being problematic for 
patients.14, 42, 143  Thus, caution must be taken when extrapolating the results of 
adherence studies focused on one particular cohort.  Investigating the effect of the 
NAGS intervention on a population expected to have lower adherence and using 
multiple topical anti-glaucoma therapies would be of value to understand the 
needs of different patient populations.  
Although the primary outcome measure was the adherence rate reported as a 
continuous variable, a dichotomised variable was calculated by splitting 
participants into those who were adherent (≥80%) and non-adherent (<79%).  The 
dichotomised adherence score was used to compare TDA measured adherence 
with self-report scores and the logistic regression analysis of predictors of non-
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adherence.  It could be argued that the 80% cut off was an arbitrary figure but 
further, although convenient to the analysis, that comparison of grouped data 
causes a loss in the variance of the data which ultimately causes a loss in 
statistical power and thus was a poor choice of analysis.  
Many intervention studies do not fully describe and check the fidelity of the 
intervention.  However, NAGS used Behaviour Change Counselling Template as 
shown in Figure 3.2 to ensure that all intervention interaction contained the same 
content and the intervention had been checked for fidelity using the BECCI scale 
to ensure that the consultation style met expectations and feedback could be given 
to the individual GSAs to help improve their BCC approach.  However, although 
fidelity was assessed at the start of the study, this was not assessed again in the 
later stages of the study to ensure that reliability was still evident.  
 
3.5.7.1 Study bias  
Using five different GSA’s ensured that the intervention design was generalisable 
and repeatable rather than specific to how one particular ‘therapist’ carried out the 
intervention.  There were no differences in the number of adherent cases per GSA 
which confirms that there was not bias in the way that an individual ‘therapist’ 
delivered the intervention.  However, to improve the fidelity all interaction between 
GSA’s and participants could have been videoed and then reviewed by a MI 
expert to ensure that all interventions met the required criteria of a BCC 
intervention.  
Hawthorne effects may have occurred in the NAGS study whereby the act of study 
participation improved motivation and thus increased adherence in both groups.57, 
196  These observational methods often alert patients to the fact that their 
behaviour is being monitored which can cause a reactivity bias resulting in 
increased adherence to medication.57, 197  A more recently published intervention 
study also found that their control group were highly motivated and had benefited 
from the rapport established with the researchers.188  Using a modified consent 
procedure which avoids the need for researchers to take consent prior to 
participation would reduce the extra attention that participants receive when they 
agree to take part in research.  Standardisation of instructions given to participants 
at the time of recruitment may also control for external variances in measured 
adherence caused by the way information is conveyed and comprehended.   
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The electronic monitoring used in the present study may also have caused a 
reactivity bias not identified in previous studies.  Adherence measured 
electronically did not diminish over time as previously reported57, 197 and the results 
did not replicate previous theories of the likely reactivity bias time found in 
observational studies.  Either participants in the NAGS study were naturally very 
adherent, or there may have been a more long term reactivity bias caused by 
study participation and/or the monitoring effects of the TDA that improved 
adherence behaviour for the duration of follow-up.  These phenomena, often 
referred to as mere measurement effects, are proposed to cause behavioural 
changes in intervention studies and are the subject of ongoing debate.198  
However, these phenomena are not well documented and the extent that study 
participation and reactivity to adherence monitoring may inflate adherence relative 
to the natural environment is poorly understood.   
 
3.5.8 Summary 
Despite the intervention design being grounded in the theory and producing high 
levels of patient satisfaction, the NAGS study did not demonstrate improved 
adherence with a behaviour change intervention.  The results may indicate that 
standard care offered by an NHS Glaucoma Clinic was sufficient to promote high 
adherence with travoprost for the population studied.  However, with the majority 
of participants suggesting that the GSA service helped them to be more confident 
about using their drops, this model requires further development as a potential 
intervention to support patients using drops for glaucoma and ocular hypertension.  
Since the time of conception of the intervention used in this study, a large amount 
of work has been invested into gathering evidence to identifying the specific 
domains that explain behaviour change.142, 199  A hierarchical structured taxonomy 
of behaviour change techniques has also been developed that can help 
researchers to report the characteristics of the active contents of interventions with 
precision and specificity to aid more rigorous reporting of the component parts of 
the intervention.141  Undoubtedly with the benefit of advancing knowledge of use of 
behaviour change techniques and design of interventions, taking a stepwise 
approach to intervention design and evaluation of this study using these 
theoretical frameworks in the future could be pursued.   
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The NAGS study is the first known study to report eight months of follow-up using 
the TDA.  At month two, only 10% of the TDA data was missing, which suggests it 
was the longevity of the study that lead to the failure of the TDA to gather 
complete data for the whole eight month period.  Whilst the failure of the TDA 
increased the uncertainty around the adherence estimate, there was no evidence 
that the failure of the TDA differed between those who were adherent and those 
who were not, and thus did not bias the results.  Thus, whilst electronic monitoring 
is often acclaimed to be the preferred method of adherence measurement, the 
NAGS study found that data were difficult to collect for the long monitoring period 
appropriate for the study of this chronic condition and might be sensitive to study 
reactivity bias.  Clinical outcomes were also found to be unsuitable as proxy 
measures of adherence in this population and disease and self-reported 
adherence is unreliable. 
No gold-standard method for measuring adherence currently exists and it is likely 
that the practicalities of data collection will continue to govern what is ultimately 
chosen as an appropriate measure of adherence for each individual study.  
Unfortunately, while a standardised and accurate measure for adherence remains 
undefined, studies will continue to produce heterogeneous adherence results.  The 
NAGS study, used multiple adherence measures and reporting methods which 
ensured that comparisons could be made with studies of shorter duration and 
those using differing statistical analyses.   
The analysis provided evidence of the potential bias induced by using self-report 
and electronic tools to measure adherence and the difficulties of using routine data 
to calculate MPRs, particularly with respect to eye drops within the UK prescribing 
system.  Whilst multiple methods of adherence measurement used in parallel to 
quantify and classify adherence could maximise precision of adherence estimates 
and facilitate comparisons between studies, the potential effect that multiple 
measures of adherence have on patient behaviour is unknown.  Potentially, the 
multiple measures of adherence used in the NAGS study may have had an effect 
on participant’s behaviour.  When research assessment prepares people to be 
more receptive to the intervention than would be the case if not participating in 
research this may either strengthen or weaken the observed intervention 
effects.102, 103, 196  Further research was required to establish the extent of study 
participation and reactivity to assessment effects in this study.  Thus, a follow-up 
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study was designed to explore the research user and provider perspective of the 
trial conduct and intervention.   
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 Exploring user experiences of the 
NAGS study 
4.1 Introduction 
The Norwich Adherence Glaucoma Study (NAGS) used an MI intervention in an 
attempt to improve adherence to glaucoma medication.  In addition, an objective 
measure of adherence, the TDA, measured the primary outcome of adherence to 
medication.  At the time of the study concept, design and implementation (2007), 
both MI and the TDA were novel approaches in glaucoma adherence research.   
As NAGS was also the first RCT to use an MI approach to improve adherence to 
glaucoma medication it was important to gain a better understanding of the 
experiences of research participants and service providers.  Thus, a qualitative 
research study was designed to explore two distinct areas of investigation; (1) 
areas of study conduct, training procedures, informed consent procedures 
together with an understanding of how the study was received by participants in 
order to assess the acceptability of the study methodology and, (2) gain a better 
appreciation of patient experiences of both the intervention and study design.   
The gathering and analysing of qualitative data relies upon the researcher 
engaging with individual’s experiences, stories and language and interpreting the 
meaning behind the accounts.  The collection of data requires the researcher to 
find rapport with the participant(s) and interpretation of the data can be affected by 
researchers own experiences, involvement in the research and agenda.  However, 
as the main researcher and responsible for the interpretation of the data, it is 
important and relevant to emphasise that I was also the principal researcher for 
the NAGS study and thus heavily involved in the design and implementation of 
NAGS and therefore had my own pre-existing opinions and expectations of the 
study findings. 
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4.2  Method 
4.2.1 Aims and objectives 
The aim of the User study was to gain an understanding of user experiences in 
NAGS with respect to study conduct and the impact of the intervention used in the 
study.  The objectives were to:  
 explore participant experiences of the intervention used in NAGS  
 understand patient experiences of standard glaucoma care to enable a 
comparison to be made with the intervention used in NAGS  
 explore participant experience of the study and related issues, such as 
informed consent, randomisation, use of the TDA and questionnaires 
 explore GSA experiences of facilitating the study and delivering the 
intervention. 
 
4.2.2 Rationale for using a qualitative approach  
Qualitative research is broadly defined as “any kind of research that produces 
findings not arrived at by means of statistical procedures or other means of 
quantification.”200  Unlike quantitative research that seeks to determine causation, 
prediction and generalisation of findings, a qualitative research method allows for 
the exploration of meanings and concepts.201  Whilst there is no single accepted 
way of carrying out qualitative research, it is often determined by the purpose and 
goals of the research, the participants, funding and position of the researchers 
themselves.202  Qualitative methods can collect thoughts, opinions and feelings 
and draw together a deeper understanding of more complex processes that 
quantitative research cannot detail.  Qualitative research instruments used for data 
collection include questionnaires, interviews and focus groups, observation and 
analysis of documents.  Three instruments were considered for use in the User 
qualitative study; questionnaires, interviews and focus groups.  
Questionnaires can gather large amounts of information from numerous people 
very quickly and cost-effectively.  Furthermore, analysis of questionnaire data can 
be analysed more ‘scientifically’ than other forms of interviews.  However, 
questionnaires may not be an adequate method for collecting information about 
emotions, behaviour and feelings; whereas face-to-face interactions enable 
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questions to be asked sensitively and in response to information provided by the 
respondents.  During face-to-face interviews, interviewers can judge how truthful 
respondents are being and if the questions are being interpreted correctly.  Thus, 
face-to-face interviews are often used if sensitive information needs to be 
discussed that requires heightened confidentiality or, when a deeper level of 
thought is required, which affords the respondent more time to explore their 
feelings with the researcher.  However, focus groups help researchers to 
understand as much as possible about an issue among a group of people chosen 
to represent a larger cohort.  Data are generated by interactions between group 
participants which is more naturalistic than interviews since individuals rarely make 
decisions on their own, but are guided and influenced by those around them.202  
Focus groups, therefore, attempt to mimic real-life interactions enabling 
participants to present their own views and opinions based on their own 
experiences but on reflection and in the context of other people’s points of view.  
Furthermore, in focus groups, participants can ask questions of each other, seek 
clarification and prompt others to reveal more as discussions progress which 
enables the individual responses to become sharpened and refined.  Focus 
groups can be synergistic in the sense that the group works together to generate 
data and insights.202  Arranging focus group meetings is more problematic than 
one-to-one interviews since scheduling a time and venue to meet requires group 
agreement from numerous people.  
For the follow-up User study, the use of focus groups involving NAGS participants 
together with study professionals, was felt to be the most appropriate qualitative 
method to utilise.  In particular it was felt that a focus group study would best 
facilitate understanding participants’ experiences of the intervention, their 
involvement in the study process and their behaviour during NAGS.  
 
4.2.3 Setting, participants and recruitment 
The User study recruited participants from NAGS at NNUH.  The results of NAGS 
had not been analysed or reported at the time of undertaking the focus groups.  
Three focus groups were conducted in a local and accessible conferencing facility 
in September 2011. 
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The final 30 participants recruited into NAGS were informed that they would have 
the opportunity of taking part in a focus group to discuss their research project 
experiences to be held at the end of NAGS.  Participants were asked to tick a 
respective box when consenting for NAGS to indicate if they would be interested in 
taking part in a focus group.  Upon completion of NAGS, participants who 
registered their interest in joining a focus group were contacted by the researcher 
and asked if they were still willing to participate in a planned focus group.   
For each participant who verbally consented to participation, an information sheet, 
consent form and covering letter were sent with a reply envelope.  Potential 
participants for the User study were contacted the following week to ensure that 
they had received the information and to answer any further questions; the time 
and location of the focus groups were discussed and formalised.  
A separate focus group was planned for the GSAs.  Four GSAs were invited to 
take part in the focus group, but were under no obligation to take part.  I was the 
fifth GSA and too involved in the design and implementation of NAGS and also 
analysed the focus group findings and therefore could not take part in the focus 
group.  The GSAs were aware that I would be analysing the transcripts from the 
focus group and this may have influenced the discussion of NAGS between the 
GSAs, but there were encouraged to speak openly as no judgement was being 
made of their roles or thoughts about the processes. 
 
4.2.4 Ethical and Research Governance Approvals 
The User study received ethical approval from the Norfolk Research Ethics 
Committee (appendix 8), and research governance approval from Norfolk and 
Waveney Research Governance Committee (appendix 9). 
 
4.2.6 Organisation of Focus Groups 
All the focus group meetings were run by a moderator and an assistant moderator.  
The moderators were both PhD students trained in focus group methodology skills 
and independent of NAGS, so that they were unknown to the participants and un-
aware of any potential problems or patient experiences that occurred during the 
study. 
 125 
The discussions for each focus group meeting were expected to last one hour.  
Tea, coffee and light refreshments were served at each meeting and travel 
expenses were paid. 
A discussion guide was tailored to each focus group and an example is shown in 
Figure 4.1. 
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Figure 4.1 Interview guide for participants completing NAGS  
 
 
1. What was the experience of being asked to take part in the study? 
- What was your motivation to participate? 
- Was it easy to take part?  
- Was the study explained properly? 
- Did you have enough time to consider taking part? 
- What did you think about the study paperwork? 
 
2. How did you feel about being randomly put into either receiving more 
information or remaining in the control group?  
 
3. Usual care  
Experiences of first appointment with clinician 
Setting and duration of that appointment   
 
4. Intervention experiences (intervention group only) 
-  What is your experience of your first appointment with the 
Glaucoma Support Assistants? 
-  Setting and duration of that appointment?  
 
5. Do you think the information or the way it was given to you could have 
been improved upon? 
 
6.  Do you think the GSAs are the best type of person to give you this 
information?  
- Do you think the timing of the information was appropriate?  
 
7. What were your thoughts and experiences about using the dosing aid?  
 
8. What did you think about the telephone helpline service?  
 
9. What do you think was the most useful part of the study?  
 
10. What was the most difficult part of the study?  
 
11. What were your thoughts about the questionnaires?  
- How did you feel about answering the questions? 
 
12. Are there any other changes you make to the study or information given? 
 
13. Would you recommend this service for all new glaucoma patients? 
 
 
14. What was the experience of being asked to take part in the study? 
- What was your motivation to take participate? 
- Was it easy to take part?  
- Was the study explained properly? 
- Did you have enough time to consider taking part? 
- What did you think about the study paperwork? 
 
15. How did you feel about being randomly put into either receiving more 
information or remaining in the control group?  
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4.2.7 Analysis  
The focus groups meetings were digitally audio recorded and transcribed into a 
script by an independent transcriber prior to analysis.  
In most qualitative analyses, the data are preserved in their textual form and 
‘indexed’ to develop analytical categories and theoretical explanations.203  
Analytical category data can be obtained either gradually or deductively.  Gradual 
extraction of data is derived inductively, as in ‘grounded theory’, where hypotheses 
are developed as they emerge from the data.  Deductive extraction of data utilises 
a top down approach, either at the beginning or part way through the data, as in a 
‘framework approach’. 
Using grounded theory entails familiarisation with the data and defining the 
hypotheses from emerging themes that may centre on particular phrases, 
incidents or types of behaviour.  Interesting or unfamiliar terms used can also form 
the basis of analytical categories.204  Constant comparison is used to examine 
data relevant to each category which requires a coherent and systematic approach 
adding in as many nuances in the data as possible.  Once collected, the data is 
indexed into the theoretical ideas developed during the research before the key 
themes are selected.   
Whilst analysis using grounded theory is a lengthy process, framework analysis is 
more structured and the analytical process more explicit.205  Framework analysis 
involves examination of the reasons for, or causes of, what exists from participant 
experiences and making these coherent, whilst retaining a hold of the original 
accounts and observations from which conclusions are derived.  The framework 
approach has been successfully used in a range of different study types; in 
particular, in applied policy research where studies work to a short time scale, 
where objectives are shaped by specific information requirements in an aim to 
form a greater understanding of issues.  Although the User study to explore 
participant and GSA experiences of NAGS was not as stringent in its aims as 
studies examining applied policy, answers to predetermined questions were 
sought.  It was considered, therefore, that a framework approach could neatly 
examine these predetermined objectives whilst accommodating any new ideas or 
theory that might need to be explored.  
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Five distinct steps in a framework approach have been developed over the years 
by the specialist qualitative research body, Social and Community Planning 
Research 202, 206 and there were followed in the User study analysis: 
1. Familiarisation of the data was achieved by reading the transcript and listening 
to original audio recording.  Gaining a feel for the material as a whole 
identifying key ideas and recurrent themes.  
2. Identification of a thematic framework was created by developing a list of 
possible topics, which was refined and sorted to develop themes based on the 
range of responses and issues reoccurring from the data.  The framework was 
a mix of the emergent themes, those derived from the research question and 
from the aims that were incorporated into the interview guide. 
3. The thematic framework was used to perform ‘topic coding’207 to annotate and 
label chunks of data judged to belong together so that collective data extracts 
could be further analysed. The thematic framework was applied systematically 
to transcripts with short text descriptors to elaborate the index heading   
4. Charting enabled the data extracts to be refined into summaries of views and 
experiences and new labels applied to the data where necessary, a stage that 
required a considerable amount of abstraction and synthesis. 
5. Mapping and interpretation was carried out using the charts to define concepts, 
map the range and nature of phenomena and find associations between 
themes with a view to providing explanations, influenced by the original 
research objectives as well as by the themes that emerged from the data.  
A précis for each participant in the User study and each subtheme was written to 
aid the interpretative stage of the analysis this being a specific analytical step 
included in framework analysis. 
 
4.2.7.1 Computer software  
Qualitative research typically produces large amounts of data.  Computer 
packages can improve the efficiency of qualitative data management208 by 
providing a way of storing and retrieving cases, statements, phrases or words, and 
thereby replacing the time-consuming process of manual coding.  However, the 
use of computer packages, are also claimed to distance the analyst from the 
data,208 since they can take the place of the close and careful analysis that is 
required to enable the researcher to become immersed in the data.  Thus, whilst 
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computer packages can help with the intensive process of analysis and 
management of the data they are not a substitute for the process of ‘immersion’ 
which is essential for  the researcher to achieve the thorough knowledge of the 
data in order to make comparisons, identify patterns and develop 
interpretations.205  It could be argued that the time and effort taken to learn how to 
use the computer programme, could be better spent processing the data manually 
and therefore absorbing oneself in the richness of the data.   
During the analysis process it is often necessary for the researcher to change the 
labels appointed to categories as the data emerges and evolves.  However, 
computer programmes can be labor intensive when reformatting the labels 
appointed to categories resulting in a reluctance from the researcher to change the 
category labels mid-analysis209 thus losing the natural ability to form and mold 
categories appropriately. 
Furthermore, as computer programmes can place greater emphasis on the 
quantitative analysis of transcripts, such as how many people said what words or 
phrases, more weight may be placed on the frequency of events whilst ignoring 
isolated incidences210 which are still an important aspect of theme creation.  
There are different packages available such as Ethnograph, Atlas and QSR 
NVIVO, but computer packages were not used to conduct the analysis of the User 
study.  Instead the data collected for the User study was organised using Microsoft 
Word to cut and paste themes and facilitate data searching using the ‘Find’ 
function.  Although considered somewhat old fashioned and laborious, the chosen 
method ensured that the researcher developed an intimate knowledge of the data. 
 
4.2.5 Sampling  
Statistical representativeness is not a requirement for qualitative research and is 
not normally sought.  Instead, the aim of qualitative research is to identify specified 
groups of people who hold characteristics or live in circumstances relevant to the 
phenomena being studied in order to enrich the exploration of attitudes and 
aspects of behaviour relevant to the research.  A homogenous group enables the 
researcher to demonstrate that the group studied is representative of the wider 
population which shares that common characteristic.211  Therefore, a convenience 
sampling method was used to select 16 NAGS participants to take part in two 
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participant focus groups with a mix of both control and intervention participants in 
each group.   
 
4.2.8 Validity 
Although some may argue that the term validity is not applicable to qualitative 
research, most would agree that there is a need to measure quality, rigor and 
trustworthiness.  As such, patient experiences were presented using excerpts from 
their interviews and the portrayal was made “truthful” as statements and 
descriptions were provided through use of the patient’s own words.202  Participants 
were selected from the final 30 NAGS participants, their shared experience should 
have been conceptually generalisable to all participants of NAGS,  however as 
fidelity had only been assessed at the initial stages of NAGS, the reliability of the 
intervention remaining at the same conformity could not be assured.  
4.2.8.1 Triangulation  
Triangulation is any method used to give credibility and confidence in the 
conclusions drawn from a study.  By using triangulation the researcher may use 
multiple methods, sources, researchers or theories to strengthen their evidence.  
There are two main types of triangulation, ‘triangulation of sources’ which involves 
checking the consistency of different data sources within the same method or, 
‘analyst triangulation’, which is achieved by  two or more persons independently 
analysing the same qualitative data and comparing their findings.75 
Studies in health care have used triangulation of sources as a method of 
verification when studying the accounts of doctors, patients and managers in order 
to identify similarities and differences in views210 and the different views have 
contributed significantly to the credibility of the findings.  The User study aimed to 
triangulate sources by collecting the views of both the GSAs and participants from 
NAGS thus enabling experiences to be compared and contrasted from different 
viewpoints.  In the User study ‘Analyst triangulation’ was more difficult to achieve 
as the researcher was working on the project in isolation.  However, the final 
analysis was reviewed by the same independent researcher who had moderated 
the focus groups and together with a research supervisor to check for consistency 
in the transcripts and resulting themes.  
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4.3 Findings 
The number of NAGS participants agreeing to take part in the focus group was 
lower than expected which meant that participants representative of different age, 
gender and control/intervention arms could not be selected.  Rather a sample of 
the 16 participants who had consented to participate (8 from the control arm and 8 
from the intervention arm) were recruited into two different focus groups, one 
group that took place in the morning and one in the evening based upon 
availability of the participant.   
The characteristics of both focus groups are displayed in Table 4.1.  There were 
equal numbers of control and intervention arm participants but these were not 
evenly distributed between the two groups.  Eight participants were organised to 
attend Group-1 and seven in Group-2.  Two female participants had consented to 
participate but were unexpectedly absent on the evening of the Group-2 meeting, 
resulting in a male dominated evening focus group.   
 
Table 4.1 Participant demographics 
 
Total 
n=13 
Group 1 
(morning) 
n=8 
Group 2 
(evening) 
n=5 
Male  No. (%)  8 (62) 4 (50) 4 (80) 
Control arm  No. (%)  7 (54) 6 (75) 1 (20) 
 
The final group was organised for GSAs alone and is discussed in Section 4.3.6. 
 
4.3.1 Summary of analysis  
The themes summarised in Figure 4.2 were applied to the data and were brought 
together under three main headings; (1) experiences of study participation, (2) 
patient experiences of control and intervention groups, (3) participant experiences 
of standard care and issues faced by patients with glaucoma.  Only interpretation 
of the themes felt relevant to the aims and objectives of the User study have been 
reported in this chapter.  
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Figure 4.2  Summary of themes applied to the data part 1 
Study participation 
Questionnaires 
 Participants did not like the questionnaires as they felt ambiguous and irrelevant 
to eye condition in question 
 Generally some participants felt sceptical towards the use of questionnaires 
Recruitment and Randomisation 
 Participants had received enough information about the study 
 Participants had no concerns about the method used in the study 
 GSAs made time for participants to ask questions which participants appreciated 
 Participants were very happy to have taken part in the study 
 Participants felt they were given sufficient time to decide whether to participate or 
not 
 
Travalert Dosing Aid 
 The TDA was large enough that it reminded participants to use their drops 
 The TDA was easier to use than a drop bottle alone 
 Participants were aware that it monitored adherence and reported modification of 
their behaviour accordingly 
 Some participants thought that the TDA was the intervention rather than the 
education session; participants in the control group reported that they had 
received ‘the intervention’ because they had used a TDA. 
 
Study participation 
Questionnaires 
 Participants did not like the questionnaires as they felt ambiguous and irrelevant 
to eye condition in question 
 Generally some participants felt sceptical towards the use of questionnaires 
Recruitment and Randomisation 
 Participants had received enough information about the study 
 Participants had no concerns about the method used in the study 
 GSAs made time for participants to ask questions which participants appreciated 
 Participants were very happy to have taken part in the study 
 Participants felt they were given sufficient time to decide whether to participate or 
not 
 
Travalert Dosing Aid 
 The TDA was large enough that it reminded participants to use their drops 
 The TDA was easier to use than a drop bottle alone 
 Participants were aware that it monitored adherence and reported modification of 
their behaviour accordingly 
 Some participants thought that the TDA was the intervention rather than the 
education session; participants in the control group reported that they had 
received ‘the intervention’ because they had used a TDA. 
Differences between control and intervention groups 
Intervention group 
 Participants found it reassuring being the intervention group and the GSA’s were 
supportive  
 The telephone helplin  was us ful particularly for advice if side effects occurred 
 A tailored approach led to different experiences of the intervention 
Control group 
 Felt disappointed because they were not in the intervention group 
 Participants sought further information as standard care information was not 
sufficient 
Future recommendations 
wanted mor  information about their own individual pr gnosis 
 Information should be specific to each patient and not generalised 
 The intervention should be made available to everyone to help support all 
p tients, particularly important as glaucoma is asymptomatic 
 
Differences between control and intervention groups 
Intervention group 
 Participants found it reassuring being the intervention g oup and t  GSA’s were 
supportive  
 The telephone helpline was useful particularly for advice if side effects occurred 
 A tailored approach led to different experiences of the intervention 
Control group 
 Felt disappointed because they were not in the intervention group 
 Participants sought further information as standard care information was not 
sufficient 
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Figure 4.2  Summary of themes applied to the data part 2 
 
 
 
 
Experiences of standard care and issues faced by patients with glaucoma  
Informing family  
 Patients with glaucoma must be told to inform members of their family and 
particularly their children  
Driving and the DVLA 
 Driving is essential for most people particularly in rural parts of Norfolk  
 Drivers don’t  appear to be aware of their obligation to tell the DVLA if they have a 
medical condition 
 Patients feel unsure about when they should report ocular hypertension or 
glaucoma to the DVLA  
 Patients felt that clinicians have a duty to advise them about criteria for driving and 
reporting to the DVLA 
Eye drops 
 Patients don’t like using eye drops just before driving 
 It is difficult to see in the bottle to know when it is about to run out 
 Easy to fall asleep before using them in the evening  
Communication at Eye Clinic Appointments 
 Doctors with poor communication / poor spoken English lead to lack of confidence 
in treatment plans  
 Patients feel uncomfortable about asking questions 
 Information is not offered you have to ask for it 
Eye Clinic Appointments 
 Long wait between tests at each eye clinic appointment which makes attending 
appointments difficult because of the length of time it takes 
 Patients do not like seeing a different doctor at each visit, as it feels like there is no 
continuity in care 
 Appointments are impersonal and feels like being on a production line  
 Nurses need to take more time to explain why each test is being carried out 
Standard Care Information 
 Not enough information given about why eye drops are used and individual 
prognosis 
 Diagnosis not clearly explained 
 Photocopied leaflets are poor quality and diagrams are meaningless 
 Patients would like opportunity to discuss eye problems in more detail 
 Experiences of side effects are common 
 
Experiences of standard care and issues faced by patients with glaucoma  
Informing family  
 Patients with glaucoma must be told to inform members of their family and 
particularly their children  
Driving and the DVLA 
 Driving is essential for most people particularly in rural parts of Norfolk  
 Drivers don’t  appear to be aware of their obligation to tell the DVLA if they have a 
medical condition 
 Patients feel unsure about when they should report ocular hypertension or 
glaucoma to the DVLA  
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4.3.2 Experiences of study participation 
Overall, participants felt that taking part in NAGS was a positive experience and 
were happy to have participated.  Participants were pleased that this topic area 
was being investigated and thought the study was a good idea.   
“I had a good experience” (F7, female, group-2, intervention arm) 
“I thought it was a good idea and if it helped in the long term, other 
people, then I am happy to participate” (M3, male, group-2, control 
arm) 
“Yeah I was glad they were showing an interest.” (F2, female, group-2, 
control arm) 
 
4.3.2.1 Recruitment and randomisation   
The information provided to the participants about NAGS was sufficient and 
helped them decide whether to participate or not.  Good ethical practice dictates 
that participants should have enough time to decide if they would like to take part 
in research.  The design of NAGS required that participants consented to take part 
before leaving the Eye Clinic on the day that treatment with travoprost eye drops 
was initiated.  Whilst the NAGS method gave rise to ethical concerns about 
patients having adequate time to consider their participation, no such concerns 
were shared by any of the participants.  Coming to a decision was felt to be easy 
as participation in the study held no significant risk to them.  Participants also 
agreed that it was made clear that they had the option to withdraw from the study 
at any stage if they wanted to.   
“I don’t recall who recruited me in the first place but certainly I received all 
the information that I felt I needed...” (M9, male, group-1, intervention 
arm) 
“I felt that [name of GSA] was very good, took us to one side and 
explained the whole thing.  I think I was the last one to leave the clinic but 
she still had time for me. I felt she was very good.” (F5, female, group-2, 
control arm) 
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“There seemed to be a lot of positive reasons why we should, rather than 
just one or two.   I mean one or two would have done it for me” (M1, male, 
group-2, intervention arm) 
“I always had the option to come out” (M7, male, group-2, intervention 
arm) 
 
Participants from the control group discussed how taking part in NAGS itself had 
encouraged them to use their eye drops and interaction with the study staff had 
had a positive influence.  The informed consent process had also provided all 
participants with more information and support than ‘standard-care patients’.   
Furthermore, study information was reinforced at several time points throughout 
the study when attending follow-up appointments and completing questionnaires.   
“That we have had this information reinforces us to take the drops… 
Because you know we have had more information than you know perhaps 
a lot of people would have had and it is probably good for the longer term.” 
(M3, male, group-2, control arm) 
...but as far as the work that’s been done here, as far as I’m concerned, I 
mean although I’ve only been on the control group but as I say, I found 
everybody absolutely great, you know, everybody’s been very 
approachable, you know, they’ve always asked whether there’s anything 
else they can do, you know.  (M11, male, group-1, control arm)  
…we don’t know what it would have been like if the study hadn’t have 
been in the background and feeding us information, but we can only 
assume that more information we get is the better and at several times, so 
it is reinforced. (M3, male, group-2, control arm). 
 
4.3.2.2 Using the TDA  
Generally, the TDA was well accepted by all participants as a good method to 
apply eye drops.   
I find it really help that gadget with the bottle (M8, male, group-2, control 
arm) 
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I would like to second that, I find that also (M3, male, group-2, control 
arm) 
Yeah I do (F7, female, group-2, intervention arm) 
Because you click it down once and it just gives a drop out (M8, male, 
group-2, control arm) 
I’ve never tried it without the sort of frame that you put over your eye and I 
also use that with the other bottle which is not in a dispenser or anything 
like that and I find it works very well and I’d like to know where you can get 
those if I have any sort of accident with the one I’ve got…(M13, male, 
group-1, intervention arm) 
 
However, there were a couple of participants who had difficulty using the TDA. 
I couldn’t it use it very well, I wasn’t sure if it clicked or not so I just started 
putting them in ordinarily. (F5, female, group-2, control arm) 
Despite the fact it has got a guide on it, you still miss the eye. (M1, male, 
group-2, intervention arm) 
 
The TDA helped participants to remember to use their eye drops because the 
dispenser was larger than a normal bottle.   
That’s another point, because it is so large, I have mine every morning, 
you know, Duotrav I think it is, it is sitting by the edge of the bed and I 
wouldn’t normally remember to take the drops but the fact that it is sitting 
there, you know, visibly, I usually think, yes, I haven’t done that and pick it 
up. (M3, male, group-2, control arm)  
 
One of the participants had to change the type of eye drops he was using during 
the course of the study which meant he also had to stop using the TDA because it 
was not compatible with the shape of the new eye bottle.  In comparison he found 
it was more difficult to remember to use his drops without the use of the TDA.   
I agree with this gentleman [M3] because it was like there, in a box big 
enough, it just reminded you to do it… and I just found it easier because, 
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when I came off that and I went onto other stuff which wasn’t in a 
dispenser, it was just in a little bottle, sometimes I had to take those twice 
a day, and sometimes I would forget the first one and I would take two that 
were closer together than more spaced out.  So I just found it easier 
because it was visible really. (M4, male, group-2, control arm) 
 
4.3.2.3 Monitoring adherence with the TDA 
Participants were aware that their eye drop usage was being monitored by the 
TDA during the study.  The participants felt comfortable agreeing to the study 
knowing that the intention was to monitor their adherence but discussed how this 
increased the attention they paid to use of their eye drops and how this changed 
their behaviour. 
But I wasn’t bothered about whether it was being, my usage was being 
recorded, no, that didn’t bother me. (M4, male, group-2, control arm) 
Yes, I mean I joked about it being like Big Brother, keep an eye on what I 
was doing [laughter from group], no pun intended,… (F2, female, group-
2, control arm) 
I was worried the other way.  If I missed I would do it again.  If I pressed it 
and nothing happened I would do it again and I was worried it would 
register too many clicks. (M1, male, group-2, intervention arm) 
 
One participant described how he had kept also kept a daily record of the number 
of drops he had used the device and the system he used for scoring this. 
I’ve kept a record, a daily record in fact of both the times, the number of drops and 
what I’ve used, the term ‘hit’ every time I’ve pressed the device. (M9, male, focus 
group 1, intervention group) 
 
4.3.2.4 Questionnaires 
Participants did not like the questionnaires that had to be completed at home after 
each study visit.  Some participants felt that the questionnaires were biased 
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towards researcher opinion and that participants might not answer accurately 
because they would not want to be too critical. 
Well, my first thought with this questionnaire, as with every questionnaire 
I’ve ever seen in my life about any subject, [sigh] is that really the right 
question or what exactly does it mean or, you know, there’s some 
ambiguity, this sort of thing…(M12, male, group-1, intervention arm) 
Some of the questions I thought well are they relevant but then perhaps 
they’re more relevant to other people.(F10, female, group-1, intervention 
arm)  
I find questionnaires very easy to fill in… So I just, you know, it is usually 
like, very good, good, not good, you know, it is just, it is just, I don’t think 
they are very accurate. (M4, male, group-2, control arm) 
The questions are always slanted to the direction they want the answers. 
(M1, male, group-2, intervention arm)  
I don’t think questionnaires are that accurate because you don’t really 
want to put anything bad unless it really is a bad service or so, you tend to 
put its either you know, whatever the best answer or the second best 
answer is, I stick on the nose.(M4, male, group-2, control arm)  
Well you right can’t judge what is very good or good because everybody’s 
going to have a slightly different standard anyway.  But I rarely put very 
good because, as you’ve just said I think they are very inaccurate 
measurements.  I don’t think I have ever said anything was bad because it 
wasn’t in my particular case. (F6, female, group-2, control arm)   
But will people answer it honestly.  I don’t know. (F2, female, group-2, 
control arm) 
 
Participants also felt that the questions about eye drops affecting their sex life and 
drinking alcohol seemed irrelevant and became a source of amusement during the 
focus group discussion.  Some participants stated that they did not answer those 
questions or that they added additional comments on the questionnaire.  If 
participants felt that the questionnaires asked irrelevant and “silly” questions then 
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this may have affected participant attitudes to answer the questionnaire fully and 
with honesty. 
Extract of conversation: 
1. I think some of the questions were very irrelevant…to the actual 
condition that we had, which amused me rather slightly… how does it 
affect your sex life? And I thought ‘Good god’…it was on my 
questionnaire and I thought, that is a peculiar thing to ask when you 
have got glaucoma! Or haven’t got glaucoma! (F6, female, group-2, 
control arm)  
2. Don’t go down that road (M8, male, group-2, control arm) 
3. Well that is what I meant, it was a silly question! (F6, female, group-2, 
control arm) 
4. Absolutely, I got my wife to fill that in! (M8, male, group-2, control 
arm) 
5. Irrelevant (F6, female, group-2, control arm) 
 
4.3.3 Participant experiences of control and intervention arms 
Both focus groups had evidence of confusion about the differences between the 
intervention and control arms.  All participants had been given a TDA to measure 
their adherence to eye drops and participants were made aware of this at the time 
of consent.  However, during discussions it became apparent that participants 
believed that they might only have received the TDA if they had been in the 
intervention group.  In the first focus group, a participant from the control group 
began to question into which arm of the study he had been randomised and 
started to believe that he must have been the intervention arm because he had 
been using a TDA. 
Similarly in the second focus group, a participant who had been in the intervention 
group, had not been aware that both control and intervention arms received the 
TDA.  He discussed how he had thought the TDA was the intervention that made 
his care different to the control group.  On learning that everybody received a TDA, 
he began to question into which group he had been recruited.  He also explained 
that his clinician had changed his glaucoma diagnosis and the drops he was using 
during the time he was taking part in NAGS, and therefore he believed that if he 
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had been in the intervention group, surely these changes would have been 
discussed with him more thoroughly.  
Can we come back to the patient in the control and intervention group? 
You know some people were saying about discussing all the notes from 
the consultants, would that happen with either group or just the 
intervention group… Well, why I’m asking this is because it’s bringing up in 
my mind the point of this control and intervention and from the discussion 
round here I think possibly some of the problems and questions that we 
had would have been covered by the intervention group and not covered 
by the control group so that one or two of us, I mean this question I 
mentioned of mine with the changing of drops and them not working and 
have I got glaucoma or not got glaucoma, that could have been brought up 
in the intervention group…(M12, male, group-1, intervention arm) 
 
4.3.3.1 Control group participant experiences 
Some participants felt disappointed when they were randomised to the control 
group, but understood that it was for the benefit of the study.  Control group 
participants were concerned that they would not be receiving the necessary 
information that would have been of benefit to them.  However, most disappointed 
participants felt reassured by knowing they would receive further information at the 
end study if required.  .  
I was in the control group and I must admit I was a bit disappointed, I must 
admit that was my first reaction but then I thought well, you know this is 
what you have to do with research to make it, that’s the way you have to 
conduct research.  And I can find out information and if I wait a bit longer 
until the end of the study, I will get this information that they think will be 
appropriate. But yeah, the first initial gut feeling was arrrgghhhh. (F2, 
female, group-2, control arm) 
I mean I certainly felt I could have benefited from more information than I 
had but I was in the control group so I accepted it, I could understand the 
reasons for that. (M11, male, group-1, control arm)  
You see I was on the control group. I sometimes didn’t feel I was getting 
enough information ……and there were a few other things that I wish I had 
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been told and I thought I might have been told but obviously if I’d been in 
the intervention group I probably would have been told those things.... 
(M11, male, group-1, control arm) 
 
Some control participants described undertaking their own research to gain the 
further information they required but found that information researched could be 
conflicting.  Control arm participants perceived that the information the intervention 
arm received was more likely to be reliable.  
But yeah, there is so much information out there and sometimes you 
would read one thing and then you would read another thing that conflicts 
and I thought well, may be the people who are in the intervention group 
will get something that is a bit more appropriate and reliable. But, yeah, 
there is a lot of information out there.(F2, female, group-2, control arm) 
Yeah me to. You know, directly I was diagnosed, I looked it up on the 
internet, what glaucoma was anyway, so you know, there is just as much 
information on the internet as what there was given in your leaflets.(M8, 
male, group-2, control arm) 
 
4.3.3.2 The Intervention  
The intervention was felt to be very useful as a support mechanism and provision 
of information.  It appeared that the intervention also offered reassurance to 
participants should additional help and support have been required. 
And again the point, sorry, the point I made earlier, to me it was a 
tremendous reassurance, this was something new, that I was with this 
group, the group was here and they were a hotline as well. So that to me 
was a very valuable feeling… That’s right and certainly in terms of the 
treatment and the use of the eye drops and the side effects of the eye 
drops, things that could happen, all of that was explained by your team 
and the best way to use them, how to use them, techniques for using them 
and so forth, all that was sort of fabulous, fantastic … (M12, male, group-
1, intervention arm) 
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I got given information from X [GSA] and I must admit, I got given loads, 
absolutely loads and loads of information and several more booklets than 
you got…but I found her very good and I found it quite reassuring to have 
that backup there, but I felt I had loads of information and I felt if I needed 
more information I could either get it myself or I could ask them and they 
would get it for me. ...and I found it really useful, really helpful and I found 
them really informative with the information they gave out. (F10, female, 
group-1, intervention arm) 
 
Although trying to deliver a standardised intervention, the BCC method utilised 
was also designed to tailor information to an individual participant.  Evidence 
suggested that a patient-centred approach led to a wide range of experiences. 
I think obviously we’ve all had different experiences and I think it probably 
needs to be a bit more consistent but I had a very good experience but 
you didn’t have quite so good an experience [referring to M13]. (F10, 
female, group-1, intervention arm)  
I’m a bit envious of these people who have got all this extra information 
(M13, male, group-1, intervention arm) 
 
Here, the participant felt aggrieved when they learnt that others might have 
received more information and support than they had, which suggested that 
patients were keen to receive as much information as possible and that this should 
be standardised in some way rather than be patient-led.  In addition to good initial 
education, participants confirmed that they required on-going information about 
their diagnosis, prognosis, treatment side effects and emerging longer-term 
educational needs if they had arisen. 
And it would be nice to have more information on the prognosis, you know, 
what does one expect?  I mean I was told last time that it should stay the 
same if I keep taking the eye drops and that I will have to take them for 
probably the next twenty years before they look at changing them or, you 
know, removing them, by which time I shall be 85ish so I shan’t be so 
concerned perhaps then as I am now! (M13, male, group-1, intervention)  
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So as I’ve said previously, the interview that you had with the doctor, 
doesn’t provide too much information and the remarks are somewhat 
staccato, i.e. they spend time taking notes or attempting to take notes 
whilst he was speaking, but it was unsuccessful. (M9, male, group-1, 
intervention arm) 
 
Despite being in the intervention arm and having seen a clinician at least three 
times during the course of the study, participants still appeared to have 
unanswered questions about their glaucoma which obviously had not been 
addressed by their clinician and participants had not felt empowered to ask. 
 
4.3.3.2.1  Telephone helpline  
The telephone helpline was reported to have been used by participants when 
suffering with side effects of using eye drops and not for other enquiries. 
I did see [a GSA] and speak to [a GSA] quite a bit because when I was 
first diagnosed, the next day I was going on a three week holiday abroad 
and I read all the side effects and I was quite frightened because nobody 
at the time tells you any of the side effects about the travatan so I wouldn’t 
take it for three weeks whilst I was on holiday in case something 
happened. (F7, female, group-2, intervention arm) 
 I had problems initially with the drops and the attachment that you put 
on…in fact it finished up with my wife putting most of the drops in and she 
still does but I’ve got to keep persevering.  [The GSA’s] certainly explained 
various techniques for doing this which were a help, like supporting here 
and so forth, so they gave all the help there and also I did this comfort 
thing in the eye, they were talking about the liqui-tears and things I can get 
to help that, so they were very very helpful there…(M12, male, group-1, 
intervention arm) 
 
However, participants did find it reassuring to know that a telephone helpline was 
available.  
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Ah yes, as far as the tests go and being in the intervention group, one of 
the things which, how can I put it, reassured me was the fact that they 
were there.  If I had a problem I could ring [GSA] or any other colleagues 
at any time and they were there as a back-up help if I’d got particular 
problems…(M12, male, group-1, intervention arm) 
 
4.3.4 Experiences of standard care 
Some participants felt as though they were on a conveyer belt when attending 
routine appointments for their glaucoma care.  The over-demand for clinic 
appointments in the NNUH Eye Clinic can cause long waiting times, but most 
patients appeared to continue being tolerant of this service on the basis that their 
eye sight was precious to them. 
Some clinicians were reported as being very approachable, giving clear 
information, whereas others needed to improve their introduction, learn to speak 
clearly, explain treatments and reasons for prescribing treatment to ensure that 
patients’ questions would be answered resulting in greater confidence in decisions 
suggested by clinicians.  It was felt that improved communication would help 
patients overcome their anxieties about seeing a different clinician at each visit 
and concerns over lacking continuity of care.   
Patients have a need for good information provision and in some instances this 
would appear to have been lacking.  It was reported that the information leaflets 
provided from the clinic were not of adequate quality and needed to be printed in 
colour to be of use to the patient.  It was suggested that certain patients could be 
given more information about the complexities of diagnosing glaucoma, 
particularly when they are a suspect for glaucoma rather than having manifest 
glaucoma; a better explanation might help patients understand why they 
sometimes receive conflicting information from clinicians. 
Participants also discussed issues with respect to driving and reporting their eye 
condition to the DVLA.  The issues pertaining to driving appeared highly emotive, 
which is not surprising given the consequences on patients’ standard of everyday 
living if informed that they should not drive.  Participants described the conflicting 
advice given by clinicians or the fact that no advice was given at all with respect to 
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the legality of driving.  Several participants reported the difficulties in trying to 
communicate directly with the DVLA.  The current DVLA administrative system 
was described as being difficult to navigate in order to obtain information, this 
making an already a stressful situation even more frustrating and worrying.  It was 
clear that better communication was required but it was not clear as to whether 
this should have been provided directly to drivers by the DVLA as the regulating 
body, or if clinicians should have a clearer role within this process.  Clinicians may 
not feel it is their place to become involved in the process of such regulatory 
affairs, but from the patients’ perspective, many of who are naïve to their obligation 
as drivers to report all medical conditions to the DVLA, it was felt that clinicians 
should be the source of such advice.  
 
4.3.5 Future intervention recommendations  
Many participants felt that the intervention should be made available to all patients 
in the future considering it worthwhile to give people more support when using eye 
drops.  Participants agreed that preventative medicine is very important to 
healthcare in general, but particularly for conditions such as glaucoma being 
asymptomatic in its early stages.   
I think it probably would be a good idea to continue giving that extra 
support to people with glaucoma because as you said, it is a disease that 
doesn’t really have any obvious symptoms so it is not like a lot of diseases 
where you take you medication and you see instant results, so I think it is 
probably something that you know, an area where it is worth giving people 
more support to take their drops. (F2, female, group-2, control arm) 
 
Some participants felt that it would be easy for certain patients to ignore their 
glaucoma diagnosis; it was considered that the role of the GSA could be important 
to ensure that such patients understand the need to use their eye drops.   
It is something that most people tend to ignore as well isn’t it?  I mean, I 
am a typical man… Tend to be laid back, so having this, not so much 
support, someone drumming it into me, you know, if you don’t follow the 
procedures and use the drops, you are going to get tunnel vision. And it 
never even entered my conscious thinking that this might happen to me.  
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Well, things like that happen to other people don’t they? (M1, male, 
group-2, intervention arm) 
Yeah, looking back a question one can ask oneself is if we hadn’t been in 
this group how do we think we would have got on? You know, would we 
have worried about this? Would we have had understood this? Would we 
have understood that?  And the chances are that somewhere along the 
line we might have gone adrift.  I mean X said ‘oh, I can’t be bothered to 
take my drops today’ or whatever, you know, this sort of thing, how 
important is it because I don’t recall actually getting that information from 
anywhere else other than this group. (M12, male,  group-1, intervention 
arm) 
 
Most participants felt that if adequate information was provided and future 
prognosis explained, adherence to eye drops would be high, since few would 
knowingly risk losing their eye sight.  Focus group analysis suggested that future 
development of an intervention would need to concentre on two different 
components.  The first component should provide basic reliable information about 
glaucoma and the use of eye drops in a consistent and accessible format for 
patients.  Patients may require access to this information at different time points 
during their glaucoma care pathway based upon personal circumstances, 
forgetting information previously provided, when there is a worsening of their 
glaucoma condition or when experiencing side effects to treatment.  Patients need 
choice in where they might access information, either from their clinician, 
information leaflets or the internet and this is likely to be determined by the 
urgency for which the information is required.  For example, if there were to be a 
sudden onset of a side effect, a telephone call may be made to the GP or hospital 
consultant.  In less urgent cases, patients may wait until their next review 
appointment, or may search for information on the internet.  The second 
component should relate to the patient-centred support that can provide specific 
information about diagnosis and prognosis over a life-time of living with glaucoma.  
It was considered that should all this information be provided adequately, 
adherence to eye drops would be certain.   
Whilst provision of adequate information might overcome barriers caused by 
intentional non-adherence, un-intentional non-adherence was not discussed by 
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focus group participants, and only a couple of participants suggested that they 
may occasionally forget to use their eye drops.  
I mean it’s just occasionally I fall asleep before I’ve put the second lot in 
but then I wake up at 1 o’clock in the morning and think oh gosh, I’d better 
put those in quick! (M13, male, group-1, intervention arm) 
 
It is clear that participants require information about glaucoma and their eye drops, 
but furthermore, they require more information about their diagnosis and 
prognosis; this aspect of information provision was not assessed by NAGS and so 
no recommendations could be made.  However, the focus groups revealed that 
this was of great concern to individuals and should be an area of focus for the 
development of future interventions.   
It would appear that due to the nature and complexity of glaucoma, providing 
diagnostic and management related information ideally needs to be provided using 
a patient centred approach, which can tailor information to an individual patient 
diagnosis in order to implement individual treatment plans and provide a 
potentially changing diagnosis over time.  The decision as to who is best 
positioned to provide patient-centred glaucoma information also requires further 
investigation.  
 
4.3.6 Glaucoma Support Assistants  
The GSAs were well known and publicly identifiable and thus, so to ensure 
confidentiality, a summary of their discussion has been provided without direct 
quotes from the transcript.  The themes for the GSA focus group are summarised 
in Figure 4.3 and were applied to the data.  Only the interpretation of the themes 
felt relevant to the aims and objectives of the User study have been reported in 
this chapter.  
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Figure 4.3 Summary of themes applied to the data from the GSA focus 
group 
 
4.3.6.1 Characteristics of the GSA focus group 
Three of the five GSAs employed specifically to work on NAGS took part in the 
focus group part of the research.  Of the two GSAs that did not take part, one was 
the study facilitator and part of the management team and was thus not invited so 
as to reduce any potential bias; the other member consented to participation but 
was absent due to illness on the day of the focus group meeting.   
 
4.3.6.2 The Intervention 
The GSAs felt that although the intervention was intended to have a patient-
centred and motivational approach, this conflicted with the study design that 
required a standardised intervention.  Thus, whilst the concept was grounded in 
providing individualised education and support, any effects of this were diluted by 
the need to follow the education template designed for the study, so as to maintain 
consistency. 
 
Glaucoma Support Assistants 
Intervention  
 Effects of individualised support diluted by the need to maintain consistency in 
delivery of information 
 Participants had too much information to take on board in one session and 
information sheets for patients to take home may have been helpful 
 
Patient reaction to diagnosis 
 Patients researched details about glaucoma to find out more information 
 Older patients appeared more willing to accept whatever the clinician told them, 
whilst younger patients asked more questions 
 Some patients were very worried and seemed scared 
 
Study method 
 TDAs became the main focus of the study 
 Questionnaires were too difficult for patients to complete 
 Haphazard completion of questionnaires because answers were contradictory  
 Standardised intervention conflicted with a patient-centred approach 
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The GSAs also felt that there was a considerable amount of information discussed 
with patients during the intervention session, too much for all patients to assimilate 
in one session.  The GSAs suggested that the use of reinforcing information by 
providing printed information, sheets for patients to take home with them to refer to 
at a later date as a reminder of the discussion, would have been beneficial.  With 
the amount of information that needed to be shared with the participants during the 
intervention, less attention may have been given to motivating good adherence 
behaviour specifically. 
 
4.3.6.3 Study methodology  
The GSAs were concerned that the TDAs, used to measure adherence, had 
changed patient behaviour and had become the main focus of the study 
intervention for at least a proportion of the patients.   
The GSAs felt that the questionnaires were difficult to complete, particularly for the 
older participants.  The GSAs had received telephone calls from participants 
calling the research office (which was separate to the ‘help-line’ and used for 
general enquiries about the study) asking questions due to the fact that they were 
experiencing problems completing the questionnaires.  The GSAs felt that the 
questionnaires had been completed haphazardly because answers often 
contradicted themselves.  GSAs were also concerned that they gave the control 
group a greater awareness of some of the information that may not previously 
have been discussed with them by their clinician in the provision of standard care.   
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4.4 Discussion  
The findings from the focus groups advocated the need for provision of education 
and support for patients with glaucoma in order to promote and maintain good 
adherence to medication.  There was evidence to suggest that existing standard 
care did not meet the needs of patients and that the intervention used in NAGS 
had the potential to improve knowledge and quality of care for all patients with 
glaucoma.  The majority of the participants from both control and intervention arms 
felt that the GSAs facilitating NAGS were extremely approachable and supportive.  
It would appear, therefore, that further exploration of the delivery and content of 
the intervention is required in order to fully discern the components of the 
intervention that were beneficial to participants.  Arguably, the opportunity for 
participants to interact with a health care professional may have been the valuable 
element that led to satisfaction with care, rather than the ‘information content’ 
provided.  Furthermore, it is well recognised that service recipients tend to report 
high levels of satisfaction because of the desire to give ‘grateful testimonials’.212   
Future development of an adherence enhancing intervention could include 
provision of information pertaining to individual patient diagnosis and future 
prognosis to better meet the needs for more personalised information.  
Participants recognised that descriptive and standard information about the 
disease, treatment and prognosis should form the basis of all basic glaucoma 
education.  In addition to the standard written leaflets, participants used the 
internet to successfully acquire information.  With the current trend towards 
increased use of the internet and mobile device applications, different vehicles to 
present information, should be considered to increase accessibility to information 
and reduce costs of intervention delivery.  However, lifelong follow-up is required 
to assess the long-term changes (or stability) of glaucoma disease manifestation 
and due to the complex, slowly progressive and asymptomatic nature of glaucoma 
this information can be difficult to impart to all patients with glaucoma.  
Standardised information provided in leaflets cannot convey this individualised 
information regarding changes in prognosis and individual treatment plans.  Thus, 
a longer-term mixed method approach intervention may be required. 
A tailored approach to the delivery of specific information is essential and would 
allow for information to be reviewed and reinforced as often as required by the 
individual needs of each patient, over the lifetime span of glaucoma care and 
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follow-up.  Greater information provision and interaction may help to empower 
patients to take a more active role in their glaucoma management and to ask 
questions of their clinicians regarding their long-term prognosis. 
Reducing patient anxiety about retaining a driving licence in both the short and 
longer-term, better provision of advice about DVLA regulations and when to inform 
the DVLA is also essential.  However, whether the NHS or the DVLA are 
responsible for making these improvements is an issue for further debate, outside 
the remit of the present research.  
Some participants felt empowered to use the telephone support line to gain 
additional information, whereas others who had reported not receiving enough 
information during their BCC intervention session and still had unanswered 
questions had not chosen to access this service.  Further investigation is required 
to understand why some participants felt comfortable with using a helpline to gain 
information, whereas others had not even considered it as an option.  Plausibly, 
participants might have forgotten about the availability of the telephone service 
and a reminder or better advertisement of the service may have improved uptake.  
However, some participants reported not using the telephone helpline, but had felt 
reassured that the facility was available, had it been required.  The variation in 
participant’s preferences for sources of information and support needs further 
exploration, particularly as some participants reported feeling disappointed with 
the level of information they had received whilst in the intervention arm. 
The participant experiences provided unexpected evidence of potential study 
reactivity effects that may have changed participants’ behaviour towards use of 
medication.  Simply asking a question, taking part in a study or monitoring 
adherence may have a consequential effect on health behaviour, such 
phenomena that cause performance bias are known as Hawthorne effects.101   
There are many different sources of potential Hawthorne effects evidenced from 
the data.  The informed consent process increased participants awareness of the 
research objective to improve adherence to glaucoma medication.  Participants felt 
that the questionnaires were also a source of additional information that would not 
have been introduced as part of ‘standard care’.  Participants also benefitted, not 
only from the ‘intervention itself,’ but the attention and care given to them by the 
GSAs facilitating the study meaning that even control group participants 
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consequently had improved availability of information and satisfaction with care.  
The control group were aware that additional information given to the intervention 
group was being withheld from them, which made them feel that their ‘standard 
care’ was inferior to that of the intervention group.  Whilst the control group were 
willing to search the internet for the additional information they required, they felt 
that the information was less reliable than that provided to the intervention group.  
Such perceptions and variation in knowledge may have had the potential to alter 
behaviour.   
Participants liked using the TDA as a method to apply their eye drops successfully 
and whilst they had no objection to their adherence being monitored during the 
study, they felt this changed their behaviour during the course of the study.  Thus 
participation in the study may have been the motivator for participants to be 
adherent to their drop regime rather than any effects of the intervention.   
Overall, adherence to glaucoma medication was higher than expected in the 
NAGS control arm.  Despite the use of rigorous research methods and adherence 
measures, the NAGS study may have overestimated adherence in both arms, 
relative to usual behaviour due to Hawthorne effects as described by the focus 
group participants.  Medication event monitoring systems, such as the TDA, are 
widely considered to be the gold standard measure of adherence, but participant 
awareness of monitoring may have accounted for the lack of statistical evidence to 
show any difference between the control and intervention arm adherence levels.  
Furthermore, the steps taken to standardise the intervention may also have diluted 
the effect of a patient-centred intervention, causing a reduction in measured effect 
size.  A retrospective consent method that could conceal information relating to 
randomisation, study objectives, and monitoring of adherence from participants 
may have led to more objective responses to the questionnaires and minimised 
any bias caused by Hawthorne effects.  Thus establishing if the NAGS results had 
been compromised by these potential Hawthorne effects was considered 
necessary.  A new area of research had become evident, although not pertinent to 
the development of a refined intervention, nevertheless essential to the justification 
in the determination of an appropriate and reliable research methodology for the 
measurement of adherence to glaucoma medication.   
 153 
4.5 Methodological critique 
The focus group setting appeared to encourage participants to share their options 
with one another and both focus groups largely mirrored each other in terms of 
content and opinion, adding to reliability of the findings of the User study.  The 
framework approach successfully extracted participant and GSA opinions from the 
data. 
There did not appear to be any relationship between age and gender with respect 
to participant opinion and random selection of participants was considered 
appropriate for the studied sample.  Participants provided a broad representation 
of patient opinion and practical issues, relevant to the majority of UK glaucoma 
patients under NHS care.  Although it is accepted that the findings may not be 
generalizable to all UK residents due to the low ethnic diversity found in the 
Norfolk population.  Furthermore, those taking part in the focus groups User study 
may have had a more positive attitude towards the study and their glaucoma care, 
since those with negative experiences might not have volunteered to participate in 
such an exercise.  However, User study participants shared opinions as to where 
NAGS had led to dissatisfaction, which demonstrated that not all those with a 
negative opinion avoided taking part in the focus group User study. 
The focus group interviews were moderated and co-moderated by two 
independent researchers to minimise bias, but the principal researcher who was 
heavily involved in the design and implementation of NAGS was responsible for 
the analysis and creation of analysis themes.  Thus, pre-existing opinions and 
expectations of the findings held by the researcher working in isolation on the in-
depth analysis could be criticised.  Another independent researcher undertaking 
an in-depth analysis to validate the findings would have improved reliability of the 
results.  However, to ensure that the themes identified were considered 
representative of the raw data a research supervisor and the moderator who 
conducted the focus groups reviewed the finished analysis, both reporting that the 
analysis was grounded in participants discourse and appeared to be a good 
indication of real thoughts and perceptions.   
 
  
 154 
Chapter 5. Exploring reactivity effects 
5.1 Introduction 
The Western Electrical Company employed 35,000 workers at the Hawthorne 
factory in Chicago to make telephone relays.  During the 1920s and 30s the 
company performed numerous management studies in order to assess the effect 
of environmental factors such as lighting, temperature, rest patterns and food, on 
workforce productivity.213  Over time, the Hawthorne factory studies revealed that 
regardless of how the environmental factor was manipulated there was always an 
increase in worker productivity.  The evidence suggested that the psychological 
stimulus of being singled out and made to feel important as a direct result of being 
chosen to take the part in a study might have caused the increased output, rather 
than any direct causal link to the environmental factor under investigation.  Thus, 
the term ‘Hawthorne effect’ was coined and is now used universally to describe the 
underlying phenomenon that human awareness of trial participation can cause 
uncontrolled and non-specific experimental effects that are detrimental to the 
outcome of studies.101  Since then, the interpretation of the original research 
carried out at the Hawthorne factories has been strongly criticised.213, 214  The 
observed effects may have been caused by other contributing factors such as 
managerial input, fear of losing one’s job (particularly as the studies were at the 
time of ‘The Great Depression’), the duration of rest breaks, human relationships, 
and because there was an overall lack of scientific rigour.  Regardless of this 
debate, the term ‘Hawthorne effect’ remains a lasting legacy of the original 
Hawthorne studies.  
An oral health study identified that a ‘Hawthorne effect’ alone can have sufficient 
impact to physically improve oral hygiene.  Adolescent patients known to have 
poor oral hygiene were enrolled into a study in which a Hawthorne effect was 
intentionally induced.  Forty patients were randomly assigned to either the 
experimental condition or a control group.  The experimental condition simulated 
participation in a study by obtaining written informed consent and providing tubes 
of toothpaste that were labelled ‘experimental’.  The experimental group were 
given instructions to brush their teeth twice a day for two minutes and to return the 
toothpaste tube at the end of the study.  Participants in the control group had no 
knowledge that they were taking part in a study and were given the standard care 
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instructions that, in order to achieve good oral hygiene, they should brush their 
teeth twice a day for two minutes, the same instructions given to the experimental 
group.  After 6 months tooth surface area covered with plaque was measured.  
Participants in the simulated experimental condition had improvement in their oral 
hygiene of 27% (p<0.05) when compared to the control group,215 thus 
demonstrating that participation in a study alone can introduce a behaviour effect 
that changed the measured outcome.   
A Hawthorne effect could be embedded in a variety of mechanisms found within 
study participation for example the materials made available and intended by the 
researcher, feedback given to the participants during the research process, 
changes in patient motivation and goals and beliefs about the action effects 
induced by the intervention.  However, a Hawthorne effect has become a catch-all 
term used by researchers to label any psychological or social factors that has not  
been controlled for, or that cannot be explained in a study to describe the changes 
in behaviour that occur purely because of participation in research.210  
Interpretation of what constitutes a Hawthorne effect is controversial and is 
discussed at length in a recent systematic review.186  In the Hawthorne effect 
review, the authors strived to identify what constitutes the operationalisation of a 
true Hawthorne effect; weak uses of the term in the literature reviewed had made it 
difficult to identify studies to include in the systematic review and heterogeneity in 
the operationalisation of the Hawthorne effect in reported studies made 
interpretation of the results difficult.  However the review concluded that 
participation in research can and does influence behaviour at least in some 
circumstances.   
As we advance our understanding of the issues that Hawthorne effects present it 
would seem sensible to abandon the use of the term Hawthorne effect not least 
because there is probably no single effect that constitutes a Hawthorne effect.186  
McCambridge et al. stated that literature as a whole is principally concerned with 
the existence of Hawthorne effects and yet has not been designed to investigate 
the hypothesised mechanisms.  Thus, development of a framework that elaborates 
the possible mechanisms of effects and thus targets a study is necessary.186  
Other reactivity effects exist and can be manifested in a number of contexts.  The 
‘John Henry effect’, also known as ‘the reverse Hawthorne effect’, is thought to 
occur when participants in a control group are aware of their ‘control status’ and 
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compare themselves to the intervention group, subsequently attempting to actively 
improve their performance to overcome their perceived disadvantage of being in 
the control group.216  Another term used in clinical trials is a ‘nocebo effect’ which 
occurs when participants are not masked to their study status; individuals may 
perceive they are receiving minimal care and therefore a second-rate service in 
comparison to those who are receiving an additional intervention.101  
Consequently, an unintended performance bias can occur because the groups of 
participants feel they have been treated differently.217 
The ‘Halo effect’ describes changes in participant behaviour because of the 
novelty of the investigational intervention.  In such cases, it is the unjustified belief 
that the intervention, such as education provision or new technology, is ‘amazing’ 
which inflates expectation of a positive effect that causes an improvement in 
behaviour rather than the effectiveness of the actual mode of action from the new 
intervention; this confirmation bias causes positive feelings, which can change 
ambiguous neutral traits to be viewed as positive.  
‘Experimenter effects’ occur when researchers communicate their expectations 
about the outcome of the study to their participants, even subtly, thus influencing a 
change in behaviour to conform to those expectations.  ‘Subtle messages’ can be 
imparted through assessments and questionnaires introduced as part of the study 
design and can impact upon respondent’s subsequent attitudes, intentions and 
behaviours.218  Answering questions about behavioural intentions increases the 
accessibility of these thoughts in the memory; subsequently they are more likely to 
come to mind and be acted out when presented with the same real-life situation.  
The very act of making a prediction about a potential future behaviour can induce 
that behaviour to be played out.219  The changes in participant behaviour caused 
by measuring participants responses are known as ‘mere measurement effects’196 
220 221  or more recently the question-behaviour effect (QBE).222  A study which 
randomised participants to receive a questionnaire about the benefits of blood 
donation found that those who received the questionnaire were more likely to 
register and attend a subsequent blood donation session than those who did not 
receive the questionnaire.223  A meta-analysis of brief interventions designed to 
change alcohol drinking behaviour also found that answering questions altered 
subsequent reported behaviour.196  A recent systematic review found some 
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evidence of QBE on health-related behaviours, but bias within studies and 
publication bias may have overestimated the observed small effect size.   
As technology has advanced, monitoring different types of behaviour by use of 
electronic devices such as MEMS, motion sensors and pedometers have become 
fashionable.  Studies have shown that measuring participants use of medication 
can potentially cause a reactivity effect; as previously discussed, the social stigma 
attached to conforming to prescribed treatment may change participants behaviour 
or, it may be that medication container itself acts as a novel visual prompt or cue.47  
As a result, the behaviour observed is a modified version of natural behaviour.  
The magnitude of influence that mere measurement effects may produce have not 
been thoroughly investigated,209 and previous studies of the effects of electronic 
monitoring have remained inconclusive.204  However, one prospective RCT found 
that electronic monitoring in patients with type-2 diabetes led to a small increase in 
adherence.47 
A dementia study using a 2 x 2 factorial design of Ginkgo biloba versus a placebo 
control, together with intensive versus minimal follow-up, revealed that intensive 
follow-up had a small effect on participant-rated quality of life (QoL) scores.101  The 
authors of the dementia study believed that the concentrated contact with 
participants in the intensive follow-up group may have improved the relationship 
with the caregiver which lead the patient to have a better recognition of their own 
needs resulting in more ‘honest’ reporting.224   
Specific participation effects likely to be found in clinical trials can be subdivided 
into components; protocol effects due to the way that treatment is delivered, care 
effects due to the incidental aspects of providing care, Hawthorne effects when 
doctor and/or patient behaviours change because they are under observation and 
placebo effects when patients are aware of trial participation.  Participation effects 
are also called ‘inclusion benefit effects’ and refer to any demonstrable benefit 
induced because of participation in research that has not been controlled for.  
However, a systematic review of oncology clinical trials found there was little 
quality evidence to show that trial participation did actually lead to improved 
outcomes219 and thus the causal relationship between trial participation and 
improved outcomes are difficult to evidence. 
As previously described, research effects can prepare people to be more receptive 
to the study intervention than would otherwise be expected, causing a bias which 
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may either strengthen or weaken the true intervention effect size and threaten the 
validity of any conclusions that are.102, 103  As such, there appears to be an 
increasing interest in the possible reactivity effects found in behavioural studies.196, 
208  Due to the heterogeneity of reactivity effects and lack of rigorous studies, it is 
not possible to make inferences about the magnitude of reactivity effects on 
behaviour.  Habitual behaviours such as adherence to medication are likely to 
show only small effects in comparison to ‘one off’ behaviours that are easy to 
perform, such as donating blood.208  The effects of bias caused by research 
reactivity, if they exist at all, are likely to vary across differing studies, 
interventions, outcome measures and study methods.  Because the measured 
effects of behaviour change interventions are known to be small, even the slightest 
of measurement errors are of particular significance since they may obscure any 
tangible findings.  Behaviour change interventions therefore need to invest heavily 
in avoiding potential reactivity effects whenever possible.208 
 
5.1.1 Reactivity effects in glaucoma adherence studies 
Reactivity effects found in studies measuring adherence to glaucoma medication 
have been documented.72, 93  In an attempt to reduce potential reactivity effects 
when observing adherence behaviour to eye drops, different researchers have 
tried concealing MEMS devices from participants.47, 122, 183, 225, 226  The studies by 
Kass et al.122, 225 used a monitoring device hidden within eye drop bottles.  
Participants were told that the bottles were “free samples” and that it was 
important to return the free sample at the next visit so that the pharmaceutical 
company could provide more medication when empty bottles were collected.  The 
study conducted by Rossi et al.47 provided patients with a TDA during routine 
follow-up and used a retrospective consent method; participants therefore, were 
unaware both of their study participation and monitoring of their adherence.  A 
study by Hermann et al.226 using an electronic monitoring device compared the 
difference in adherence behaviour in participants that were told that their 
monitoring device measured the temperature of the medication, compared to a 
group that were told that the device monitored adherence.   
The study by Herman et al.226 had its own a control group so the observed 
difference caused by reactivity effects was easy to establish.  However, the study 
was not powered sufficiently to show any discernible differences between the 
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groups (n=36).  Participants taking part in the Kass et al. study 122 administered a 
mean 82.7% (CI ± 3.6) of prescribed timolol doses and 76.0% (CI ± 3.5) of 
prescribed pilocarpine doses and the study by Rossi et al. found a mean 
adherence of 77% (CI ± 6.95) to travoprost doses.47  As the studies by Kass et 
al.122 and Rossi et al.47 masked all their participants to the fact that their adherence 
was being monitored, it might be considered possible to compare these results to 
studies that used an unmasked method of measuring adherence to assess 
differences.  For example, the NAGS results had a median adherence score of 
80.9% (IQ=65.3, 93.1, n=83) in the control group which is higher than the masked 
results from Kass et al.122 and Rossi et al.47, but as discussed in Chapter 1.2.5, 
due to the differences in the definition of adherence, dosing regimens and length 
of monitoring periods, variances in measured adherence could be attributed to 
many varying factors.  An example of this problem is perhaps better evidenced 
when considering the study by Robin et al. 72  which used a similar observational 
study to NAGS, also using a MEMS, and informed participants that their 
adherence to eye drops would be monitored.  However, adherence was measured 
in terms of percentage of pharmacologic dosage covered by dosing, a different 
measure to percentage of adherence doses taken, which was used in NAGS, 
making the comparison of results between studies difficult.  However, Robin et al. 
found that measured adherence was much higher than they had expected at 97% 
± 6.7%.and the authors felt this could possibly have been due to the monitoring 
effects of the MEMS. 
 
5.1.2 Reactivity effects in NAGS  
The study of reactivity effects is a relativity new area of research with conflicting 
opinions as to whether reactivity bias actually exists.  It was felt, therefore, that 
identifying the potential reactivity effects which might have been present in NAGS, 
required further examination.  Figure 5.1 details previously described reactivity 
effects identified from the literature coupled with a description of the possible 
reactivity effect in NAGS.  In light of so many conceivable reactivity effects it 
became evident that there was a significant chance that the NAGS results could 
have affected the studies internal validity. Although reactivity effects are thought to 
cause only small changes,47, 196, 208 there is no known literature that suggests, if, or 
how the effect size is affected when a number of different reactivity effects 
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combine together.  The overall effect could cause a synergistic relationship 
resulting in greater reactivity effects than would be found in studies that have 
fewer reactivity effects.  Thus, if use of the TDA did change behaviour, it was 
important to establish if a reason for this could be identified and how likely it was to 
have occurred when participants were taking part in NAGS.   
A follow-up study was required with a qualitative approach to examine and 
understand how adherence behaviours might be affected when using the TDA 
compared to administering eye drops with the standard bottle of eye drops, 
specifically looking for evidence of reactivity effects.   
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Figure 5.1  Potential reactivity effects associated with NAGS 
  
• Control group may have improved their 
performance to overcome perceived 
disadvantages
John Henry
Effect
• Novelty of meeting with the Glaucoma Support 
Assistant at study visits may have improved 
expectations and adherence behaviour during the 
study in control and intervention group
• Novelty of using TDA improves behaviour in 
control and intervention group
Halo Effect
• Researcher communicates their expectations for 
the study through participant information leaflet, 
consent process and during discussions at study 
visits
Experimenter 
Effect
• Questions could have introduced subtle messages 
to participants
• Additional information or messages that patients 
would not normally received were given 
• Participants to conform or motivate a behaviour 
change in response to these queues
Mere 
Measure 
Effect
• Participants may have improved their adherence 
behaviour because they knew they were being 
observed and had to self-report their behaviour
Observation 
Effect
• Trial participation could improve adherence 
behaviour
• Participants were given more attention by research 
staff
• Additional information received becuase of consent 
procedure
Hawthorne 
Effect
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5.2 Method 
5.2.1 Aims and objectives 
The aim of the study to investigate reactivity effects was to observe the effect of 
using the TDA on adherence to travoprost.  The objectives were to elicit patient 
experiences of administering travoprost eye drops using the bottle alone 
compared with use of the bottle with the TDA specifically exploring potential 
reactivity effects that this might have on adherence behaviour.   
 
5.2.2 Study design  
A flow-chart of the study design is shown in Figure 5.2.  The study received ethical 
approval from the Norfolk Research Ethics Committee, (appendix 10) and 
research governance approvals from the East Norfolk and Waveney Research 
Governance Committee (appendix 11).   
 
5.2.3 Setting, participants and recruitment  
Patients attending the glaucoma out-patient clinic at NNUH diagnosed with either 
POAG or OH, previously naïve to treatment with eye drops, and prescribed 
travoprost were invited to participate.  Patients were over 18 years of age, able to 
give signed informed consent, as well as being able to read and understand 
English.  Patients whose eye drops were applied by care home staff, carers such 
as relatives or friends, or home-helpers were excluded, since the study sought to 
understand patients own experiences of applying drops and not those of their 
carers who can influence drop taking routines, techniques and motivations.   
All patients attending for their standard care follow-up appointment, who met the 
criteria were referred to the researcher by their clinician.  The researcher informed 
each patient about the study and gave them an information leaflet.  Patients were 
given time to consider their participation before written consent was obtained.  A 
short questionnaire-interview was carried out by the researcher to establish 
demographic information such as; age, gender and type of glaucoma in order to 
maximise variation within the sample.209  
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Participants were assigned a study number for the duration of the study, allocated 
consecutively.  Participants assigned an odd study number were allocated to 
Group A, ‘use of TDA first’ and even numbers to Group B, ‘use of TDA second’.  
Group A were asked to use the TDA for one month followed by the bottle alone for 
the second month.  Conversely participants assigned to Group B used the bottle 
alone for the first month then switched to using the TDA for the second month.   
Patients were withdrawn from the study if travoprost eye drops were stopped for 
any reason, such as poor efficacy, hypersensitivity or other unwanted side effects.  
 
5.2.4 Travalert Dosing Aid  
The study used the TDA which electronically stores the time, date and number of 
drops administered during the study period as described in Paragraph 3.3.2.4.  For 
the purposes of the study, the alarm feature was disabled during the study period 
as in NAGS.  However, many of the returned TDAs used in NAGS appeared to 
have had been tampered with and the stickers which prevented participants 
seeing the visual cue window that displays a ‘tear drop’ when it was time to 
administer a dose had been removed.  To prevent the desire for curious patients 
to remove the stickers themselves, it was felt better to leave the visual cue window 
clearly visable to all participants from the outset.  Therefore, in contrast to NAGS 
that covered the visual reminder with a sticker, the visual cue window was not 
covered and programmed to appear at between 9 pm and 1 am.   
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Figure 5.2 Patient flow through the qualitative study to observe 
the effect of using the TDA 
 
Figure 5 2. Patient flow through the qualitative study to observe 
the effect of using the TDA 
  
Drop naive patient asked by their clinician if they would like to 
participate in a study reviewing the use of a dosing aid.  
Patient agrees Patient disagrees 
Baseline visit:  
Informed consent obtained 
Demographic information collected 
Patient consented and randomised to Group A or B. 
 
Patient continues 
standard care. 
Week 1: Participant telephoned to establish use of travoprost 
and any side effects.  Start date for 28 days monitoring. 
 
Group A  
Demonstration of TDA given 
and advised to use TDA.  
 
Side effects reported = 
patient stops using 
travoprost. Patient 
continues standard 
care. 
TDA retrieved and 
Eyeot dosing aid 
dispensed if required 
 
Group A  Visit 1: 
 
After 28 days, researcher 
visits participant.  TDA 
collected, and advises to use 
the bottle without TDA. 
 
Group B 
Advised to use the bottle 
without TDA . 
 
Study completion: TDA dispensed if required.  Continue 
standard care. 
 
Group B   Visit 1: 
 
After 28 days, researcher 
visits participant. 
Demonstration of TDA given 
and advises to use TDA. 
 
Visit 2: Participants interviewed by researcher. 
 
Group A  Visit 2: 
After 28 days, researcher 
visits participant. 
 
Group B  Visit 2:  
After 28 days, researcher 
visits participant. 
TDA is collected. 
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5.2.5 Group A, ‘use of TDA first’ 
At the time of recruitment, the researcher demonstrated how to use the TDA and 
dispensed it with an instruction sheet (See appendix 12).  Participants were 
informed that the TDA would monitor their adherence to eye drops by storing the 
dates and time of each use during the 28-day study period and that the information 
would be reviewed by the researcher at the end of the study period.  One week 
post-baseline visit, the researcher telephoned the participant to check their ability 
to use the TDA and to check that they were not experiencing side effects to 
travoprost which might prevent continuation in the study.  Once the successful use 
of eye drops with the TDA had been confirmed the participant continued to apply 
the eye drops for 28 days, after which the researcher visited the participant at 
home to collect the TDA.  Participants were then asked to apply their eye drops 
using only the bottle for a further 28 days at which point the trial period was 
concluded and an interview scheduled with the researcher.   
 
5.2.6 Group B, ‘use of TDA second’ 
At the time of recruitment participants were asked to apply their eye drops as is 
standard practice with a bottle alone.  Participants were informed that after one 
month the researcher would contact them to organise a visit to their home to 
demonstrate how to use the TDA and dispense it with an instruction sheet (See 
appendix 12).   
One week post-baseline visit, the researcher telephoned the participant to check 
their ability to use the eye drops and ensure that there were no side effects to 
travoprost, which might prevent continuation in the study.  Once successful use of 
eye drops was confirmed the participant continued to apply the eye drops for 28 
days. 
After using the TDA for 28 days, the researcher visited the participant at home to 
dispense the TDA and participants were asked to apply their eye drops using the 
TDA for a further 28 days.  The participants were informed that the TDA would 
monitor the time and date of each application of drops and that the data would be 
reviewed by the researcher at the end of the study.  At the end of the 28-day 
period, the researcher scheduled an interview with the participant. 
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5.2.7 Semi-structured interviewsz` 
As discussed in Chapter 4.2.2, a qualitative research method allowed for the 
exploration of meanings and concepts201 to be explored.  One-to-one interviews 
were chosen to encourage discussion of sensitive information and to enable 
exploration of feelings and underlying motivations to use eye drops, the TDA and 
participation in research with the researcher.  Adherence to medication was not a 
topic that participants in the NAGS focus group, described in Chapter 3, chose to 
discuss openly.  One possible reason for this is the social stigma attached to using 
medication that might have prohibited a feeling of freedom to discuss such issues 
in a group setting.  Thus, it was felt that the issue of adherence could be explored 
more sensitively and freely using one-to-one interviews, allowing participants to 
speak openly about their experiences and personal perspectives of applying eye 
drops using the two different methods of application.    
The interviews were carried out in the participant's own home to make them feel 
more comfortable and to "dilute" the relationship between the researcher and the 
hospital.  However, participants were given the option of conducting their interview 
at the hospital, if they felt more comfortable with this, rather than having the 
researcher visit their home.   
Each interview followed the interview guide shown in Figure 5.3.  The interview 
structure was flexible to allow the researcher to continue discussion of any 
associated topic if it was felt relevant.  The order of questions was flexible so that 
conversation flowed naturally with the narrative of each participant.  Through the 
use of prompts, the researcher directed the conversation, where necessary, so 
that it remained focused on the topic.  All interviews were digitally recorded and 
field notes taken by the researcher either by jotting down brief notes during the 
interview and/or fuller notes made after each interview had drawn to a close and 
the researcher returned to their office. 
The data collected from each TDA was also discussed with each participant at the 
end of each interview.  For participants who were in Group A the data were printed 
out and taken with the researcher to the interview, for those in Group B, the TDA 
was collected at the time of their interview and the researcher downloaded the 
TDA data on the laptop computer.  
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5.2.8 After the study  
Standard care continued when participants completed the study.  Participants 
where supplied with a TDA to keep if they had found it useful during the period of 
the study. 
 
5.2.9 Sampling  
The study to explore reactivity bias used purposeful sampling to select a maximum 
of twenty interviews.  There are no fixed rules as to the number of interviews that 
are required in qualitative research, therefore after each interview had been 
conducted an initial analysis was carried out to assess the nature and diversity of 
the data.  The researcher was then able to decide when a varied range of patients 
had been interviewed and when the data were reporting the same emerging 
themes.  
 
5.2.10 Analysis  
All interviews were digitally recorded and then transcribed by an independent 
transcriber.  The data were analysed by the researcher using a framework 
approach, as described in Chapter 4.2.7.  In contrast to the analysis of user 
experience of NAGS described in Chapter 4 using three focus groups, the present 
study was likely to generate more data from the use of up to twenty interviews.  
Although not essential, the researcher had the opportunity to learn and use NVIVO 
and it was thought use of NVIVO might aid the systematic analysis of a large 
dataset.  Furthermore, trialling out methods of analysis was an important 
experience for the researcher.  NVIVO version 9 software was used to organise 
the data during the analysis.   
 
5.2.10.1 Patient demographics  
The patient population was characterised by using a descriptive analysis (date of 
birth, gender, ethnicity, living alone, and type of glaucoma).  
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5.2.10.2 Calculation of adherence from TDA data 
The calculation of the percentage adherence rate was derived from the number of 
doses administered over the monitoring period, as recorded by the TDA, using the 
adjusted adherence calculator105, 227 as described in Chapter 3.3.5.   
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Figure 5.3   The topic guide used in the participant interviews 
Introduction and warm-up 
1. Why did you decide to participate in this study?  
- Try to expand on general themes emerging where appropriate. 
General feelings about using eye drops 
2. Think back to the first time you used your eye drops. 
What were your first impressions? 
3. What has using eye drops been like for you? 
4. What do you feel about the eye drops you are currently taking? 
How do you feel about the dosage? 
What do you like most about the drops you use? 
What do you like least about the eye drops you use? 
What drawbacks/side effects, if any, are there to using eye drops? 
Motivation 
5. Would you say there is anything that has motivated you to take 
your eye drops? 
In what way does this motivate you? 
How often does it motivate you? 
TDA/bottle comparison 
6. What was it like using your eye drops without the Travalert? 
7. What was it like using your eye drops with the Travalert? 
8. Which did you prefer? 
Try to expand on reasons for this.  
9. The TDA recorded each time you used your travoprost.  What are 
your thoughts about this? If you had the choice, would you 
continue to use the Travalert or not? 
Why is that? 
Adherence 
10. I know it can be quite difficult to use eye drops every day.  Can 
you remember how many times you did not use them in the past 
month? 
Can you think back to the days that you missed a dose and what 
happened or what you thought led to you missing a dose?  
Do you think this was the same for both the month you used the 
Travalert and the month you used the bottle? 
11. Review adherence data collected with the TDA device with the 
participant. 
Summary 
12. Summarise the discussion and check if there is anything else the 
participant would like to add. 
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5.3 Findings 
The study recruited seven participants.  One participant had to be withdrawn 
because they suffered side effects to their eye drops during the observation 
phase.  Thus, six participants were interviewed, three in their home and three at 
NNUH, and the data analysed.  Of the six participants interviewed, one participant 
did not return their TDA so the data could not be extracted as they had 
misunderstood the instructions about returning it.  On review of the themes 
emerging from the six interviews, it was felt that the data had provided varied 
evidence with repeating themes, so the decision was taken not to proceed with 
any further interviews. 
The characteristics of both groups are displayed in Table 5.1.  Only one participant 
had less than 80% adherence and he reported that this was due to running out of 
medication.  
 
Table 5.1 Characteristics for each participant  
ID/ 
Group 
Gender Age Diagnosis 
% Adherence 
measured by TDA 
(duration of use) 
Participant 
preferred 
application 
method 
1/A Female 51 
Ocular 
hypertension 
100% (28 days) Travalert 
2/B Female 72 Glaucoma  100% (28 days) Travalert 
3/A Male 87 Glaucoma  78% (27 days) Travalert 
4/B Female 74 Glaucoma  TDA not returned Travalert 
5/A Female 81 Glaucoma  Withdrawn – side effects to drops 
6/B Male 56 
Glaucoma 
suspect 
91% (23 days) Travalert 
7/A Male 55 
Glaucoma 
suspect 
93% (28 days) Bottle 
 
 
5.3.1 Summary of analysis  
Six overarching themes were identified and applied to the data; (1) Initial 
experiences of diagnosis and initiating treatment, (2) motivations to use eye drops, 
(3) reasons for taking part in the study, (4) administration of eye drops, (5) 
experiences of monitored adherence and (6) differences between administrating 
eye drops with the TDA and the bottle.  Only the themes that were felt to be 
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relevant to the study aims and objectives have been reported in this chapter. The 
themes were brought together under four main headings that highlighted potential 
reactivity biases which could have affected patient behaviour.  
5.3.1.1 Study participation motivates use of eye drops  
Commonly, participants reported that protecting their eye-sight was their main 
motivation to use eye drops.   
Because I need my eyesight, I mean that is the biggest thing isn’t it, there 
is no way you can function without your eyes properly. (01, female) 
 
However, taking part in the study was also described as a motivator to use 
treatment and additional information provided as part of the informed consent 
procedure reinforced the necessity to use eye drops.  
…well you told me that was what you were going to do and so… it is quite 
a good motivator. (01, female)   
It was just something I knew that when I came up here and first spoke to 
you and found out what was the matter, I knew I had to keep doing it and 
after talking to you, you said set a time and der, der, der… that’s what I 
tried to do. (07, male) 
 
There was also evidence that the novelty of the TDA itself was a motivation to use 
eye drops. 
Well, If I hadn’t met you [referring to moderator] I would have carried on 
using the bottle, I wouldn’t have known no different would I?  I love it, I’ve 
never known anyone use anything like this before. (02, female) 
 
5.3.1.2 Use of the TDA makes administration of eye drops easier 
Some participants reported that using eye drops was problematic particularly 
initially.  Trying to find the correct position to hold the bottle to avoid the eye drops 
running down the cheeks was difficult. 
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When I first started using the bottle, because I was looking in the mirror 
and I was trying to put in, but because it was just going down there wasn’t 
it [refers to rolling down cheeks]. (02, female) 
 
However, the application of eye drops was felt to get easier over time. 
Yeah it took some time to get used to, get the sort of right position, you 
know, a couple of times it went out, at first, but now I am so used to it. (04, 
female) 
 
Most participants reported that the TDA was easier to use than the bottle alone.  
The lever was easy to use which was better than trying to squeeze the bottle and 
the device was bigger and thus easier to hold and precisely apply the drop into the 
eye than the small bottle on its own.   
I can sort of press it [the lever] and you get a drop straight away.  
Otherwise, with the bottle you had to sort of struggle, you don’t know how 
much pressure you should put in whether you get too much sort of drop, 
bigger drop than normal. (04, female) 
The lever was quite handy rather than having to squeeze the bottle, 
definitely. (01, female) 
But that machine [referring to TDA] was good because it is bigger and as I 
say you can get that over your eye and err, and you stand more of a 
chance of hitting the bulls-eye! (03, male) 
I think Travalert would be better because, you can, it is easier to hold in 
your hand. (04, female) 
If I do use it, if my wife wasn’t there to put the eye drops in, I probably 
would use the little machine more.  I feel that I would probably get a, if I 
was doing it myself, a more accurate shot. (03, male) 
 
Only one participant chose not to keep the TDA after the study.  He preferred to 
control the pressure on the bottle himself as he felt he could get the right amount 
of liquid out of the bottle, which he could not do with the TDA.   
 173 
5.3.1.3 Use of TDA makes administration of eye drops easier to remember  
Remembering to use eye drops was reported to be easy if it was part of a daily 
routine.  However, participants did report that the TDA was a visible reminder to 
use drops, which aided the memory.   
Because it’s your routine, I mean, it’s not 10 o’clock every night it’s 
between 10 and I say 11.30, 12 o’clock but its every time I go to bed there 
is it is sitting there and you just go click and its in that’s done it’s not a 
problem at all. (06, male) 
But once the machine [Travalert] went back I thought well I just ain’t going 
to remember, you know I’m sort of not forgetful but I just need that little 
nudge to make me remember I’ve got to do it at 9 o’clock…I set my phone 
so I know what I’ve got to do at 9….(07, male) 
Yeah, it does remind you, being the container there [referring to 
Travalert]….(04, female) 
I knew it was there and I knew I had to use it because it was you know it is 
quite large thing well, it’s a nice handy size…(07, male) 
 
The TDA also had a tear drop symbol, which flashes on the display screen when it 
was time to apply drops in the evening, and flashes continually until the dose has 
been taken.  Some participants commented on how helpful the flashing was and 
actually prevented them from forgetting to use their drops. 
The times when I am out of the routine is the times when I sometimes 
actually get my head down and think, oh, I haven’t done my eye drops.  
Urm so that you know as you turn the light off you saw it flashing…(01, 
female) 
[moderator asks “do you think there was a time that you missed your 
drops]… definitely not with the Travalert because that did flash at you, 
possibility once I might have done it without with the Travalert. (01, 
female) 
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5.3.1.4 Monitoring adherence 
The majority of participants reported that they were more aware of their eye drop 
use when their adherence was being monitored.  They felt that they would be 
“discovered” if they had not administered them and this made them feel more 
conscious of the need to use their drops. 
even though I was routined, it did make me, I mean there was occasions 
its gone passed certain times like, it did make me think about doing it a lot 
more because you don’t want to miss it, I don’t want to be in a position 
where it is like four days I’ve missed it you know. (06, male) 
well I suppose that would make you, well, knowing full well that I 
mentioned to you that you can’t get away with nothing, yes, then you do 
get on with it because you say you’ve not used it! (03, male) 
I was conscious, it’s like your phone, I’m conscious it is there so whatever 
I’m doing every now and again I’m looking, I wasn’t looking at the time, I 
was looking to see if the tear drop had turned up…and all of sudden I think 
to myself “how long has that been on there”. (07, male) 
…plus the alert thing… that really does get you going. Yes a couple of 
times as I have said when I’ve come home later or something it has been 
flashing at me, you know, and I think oh yeah, that is definitely… whereas 
you think yeah, I must do that.  (01, female) 
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5.4 Discussion 
There were equal numbers of males and females interviewed in the study and 
representation from the range of ages expected of the glaucomatous population at 
the recruiting site. 
Largely, participants acknowledged being highly motivated to use their eye drops.  
The fundamental reason given for good adherence with their drops was to 
preserve their sight, which is consistent with previous findings in a qualitative study 
undertaken with the same patient population in 2008.42  All participants discussed 
some form of routine to help ensure they were able to use their eye drops as 
prescribed which was also consistent with previous research.42, 228  As expected 
from motivated and routine driven participants, their adherence measured by the 
TDA was high; only one participant had less than 80% adherence reportedly 
caused by running out of eye drops. 
Participants gave insightful accounts of their experiences during the study period, 
which gave a better understanding of patient behaviours not only when 
participants use the TDA but also when participating in a study.   
One modification made to the TDA used in the present study was leaving visual 
cue window on display rather than being covered with a sticker in NAGS.  Whilst 
this might have reduced the amount of ‘tampering’ with the device, since 
participants were not curious to see what was being concealed, some participants 
did reflect on the usefulness of the ‘tear drop’ appearing when it was time take a 
dose and that it reminded them whether they had used their drops that evening.  
Such a modification was felt necessary to reduce over interest in the workings of 
the TDA but did introduce another potential reactivity effect that was not present in 
NAGS.  
Overall, the findings evidenced possible reactivity effects which could have caused 
a study bias during NAGS; awareness of monitoring adherence, the novelty of 
using the TDA together with participating in a study changed motivation to be 
adherent to medication as well as inflating expectations of using drops in 
comparison to standard use of the bottle.  The researcher also acted as a 
promoter of good adherence through the information given during the informed 
consent process, study visits and general interaction during the course of the 
study, which patients would not normally have received through standard care.    
 176 
5.5 Methodological critique 
It is widely accepted that participants who take part in research are more 
motivated individuals than those who decline and may be more likely to be 
focussed to use their medication.  If study participation is a motivator, a 
fundamental positive sampling bias might have been introduced and patients 
prone to non-adherence may have been missing from the sample. 
The interviews and framework approach to analysis successfully unearthed 
participant experiences of using the TDA in a study setting.  The sample of only six 
interviews was relatively small but the range and consistency of the data collected 
was good with a wide representation of ages, even mix of male and females, those 
with POAG or OH/GS and equal numbers from groups A and B.  The interviews 
revealed that the participants were also from a range of social backgrounds.  The 
data was rich in terms of examples used and details given by participants.  The 
emerging themes were repeated by the latter interviews with no new evidence 
emerging and therefore data saturation was reached in six interviews. 
Because non-adherence is felt to be a socially unacceptable behaviour, 
participants may have felt uneasy about admitting non-adherence with the 
researcher even though anonymity in the research process was guaranteed.  
However, review of the data showed evidence of a good rapport with the 
researcher and participants’ freely discussing evidence of instances of non-
adherence.  Some participants thanked the researcher for including them in the 
study because it had given them the opportunity to discuss their experiences.  The 
transcripts suggested that participants were very willing to share their experiences 
and there was ease in the conversation without signs of embarrassment when 
disclosing information about their adherence.   
However, as described in Section 4.1, as the main the researcher in the NAGS 
study, and the main author on the exploring reactivity study, the fact that I 
undertook the analysis in isolation could be criticised.  Building rapport and 
creating a discussion with participants may have altered the topics that were 
discussed and the information that was shared with me.  Certainly, embarking on 
the research in the first instance was influenced by the need to find out what 
individuals felt about using the TDA and without a vested interest in the NAGS 
study the projected would never have been conducted.  However, during the study 
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I was very much aware of these potential influences and am confident that I was 
able to explore all the data collected impartially. 
Carrying out the interviews in participants own homes was an enlightening 
experience for the researcher.  Some participants wanted to actually show the 
researcher where they physically kept their medication or pointed or made 
suggestive movements about elements of their environment to help them illustrate 
the point they wanted to convey.  Compared to the interviews that were carried out 
in the eye clinic, this made the interview feel more real and brought the 
conversation to life.  Furthermore, when analysing the data it was easier to 
remember parts of interviews that had taken place in people’s homes, the 
surroundings, noises, interruptions in some cases, all added to a sense of reality 
and was overall was considered a helpful method.  
Creating themes and topic coding was efficient with the use of NVIVO and 
retrieving themes and particular phrases was made much easier.  The initial 
training was a two-day workshop followed by a few sessions getting more familiar 
with the software, but it was a relatively easy process to learn.  There were many 
more additional functions that the software could have performed if more time had 
been spent learning these but with only 6 interviews to analyse, the quantitative 
functions of NVIVO were not considered valid and were not utilised. 
  
 178 
5.6 Conclusions 
Whilst the focus groups described in Chapter 4 confirmed that the NAGS study 
had been well received, the study methods could have introduced various 
reactivity effects.  Further exploration of the use of the TDA described in Chapter 5 
also highlighted the specific reactivity effects caused by the TDA.  Further 
research was required to ascertain the effect size caused by these reactivity 
effects in order to establish a reliable measure of behaviour change.  The 
contribution of such a study would provide an estimate of the extent to which 
research procedures cause an underestimate of the true magnitude of patient non-
adherence to medication.  Even if the effects were subtle, they would still be 
important to the conclusions drawn from adherence intervention studies in an area 
of research lacking empirical evidence and where bias is inadvertently introduced 
by experimental design errors.  If the effects were negligible it could be argued that 
the methods used in NAGS remain valid and could be recommended for future 
intervention studies, thus suggesting that the majority of patients do not require 
additional support to obtain good adherence with use of eye drops.  However, 
significant changes in behaviour caused by the reactivity effects might suggest 
that the intervention used in NAGS holds some credibility and that better methods 
to measure adherence are required. 
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Section 3. Establishing Patient and 
Public Opinion of a 
Modified Consent 
Procedure 
Presentations resulting from this section: 
Cate H, Bhattacharya D, Clark A and Broadway DC. Attitudes 
towards the use of a modified consent procedure in a study to 
measure adherence to glaucoma therapy (oral). UK Society of 
Behavioural Medicine, Newcastle, 2015. Winner of a High Scoring 
Presentation Award.   
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Chapter 6. Consultation with patients 
6.1 Introduction 
Previous evidence has suggested that reactivity effects have a minimal effect on 
study outcomes,208 but the follow-up work to NAGS discussed in Chapter 4, 
‘Exploring the user experiences of the NAGS study’ and Chapter 5, ‘Exploring 
study reactivity bias’, identified multiple reactivity effects.  The magnitude of the 
effect size could have been further amplified if a synergistic relationship occurred 
between these different reactivity effects; a hypothesis with limited prior reporting, 
evidence or investigation.  Deciding to explore the extent to which reactivity effects 
could cause changes in behaviour was not only important to improve our 
understanding of the NAGS methodology but also for the wider research 
community in order to comprehend patient behaviour when involved in 
interventional studies more generally.  If a reactivity effect could be observed and 
quantified, then all future studies that monitor behaviour could either modify their 
study method to control for these biases or apply a corrective calculation value to 
outcome data to account for such biases.  
A study was designed to measure the change in behaviour when participants were 
exposed to simulated reactivity effects.  Two designs were considered; an 
independent group RCT, or a cross-over study.  The ‘reactivity stimuli’ was 
awareness of participating in a study and measuring adherence to medication 
using a TDA and questionnaires.  The RCT was designed to compare the 
medication adherence behaviour between two independent groups, one group 
subjected to the ‘reactivity stimuli’ and one group assigned as a control arm, which 
would not receive the ‘reactivity stimuli’.  The cross-over study would first measure 
medication adherence behaviour in a control phase when participants were not 
aware that they were taking part in a study and that their adherence to eye drops 
was being monitored, compared to the experimental phase when participants were 
exposed to the ‘reactivity stimuli’.  Whichever study design was selected, 
participants would need to remain masked to the fact that they were taking part in 
a study and that their adherence was being monitored when participating in the 
control arm of the study.  Withholding such information and not taking consent 
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prior to participation in a study is rarely considered acceptable, such practice 
having important ethical implications.   
 
6.1.1 The ethical debate  
The arguments for and against obtaining informed consent or use of deceit in 
medical studies are discussed in a series of articles in the British Medical Journal 
(McLean, Dennis,229 Kale, Bhagwanjee et al.,230 and Seedat230).  Over many 
decades the move towards fully informed consent for all participants in clinical 
trials has been formalised in various guidelines.   
The British Psychological Society (BPS) have published ethical guidelines for good 
research practice.231  The use of deception is discouraged due to the potential to 
cause distress and harm and make recipients cynical about research activities.  
However, because behaviour can be modified if individuals are aware that they are 
being studied, it is recognised that in some cases deception is necessary.  If 
research does need to involve deception then it should be designed in such a way 
that it protects the dignity of the participants and that the objectives have strong 
scientific and medical justification and appropriate risk management.231   
The declaration of Helsinki and International Conference on Harmonisation for 
Good Clinical Practice offer no guidance on the use of deception, but the Council 
for International Organizations of Medical Sciences / World Health Organization,232 
and The Royal College of Physicians (2007) acknowledge that some research, 
must deliberately misinform subjects to ensure participants do not modify their 
behaviour in response to knowledge of the study protocol.233   
The NHS National Research Ethics Service (NRES) undertook a shared ethical 
debate exercise involving 20 Research Ethics Committees in 2009.233  The NRES 
debate reviewed the issues, guidance and evidence for use of deception in 
medical research specifically and determined that ethical review committees 
should ensure that the proposed research: 
 is such that the deception only poses minimal risk  
 is indispensable to the methods of the study  
 is planned after considering that no other research method would suffice 
 will lead or is likely to result in advances in knowledge, and  
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 follows wide consultation undertaken at the protocol design stage.   
The evidence suggests that there are legitimate cases which advocate the need 
for the nature, purpose and duration of the experiment (including the method and 
means, hazards and inconveniences expected, effects on health or person which 
may result from participation in the study) to be provided to avoid “force, fraud, 
deceit, duress or coercion” of participants in research.234  However, others insist 
that good reasons not to seek such consent often exist, one of those being where 
methodological reasons would exclude this.229, 230, 234-237   
A study investigating the effectiveness of stroke care after discharge from hospital 
provides a case example of a modified informed consent procedure.235  Patients in 
the intervention group could not be informed that they were taking part in a study 
to examine the effectiveness of outreach stroke-care since they needed to remain 
masked to their allocation strategy in order to avoid this introducing bias in 
participant responses to the evaluation of their own care.  After six months in the 
care programme, researchers sent a letter to all 102 participants informing them 
that they had participated in a study and the reasons for the study.  An ethics 
committee approved the study on the basis that there was no risk to patients and 
the reason for the study was clarified retrospectively.  The participants were 
interviewed two weeks after their participation in the study had been revealed to 
them, in order to evaluate the effects of withholding study information.  The results 
revealed that trust in doctors did not decrease because information had been 
withheld; only one patient said that their willingness to participate in future studies 
had decreased, and two participants had negative feelings after finding out the 
information had been withheld from them.  The majority reported not feeling any 
sense of negativity because the information was unimportant, the patient 
understood the reason why the information was withheld, or it was acceptable that 
the information was withheld.  The results suggested that a modified procedure to 
withhold information deserves consideration when patients need to be masked to 
study outcomes and if this entails no risk to the participant.   
 
6.1.2 Adherence studies using deception 
There are examples of glaucoma studies that have used deception to conceal the 
monitoring devices that monitor the eye drop use.  The studies by Kass et al.122, 225 
 183 
used a monitoring device hidden within eye drop bottles.  Participants were told 
that the bottles were “free samples” and that it was important to return the “free 
sample” at the next visit since the pharmaceutical company would provide 
additional medication to the clinic when empty bottles were collected.  The study 
conducted by Rossi et al.,47 provided patients with a TDA during routine follow-up 
and used retrospective consent.  Patients were therefore unaware both of study 
participation and monitoring of their adherence.  In the studies by Hermann et 
al.183, 226 not all patients were explicitly told that their adherence was being 
monitored, instead they were told that the monitoring device attached to their eye 
drops measured the temperature of the medication.  However, these studies were 
not carried out in the UK and different countries follow different guidelines for 
ethical research practice.  
However, two examples of general adherence studies undertaken in the UK have 
been published.  In a study carried out in 1995, 102 patients with asthma were 
provided with terbutaline and budesonide turbohalers238 that were fitted with 
turbohaler inhalation computers to measure adherence, these being concealed 
from the patient.  The turbohaler study aimed to examine psychological factors 
such as patient attitudes to asthma and its treatment, as well as anxiety and 
depression as possible reasons for non-adherence.  On the basis that masked 
observation was required in order to obtain an accurate picture of “normal” 
behaviour, ethical approval was given by the United Medical and Dental Schools 
Ethics Committee.  However, the authors did not describe how the study was 
conducted, if any form of consent was taken from participants, or any follow-up 
work to assess the effect that masking had on participants.  
The second UK adherence study aimed to determine factors associated with 
adherence and persistence to bisphosphonate therapy in osteoporosis, but the 
researchers concealed the purpose of the study from participants, informing them 
instead that  they were gathering information on their experience of osteoporosis 
and its treatment.239  Participants were recruited through advertisements placed in 
the UK National Osteoporosis Society magazine.  A telephone interview was 
undertaken and participant responses were used to assess self-reported 
adherence.  In this cohort of patients with osteoporosis, self-reported non-
adherence was unexpectedly high with 52% of participants reporting that they 
were non-adherent.  Participants are often thought to underestimate true non-
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adherence, which is attributed to both the social desirability to be adherent 
resulting in reporting and memory bias.  However, the results of the osteoporosis 
study support the hypothesis that when people are not aware that their adherence 
to medication is under scrutiny they are more likely to behave naturally and 
respondents may have felt at ease to report their true non-adherence to 
medication demonstrating that ‘reactivity to monitoring effects’ can exist. 
 
6.1.3 Conclusions   
Whilst the use of modified consent and deception in research had been used in 
previous research practice, there are clear signs that many issues still remained 
unresolved.  How patients might feel if they were to be involved in a study using 
modified consent methods required further exploration involving consultation with 
patients and individuals who share the same social and cultural background as to 
those who might become participants in such studies.   
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6.2  A mixed method study to elicit views of a modified 
consent method  
 
6.2.1 Aim 
A study was designed to elicit opinion from patients and members of the public 
regarding the use of a modified consent procedure, specifically an initial 
withholding of information and use of a later, retrospective, consent method 
process.  The aim was to use opinion captured from this population to shape the 
design of a subsequent study to observe patient adherence to glaucoma eye 
drops and determine if such a study design would be acceptable to participants. 
 
6.2.2 Objectives 
The objectives of the initial study were to consult with members of the public, and 
patients with glaucoma, as representatives of the population affected by 
glaucomatous disease:  
1. to capture opinion about the use of modified informed consent procedure  
2. to measure acceptability of using a modified consent method and quantify 
factors that might change opinion of acceptability  
3. to understand the concerns that may arise when using a modified consent 
method in order to design a study which minimised these fears. 
 
6.2.3 Study pathway 
The Norfolk Patient and Public Involvement in Research (PPIRes) group provide 
support to the local research community and ensure that public and patient 
perspectives inform the design, delivery and dissemination of research.  The 
PPIREs panel are ‘informed volunteers’ from a range of backgrounds and thus, 
they were an obvious place to start the consultation process.  The researcher gave 
a short presentation at the start of a group meeting to set the scene and give 
background information from which a discussion was encouraged.  One of the 
members had previously worked on the NAGS Steering Group Committee and 
was aware of the TDA and the complexity of measuring adherence.  It was clear 
from the initial discussion with the PPIRes group that opinions would be wide-
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ranging and a discussion template was drawn from this preliminary work as 
presented in Table 7.1, to be used with subsequent focus group meetings. 
As individuals are ‘products of their environment’ and are influenced by the people 
that surround them all of the time, the majority of opinions are not formed in 
isolation.240  Thus, focus groups were chosen as an ideal method for examining 
the reality of the modified consent subject, since a group dynamic encourages the 
social interaction that can develop ideas between individuals.241  For complex 
topics, a small sample size of 5 to 7 people per focus group is ideal and allows for 
the moderator to probe the key concepts using ‘structured’ and ‘free’ probes.240  
The focus group methodology and findings are discussed in Chapter 7.  A 
qualitative approach enabled patient and public views about this complex topic to 
be explored and a fresh perspective to be understood rather than the researcher 
making assumptions about the likely opinions and feelings that withholding 
information were likely to elicit.   
The qualitative phase informed the design of a questionnaire that would enable 
engagement with a wider population of patients and members of the public, from 
which quantitative data could be drawn to provide a measure of what people 
thought.  The design of the questionnaire is discussed in detail in Chapter 8.   
Chapter 9 describes the evaluation of the questionnaire design which was required 
before use.  Focus groups were not a suitable forum for evaluating the design of a 
questionnaire, since members within groups can tend to speculate about what 
other individuals might do when answering survey questions as opposed to 
reporting how they would react themselves.241  Thus a panel of researchers with 
previous experience of designing questionnaires and the local PPIRes group 
members independently reviewed the design and content of the questionnaire and 
made revisions.  Further testing of the questionnaire was undertaken using 
cognitive interviewing techniques to evaluate the questionnaire for reliability and 
validity with a sample of patients with glaucoma and the general public.   
Chapter 10 describes how the questionnaire was used to consult with patients with 
glaucoma and the general public visiting a general out-patient hospital, together 
with an examination of the results. 
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6.2.4 Ethical and Research Governance approvals 
The mixed method study to elicit views of a modified consent method received 
ethical approval from the Southampton B Ethics Committee (appendix 13) and 
research governance approval from the Norfolk and Norwich University Hospital 
(appendix 14). 
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Chapter 7. Focus groups to elicit views of a 
modified consent method  
7.1 Method 
7.1.1 Identification and recruitment 
A poster advertisement in the eye clinic of the NNUH was used to invite people 
with glaucoma to attend the focus groups (appendix 15).  Patients interested in 
participating in a focus group either approached the researcher via the reception 
staff in the eye clinic, by telephone or email to request further information.  
Additional posters were displayed at a patient glaucoma education meeting 
organised by and held at the NNUH.  A participant information sheet was provided 
with a consent form, which patients returned to the researcher if they wished to 
participate.  In addition, participants received a written information sheet about the 
research process and how ethics committees operate in the UK (appendix 16).  
Once consent was received, the following information was collected to inform 
sampling: age, sex, ethnicity, employment and marital status. 
 
7.1.2 Participant selection 
Five to six participants were required for each focus group.  Factors that may 
influence perceptions regarding the acceptability of modified informed consent 
procedures were not found during the review of the literature.  Thus, participants 
were purposively sampled to represent the widest range of demographic 
characteristics possible.   
Participants were contacted by email or telephone to confirm the meeting dates.  
However, once selected and contacted to confirm their attendance, some 
participants were unable to attend meetings on dates offered.  Therefore, all 
participants who had registered an initial interest were invited, irrespective of any 
sampling methodology to ensure adequate numbers for the planned focus groups. 
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7.1.3 Focus group interview guide and scenarios 
The initial PPIRes consultation group held in March 2012 described in Chapter 6.2 
helped to design a topic guide for two planned focus groups described in Figure 
7.1.  The focus group topic guide was designed to address the following: 
 patient expectations of the informed consent procedure 
 opinion of research designed to withhold information 
 opinion of research which deceives participants  
 opinion of the role of an ethical committee in research 
 
Two vignettes were used during the focus groups.  Vignettes are short scenarios 
in written or pictorial form, intended to elicit perceptions, opinions, beliefs and 
attitudes from responses to the circumstances described.242  In qualitative 
research, participants are usually asked to respond to a particular situation by 
stating what they would do, or how they might imagine a third person would react 
to certain situations and often entail some form of moral dilemma.  Vignettes can 
be used with individuals or within focus groups, although little has been written 
about the latter,243 and are often used as ice-breakers to engage participants in 
the topic and encourage dialogue within a group.  Vignettes may reflect what 
individuals believe and how they respond in reality and therefore, the discourse 
that emerges helps researchers to make links between beliefs and actions.  
However, not enough is known about the relationship between vignettes and real 
life responses to be able to draw parallels between the two.244  
When using vignettes, the stories must appear plausible and real to participants.  
Thus, the vignettes featured a research situation about a glaucoma study to 
enable the participants to engage with a scenario that related to their own medical 
condition and experiences of attending the eye department.  Sufficient context was 
provided to ensure respondents had enough understanding of the situation being 
depicted, but vague enough to ‘force’ participants to discuss any arising additional 
factors that might have influenced their decisions.  Some ambiguity in scenarios 
can be advantageous to the researcher, since it leaves space for participants to 
define the situation in their own terms.245 
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Introduction: Introduce yourself and tell us if you have taken part in any research 
before. 
1.  Review experiences of participation in research. 
2. Would anyone consider taking part in clinical study? 
Review opinion, if so why / or why not? 
Would this be for glaucoma / other medical conditions or both? 
Check that participants are sufficiently briefed on the information contained in the 
patient information sheet regarding the research process, what is an ethics committee, 
what is informed consent, and the research process. 
3. What would they expect when taking part in a clinical trial? 
Review opinion and ideas and where these originate from. 
4. Do you think it is ever right for researchers to withhold information about a study? 
Review ideas.  
Specific areas to drill down to: 
Is this the same for any research topic or specific to glaucoma studies? 
Would you feel that you weren’t being treated with respect? 
Would you feel negatively about research to the point you would never take part 
in research again? 
Would it reduce your trust in all doctors? 
5. What if there was a good scientific reason to withhold information?   
6. How do you think you would feel if you took part in a glaucoma study and some 
information was withheld from you?  
If you had taken part in a study that you were not aware of would you like to know 
about this at the end of the study and have this explained to you? 
7. How would you feel about being deliberately being deceived about a study you 
were taking part in?   
Is withholding information and deceit different? 
8. How would you feel if you your clinician were collecting information about your 
glaucoma to use in a study without your permission? (Audit work) 
Is this ever right? Why or why not? 
9. Do you think you would feel differently if you knew that the study had been 
reviewed by an ethics committee? 
Is it reassuring to know that a study has been reviewed in this way? 
Review ideas. 
10. What do you think are the most important aspects for researchers to consider 
when taking consent and informing patients about research? 
11. Is there anything else you would like to add or think I may have missed that you 
wish to discuss? 
Scenarios: I will read you a scenario followed by 5 options to choose from. The 
scenario describes a hypothetical glaucoma studies Please try and imagine yourself in 
the situation then chose which option best describes your opinion. When everyone has 
made a decision I will ask you all to hold up the card with your chosen option (cards 
provided to each participant) to display to the group. We will then take a moment to 
discuss the reasons behind your decisions.  
1. There is a new eye drop available for the treatment of glaucoma and your 
clinicians would like to test if it is better than your existing eye drops for treatment 
of your glaucoma.  Your clinician is going to do a study where patients will be 
asked to use either their existing treatment or the new treatment for comparison, 
but the bottles will look exactly the same so patients will not know what they have 
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been asked to use.  You have a 50/50 chance of using the new eye drops or using 
your own current drops (this method is used frequently in these types of study 
already).  You will be reviewed more frequently during the study to ensure that 
your condition is not deteriorating, however, your clinician does not want to tell you 
anything about the new drops or its side effects in case it changes the way in 
which you use the drops or what to expect when you start to use them.   
A You give your consent to take part as long as you are fully informed after the study 
has finished about what the drops were and their side effects. 
B You would consent to take part if you were fully informed at the end of the study 
about the drops and their side effects, and could withdraw your consent to your 
results being used if I did not agree with the new treatment. 
C You consent to taking part and would not need to be fully informed after the study, 
as you trust clinicians/researchers/and ethical committees enough to ensure your 
safety is not compromised. 
D You don’t think patients should need to give consent or be fully informed about the 
study as clinicians should be allowed to test new treatments as they see fit. 
E You would not consider taking part in this study.  Please consider and state your 
reason why. 
2. Your clinician would like to undertake a study to see if patients use their eye drops 
as prescribed.  Your clinician knows how difficult it is for patients to use drops and 
to remember to use them every day.  He would like to try and find out if this is a 
significant problem for glaucoma patients.  He is going to use an eye dropper aid 
that helps patients administer an eye drop into the eye, but electronically keeps a 
record of the time and date that the dropper aid has been used.  The electronic 
recording device is held within a plastic sleeve that fits around a bottle of eye 
drops and so it is not possible to tell that it is actually recording the use of eye 
drops.  The clinician is aware that patients might be more inclined to use their eye 
drops differently if they know they are taking part in a study and being monitored 
for eye drops use, so decides not to tell you anything about the study and just asks 
you to use the device to see if it helps you administer the eye drops (he does not 
mention that it is measuring every time you use your eye drops).  The clinician 
feels this is acceptable because there is no risk to you taking part in the study, 
your eye drops and glaucoma care continues just the same, and yet he will collect 
some very important data about the way in which you use your drops. 
A I agree that as there is minimal risk and it makes no difference to my glaucoma 
care. The clinician is right to carry out a study like this.  
B I agree that a study like this is useful, but the clinician should still ask me if I would 
like to take part even if I do change my behaviour because of it. 
C I agree that a study like this is useful and the clinician should tell me after the study 
has finished exactly what he was doing and why, and ask me if I will consent to 
him using this information. 
D I don’t think patients should need to give consent or be fully informed about the 
study as clinicians should be allowed to test as they see fit. 
E I don’t think clinicians should ever deceive patients, or do research without patient 
consent under any circumstances. 
 
Figure 7.1 Focus group discussion template 
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7.1.4 Analysis  
Both focus group discussions were digitally recorded and transcribed by an 
independent transcriber.  The collected focus group data were analysed by the 
researcher using a framework approach, as described in Chapter 4.2.7.  NVIVO 
version 9 software was used to organise the data during the analysis. 
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7.2 Findings 
The characteristics of both focus groups are displayed in Table 7.2.  There were 
more females than males and all participants were white British.  The groups were 
comprised of people largely of retirement age which accounted for the high rate of 
unemployment. 
 
Table 7.1 Participant demographics 
 
 
Total 
n=9 
Group 1 
n=5 
Group 2 
n=4 
Age (years) 
Median (IQ) 66 (63, 78) 66 (63, 79) 68 (57, 76) 
Male  
No. (%)  3 (33) 2 (40) 1 (25) 
Employed  
No. (%)  1 (11) 1 (20) 0 (0) 
British  
No. (%)  9 (100) 5 (100) 4 (100) 
Living alone 
No. (%)  2 (22) 5 (100) 2 (50) 
 
 
7.2.1 Experience of research 
One member of group 1 (1M) had previously been involved in a glaucoma clinical 
research placebo/control research study within the eye clinic at NNUH.  ‘1M’ spent 
time describing his experiences of taking part in the study; he had not known if he 
had used  placebo or active treatment for his glaucoma, but regardless of this he 
had found taking part to be a very positive experience. 
Two members of group 2 described different experiences of their previous 
involvement in research.  Participant ‘2F’ had taken part in a large cancer study for 
about 10 years, undertaking various fitness tests.  ‘2F’ explained that whilst she 
had not suffered with cancer herself, it was important to volunteer for something 
that might help others in the future.  When the study had finished she received a 
letter thanking and updating her on the outcome of the study, which had made her 
feel very proud to have been involved in something positive.  Participant ‘3F’ had 
also taken part in a clinical trial because she “had a medical condition which 
caused her body to produce cancerous cells”.  However, her experience had been 
rather negative because she felt that she had not received enough information and 
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had not received any feedback from the study in which she had participated 
making her feel unappreciated. 
 
7.2.2 Behavioural levers affecting research participation 
All focus group participants considered that they would take part in a clinical trial or 
research [the term was used interchangeably throughout the dialogue] not only for 
their own personal benefit but to help their family and future generations as well.   
I think the idea of research is a positive thing, we are never going to 
progress with problems are we, unless people do look into it and research 
for future answers. 4M, group 2.    
 
“My father had ordinary glaucoma and my son’s pressure is slightly raised, 
so I would be very interested if it helps people.” 5F, group 1.  
 
Participant ‘KR’, who had participated in a previous glaucoma study, described 
how he had consistent contact with his clinician and members of the research 
team during the course of the study from which he had benefited. During the study 
other health issues had been identified and reported to his GP that might 
otherwise have gone unnoticed.  Other participants felt that taking part in a 
research study meant that they would see a consultant more regularly and have 
greater reassurance in the continuity of care and additional tests.  
Being horribly cynical, as the situation is at the moment we come once a 
year if we are lucky, I have never actually seen my consultant,… I have 
only ever seen a registrar at the most, mostly nurses, which might indicate 
that my condition is not very serious, but if you took part in something like 
this [referring to a research study], then presumably you would get to see 
the big man himself quite frequently! 6M, group 2. 
Yes, I only saw [consultant name] once in the eighteen months, and I 
thought when you said what you were doing, I thought that, arrghh, 
perhaps I will see him more often. 2F, group 2. 
 
However, participants also discussed their perceived risks associated with 
research.  Some participants used examples of clinical trials involving eye drops.  
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Eyesight was felt to be “extremely precious” and all participants agreed that they 
would consider taking part in future eye research, despite the significant perceived 
potential risk associated with this.  Participant ‘7F’ discussed how she was willing 
to participate in eye research but stated that she would not want to take part in a 
study which used a placebo eye drop as she knew this would put her eyesight at 
risk of further damage from high eye pressure.  Both groups agreed that 
participation in research was about evaluating the risks involved and comparisons 
where made between which type of research would hold the greatest amount of 
risk.   
Oh yes, well obviously with drugs trials there is a certain amount of risk to 
patients isn’t there?  Well, I mean, not just necessarily to their overall 
health but it might make them feel very unwell, you know, but obviously, a 
group like this [referring to the focus group]... you know... well, there is no 
risk is there? 6M, group 2. 
 
Group 1 participants referred to studies where physical harm had been caused; 
Northwick Park in 2006 and the lack of ethical oversight that led to the distribution 
of thalidomide in the 1960s.  After much discussion, the group concluded that 
research within the NHS did now have a reliable system of testing drugs through 
different phases of trials, so that if something adverse was going to happen, it 
would have done so in an earlier phase of the trial.  Thus, the phase of the study 
would be used by patients to help guide them in making a decision about what 
risks might be involved should they have to decide if they felt taking part a study 
was acceptable.   
 
7.2.3 Ethical committees 
Participants felt reassured by the presence of the NHS ethical review system.  The 
differences between different types of research studies, such as observational, 
interviews and clinical trials, were discussed and most agreed that all studies 
should undergo the same ethical review processes regardless of the type of study.  
Some participants were surprised to learn that all research underwent a rigorous 
ethical review process even if relating to a study not involving an investigational 
drug. 
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Participants felt that involvement from an Ethics Committee gave reassurances to 
patients that the potential risks had been considered before a study would be 
given approval and that an Ethics Committee would be in control during the whole 
study process. 
With the ethics committees being there at every step you have to assume 
that things are going along alright. 7F, group 1. 
You have to have trust in the ethics committees I suppose don’t you.  You 
are putting your fate as it were in their hands, they have agreed that it is ok. 
5F, group 1. 
 
In general it was felt that the current system used to ensure good ethical conduct 
gives research credibility and reassurances to participants.  The focus group 
participants felt that patients diagnosed with the health condition under 
investigation can act as representatives of that patient population in order to give 
their opinion about the study design and that these opinions should inform the 
ethical review process on a systematically, particularly with studies that contain a 
degree risk or specific ethical concerns.  
...especially if something is particularly controversial or slightly dangerous 
or that could help you know...yes, I have proof here that, you know, 
several people I have spoken to who have got it, and would like this to go 
ahead as it could help. 5F, group 1. 
Possibly have someone from the patient group on the ethics committee to 
be able to put their view across. 3F, group 2.  
 
Another issue that arose in the focus group meeting related to feedback.  It was 
felt that participants of research would find it beneficial to be able to provide 
feedback to an ethics committee about researcher conduct, whether they felt that 
they had received enough information during the study and how they had been 
treated during the research study.  Focus group members felt that the ability to 
offer feedback would help research participants to feel more empowered and that 
an ethics committee could learn valuable lessons about researcher conduct and 
research standards.   
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So would they want feedback from us and how we felt, we had been 
treated within this trial, within this research, if there was a feedback form to 
say, yes we enjoyed it, yes we were kept informed, no we didn’t like this 
part of it, yes we think this.  Is there feedback to the ethics committee to 
say that your research was worthwhile and it was beneficial? 3F, group 2 
 
7.2.4 Ensuring patient confidentiality when collecting data for research 
purposes 
Some participants from both focus groups had fears relating to data protection and 
confidentiality of their information.  Because participants are aware that large 
amounts of information are stored electronically it was felt that this could be more 
easily ‘lost’ in error.  Participants also shared their experiences of doctors and 
health workers breaching confidentiality by discussing patient details in public 
areas and that pharmaceutical companies could corrupt NHS employees in order 
to get access to confidential information. 
And confidentiality, I think that is important, even though this [details about 
your eyes] isn’t you know terribly personal, as it were, you wouldn’t want 
other people to know… 5F, group1.  
And it isn’t just doctors.  I can remember going for my lunch one day in a 
pub… and there were two social workers there talking about one of their 
clients on the ward and I was sitting three tables away and I suddenly 
thought, you can’t do that, I’m beginning to know who you are talking 
about and I think that everyone else does too... 8F, group 1.  
...think about pharmaceutical companies that charge such exorbitant fees 
for medicines, you know, to the National Health.  They like to get hold of 
all sorts of information you know.  So they could use someone in the 
hospital couldn’t they. 2F, group 2. 
 
Some participants felt that better safeguarding systems were required to protect 
patient information and thought that researchers should be respectful of the 
information they have access to since it belongs to the patient.  Access to patient 
hospital records should only be granted to researchers if the study is worthwhile 
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and beneficial to patients.  The ethics committee was seen to be a suitable 
governing body that could oversee these safeguarding systems and give access to 
information where it was appropriate based upon the competence of the 
researcher to review, extract and store patient data appropriately.   
However, there were mixed opinions among the groups when determining what 
was felt to be an acceptable level of data extraction for researchers to carry out 
without consent from the patient.  There were those who felt that researchers 
should always seek consent from patients before gathering data from medical 
records.  Conversely there was those who felt the practice of data extraction from 
notes was acceptable without patient consent providing that the research had 
been agreed by an ethics committee.   
I suppose it is different if you have something you don’t want people to 
know about, AIDS or HIV or something like that, urm but for something like 
glaucoma I don’t think anybody would mind anybody knowing. 5F, group1 
My daughter is a hospital pharmacist and she is always having to be 
involved in doing audits on this that and the other, and again selecting 
information anonymously has got to be done… How else are they going to 
get the information? 9F, group 1. 
I think the principle needs to be approved… It should be part of the 
parameters you’re working with presenting your, your urm sort of rationale 
for your research project…7F, group 1  
I think that ought to be as well, that they would ask, not just go through 
random batches of files.  It is personal without, and unfortunately in this 
day and age the way that things are going, it is so easily abused with the 
technology. And I think that is a frightening aspect, quite frankly. 4M, 
group 2 
I suppose really, all our information is there for anybody to look at anyway, 
how many people have looked at it in the first place … so I think it can all 
be quite academic at the end of the day.  3F, group 2 
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7.2.5 Withholding information from participants 
Providing information to participants during all stages of the research process was 
felt to be important namely at the time of consent, during the study participation 
phase and after the study, when it was felt the conclusions should be shared with 
research participants.  However, there were mixed views as to the level of 
information that should be given to participants in research studies.  Some 
participants felt that as much information as possible should be given at every 
opportunity, whilst others acknowledged that there may be circumstances when 
this may not be possible or even necessary.  Discussions focused on the fact that 
not all participants may require the same level of information from researchers; 
this being dependent upon literacy levels, personal need for information and ability 
to understand complex information.  Participants also acknowledged that too much 
information might actually change the way that patients might react and feel about 
a study if trying to please the researcher.  
I can see that there would be occasions when subjects [referring to 
participants] of the research might colour their findings to basically be nice 
to the researcher. 6M, group 2.  
 
Participants suggested that information should always be given in layman’s terms, 
a brief synopsis of the research project should always be given and on-going 
communication throughout the study should be provided so that if a patient’s 
condition were to change or new information becomes available, participants 
should have the reassurance that this will be communicated with them.  As 
patients have the freedom to choose to opt out of research at any point, if they feel 
that the new information changes their willingness to continue with the study they 
may withdraw their consent.  It was agreed that the specific important information 
that should always be shared with participants are the possible risks associated 
with a study, such examples discussed were side effects and first-in-human drug 
trials. 
The idea of researchers deliberately withholding information from participants was 
discussed within the focus groups.  Participants from both groups chose to discuss 
the topic in terms of the physical risks that participants may unknowingly be 
agreeing to.  No definitive answer could be given as to whether it was right or 
wrong to withhold information, since it was felt that this was dependent upon the 
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merits of each individual study.  The participants felt it was important that there 
should be a legitimate reason for withholding information and the information that 
was going to be withheld should be evaluated by an ethics committee, along with 
the type of patient safety strategies that would ensure that participants would be 
kept from any harm.   
If it was something like ‘a cold’ then, so be it.  But if they know that it is 
likely to cause blindness, to go to the extreme, then I would damn well 
want to know.  Then I’m afraid that my answer would be no, I would not 
take part. 9F, group 1 
Because there are different types of research, so there’s just paper, and a 
consensus of information or a consensus of knowledge or whatever you 
want to call it, others it is going to be more in depth.  And I think the more 
in depth it goes, then I think you would have to ask the question, ‘well why 
would you need to keep that information to yourself’.  Why would you not 
share that with me?  If I’m prepared to take part in a drug trial, why have 
you withheld information from me? 3F, group 2. 
 
The guidelines followed by ethical committees in order to protect participants from 
feelings that they have not been treated with respect, which would have a negative 
effect on future research, or cause a loss of trust in their doctors were not referred 
to during the focus group discussions.  When probed specifically on the subject, 
only one person suggested that they might not be able to trust a doctor who had 
been involved in deceiving them.  
Neither of the two participants who had previously had negative experiences of 
research (3F and 6M) felt that this experience would change their opinion in 
considering participation in future research studies.   
Participants also discussed what they felt was the difference between ‘withholding 
information’ and ‘deception’.  There was total agreement that it was not 
permissible to use deliberate deception whereas withholding information would be 
acceptable in certain circumstances.  Examples given of deliberate deception were 
not telling somebody they might be using a placebo or giving false information to 
patients.  
 201 
I think there has to be a distinction between the two.  I don’t think you 
could ever condone deliberate deceit and deliberate misleading, but um, 
as I say, if the information is just not offered and the patient doesn’t ask, 
then I can’t see that there is too much of a problem.  6M, group 2.  
…you might well want to do a similar sort of thing in any trial and that’s 
withholding information, that is perfectly acceptable.  But to deceive 
somebody by saying oh we have had no problems with this or something 
and they have actually been having problems obviously that would be 
perhaps a step too far. 7F, group 1.  
 
7.2.6 Scenarios 
The scenarios are presented in Figure 7.1. 
 
Scenario 1  
All participants reported that they would give their consent to taking part in the 
study described in the first scenario.  Eight participants chose option ‘A’; to give 
their consent to take part as long as they were fully informed after the study had 
finished about what the drops were and their side effects.  One participant chose 
option ‘C’; to give consent to take part but would not need to be fully informed 
about the study, since they trusted in clinicians/researchers/ethical committees 
enough to ensure their safety was not compromised.  
 
Before making their choice, participants in focus group 2 discussed the risks 
associated with the study and the fact that information about the eye drops was 
being withheld.  Together the group defined the situation and decided a course of 
action to overcome the perceived risks.  The main elements of concern appeared 
to rest upon the perceived physical risk from the use of eye drops, not the fact that 
researchers were deliberately withholding information from participants.  Once the 
degree of risk had been established, it was felt that the risk would be minimised 
because research clinicians would monitor patients more closely.  Furthermore, it 
was felt that if a participant did have a problem with the use of eye drops and they 
were able to stop using the eye drops, participation would be satisfactory.  
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But as long as I am informed beforehand of what why and when and as 
long as I know I am going to be monitored throughout, so if I thought they 
were going to affect my eye in anyway or myself personally, then yep I 
would actually say, “I don’t think I want to carry on with that” or the doctor 
would say, “no, I think you need to come off these drops” you know.” 3F, 
group 2. 
 
Scenario 2 
Scenario 2 was of particular significance as it was based upon the future planned 
study to investigate research reactivity effects.  All participants agreed that they 
would take part; 5 participants chose option ‘C’ to have the study explained and 
retrospective consent obtained at the end of the study, 3 participants chose option 
‘A’ because they felt that as there would be no change to their glaucoma care and 
that it involved no risk, the study could be carried out without consent, although 1 
participant felt that regardless of possible changes to behaviour, consent should 
still be obtained at the beginning of the study.   
In general participants felt that because the study would be reviewed by an ethics 
committee and because it would not change their way or life, or their medication, 
that the study was acceptable.  Participant 3F had previously been adamant that 
all information about research should be discussed with participants prior to 
participation.  However, when considering this scenario, she felt differently:   
I think because of, it’s just monitoring how you are using your drops or not, 
so it is not going to change my way of life, you know the tablets or drops 
are not going to change me in anyway shape or form in the research, but 
as long as I know it has been through an Ethics Committee, obviously it 
has had permission to go through the research, but as long as I know 
afterwards, they say, “well look, we wanted to monitor you because now 
we are going to try and do a new type or dropper, or a new way of 
reminding somebody to use their drops and we needed to know who is at 
risk, and how they are going to use it. 3F, group 2.  
 
Option ‘C’ appeared to have been favoured because participants felt the need to 
have information about research in which they had participated.  Those who chose 
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option ‘A’ felt that it would be absurd to go through a whole study only to decline 
consent right at the end. 
It just seems to be silly that you would go through the whole procedure 
and then say “no, you can’t use my results”.  It’s just, it just seems daft! 
6M, group 2.  
 
However, the participant who chose option ‘B’ was completely adamant that 
participants have a right to information, and consent should be taken regardless of 
the perceived benefits of the study. 
From my point of view that negates my earlier thing, that we ought to be 
told, we have got a right, and I would like to be told… 4M, group 2. 
 
Many of the participants discussed the merits of such a study and felt it would 
really help clinicians to understand patients and potentially stop prescribing 
stronger drops that might not actually be necessary.  It was felt that there would be 
no other way of collecting this information without changing the consent 
procedure.  Participants did not consider the study described in scenario 2 to be 
classed as deception.  
As far as I can say that is a brilliant idea. 8F, group 1. 
I don’t feel in this case it is deception as such,… if you told people what the survey 
was then it would actually skew the results.  I can’t see any other way of getting 
the information without tweaking it. 9F, group 1. 
… in this particular scenario it must help the clinician to understand why your 
condition isn’t responding to the eye drops if you are not regularly taking them ...I 
think it is a win win situation. 5F, group 1. 
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7.3 Discussion 
The results from the focus groups used to elicit views of a modified consent 
method suggested that there were behavioural levers that would either increase or 
reduce the likelihood of patient participation in research.  Focus group participants 
predominantly based their initial decision as to whether they would participate in 
research on the perceived risks of any study, a common factor cited in other 
survey studies.246-248  The findings confirmed the established standards that 
research participants should be given information about the research and that this 
should be in understandable layman’s terms and clearly identify any associated 
risks with participation in the research.  However, when patients need to be 
masked to study the fact that they are taking part in research, it appeared that use 
of a modified consent procedure and at least the initial withholding of information 
might be acceptable to participants, should this entail no, or minimal, risk.  
Interestingly, previous research by Boter et al., has shown that only a small 
minority of participants had negative feelings after finding out that information had 
been withheld from them when involved in research.235 
An ethics committee has an important role in the research process and is trusted 
by patients to represent them and make decisions on their behalf.  However, the 
focus group participants felt that additional consultation with representative patient 
groups would be ideal before approval is given to research.  Furthermore, it was 
felt that research participants should be given the opportunity to give feedback to 
an ethical committee about the conduct of the research once a study was 
completed.  Focus group participants also stated that for studies that collect 
information from patient medical records there should be close regulation to 
ensure that the research is worthwhile, that researchers have the required 
competency to complete the task and that they would safeguard patient 
confidentiality.  In certain circumstances, particularly if a study where to involve the 
collection of highly sensitive data, the focus group participants agreed that consent 
should be sought from patients before data collection.  
An important conclusion that was made in the focus groups was that an ethics 
committee should work in conjunction with patient groups to decide when the use 
of a modified consent procedure was justifiable and ensure that such studies 
would not cause harm, distress or hold additional perceived risks to participants.   
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In the mock scenarios, the focus group participants tended to agree that they 
would take part in a study that withheld information from patients.  When the mock 
study was specifically aimed to assess patient behaviour towards medication 
adherence, all but one participant agreed they would be happy to participate 
without giving prior consent.  In general, participants favoured the idea of 
debriefing participants that may have taken part in a study without their 
knowledge, but stated that a formal retrospective consent process was not always 
entirely necessary.  
The findings from the focus group meetings suggested that designing a study 
using a retrospective consent design was justifiable and would be be acceptable in 
a local glaucoma patient population for the specific purposes of monitoring 
adherence to medication.  However, it was felt that consultation with a wider 
patient population was required to show the generalisability of these opinions.  
Building on the knowledge gathered from this preliminary work, Chapter 8 
describes the body of work that was undertaken in order to design and implement 
a questionnaire that could seek opinion from a wider population of both patients 
and members of the public.  
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7.4 Methodological critique 
The focus groups involved the use of hypothetical questions where respondents 
were asked to make predictions about their future behaviour.  Such questions may 
reveal intention or a state of mind at the time of asking, but have often been found 
to be poor predictors of actual future behaviour.249  Furthermore, often in a 
hypothetical situation there is not enough relevant information given to the 
respondent in order for them to make a judgement.241  Use of hypothetical 
questions could therefore be considered an unsuitable method for collection of 
participant opinions and attitudes.  However, the researcher was careful to use this 
type of questioning in the context of a study scenario that gave specific information 
in which respondents were able to identify with, which may have negated some of 
these misgivings.   
The focus group identified that participants found it difficult to express their explicit 
opinion about the acceptability of research due to the range and complexity of 
different types of research.  Participants needed to know more information about 
the reasons for a study and exactly what was involved, including the potential risks 
and benefits to patients.  Thus, the use of two scenarios enabled participants to 
clearly identify and discuss their opinions in context and were better able to give 
specific examples and explain their judgements in context.  More importantly, the 
scenarios gave a systematic comparison of individual responses to different 
behaviours.  However, use of scenarios can involve subjective interpretations so 
respondents may distort the information given through recall error and report 
based on their selective perceptions.  In addition, participants may have been 
keen to provide a socially desirable response.  However, in the probing session, 
participants maintained their initial response and gave good evidence to support 
their opinions.  
By virtue of the fact that the participants taking part in the focus groups had 
willingly volunteered to take part, they were likely to represent the characteristics 
held by more motivated individuals and therefore those more likely to be willing to 
volunteer for research generally.  Therefore, in order to seek opinion from a wider 
range of individual characteristics, a follow-up questionnaire survey was 
considered to be beneficial.  
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Chapter 8. Questionnaire Design  
 
A questionnaire method was chosen for use in the collection of standardised 
responses from a large population and assess whether the opinions elicited from 
small focus groups could be verified.  The questionnaire had to be designed in 
such a way as to yield reliable, valid, sensitive, unbiased and complete data to 
ensure the differences recorded were not due to artefact, or variances in the way 
the data were collected. 250  Literature on the principles of questionnaire design 
aided the design of the questionnaire and is discussed in this chapter.  
 
8.1 Questionnaire specification 
The primary outcome variable was designed to measure respondents’ opinion of 
taking part in a research study that used a modified consent method.  The focus 
groups described in Chapter 7 had revealed the core concepts that were 
interwoven with the primary outcome variable and these had to be measured by 
the questionnaire.  The extracted themes from the focus groups were categorised 
into three main domains; experiences, opinions, and attitudes.  Table 8.1 
summarises these core concepts derived from the focus group study, separated 
into their respective domains and how these were matched to questionnaire 
outcome variables.  Demographic information, previous experiences of research, 
experience of health services and diagnosis or knowledge of glaucoma 
parameters were also collected to establish variances in primary outcome due to 
these variables, this being a benefit of using a questionnaire method with a large 
cohort.  
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Table 8.1 The matrix of core concepts with their respective questionnaire 
outcome variables 
Domain Core Concepts Question objective 
O
p
in
io
n
s
 
Concerns about taking 
part in research. 
 
Describe the concerns participants have 
about taking part in research.   
Identify whether there is an association 
between previously taking part in a 
research study (attitude) and opinion 
about possible concerns when taking part 
in research? 
Expectation about 
information provision and 
advice about the possible 
risks when taking part in 
research? 
Report the percentage of respondents that 
would expect to receive information about 
the possible risks associated with taking 
part in research. 
Is it acceptable for 
researchers to withhold 
information from 
participants? 
Report the percentage of respondents that 
feel it is acceptable to withhold information 
from participants.  Describe opinion about 
the main concerns and report if this has 
any association with the main outcome 
variable. 
Is it acceptable for 
researchers to omit 
participant consent 
before entering a study? 
Report the percentage of respondents that 
feel it is acceptable not to take consent 
before entering a study and any 
association with the main outcome 
variable. 
Satisfaction with services 
provided at the eye clinic. 
Describe experiences of the eye clinic and 
any association with the main outcome 
variable. 
Does taking part in 
research improve 
satisfaction with health 
care received? 
Report the percentage of participants that 
would expect an improvement with their 
health care when taking part in research 
and any association with the main 
outcome variable. 
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Domain Core Concepts  Question objective 
E
x
p
e
ri
e
n
c
e
s
 
Previous experience of 
research. 
Report the percentage of the cohort which 
had previously taken part in research and 
any association with the main outcome 
variable. 
Positive or negative 
experience of research. 
Describe experiences and any association 
with main outcome variable.  
Type of research 
participants have taken 
part in previously. 
Report the percentage of respondents 
who have previously taken part in and any 
association with the main outcome 
variable. 
A
tt
it
u
d
e
s
 
Reasons why participants 
do not value research. 
Open question for participants to report 
any reasons why they did not value the 
research they participated in. 
Willingness to participate 
in research. 
Report the willingness of participants to 
take part in research and any association 
with the main outcome variable. 
Concerns associated with 
information being 
withheld when taking part 
in research?  
Describe the main concerns when 
information is going to be withheld from 
participants.  
What are the main 
concerns with consent 
not being taken before 
entering a study?  
Describe the main concerns associated 
with consent is not being obtained before 
entering a study. 
D
e
m
o
g
ra
p
h
ic
s
 
Do demographic 
variables influence the 
main outcome variable? 
Describe patient demographics and any 
association with the main outcome 
variable. 
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8.2 Questionnaire Construction 
8.2.1 Presentation  
The presentation of a questionnaire is important to enhance readability, 
understanding of the questions and response options and encourage successful 
completion.  The recommended format is to print questionnaires as booklets to 
give greater ease in reading and turning pages, reduction of the risk of losing 
pages and facilitate the use of a double page format.251  The placement of the 
questions on the page must ensure that respondents do not accidentally skip 
questions or need to turn a page mid-question since this is more likely to result in 
response errors.  Splitting response categories over two pages may also introduce 
a subtle form of loading, as respondents may not read or give less consideration to 
items on the second page.252   
Questions should not be crowded onto the page in order to make the 
questionnaire look shorter; it is argued that a longer questionnaire, which is less 
cramped and has more “white space”, looks easier to complete, generally resulting 
in higher response rates and less errors.  Sufficient space should be available for 
responses to open-ended questions, particularly as the amount of space available 
is likely to act as an indication of the level of detail required by the respondent.  It 
has been shown that using lines for open-ended questions, makes the 
questionnaire look more crowded and should only be used with short answers of 
one or two words or a number.253  A font size of 12 points is considered sufficient 
but a minimum 14 point san serif font should be used if respondents are likely to 
have visual impairment.254 
There is a paucity of evidence for the suggested use of colour in questionnaires 
and its impact on response rates and errors.254  The paper upon which any 
questionnaire is printed has been recommend to be white or off-white252 and the 
contrast between the type and the paper is important for legibility; black on a white 
or yellow background has been shown to give the best contrast.255  The use of 
thicker paper has been recommended to reduce print showing through from the 
previous page.256 
Graphic non-verbal language such as achieved with spatial arrangement of 
information and other visual phenomena such as colour and brightness should be 
considered.  There is a need for consistency in the brightness, colour, shape and 
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location in order to define the desired navigational path for respondents to follow 
when answering a questionnaire.254  Questions should also be numbered to 
minimise the risk of skipping questions and to facilitate cross referencing in data 
processing.251   
The layout of the questionnaire was designed using the above recommendations 
to maximise the response rate.  An envelope with a bright design was chosen to 
attract initial attention to the questionnaire.  A pen was enclosed in the envelope 
for respondents to use to complete the questionnaire whilst attending their 
appointment at the hospital if they chose too.  A booklet style of high quality paper 
was chosen in order to look professional and make the questionnaire easier to 
complete without a desk.   
 
8.2.2 Response alternatives  
A list of suggested responses from which respondents can select their most 
appropriate answer(s) to questions are termed ‘response alternatives’.  Response 
alternatives can clarify the intended meaning of a question and direct the 
respondent as to what is important to the researcher or what is expected.  A 
question may state, “What have you done today?”  Such a broad question can be 
interpreted in multiple ways and only when respondents are given a list of options 
might they know what was intended by the question for example, “had a shower”, 
“drove to work”, “drank a cup of tea”, or the question could have intended to 
search activity based responses such as “went to work”, “took part in a leisure 
activity”, “did the cleaning”.  However, listing items in this way reduces the 
likelihood that respondents report other activities that have not been suggested.253  
Whilst response alternatives can be used to frame intention of the question, the 
subtle unintentional influences that they can introduce may change the meaning of 
a question, an issue that is frequently overlooked when designing a 
questionnaire257 and a problem which is discussed again when considering the 
order of questions in paragraph 8.2.4.  
Questions such as “Did you ever do…?” are straightforward, with the respondent 
searching through their own memories for a suitable example.  However, if a 
respondent does not have a suitable answer stored in their memory, the 
judgement they make will be strongly affected by the context and question cues.253  
 212 
Using the same posed question “What have you done today?”, if the respondent is 
aware that the questionnaire is about driving to work, they might automatically 
offer this as a sensible answer and not give any thought to the other activities that 
they have carried out that day, since their memory recall is focused on thinking 
about driving to work.   
When providing respondents with a list of multiple-choice answers, ordinal biases 
may occur as people tend to choose figures that are near the average or middle of 
a series.  Therefore, the sequence order of the response options can be 
randomised into different orders during piloting, presenting different answer 
sequences to different groups to gain a measure of the ordinal bias and make 
allowances for it.249   
 
8.2.3 Type of questions 
Questions can be divided into two classes; those which are verifiable, for example 
behavioural and factual information, or psychological states and attitudes which 
are non-verifiable. 
Attitude questions/statements deal with awareness, perceptions, opinions or 
beliefs, and essentially the state of mind of the respondent.  An attitude or belief is 
likely to be more complex and multi-faceted than a question of fact and may 
therefore need to be approached from a number of angles rather than relying on a 
single question to gather this type of information.  In such cases, multiple 
questions using ‘scaling’ approaches can be used.  Scaled ‘attitude statements’ 
consist of approximately eight statements that have been selected and put 
together from much larger sets of statements.  The traditional method used to 
compose scaled attitude measures is a complex process requiring extensive 
piloting and statistical analyses.  The resulting attitude scales are not designed to 
yield subtle insights into individual cases, but give estimates of attitudes of broad 
groups and how these attitudes may relate to other variables within the survey.  
‘Attitude statements’ are usually single sentences that express a point of view, 
belief or judgement, and are phrased so that the respondent can either agree or 
disagree; these require careful composition in order to encourage the respondent 
to express their response in their own way.  Thus, using double questions, double 
negatives and statements which are too long should be avoided.249  
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The majority of respondents were unlikely to have taken part in previous research 
and thus would not be able to draw on previous experiences in order to answer 
questions on this topic.  Therefore, the vignette about a glaucoma research study 
that had been successfully used by participants in the focus groups described in 
Chapter 7 was modified for use within the questionnaire.  In this way, respondents 
were able to engage themselves in a scenario that could be applicable to them 
and provided the context from which to base their responses to the questions.  
Classification questions about personal information, used for stratifying the 
sample, (for example, age, sex, marital status, income and education) were placed 
at the end of the questionnaire and preceded with an explanation for their 
necessity.  Reassuring the respondent that the inquiry was genuine and for a good 
reason has been suggested to avoid any offence to be caused by questions that 
could be regarded as sensitive.249   
Questions that could be considered threatening or sensitive to a respondent 
required careful construction to avoid potential negative response effects or under 
reporting.  By deliberately loading questions and acknowledging that certain 
behaviours that are perceived as ‘socially undesirable’ are commonplace, or citing 
authority to justify the behaviour, for example “Many doctors say…”, it has been 
shown that responses can be optimised.254  Thus, an explicit statement to confirm 
confidentiality was used to overcome any possible apprehension that respondents 
might have felt about completing a ‘health questionnaire’.  The introduction page to 
the questionnaire explained why the respondent had been ‘chosen’, with 
endorsement from two ‘sponsors’ (UEA and NNUH) to give further reassurance to 
respondents who might have been sceptical about completing questionnaires.   
 
8.2.4  Ordering of questions 
Questionnaires can become unpleasant for a respondent if the ordering and 
phrasing of the questions are not synthesised correctly.  Care must be taken to 
ensure that questions work from the easiest through to the more difficult in a 
logical sequence, with one question setting the context for later questions, or 
conversely that earlier questions do not influence later questions, since the order 
of questions may affect the overall semantics of any given question which can 
influence participant response rates.  ‘Order effects’ caused by the context of a 
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question can be set deliberately to clarify the meaning of a question, or encourage 
respondents to consider an issue in the context that is of interest to the researcher 
and aids the respondent to retrieve information.  Unfortunately, the context is 
sometimes set unintentionally and this leads to adverse ‘response effects’ or 
‘response errors’.253  Thus, researchers need to evaluate the design of the 
questionnaire so that as far as possible, context effects are deliberate rather than 
unanticipated. 
Estimations of order effects can be quantified using statistical models.  If the bias 
cannot be treated statistically, then randomising question order across participants 
can be implemented.  In this case the researcher produces different 
questionnaires, with random ordering of relevant items.249, 254, 258, 259  Unless there 
is some natural ordering required, randomising response alternatives will not 
eliminate context effects, but will ensure that conclusions do not reflect on the 
specific order of response alternatives.253  General or ambiguous questions will 
increase context effects, although the context effects will be much smaller or may 
vanish completely if the respondent already has a judgment or substantial 
amounts of relevant information accessible in memory.   
Leading questions can suggest what an answer should be, in the opinion of the 
researchers, or indicate the researchers’ points of view.  Loaded questions or 
words may also suggest feelings of approval or disapproval.  Furthermore, certain 
words may be more or less neutral in one context or group than in another and 
careful consideration of words and piloting has been shown to help control for 
these dangers.249  
The preliminary work with the focus groups described in Chapter 7 highlighted that 
the context of the questionnaire would be important to the way that respondents 
interpreted the questions and that additional background information was required 
to help respondents answer the questions in the correct context.  Therefore, 
additional information was provided between questions in order to clarify why 
researchers would wish to use a ‘modified consent procedure’.  The order of the 
questions was purposefully executed to encourage respondents to consider the 
issues in the context of the research study scenario from the outset.  However, it 
was possible that in setting the context, responses to the main outcome variable 
may have been altered if respondents had felt led to answer either positively or 
negatively by these ‘context setting’ exercises.   
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Therefore, two versions of the questionnaires were produced.  Version 1 had the 
main outcome variable positioned near the end of questionnaire whilst Version 2 
was configured to present the main outcome variable at the beginning of the 
questionnaire to determine whether the responses to the main outcome variable 
could be collected without bias or order effects.   
However, two main concerns with the Version 2 configuration were considered.  
Firstly, respondents might not have understood the context within which to answer 
the questions and secondly, respondents might have returned to the beginning of 
the questionnaire and changed their response once they had read subsequent 
questions that set the context. 
To test these context effects and to see if question order had an effect on 
responses, ten non-clinical colleagues from the UEA and NNUH, naïve to the 
research aims, were asked to complete a pilot version of the questionnaire and 
give feedback to the researcher.  Five colleagues completed Version 1, and five 
colleagues completed Version 2.  Feedback was recorded from each colleague 
using probing questions and open dialogue:  
 What were your experiences of completing the questionnaire?  (i.e. difficult, 
easy, hard to read, too much to read, too many questions etc.)? 
 Were there any improvements that you would suggest? 
 How did you find the order of the questions? 
 Were you tempted to go back and change any of the answers you had 
given to previous questions at any stage? 
 Do you have any other comments? 
 
The responses were analysed qualitatively to look for context effects and to decide 
which questionnaire would provide the best format to be taken forward for further 
testing; Tables 8.2 and 8.3 summarises the feedback and summary of suggested 
changes for Versions 1 and 2 respectively.  There were no notable differences 
with respect to the order of the questions between the two versions, thus order 
effects were not thought to be significant.  However, there was still a possibility 
that the justifications given within the questionnaire may have had an effect on the 
main outcome variable.  To overcome the potential bias, the main outcome 
measure was presented both at the beginning of the questionnaire, before any 
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justification for using such a methodology was given, and again at the end of the 
questionnaire.   
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Table 8.2 Feedback from Version 1 of the questionnaire 
 
  
ID 
no. 
Feedback question 
Summary of outcome 
or 
Changes implemented 
 What were your experiences of completing the questionnaire? 
11 Did not take longer than 20 mins and was OK 
to complete 
No overall changes made to the 
length and readability of the 
questionnaire as it was well 
accepted by respondents. 
12 Not too difficult or too long 
13 Took 11 minutes. Easy to follow and read.  
Liked the scenario. 
14 Easy to read.  A little daunting at first as the 
booklet seems big, but doesn’t take long to 
complete. 
15 Easy to read 
 Where there any improvements you would make? 
11 Did not think ‘value’ was the right word, for 
experiences of research question, and think 
‘enjoy’ would be better.  
To be tested in the cognitive 
interviewing pilots. 
12 Wanted to be able to tick more than one box 
in the scenario question. 
Response options were revised. 
12 Highlight within the text that the difference 
between the withholding information question 
and not gaining permission.  
Withholding information and 
consent issues, now combined 
into one question. 
12 Felt it was difficult to answer questions about 
how you might ‘feel’ and was uncertain about 
‘feelings’ on the subject. 
Questions about ‘feelings’ 
removed. 
13 Did not read bold headers at top of page, so 
could be clearer. 
Could not improve. 
 How did you find the order of the questions? 
11 No problem 
Respondents were happy with the 
order of questions. 
 
The questions relating to the 
research example should follow 
on directly rather than being split. 
12 No problem 
13 No problem 
14 Question about the research example should 
come directly after the research example, not 
at the end.  
15 No problem 
 Where you tempted to go back and change any answers? 
11 No 
No respondents reported being 
tempted to and change their 
answers. 
12 No 
13 No 
14 No 
15 No 
 Other 
12 The scenario box needs to be made bolder 
with a darker box or symbol ‘I’ to indicate 
information. 
The scenario box was redesigned 
to be more ‘highlighted’. 
12 Introduction too long and does not need an 
explanation about glaucoma or ‘a glaucoma 
patient has tested this questionnaire’. 
The introduction was made more 
succinct. 
14 Found it difficult to just pick one opinion for 
the final scenario question. 
The response options have been 
revised. 
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Table 8.3 Feedback from Version 2 of the questionnaire 
ID Feedback question 
Summary of outcome 
or 
Changes implemented 
 What were your experiences of completing the questionnaire? 
1 Easy to complete and understand. 
No overall changes to be made to 
the length and readability of the 
questionnaire as it was well 
accepted by respondents. 
 
One comment about scenario 
being part of the questionnaire was 
addressed by making the scenario 
clearer within the text. 
2 
Difficult to read the first page and understand 
the scenario was part of the questionnaire. 
4 Well written and did not feel too long. 
5 
Not too long and no problems answering the 
questions. 
 Where there any improvements you would make? 
2 Clearly label ‘The example’ as such. 
The scenario was given an 
additional heading:  ‘The Example’ 
3 Introduction was too long and wordy. 
The introduction was re-written 
introduction to be more succinct. 
3 The questions were repetitive. Questionnaire was made shorter to 
be more succinct. 4 Felt repetitive. 
5 
Grammatical problems with question 5 once 
ticked box ‘c’. 
Question 5 has been removed. 
5 
The introduction was too long and felt that 
you needed to be a glaucoma patient to 
answer the questionnaire. 
Introduction was re-worded to 
avoid this. 
 How did you find the order of the questions? 
1 No problem. 
Added more information to the 
introduction to set the context 
better from the outset. 
 
Respondents were happy with the 
order of the questions. 
2 
Needed to read the whole of the 
questionnaire to understand the reason for 
the scenario and question that followed. 
3 No problem. 
4 No problem. 
5 
Helpful to have the question about the 
scenario directly following it (has dyslexia). 
 Where you tempted to go back and change any answers? 
1 No 
No respondents reported being 
tempted to and change their 
answers. 
2 Did review the questions first. 
3 No 
4 No 
5 No 
 Other 
2 Gave two answers to the scenario instead of 
one because she could not choose only one. 
Changed response options to the 
scenario question. 
3 Withholding information question – was not 
able to only give one answer. 
Changed response options to the 
scenario question. 
3 Withholding information question “depends on 
type of research”, is too open. 
This response option was 
removed. 
3 Would like to have the questions linked to a 
particular scenario as had to tick ‘would 
depend on research’. All questions revised to be linked 
to the scenario. 4 Would like to have the questions linked to a 
particular scenario as had to tick ‘would 
depend on research’. 
4 Question ‘Withholding information’ needs to 
add a response about risk to patients. 
The response options were 
revised. 
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8.2.5 Reliability and validity 
The aim of questionnaire design is to give a valid and reliable measure of a 
particular construct; reliability referring to the probability of obtaining the same 
results again should the measure be duplicated and validity referring to whether 
the question measured what it intended to measure.241, 249   
Evaluation of reliability can be measured in terms of scale consistency using a 
Cronbach’s alpha, or a test-retest method.241, 260  Questionnaires using such 
methods to test for reliability must contain multiple measures which can be 
correlated with each other.  For example, to test reliability of factual questions, 
asking the same question twice with slightly different phasing can identify errors in 
question wording, serial or contextual effects and is therefore a measure of 
internal validity.249, 261 
Content validity cannot be properly quantified since it refers to how representative 
the measure is to the specific construct.  Preliminary work on the questionnaire 
design confirmed the validity of the content to ensure that all of the aspects of the 
concept informing the research question had been captured within the 
questionnaire.  Interviews and focus groups enabled a “feel for the problem” and 
generated a pool of questions to meet this aim.260   
Measurement error can in principle be verified in reports about behaviours or 
events, but this is not possible with attitude or non-factual topics, which deal with 
state of mind.253  Questionnaires reporting subjective evaluative judgements are 
much more difficult to measure and validate than questions of fact, due to the lack 
of criterion groups to compare with the questionnaire.  Furthermore, non-factual 
questions are more open to bias caused by wording, response sets, leading 
questions, social desirability and contextual effects.  In general, the more difficult it 
becomes to find a suitable external criterion, the more researchers will concentrate 
of content validity to ensure the questionnaires are a well-balanced sample of the 
content domain to be measured.249 
Construct validity offers a measure of external consistency by comparing the new 
scale or questionnaire to another independent measure of the same variable and 
ensures the content of the questionnaire measures the intended construct.249  
However, in the case of a questionnaire designed to evaluate opinions on modified 
consent for adherence research, there were no comparable criteria available.  The 
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questionnaire was designed to feature mainly non-factual data relating to each of 
the respondent’s own opinions.  Furthermore, with no previous evidence to 
suggest what factors might determine behaviour decisions regarding use of a 
modified consent procedure together with no previous measures for comparison, 
testing validity and reliability involving correlation of test items was not deemed 
possible; instead, the focus remained upon determining good content validity and 
context effects.   
Face validity, confirms the extent to which a measure appears to measure what it 
is supposed to measure.  A questionnaire that seems relevant to the lay person is 
said to have “face validity”.262  Face validity was sought from non-clinical hospital 
staff and university staff reviewing the questionnaire.  Following these preliminary 
checks, a focus group with PPIRes group members reviewed different ideas for 
the design and wording used in the questionnaire.  Seven PhD students from the 
Medicines Management Group at the UEA with experience of questionnaire 
design were also asked to critique the design and content of the questionnaires.  
Minor revisions to the wording, design and content used in pilot questionnaires 
were made based upon their recommendations.  With endorsement from these lay 
and experienced representatives the first full version of the questionnaire was 
drawn together resulting in questionnaire version 3 shown in appendix 17.  
However, further piloting was required before the questionnaire could be 
considered complete.  Chapter 9 describes the cognitive interviewing approach263 
used to gain further face validity.  
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Chapter 9. Cognitive interviewing 
9.1 Introduction 
Before using the questionnaire designed to determine the acceptability of an 
adherence study involving modified consent, it was considered necessary to test 
the questionnaire using a cognitive interviewing technique.  Cognitive interviewing 
was considered an ideal technique to reduce measurement error due to poor 
content validity or context effects and to identify problems relating to format and 
interpretation of the questions.   
 
There is complexity in the thinking processes that are involved in answering a 
question. In general, it is known that respondents will do their best to answer all 
questions put to them in a questionnaire and they are likely to modify the question 
in their own mind, if they have to, in order to answer them.  Particular questions 
that are prone to modification are questions that call for mental calculations for 
example, ‘how much do you use per month?’, questions that do not apply directly 
to the respondent, issues that they do not have any experience of and general 
questions or questions with conflicting parts.264   
 
Several proposed models have defined the sequence of cognitive processes that 
occurs when respondents are asked a survey question.  In its simplest form, there 
are four actions that respondents must complete in order to answer a question.  
Firstly, a respondent must comprehend the question, and then retrieve the 
necessary information from their long-term memory.  A respondent must then 
make a judgement about the information needed to answer the question and then 
respond to the question.  However, the process is probably more complex than 
this simple linear model would suggest involving numerous interactions between 
the different phases.250  Figure 5.1 illustrates a task-focused ‘question-and-answer’ 
model.  The model can help to identify the cause of measurement errors and 
identify whether the problem is connected to comprehension of the questions, 
process or communication errors.250 
 
 Comprehension - the key concern is that respondents understand the 
question in the manner that the researcher intended.  Interpretation of the 
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question is often based upon the respondents background stock of 
knowledge and what the questionnaire requires.253  Literally understanding 
the words will not enable the respondent to answer the question, they will 
need to draw upon their knowledge and background information to interpret 
the text to give a meaningful answer; these two intertwined processes must 
work together to provide a semantic understanding of the question with a 
pragmatic meaning.265   
 
 Retrieval of information - information retrieved from the long-term memory 
will either be factual (current of historical) or attitudinal.  If the retrieval 
context is different to the original encoding context, then the respondent 
many not be able to recognise that the event took place or be able to recall 
the correct event.  The rarer and more distinctive the event was, the more 
likely a respondent is to remember it, so that commonly occurring events 
will be harder to distinguish and recall individually.  There are several 
processes involved in retrieval that might result in respondents being 
unable to recall an event, or recall it accurately.  Giving context to the 
question may help respondents to use their own recall strategies250 and 
behavioural questions are more likely to be accessible to respondents if the 
behaviour is of personal importance to them.  When designing questions, it 
is also important to assess how easily respondents will be able to retrieve 
the information required and to what level of detail.   
 
 Judgement - judgement is very important in the question-and-answer 
process since information is often difficult to recall accurately, may be 
incomplete, or the question requests a view or opinion on something which 
may not have been thought about for some time or in that context.253  A 
respondent must first consider if they understand the question in relation to 
their situation and determine if they have access to the information 
requested.  Following this, the respondent will modify their answer to meet 
the perceived needs of the question in terms of detail and accuracy.  In 
addition, judgemental heuristics will affect a respondent’s ability to answer 
frequency questions.  People tend to estimate the frequency, likelihood or 
typicality of events by the ease with which they can bring relevant examples 
to mind.250, 253 
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 Response - having formed a judgement, a respondent must format the 
response in accordance with any pre-defined answers on the questionnaire.  
Thus, the choice of response method originally chosen by the researcher, 
may affect the way the respondent decides to answer the question and, 
therefore, the results.  Likewise, the response alternatives, may also affect 
the interpretation of the question and thus the recall and judgement 
strategies used.  Respondents may also wish to edit their answers before 
communicating them in order to conform to social desirability.  However, 
this is normally limited to sensitive and potentially threatening questions.   
 
Figure 9.1 Question and answer model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To reduce measurement error due to the respondent question-and-answer 
process, the cognitive processes known to influence respondent behaviour must 
be considered in questionnaire design.  For this reason, it is recommended that 
questionnaires undergo extensive pre-testing with focus groups and cognitive 
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experts, followed by cognitive interviewing with the intended population of 
respondents, in order to identify problems relating to format and interpretation.253  
 
9.1.1 Cognitive interviewing  
Cognitive interviewing is a tool for pre-testing survey instruments uniquely 
sourcing information about the cognitive process.  Collecting verbal reports has 
become a standard method of research in many applied areas; accounting, 
management of learning disabilities, development of survey questions, validation 
of multiple-choice questions and user testing of computer products.263  The use of 
verbal reports focuses on the mental processes involved with answering 
questions; question comprehension, retrieval of information from memory, 
judgement processes and response processes.  
The use of verbal probing is the basic technique of giving “probes” to a 
questionnaire respondent in order to gain an insight into specific information 
relevant to a question or an answer given by a respondent.241  The probing is 
either carried out during the task (concurrent), or once the questionnaire has been 
completed (retrospectively).250  Whether probing is done concurrently or 
retrospectively, probes will either be scripted prior to the interview, or 
spontaneously ‘thought up’ during the interview by an interviewer.  The 
"spontaneous" approach to probing may be less scientific, but the most interesting 
and productive forms of probing often develop through the course of an interview, 
as a product of the particular relationship between the interviewer, respondent and 
questionnaire.  One of the key underlying assumptions of the cognitive 
interviewing approach is that these developments often cannot be anticipated in 
advance of the interview.  Further, a subject’s answer to a particular probe may 
well lead the interviewer to use other probes and to follow-up on the issues that 
emerge as the most interesting or important.241 
Probing methodologies tend to lead a respondent to report their thought processes 
in a coherent and intelligent dialogue with the interviewer.  A respondent has time 
to rationalise their behaviour before reporting their thoughts to the interviewer.  
Probing during a questionnaire task itself may reduce the time respondents have 
to ‘smooth over’ their answers, but interrupts the thought process of completing 
the questionnaire.  
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The think-aloud method, was largely developed by Simon, Newell and Ericsson263 
and first used in the 1990s as a method for piloting questionnaires.  The 
concurrent think-aloud method asks a respondent to keep talking about whatever 
thoughts come to mind, whilst completing the questionnaire.  No interruptions or 
suggestive prompts, or questions are required, as a respondent gives a concurrent 
account of their thoughts.  Because all conscious effort is directed at solving a 
problem, a respondent has no room left for reflecting on the task and therefore 
talking aloud does not interfere with the task as can happen using probing 
techniques.263   
For most individuals, expressing their thoughts by talking out aloud becomes a 
routine within a few minutes and most respondents immediately forget the 
presence of a recording device or interviewer.253  The data gathered by cognitive 
interviewing is also very direct since there is no delay in relaying thoughts.  
However, because there is no interpretation by the respondent, the think-aloud 
protocols are not necessarily complete since the respondent may only verbalize 
part of their thoughts.  Therefore, the structuring of the information gathered by 
cognitive interviewing is left to the person analysing the protocol.  Furthermore, the 
information collected may be less detailed and may miss some problems with the 
questionnaire.266   
However, a retrospective think-aloud method allows an interviewer to ask 
questions about completion of the questionnaire at suitable intervals during the 
process, perhaps after a question, or at a section break.  More detailed data is 
obtained using the retrospective method compared to concurrent think-aloud and 
the interview probes may encourage quieter respondents to talk.  However, 
interviewer probes could cause equal contamination of any results by interrupting 
the task process.  If a respondent is particularly quiet and prompting or probing is 
required by an interviewer, this could potentially change what was intended as a 
concurrent think-aloud method into a retrospective think-aloud method, thus 
‘muddying the water’ between the two.253  
Neither concurrent nor retrospective think-aloud methods change the kinds of 
strategies used by respondents to retrieve information.  The only possible effect is 
that think-aloud methods may spur respondents to make greater cognitive efforts 
to retrieve information.267  Most respondents are ‘cognitive misers’, doing just 
enough retrieval to come up with an answer that they think is acceptable.  
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Questioning the processes that a respondent uses may increase this level of 
effort, a possible Hawthorne effect in its own right, but studies to test this have 
been inconclusive.253 
Practitioners of cognitive interviewing techniques often mix think-aloud and 
probing techniques into the same interview.  In fact, procedural flexibility, as 
opposed to rigid adherence to one dogmatic approach, has been often viewed as 
one of the most attractive features of the cognitive interviewing approach.241 
Think-aloud protocols and probing methods are qualitative in nature and whilst 
they might indicate the existence of a problem, they cannot provide quantitative 
information on its extent or with respect to the size of effect.  Furthermore, the 
method relies upon the skill of the respondent to verbalise their thought processes 
which discriminate against less articulate respondents.250   
Despite the reservations and limitations outlined, cognitive methods have greatly 
improved our understanding of sources of measurement error in questionnaires 
and survey methodology and should be seen as a component of the assessment 
process of questionnaire design.  Cognitive interviewing techniques are used by 
several research groups working within healthcare fields.  The use of cognitive 
interviewing in questionnaire development, however, has gone unreported in many 
publications, possibly because of the space constraints for the methods sections 
of published papers, particularly with respect to piloting components.268   
 
9.1.2 Sample size  
For the successful use of cognitive interviewing in questionnaire design, 
determining the number of interviews requires judgement by an interviewer.  If it 
becomes obvious after several interviews that there are major problems to be 
rectified, then there is little benefit in conducting more interviews before 
modifications are made to the questionnaire.  In the very early stages of 
questionnaire development, as few as four interviews may be sufficient to make 
improvements to an initial draft questionnaire.  An advantage of the cognitive 
approach is that, if the basis for the failure of a particular question is understood, a 
resolution to the problem may be apparent.  After the questionnaire has been 
revised, a new round of interviewing can be conducted to test the changes.  
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However, such small sample sizes have been criticised.269  More important than 
sample size when using cognitive interviewing, are the characteristics of the study 
participants.  Participants need the skill to verbalise their thinking processes as 
previously discussed.250, 266, 270  Furthermore, researchers expect that the sample 
will be representative of the population of investigation and will reveal all the 
dimensions of a research question.271  
In general, due to the small samples involved in cognitive interviewing, a 
researcher’s judgment is required, in determining the implications of any findings.  
For example, a particular interview may have been uncharacteristic, and could be 
ignored.  Alternatively, it may be found that a set of subjects tested were more 
highly educated, on average, than the population to be surveyed, such that only a 
small number of interviews would be necessary to achieve significant 
improvements.  
 
9.1.3 Processing data from cognitive interviews  
There are a variety of methods used for compiling the results from cognitive 
interviewing.  In early work, protocols of subjects’ thinking-aloud consisted of the 
researchers’ notes summarising the vocalisations of respondents rather than direct 
transcriptions of actual words.  Until tape recorders became available (1945) there 
was no practicable means to record verbalisations.263  However, from written 
transcripts, a researcher can obtain almost instant access to all the verbalizations 
corresponding to a given process and coding reliability can be addressed by 
several coders with the same raw transcription.   
Some researchers listen carefully to the recording of each interview, whereas 
others will work only from written notes.  Many researchers will make a report for 
each interview conducted, whereas others may produce one written report 
encompassing the results from all interviews.  Sometimes it is necessary to 
compile the exact responses from respondents whereas, in some circumstances, 
the response data is less relevant, since the qualitative element is of much greater 
importance. 
Some researchers prefer to rely on standardised analysis of recordings of 
interviews; however, this is a time-consuming activity and the appropriateness 
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depends on the nature of the testing.  When revisions are required quickly, it is not 
often possible to devote the resources necessary to transcribe and analyse 
recorded interviews; in this case, reliance on written outcome notes alone may be 
sufficient.  Recording is still valuable where project staff or a sponsor/client may 
want to listen to a recording to get a first-hand impression of how a questionnaire 
is working.   
There has been debate about whether formal or informal analysis of cognitive 
interviews is most useful.  In a study by Murtagh et al268 formal analysis consisting 
of transcription and content analysis of the interviews was undertaken.  However, 
for the present study it was felt unnecessary to go to these lengths of analysis 
since it was considered straightforward to identify the difficulties and those 
questions that worked well.  In addition, complex and intensive coding has been 
shown to be ineffective in diagnosing problems that require expert judgement, 
such a faulty question ordering.  Thus subjective interpretation remains key to 
analysis and a reasonable trade-off between completeness and timeliness is 
recommended.241   
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9.2 Method 
In order to reduce measurement error due to poor content validity, context effects, 
and to identify problems relating to format and interpretation of questions, 
cognitive interviewing was used to test the questionnaires that had been designed 
to assess the acceptability of an adherence study involving modified consent.   
 
9.2.1 Participant identification and recruitment 
An invitation to participate in a cognitive interview was sent to all hospital staff at 
the NNUH via the weekly electronic intranet newsletter.  An e-mail was also sent 
to patients who had previously registered an interest in current adherence 
research whilst recruiting focus group participants.  Individuals interested in 
participation were provided with a copy of the participant information sheet and 
consent form either sent electronically or posted as requested.  After reading the 
participant information sheet, those willing to volunteer were asked to contact the 
Glaucoma Research Unit to register their interest and arrange a date for their 
interview.  The written consent was taken at the time of their interview.  Interview 
appointments were arranged to suit the participant and took place in the NNUH 
Glaucoma Research Unit office or in participants’ own homes, as preferred.   
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Figure 9.2.   Flow diagram of questionnaire development using cognitive 
interviewing techniques 
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9.2.2 The cognitive interviewing task 
During each participant session, the researcher guided the participant to use a 
think-aloud procedure, audio recorded the participants’ voice, observed the 
participant and took notes.  Based on evidence from Sudman et al. (1996)253 and 
Van Den Haak et al. (2003)270 the following procedure was undertaken: 
Upon arriving, each participant had the opportunity to ask questions about the 
task.  If still agreeable to participation, each interviewee was asked to complete 
the consent form and demographic collection form.  The demographic information 
(age, sex, ethnicity, employment and marital status) was collected to enable a 
description of the population. 
The interviewer taught the participant how to perform the think-aloud procedure.  
The training generally involved practicing at the start of the interview.  An example 
think-aloud exercise would start with the interviewer saying 
“Try to visualise the place where you live, and think about how many windows 
there are in that place.  As you count up the windows, tell me what you are seeing 
and thinking about.” 
Depending on how well a subject responded to this exercise, further training was 
carried out, prior to beginning the core part of the interview as suggested by Willis 
in 2005.241 
The following instructions were read out verbatim to ensure consistency: 
“Think-aloud while completing the questionnaire.  Please pretend that I am not 
here, so do not ask for assistance.  If you fall silent for a while, I will remind you to 
keep thinking aloud.  Of course, if you feel uncomfortable at any stage, please just 
tell me you would like to stop.  Finally, remember that it is the questionnaire, and 
not you, that is being tested.  Do you have any questions before we start?”   
The researcher sat out sight of each participant to minimise the influence of the 
researcher presence, although this was not always possible when the interview 
took place in a participants’ home.  When not possible to sit out of site, the 
researcher would tell the participant “I am not watching what you are writing in 
your questionnaire, just listening to what you say”.  Once participants began 
completing the questionnaire, they were not interrupted, unless they fell silent for 
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about 10 seconds, in which case they were instructed to “keep talking” or probing 
was instigated.  
When each participant had finished their questionnaire, or if they were struggling 
with the think-aloud method, probes were used to try and gain further information.  
Examples of probes used:  
 What did you think you needed to do in order to answer that 
question? 
 What were you thinking about when you answered that question?  
 I noticed that you hesitated before you answered that question. Why 
was that? 
 Can you repeat the question in your own words?  
 What does that word mean to you? 
 
When the interview was complete, participants were thanked for their help and 
asked if they had any additional feedback.  Feedback helped to elicit patterns 
appearing across users that might have inferred a significant problem that might 
otherwise have been missed if individuals had not been given the freedom to 
report any other thoughts. 
Figure 9.2 demonstrates how the cognitive interviewing process continued until no 
more revisions of the questionnaire was required. 
 
9.2.3 Data analysis of cognitive interviewing task  
The number of interviews required in each round was determined by the 
researcher and ranged between 2 and 5 interviews.   
The think-aloud protocols were scanned for verbal or observed indicators of 
problems experienced: referring to doubt, task difficulty and incomprehensibility 
(adapted process from Cannell, Fowler and Marquis, 1968).272 
The types of problems encountered were defined and categorised.  There was no 
standard list available, but the likely categories were based upon the study by Van 
Den Haak et al. (2003):270  
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 Layout problems: the participant fails to spot particular instructions within 
the questionnaire. 
 Terminology problems: The participant does not comprehend part(s) of the 
terminology used in the questionnaire. 
 Data entry problems: The participant does not know how to reply to a 
question. 
 Comprehensiveness problems: The questionnaire lacks the information 
necessary to use it effectively. 
 Feedback problems: The questionnaire fails to give sufficient data entry 
options or free text. 
 
After each round of interviews were completed, the researcher summarised the 
findings on a question-by-question basis.241 
 Feedback requested at the end of the think-aloud session was collated and 
analysed. 
 The outcome of the ‘probing’ was then included along with the question-
specific comments on a question-by question basis.  
 Comments were further aggregated, for a complete review of the 
questionnaire. 
 A cognitive interviewing outcome report was written which contained the 
final annotated questionnaire with an overall written summary of the most 
significant problems that were found and how these were overcome.  
 The renewed questionnaire entered the next round of ‘interviewing’ until no 
further revisions were required as described in Figure 9.2.  
 
9.2.4 Pre-study pilot survey  
As a final test of the questionnaire, a small pilot study was carried out to ensure 
that the questionnaires were completed as expected when not being tested under 
‘experimental conditions’.  Fifteen questionnaires were distributed to patients and 
members of the public attending the eye clinic at the Cromer hospital in order to 
emulate the main study conditions.  Errors from respondents or missing data were 
reviewed, to ensure usability of the questionnaires; this enabled any errors to be 
rectified and improvements made to the questionnaire should that have been 
necessary.   
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A population from the Cromer hospital (a satellite hospital to the NNUH) was 
chosen to avoid patients who had previously taken part in NAGS at NNUH and 
who would already know about the TDA and could have induced a response bias. 
The data from the completed questionnaires were entered into the data collection 
tool, to ensure usability and reliability in the data entry method.  The research 
assistant entered the data and this was verified by the researcher.   
 
9.2.5 Review of question objectives 
Although not considered crucial to the cognitive methods, reviewing the question 
objectives is well within its scope and was the final stage of the cognitive 
interviewing and piloting process.  A respondent may be able to answer a 
question, but it must still be a meaningful outcome measure.241  All questions that 
had presented difficulty and had to be changed to improve their understand-ability 
were reviewed to assess their utility as a measure.   
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9.3 Findings 
Four cognitive interviewing rounds were required with a total of 17 participants; the 
results from each round with a review of the changes made to the questionnaire 
are detailed in Tables 9.1 to 9.4.   
Following the round 2 interviews, it was apparent that participants were finding it 
difficult to make a decision as to whether the study used an acceptable consent 
method or not.  Forcing respondents to answer either ‘yes’ or ‘no’ may have led to 
a response bias and thus their report would not truly reflect their real attitude 
towards the use of modified consent method for proposed study.  Therefore, a 
visual analogue scale (VAS) was designed to replace the ‘yes/no’ answer, which it 
was predicted would reduce the chance of the question not being answered and 
provide an assessment of the level of acceptability. 
The VAS is a psychometric response instrument used to measure subjective 
characteristics or attitudes that cannot be directly measured in questionnaires.  
When responding to a VAS item, respondents specify their level of agreement to a 
statement by indicating a position along a continuous line between two end-points.  
The continuous aspect of a VAS differentiates it from discrete scales associated 
with the Likert scale or dichotomised responses.  There is evidence showing that a 
VAS has superior metrical characteristics than discrete scales, thus a wider range 
of statistical methods can be applied to the measurements.273 
However, question 2 of the questionnaire, as shown in appendix 18, still gave the 
option for respondents to specifically state if they felt the doctor should not carry 
out the study under any circumstances, thus acting as an alternative measure of 
acceptability using a yes/no option. 
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Table 9.1 Final report for round 1 cognitive interviewing  
4 Participants - All white British, not living alone and in paid work 
1 Male, 43 years old, IT technician at NNUH with an interest in questionnaire design 
 This participant managed the think aloud task well.  He approached it methodically 
from a design perspective rather than a personal perspective which enabled him to 
complete the questionnaire quickly as he did not take long to consider and answer 
the questions. 
The remaining participants all took a lot of time to consider each question and at times 
even showed some angst when having to make a decision. 
2 Female, 58 years old, glaucoma patient and secretary at NNUH. 
 
The participant struggled with the fact she was being recorded and was a ‘guinea 
pig’ and even reported this during the interview as she felt she was not doing very 
well.  She felt that this had hindered how she would normally have completed the 
questionnaire.  She found the think aloud technique difficult and so the think aloud 
task was abandoned in favour of probing on completion of the questionnaire. 
She felt very strongly that participants should be informed about a study, but could 
also understand why it was important to do a study like this. She therefore found it 
difficult to complete the questions, and spent a long time thinking about her 
answers because she felt it was difficult to justify her reasons. 
3 Male, 63 years old, glaucoma patient and health records clerk at NNUH 
 
The participant completed the think aloud task very well and entered into the task 
whole-heartedly.  He said afterwards that he had found it very difficult to complete 
the task whilst also trying to answer the questions within the questionnaire.  During 
the probing session on reviewing his responses he felt that he wanted to change 
some of his answers as he had time to reflect on it and had changed his opinion. 
4 Female,55 years old, consultant, at NNUH 
 
The participant did not complete the think aloud task very well.  However a 
combination of probing during the completion of the questionnaire and at the end of 
the task was carried out instead.  She found it very difficult to put her clinical 
knowledge and thinking aside in order to answer the questionnaire with her own 
thoughts and opinions.  She was considering her patients rather than her own 
views.  As a patient she would not mind taking part in this study at all, but with her 
‘clinical hat’ she knew it probably was not ethical and therefore found it hard to 
distinguish between the two. 
Time taken to complete questionnaire 
1 5 minutes 
2 13 minutes 
3 17 minutes 
4 14 minutes 
Review of each element of the questionnaire 
Envelope 
 
The envelope and instructions were acceptable. 
People liked the fact that there was a free post envelope that gave 
responders the option of when and where to complete the questionnaire. 
All liked the idea of free pen. 
One participant commented on how much the questionnaires must have 
cost to produce as they were of very good quality and in colour.  She 
worked for NHS and so was aware that the NHS did not allow the use 
colour printing. 
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Introduction They liked the fact that it should only take 10 minutes to complete the 
questionnaire and introduction was a good setting for the whole 
questionnaire. 
The introduction also let people decide if they want to commit to 
completing the questionnaire or not. 
Scenario 
The scenario was easy to read and understand.  None of the 
participants thought this could have been a real study, they really did 
think it was just a scenario. 
Only one participant was curious and asked about the device at the 
end of the questionnaire. 
However one participant felt that the wording could be changed to the 
research ‘case’ as ‘example’ made him feel that we were just providing 
an example of what was to follow during the questionnaire, rather than 
it being part of the questionnaire itself. 
Changes made: Second sentence changed to make it clearer that the 
example research project forms part of the questionnaire: 
“Although we use an example of a research project…” 
changed to 
“We will use an example of a research project…” 
Question 1 This proved a problem for one participant who felt that the question 
was fine but answered ‘yes, the research is acceptable’ and also ‘that 
participants should not be told the information upfront’.  This is a 
contradiction.  During probing, it became apparent, that he meant, ‘yes 
the research concept is acceptable’, but not the method of withholding 
information and retrospective consent’. 
Changes were made to the questionnaire to make it clear it referred to 
the research study, not just the concept. 
Changes made: The final paragraph was shortened and the text added 
to the introduction to question 1 so that the questions flowed more 
easily from the scenario. 
Question 1 was also re-phrased in order to ensure that the reader was 
clear that we are referring the “example” rather than the research idea 
in general. 
Question 2 There are so many options for participants to choose from that they 
couldn’t process them all.  In addition, it was too difficult to select just 
one answer.  There were too many ‘yes’ options and the no option was 
too harsh in comparison that respondents felt that they should not tick 
it. 
Changes made: The number of options was reduced and the question 
re-phrased so that participants could choose however many options 
was applicable to them. 
Question 3 Two participants answered this incorrectly as they had mis-read the 
question.  They felt the error was probably just because of the pressure 
of doing the ‘think aloud’ and could not really explain why they had 
done it wrong. 
Changes made: This question was changed to use the same format as 
question 2 so as to avoid any misinterpretation of the instructions. 
Question 4 No comments 
Question 5 One participant had no concerns so did not tick a response box, but 
would have preferred to have ticked something, just to ensure this was 
reflected and not simply look like she had forgotten to answer the 
question. 
Changes made: An additional box added for “I have no concerns” was 
added. 
Question 6 No comments 
Question 7 No comments requiring action. 
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Table 9.2 Final report for round 2 cognitive interviewing  
5 Participants - All white British, not living alone, 5 retired, and 1 in paid work. 
5 
Female, 60 years old, previously seen in the glaucoma clinic as had been referred 
by her optician with suspected glaucoma.   
 
She did not complete the think aloud task very well and therefore probing at the end 
of the questionnaire was used to good success. 
6 Female, 58 years old and a current glaucoma patient with suspected glaucoma. 
 
This participant completed the think aloud task very well and added insight into the 
reason for her answers as she went along.  She is a retired mental health nurse and 
referred to her training and experiences of this as she went along, commenting what 
she knew was not ethical from a patient perspective and how personally she felt 
differently to this.  She had to make a real effort to answer the questionnaire from 
her own personal perspective rather than as an ex-professional. 
7 Female, 54 years old, working at NNUH and patient with glaucoma. 
 
This participant was very good at the think aloud task explaining her reasons as she 
went through the questionnaire with great success.  She had previously taken part in 
a study using the TDA described in the scenario and drew upon these experiences 
during the completion of the questionnaire.  
8 Male, 72 years old, patiet with glaucoma.  
 
This participant struggled with the think aloud, so probing during and after the 
questionnaire completion was used.  He had heard of the TDA described in the 
scenario after attending a lecture at NNUH.  
9 Male, 65 years old, patient with glaucoma.   
 
The participant was dyslexic and therefore requested his wife to join him to help him 
with the questionnaire.  This made it problematic to do a think aloud, but a realistic 
example of how the questionnaire might be completed in real life so we went ahead 
and I used probing throughout and after the questionnaire was completed. 
Review of each element of the questionnaire 
Envelope  
 
One participant felt the freepost envelope gave freedom for respondents 
to decode as to whether they would like to take part in the questionnaire 
and when to do this.  If completing the questionnaire whilst at the hospital 
was not appropriate then the questionnaire could be taken home to 
complete when they are able to concentrate on it, or get help to answer 
the questions if they found reading it difficult.   
Intro  Easy to read.   
Scenario  The scenario was easy to read and understood.  
Question 1  
 
Participant 5 found this difficult to answer and felt it was a 50/50 decision 
but decided that overall the doctor should ask permission before starting 
the research. 
Participant 6 answered this question without any problems, and 
immediately felt that it was important to know why you are doing 
research and what it is all about and permission should be asked. 
Participant 7 took a lot of time to consider her answer but decided that 
patients should be told about the research and that it is unacceptable to 
withhold information.  “Patients should know that they are going to be 
tested for their usage of eye drops.” 
Participants 8 and 9 answered ‘yes’ straight away. 
Points to consider and changes to be made:   
 239 
Overall opinion on this question is mixed.  If participants ticked ‘no’ it was 
always followed by ticking ‘participants should be informed about 
participation’.  It was possible that this question could be removed from 
the questionnaire, particularly as there were no response options related 
to ticking ‘yes’.  The impression was that patients felt uneasy about 
answering the question and that it was difficult to make a decision. 
Forcing a participant to make a decision of either ‘yes’ or ‘no’ may lead to 
a response bias and the answer will not truly reflect the real attitude 
towards use of modified consent method for this study. Therefore, a 
visual analogue scale was more appropriate in order to assess level of 
acceptability. 
Question 2  
 
After the justification in the introduction to question 2, participant 5 
changed her mind and ticked ‘yes,’ that the research example was 
acceptable.  
Participant 6 also changed her mind, but it took her a long time to get to 
that conclusion, stating she could see both sides of the argument.  She 
knew that people do act differently when they are being observed so 
could understand the justification, but also felt that patients should really 
know that they are taking part in research and why they are being 
observed.  Although she felt forced to make a decision, she understood 
why, and did not feel uncomfortable about this. 
Participant 7 also changed her mind as she considered that patients 
would change their behaviour, and therefore the study would need to 
withhold that information from patients. However, she went onto to state 
that she would not tick statement C ‘participants are told the real reason 
for the research project at the end’ because she felt that patients should 
be told at the beginning of the study, not at the end, so the question 
needed rephrasing. 
Participants 8 and 9 were the only ones to answer ‘no’ to this question 
because they thought patients should be given information, however, 
they answered ‘yes’ to the first question and so contradicted themselves 
with no reason for this.  
Points to consider and changes to be made:   
It was important to ensure that participants realised that this question 
was still in relation to the scenario, and changes were made to the text to 
ensure this was clear.  
A visual analogue scale was more appropriate in order to assess level of 
acceptability towards use of modified consent method for the study 
instead of a ‘yes’ or ‘no’ answer. 
One participant misread the instruction to only tick the statements if 
answered ‘yes’, so the instruction was made bold.   
Question 3  
 
Participants seemed happy to choose which statements applied to them 
with ease.  
Participant 6 acknowledged that she had contradicted herself in saying 
that she would not be concerned about taking part in this research, but 
then stated that she would like to know if she were taking part in 
research.  She felt it was more about the risk, and if the risk is low and 
the benefit high, then it was OK. 
Participant 8 wanted the question to give a fuller explanation of exactly 
what information would be given.  The concern is that this makes the 
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question too lengthy, so the question was changed to state ‘fully 
informed’ in order to add clarity. 
Question 4  
 
The initial question ‘Have you ever taken part in any health research’ has 
caused some confusion because of the response options are ‘Yes’, ‘No’, 
or ‘Don’t know’.   
The ‘don’t know’ option makes participants feel that in the past they may 
have been deceived about participation in research and therefore have to 
answer ‘don’t know’.  This response option will be changed to ‘don’t 
remember’.  
Question 5  No changes. 
Question 6 
 
Participants 5 and 6 found it easy to answer ‘yes’ after reading the 
justifications. 
Participant 7 struggled to come to a decision about this question and so 
started to draw on her previous experiences.  After she had finished the 
questionnaire she went on to say how difficult it was to make a decision 
because it was not clear cut, even though the questionnaire may suggest 
that such a decision was clear cut.   
Participant 8 answered ‘yes’ easily, and had maintained it was 
acceptable to undertake this study all the way through the questionnaire.  
Participant 9 answered ‘yes’ easily which was a contradiction to what had 
been answered in question 2.  When asked directly they said it would not 
really bother them whether they knew about the study or not, but then 
went on to say that they would feel abused if they had not been told 
about the study.  It was impossible to get an answer from them to 
convince me as to whether they were happy with the scenario or not.   
Points to consider and changes to be made:   
With all the interviews undertaken in this round, I felt that the participants 
understood why the study should be undertaken and agreed that it 
should be carried out, but they found it difficult to decide if it was 
acceptable to withhold information from patients and not take consent. 
This clearly showed the complexity of the subject and that weighing up 
whether it is acceptable or not is problematic. Forcing a participant to 
make a decision of either ‘yes’ or ‘no’ may lead to a response bias and 
the answer will not truly reflect the real attitude towards use of modified 
consent method for this study.  Therefore, a visual analogue scale may 
be more appropriate in order to assess level of acceptability. 
 One participant had become a bit confused as to whether she was 
supposed to be ticking each justification statement to indicate whether 
she agreed with it or not because the questionnaire states “please think 
about the example again” which made her feel that she was being asked 
a question about the statements.  This has been made clearer in the 
wording.   
Question 7  
 
Participant 5 found it hard to answer all the questions as there was no 
option to describe that she had been discharged from the glaucoma 
clinic.  Participant 8 could not indicate that he attended a private hospital. 
These response options were modified accordingly.  
Participant 6 would have liked an additional box for ‘I do not find the 
doctor approachable’ rather than have to write it in the free text box.  This 
list has been modified to include this. 
The final question “do you think that taking part in a research study in the 
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glaucoma clinic would change the experiences you have described 
above” appears too difficult to answer because respondents feel the 
question is too open.  Participant 6 did not like the question or know how 
to answer it.  Other participants misinterpreted the question believing it to 
mean that research in general might improve the experiences of patients 
due to advances in knowledge, rather than the intended meaning.  Due 
to possible confusion and the fact that question 7 had little potential as 
an outcome measure it was removed.  
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Table 9.3 Final report for round 3 cognitive interviewing  
6 Participants - All white, 1 of South-African origin, 1 living alone, and six in paid work. 
10 
Male, 62 years old, and from South-Africa originally, glaucoma patient seen 
annually in the glaucoma clinic.  
 
This participant was extremely interested in the topic because he has glaucoma.  
He produces teaching materials for ‘group learning education’, and so was 
particularly interested in the cognitive aspects of completing a questionnaire.  He 
was very ‘pro’ glaucoma research and was disappointed he had never taken part 
in research before. 
11 
Male, 47 years old. Glaucoma patient and using eye drops and seen annually in 
the glaucoma clinic.  
 
This participant was interested in the topic because he has glaucoma.  He works 
in the hospital in the technical team and does not have contact with patients.  He 
undertook the think aloud well, but I used concurrent probing during the interview 
as well to try and understand some of his comments a bit better.  This approach 
worked well as he was good at explaining himself and providing as much 
information about what was informing his beliefs or thoughts.  However, 
completion of the questionnaire became more of an open dialogue between us, 
rather than him completing the questionnaire without assistance. 
12 Female, 48 years old, not a glaucoma patient but likes to participate in research. 
 
This participant worked in the hospital pharmacy.  She did not have any personal 
or family experience of glaucoma and came the questionnaire completely open 
minded in that respect.  She was able to use think aloud successfully and we 
carried out some retrospective probing at the end. 
13 Male, 47 years old, glaucoma suspect. 
 
This participant was interested in the topic area as he is a glaucoma suspect.  He 
works in the Diabetic Eye Screening service with patients and therefore found it 
difficult to detach his own opinions from what he thought patients might feel. A 
combination of think aloud and concurrent probing was used. 
14 Female, 56 years old, family history of glaucoma. 
 
This participant was interested in the topic area as she enjoys taking part in 
research and has a family history of glaucoma.  She was thinking about the 
perspective of her mother and father and other people, rather than giving her own 
opinion and what she was able to read and understand herself.  I felt in this case, 
she was giving an opinion of what others might feel, rather than just reporting her 
own perspective. 
15 Female, 40 years old, glaucoma suspect. 
 
This participant was interest in the topic as she is a glaucoma suspect.  She works 
in hospital governance and has a background in nursing.  No concurrent probing 
or think aloud was used, just retrospective probing.  
Review of each element of the questionnaire 
Front cover Participant 11 felt that the front cover needed to be more eye catching 
and to ‘sell’ the questionnaire to potential respondents.  He felt that the 
word research would draw people in.  Participant 14 agreed with this and 
thought the current title was ideal. 
Intro  Easy to read.   
Scenario  Participant 11 may have misunderstood the reason for the research and 
was trying to establish how it helped people who needed to use eye 
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drops.  From this, he felt that it was unnecessary to give the device to 
everyone, as someone like him, knew how to use drops.  The scenario 
needed to make clearer the reason for the research? 
Participant 12 may also have misunderstood the reason for the research 
in the same way as participant 11.  She thought that if the drops were to 
help patients use eye drops by telling how many drops they had used, 
then this information should not be kept from patients who might need 
this information to help them.  
Participant 14 thought it was hard ‘for others’ to take the information in 
and that it may need pictures or be spaced out further. 
Participant 15 thought the scenario was a bit stilted and patronising.  
Changes to be made:  
The scenario has been updated to make the reason for the research 
clearer and read easier with a little more spacing.  
Question 1  No problems using the scale to report opinion of acceptability. 
Question 2  
 
Participant 10 had to check why the question was exactly the same as 
question 1 and could not understand why.  An immediate modification 
was made.  
Participant 11 had to check if he should answer the response options 
because he had answered unacceptable.  He thought they were good 
questions, and therefore should be ‘allowed’ to answer them. Participant 
15 also wanted to be able to answer the response options. 
Participant 13 thought that response option A was too difficult to 
understand.  He did understand it but had to read it several times and 
thought the term ‘patient representative’ was too difficult to understand 
and could be misinterpreted. 
Points to consider and changes to be made:   
Wording changed immediately after participant 10 (before the following 
participants had completed questionnaire) as immediate resolution was 
required:  
“Does this change your opinion of the research example?  Please 
indicate your opinion on the line below, whether it is the same as your 
answer to question 1, or different now.” 
 The response options were made available for everyone to answer 
regardless of whether they responded acceptable or unacceptable and 
additional response option B added. 
The response option A was made easier to understand. 
Question 3  
 
Participant 13 was initially concerned about the research example 
because of the ethical issues that might surround such research.  
Therefore he felt there should be another response option that bridged 
the gap between option A – ‘I have no concerns’ to options B-E which 
are too extreme.   
Points to consider and changes to be made:   
Add another response option:  
“I might be initially concerned, but not once the research had been fully 
explained.” 
Question 4  No problems. 
Question 5  No problems.  
Question 6 
 
No problems.  Participants did not mind being asked the same question 
for a 3rd time and understood why we might want to do this.  
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Question 7  
 
Participant 10 struggled with the response options relating to his 
satisfaction with the clinic.  He did not like the word ‘reassuring’ as that is 
not the right word.  A participant in the last round also mentioned this, so 
an immediate change was made.  
Participant 11 could not answer how often he was seen in the Glaucoma 
Clinic as he was seen about once every 18 months – 2 years. 
Changes to be made:  
An immediate change was made after participant 10 (before the following 
participants) as immediate resolution was required.  And changes to the 
response options made.  
Need to add “I attend a Glaucoma Clinic about once every one – two 
years” to capture those whose appointments who fall 18 monthly. 
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Table 9.4 Final report for round 4 cognitive interviewing  
2 Participants – Both white, living with others, and in paid work. 
16 Female, 61 years old, family history of glaucoma 
 This participant was interested in the topic area as she enjoys taking part in 
research.  She has a family history of glaucoma.  She did the think aloud task well 
combined with retrospective probing.  
17 Female, 53, years old, glaucoma patent using eye drops. 
 This participant was interested in the topic because she has glaucoma. We used 
retrospective probing.   
Review of each element of the questionnaire which was problematic 
Justification 
section 
Participant 16 felt that the justification needed to be clearer to impress 
upon respondents that we know that patient do change their behaviour 
when taking part in research rather than using ‘may’ and ‘might’. 
This paragraph was changed to reflect this. 
Question 2  
 
Even though response option A has been re-worded many times to try 
and make this understood both participants still did not understand this, 
and it actually distracted participant 17 from answering correctly, 
because when we discussed it, she had totally missed response option 
D, which would have been the response she needed to select, but 
missed it as she was confused about response option C.  The response 
was removed from this section, as it has not been possible to make this 
option acceptable to all users, during each round of testing.  
Added an additional instruction before the response options:  
“Read the statements from the list below then tick all which might 
apply.” 
Question 3  
 
Added an additional instruction before the response options:  
“Read the statements from the list below then tick all which might 
apply.”  
Final 
Comments 
Apart from a few further refinements, the questionnaire was completed 
by both under 10 minutes, with no further discussion about problems 
encountered, other than those addressed above, which have been 
remedied easily.  The questionnaire is felt suitable for pilot testing with 
the study population.  10 questionnaires should be collected to ensure 
they are completed fully and the collection technique works as 
expected. 
 
 
9.3.1 Review of question objectives  
Each question was reviewed to ensure it could be analysed in order to meet its outcome 
objective.  The results of the review are shown in Table 9.5. 
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Table 9.5 Review of question objectives  
 Question Issue 
1. Is the research example acceptable? What is felt about a research study which 
withholds information from participants and 
does not take consent?  Baseline 
measure. 
Free text comments Identify any areas of concern or additional 
information. 
2. Now what do you feel about the 
research example? 
 
What is felt about withholding information 
and not taking consent after a justification 
has been given for doing this. 
If you do think this is acceptable, 
would any of the following be 
important to you?  
Identify the important issues for 
respondents who would be willing to take 
part in research. 
3. If you had taken part in the research 
example without your knowledge, 
please consider how you would feel 
once you had been fully informed 
about the research. 
Explore further issues:  
Feelings of not being treated with respect? 
Reduce trust in doctors? 
Would they not take part in research 
again? 
Other, please describe. Identify any other concerns about taking 
part in this research. 
4. Have you ever taken part in any health 
research e.g. at a GP surgery or 
hospital. 
Does previously taking part in research 
affect opinion? 
 
How would you describe your overall 
experience? 
Does positive or negative experiences of 
research affect opinion? 
Please describe why you did or did not 
value the experience 
Identify any other reasons for not valuing 
research. 
Please describe what sort of research 
it was 
Understand the types of research people 
have taken part in before. 
5. Would you ever consider taking part in 
research undertaken by a Hospital or 
GP surgery? 
Does being willing to take part in research 
affect opinion? 
Do you feel any of the statements 
below describe concerns you might 
have about taking part in research? 
Do perceived ‘risks’ associated with 
research affect opinion? 
 
Are there any other issues or concerns 
that you feel could affect you if you 
were involved in research. 
Collect other concerns that could affect 
people taking part in research. 
Would you expect to receive 
information about the possible risks of 
taking part in a research study if there 
were any? 
Would information about the possible risks 
of participation be expected? 
 
6. Would you think the research example 
is acceptable? 
What is felt about withholding information 
and not taking consent after a justification 
has been given for doing this. 
 Does strength of conviction about 
acceptability change with increased 
justification for the study. 
7. Demographic information: Does gender or age affect opinion?  
Type of patient or member of public Does the type of glaucoma patient or 
member of the public affect opinion?  
Glaucoma patient information: Do patient experiences affect opinion? 
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9.3.2 Pre-survey test 
Pilot questionnaires were given to 15 patients or members of the public for 
completion.  Eight questionnaires were returned using a reply envelope, which 
confirmed that instructions for return of the questionnaires were understood.  Only 
one question failed to be completed by one participant and the heading of this 
questions was emboldened to highlight that question continued overleaf, in case 
that was the reason for the question being overlooked.  A relatively high, 53% 
response rate, with only one item of missing data, confirmed that the questionnaire 
was both suitable and usable within the patient and public population intended.  
The data collection spread sheet was tested for ease of data entry and small 
modifications made to improve usability. 
 
  
 248 
9.4 Discussion 
Volunteers for cognitive interviews are to some extent self-selected and are not 
likely, therefore, to be representative of a survey population as a whole.  Most 
importantly, these volunteers may tend to be higher in their level of educational 
attainment, in comparison with an average survey respondent, with the potential to 
overlook problems that occur in ‘real life’ and ‘interview’ findings might, therefore, 
underestimate the severity of problems.  However, the participants recruited from 
NNUH ranged from a variety of working backgrounds, from a filing clerk to a health 
practitioner; it was felt, therefore, that individuals with an adequate range of 
educational attainment were consulted.   
The environment in which the questionnaire was completed during cognitive 
interviews might have placed the responder under greater pressure to think about 
and answer the questions than would be expected of a respondent not 
undertaking a think-aloud process.  However, the type of questions administered 
where mainly testing comprehension processes which do not appear to differ 
greatly between the experimental setting and that of real life; for example, if 
someone does not know the location of his or her abdomen, it is doubtful that they 
would know this wherever the test was executed.  Retrieval processes, may be 
different since the ‘home environment’ may provide different cues that affect recall 
of thoughts.  Furthermore, opinions may have been altered if the respondent had 
been trying to please the researcher during the interview.  Thus, a small pilot 
survey was appropriate to assess that the questionnaire was effective in ‘real life’ 
circumstances and to explore any unexpected results or failure to complete the 
questionnaire.  In addition, whilst the cognitive interview could not test the likely 
response rate, since no-one declined to answer any part of the questionnaire, the 
pilot study found that not all participants who received the questionnaire 
responded.  However, those that were returned gave full and complete responses, 
which confirmed that the questionnaire was accessible and understood by those 
within the pilot cohort.  
Some might argue that a cognitive interviewing approach was deficient, because 
the samples used were too small to make reasonable conclusions.  However, the 
purpose of the interviews was not for statistical estimation, but to gain the 
opportunity to interview a variety of individuals’ representative of the sample 
population.  Furthermore, the qualitative aspect of the interview ensured that the 
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problems occurring were evaluated and immediately addressed, rather than simply 
counting the number of interviews in which a problem occurred.  The qualitative 
nature of the process also meant that a finding could be based on just one 
interview and did not need to be verified by a large number of other individuals 
with the same reported problem.  
Cognitive interviewing was an effective means of identifying potential problems, 
before the problems were encountered repeatedly in the ‘field’.  With no previous 
evidence on which to base this questionnaire, the entire process of building the 
questionnaire starting from focus group feedback, moving to questionnaire design 
and then using cognitive interviewing not only established a reliable measure, but 
provided a comprehensive overview of the subject area.  Each cognitive interview 
led to a conversation about respondents’ own thoughts on the subject area beyond 
that of the questionnaire data.  The willingness for respondents to share their 
opinions was a profitable process in terms of gaining a greater understanding of 
the subject area for the researcher.   
Cognitive interviewing was not so useful for assessing issues of question burden; 
participants in cognitive interviews have been reported to be more patient and 
attentive, relative to respondents in the field.  Thus, piloting the questionnaire was 
essential to test for any burden effects not detected during the cognitive 
interviewing process.  
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9.5. Methodological critique 
Running a cognitive interview is largely a social encounter and the notion that it is 
purely a programmed exchange is unrealistic.  There are two facets to cognitive 
interviewer behaviour that must be balanced and co-ordinated for maximum effect; 
technical ability and interpersonal skills.241  Although not trained in cognitive 
interviewing specifically, a wide breadth of clinical and social research had 
previously been undertaken by the researcher.  In addition, the researcher 
benefitted from the previous experience of having dealt with the type of patients 
inherently involved in the interviews.  Of particular importance, the researcher was 
aware of bias and context effects, was familiar with the questionnaire design 
process and was, therefore, well suited to appraise the questionnaire.   
Previous exposure to cognitive interviews and the opportunity to observe 
experienced interviewers would have been beneficial, but without such an 
opportunity, additional reading of the subject area and potential pitfalls was vitally 
important.  In particular, knowledge of the Cognitive Aspects of Survey 
Methodology approach was obtained.253  The researcher also undertook a practice 
session, before embarking on the first test case.   
Each interview was different with respect to the social exchange required for each 
individual, but the instructions given and initial think aloud training remained 
largely the same; this confirmed a consistency in the ability of the researcher to 
interact and give instructions to each participant successfully and the extent of 
probing and discussion was flexible according to the needs of each interview.  
Since there was only one researcher working on the project, it was not necessary 
to control for different approaches and evaluations of the interview, which is 
required when using multiple interviewers.  
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Chapter 10.  Questionnaire data collection  
10.1 Method  
After extensive testing of the questionnaire through cognitive interviewing and 
piloting, the questionnaire (appendix 19) was ready for distribution among the 
sample population and ethical approval for use of the revised questionnaire was 
sought. 
 
10.1.1 Participant identification and recruitment  
A hospital setting was felt to be the best location to capture responses compared 
to any other arbitrary public area.  Thus, questionnaires were given to all adults 
entering the Cromer hospital out-patient department.  The entrance to the 
glaucoma clinic was just inside the main entrance of the hospital.  Therefore, 
respondents were likely to be a mix of people who were either attending the 
glaucoma clinic and would therefore have experience of glaucoma care, or those 
attending other out-patient services within the hospital, these representing 
individuals found in the general population with less knowledge about glaucoma.   
Respondents had the option of completing the questionnaire whilst waiting for their 
consultation with their clinician and returning it to the collection box before leaving 
the hospital, or to take the questionnaire home for completion and return it in a 
freepost reply envelope.  Respondents who declined to participate had no further 
involvement. 
 
10.1.2 Data processing 
On collection of each completed questionnaire, a case number was assigned, for 
identification purposes.  Pre-coded question data was entered into the database 
by the coder (assistant researcher) and then verified by the researcher.  
Responses to open questions were transcribed verbatim.   
The data were checked for internal consistency to pick up any inconsistencies in 
the filter questions.  A review of missing data was undertaken to decide if list-wise 
or pair-wise deletion should be undertaken. 
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Respondents were asked to mark their attitude towards the use of a modified 
consent procedure using the VAS.  The number nearest the participant mark on 
the scale was used to give a metrical characteristic of attitude.  Marks exactly 
between the division lines were rounded up.  
 
10.1.3 Sample size for questionnaire study 
Without a similar study for comparison of expected range of opinion and because 
the population criterion was undefined, a sample size calculation was not possible.  
However, the aim was to collect responses from 200 people to give a 95% 
confidence interval and ± 5% margin of error for a population of 500 people.  The 
pilot test achieved described in Chapter 53% response rate, and therefore 400 
questionnaires were prepared to achieve approximately 200 responses.  
 
10.1.4 Analysis of the questionnaires 
Table 10.1 describes how each question within the questionnaire was used to 
meet the objectives of the study.   
The study scenario (appendix 19) was presented to the respondent at the 
beginning of the questionnaire.  Perceived acceptability of the study scenario was 
then measured at three different points during the questionnaire (Attitude 1, 2 and 
3).  The first measure of acceptability was directly after the scenario had been 
presented in order to capture the respondents’ initial reaction to it (Attitude 1).  The 
next section of the questionnaire informed respondents about behaviour changes 
likely to occur when patients take part in research.  A justification for use of the 
study scenario was then presented to the respondent and their reaction to the 
acceptability of the study scenario was measured again (Attitude 2).  The 
questionnaire then went on to examine the wider attitudes towards research; if 
respondents would consider taking part in research, and respondents’ previous 
experiences of research.  Finally, further justifications for using the study scenario 
were given and acceptability of the study scenario was measured for the final time 
(Attitude 3).  Changes in attitude between the Attitude 1 and Attitude 3 could be 
explored and in this way used to determine if justifications for use of the study 
scenario influenced attitudes.   
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The median score of acceptability of using a modified consent procedure was 
calculated for each VAS (Attitude 1, Attitude 2 and Attitude 3) and a Wilcoxon 
signed rank test used to compare results at each of the three test points during the 
questionnaire to establish changes in attitude.  
Median scores were also categorised into three groups; responses measuring 1-4 
on the VAS indicated a mild to strong opinion that the study scenario was 
unacceptable, whilst scores 6-9 depicted a mild to strong opinion that the study 
scenario was acceptable and a response of 5 indicated no opinion.   
The median scores of acceptability were compared using the attitudes of ‘patients 
who attend a glaucoma clinic’ to assess if experience of glaucoma care had any 
effect on attitude to participating in the study scenario using an independent 
samples Mann-Whitney U test at all three test points (Attitude 1, Attitude 2 and 
Attitude 3). 
Logistic regression was used to identify predictors of respondents likely to 
participate in a glaucoma study using a modified consent procedure.  Explanatory 
factors were entered into a univariate model by estimating the odds ratio of the 
study scenario being acceptable at Attitude 3 along with the corresponding 95% 
confidence interval and p-value.  Statistically significant independent factors were 
manually selected to construct a multivariate model.   
Cross tabulation of results over the three test points (Attitude 1, Attitude 2 and 
Attitude 3) was used to establish if respondents changed their opinion during the 
course of the study.  
Logistic regression was used to identify any predictors of respondents most likely 
to change their opinion of the acceptability of the study scenario, throughout the 
exercise.  Explanatory factors were entered into a univariate model by estimating 
the odds ratio of the study scenario being acceptable at Attitude 3 along with the 
corresponding 95% confidence interval and p-value.  Statistically significant 
independent factors were manually selected to construct a multivariate model.   
Descriptive statistics were used to report what respondents thought were 
important factors to consider if using the study scenario and what they would have 
felt if they had taken part in the study scenario, experiences of previous research 
and if they would take part in research in the future.  
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The respondent population was characterised using descriptive statistics.  
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Table 10.1 Description of outcome measures 
Question Question Outcome 
Secondary 
outcomes 
1. Is the example 
research study 
acceptable? 
Describe opinion of the cohort:  
% who felt the study is acceptable (1-4) 
% who felt the study is unacceptable  (6-9) 
% undecided (5) 
None 
Free text comments Qualitative analysis – report different 
reasons and quantify if possible. 
None 
2. Now what do you 
feel about the 
example research 
study? 
 
Describe opinion of the cohort:  
% who felt the study is acceptable (1-4) 
% who felt the study is unacceptable (6-10) 
% undecided (5) 
Does attitude to 
acceptability 
change when the 
justification for the 
study is stated. 
If the example 
research study is 
acceptable, 
would any of the 
following be 
important to you?  
Describe what the cohort thinks is 
important if information is withheld.  
% as long as there is no risk to participants 
% participants should be told at the end of 
the study.  
. 
Should the doctor 
carry out the 
study? 
Primary Outcome:  % of the cohort that 
think the doctor should not carry out the 
study either way 
Yes/No option of 
acceptability of the 
research example 
3. If you had taken 
part in the example 
research study 
without your 
knowledge, please 
consider how you 
would feel once you 
had been fully 
informed about the 
research. 
Describe what the cohort might feel if they 
had taken part in this research. 
% it would not concern me at all 
% would feel initially concerned 
% would feel they had not been treated 
with respect 
% would feel it would break rapport with 
their doctor 
% would not trust doctors or researchers in 
the future 
% would not take part in research again 
% who thinks research should not have 
been undertaken 
Enter into logistic 
regression 
models: 
1. Factors that 
may influence 
acceptability of 
the study 
scenario 
2. Factors that 
may influence a 
change in 
opinion. 
Other, please 
describe  
Qualitative analysis – report different 
reasons and quantify. 
None 
4. Have you ever 
taken part in any 
health research e.g. 
at a GP surgery or 
hospital 
Describe cohort: 
% have taken part in research 
% have not taken part in research 
 % don’t remember 
Enter into logistic 
regression models 
 
How would you 
describe your 
overall experience? 
Of those who took part in research: 
% found the study interesting 
% given enough information 
% valued the experience 
% found the study dull 
% was not given enough information 
% did not value the experience 
Enter into logistic 
regression models 
 
Please describe 
why you did or did 
not value the 
experience 
Qualitative analysis – report different 
reasons and quantify. 
None 
Please describe 
what sort of 
research it was 
Qualitative analysis – report research 
experience of the cohort. 
None  
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5. Would you ever 
consider taking part 
in research 
undertaken by a 
Hospital or GP 
surgery? 
Describe cohort:  
% consider taking part in research 
% not consider taking part in research 
% depend on the type of research 
% don’t know 
Enter into logistic 
regression 
models 
 
Do you feel any of the 
statements below 
describe concerns 
you might have about 
taking part in 
research? 
Describe concerns about research: 
 % concerned about confidentiality 
 % concerned information might be 
withheld 
 % there could be risks to health and 
wellbeing 
 % that have no concerns 
Enter into logistic 
regression 
models 
 
Are there any other 
issues or concerns 
that you feel could 
affect you if you were 
involved in research 
Qualitative analysis – report different 
concerns and quantify 
Enter into logistic 
regression 
models 
 
Would you expect to 
receive information 
about the possible 
risks of taking part in 
a research study if 
there were any? 
Describe cohort 
% would expect to receive information 
about risks 
% would not expect to receive information 
about risks 
% don’t know 
None 
6. Would you think the 
research example is 
acceptable? 
Primary Outcome: Describe opinion of the 
cohort: 
% who felt the study is acceptable (1-4) 
% who felt the study is unacceptable (6-9) 
% undecided (5) 
Describe 
differences 
between 
attitudes of 
acceptability at 
different points 
throughout the 
questionnaire.  
7. Demographic 
information 
% Male 
% Female 
Enter into logistic 
regression 
models 
% 39 under 
% 40-64 
% 65+ 
Enter into logistic 
regression 
models 
% Patient  
% carer/friend/relative visiting hospital 
% Other – qualitative analysis 
Other – qualitative analysis  
Enter into logistic 
regression 
models 
Glaucoma patient 
information 
% First visit 
% once a year 
% more than once a year 
Enter into logistic 
regression 
models 
% have used eye drops before 
% have not used eye drops before 
% don’t know 
Enter into logistic 
regression 
models 
% satisfactory experience of eye clinic 
% not satisfactory experience of eye clinic 
% no opinion 
Enter into logistic 
regression 
models 
Reasons for opinion about eye clinic:  
% travelling  
% waiting times 
% tests 
% Don’t like seeing a different doctor  
% questions 
% approachable 
% other – qualitative analysis  
Enter into logistic 
regression 
models 
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10.2 Results  
In March 2013, a questionnaire was offered to every person entering the main 
hospital entrance at the Cromer hospital, over three consecutive mornings.  Four 
hundred questionnaire packs were distributed and within 5 weeks of distribution, 
208 questionnaires had been returned, a response rate of 52%.  Missing data was 
minimal from the returned questionnaires; of the 1456 expected responses, only 
22 questions had an answer been omitted (1.5%) and most omissions occurred 
from questions relating to personal demographic information (32%).  Therefore, no 
techniques were required to handle the missing data to avoid bias.  
Table 10.2 describes the respondent demographics.  A greater number of 
responses were received from females than males and the largest proportion of 
responses were from those aged over 65 years.  A response rate could not be 
calculated as the demographic data for those who received the questionnaire was 
not collected.  Most respondents were patients attending the hospital, of which a 
proportion were patients with glaucoma n=34 (16.4%); of which 16 (47%) were 
diagnosed with glaucoma, 9 (27%) were diagnosed as a glaucoma suspect and 9 
(27%) did not know their diagnosis. 
 
Table 10.2 Respondent demographics and reason for visit to hospital 
Demographic characteristic N % 
Gender 
N=208 
Male 
Female 
Not disclosed 
92 
109 
7 
44.2 
52.4 
3.4 
Age 
N=208 
39 under 
40-64 
65+ 
Not disclosed 
8 
72 
119 
8 
3.8 
34.6 
57.7 
3.8 
Reason for 
visiting hospital  
N=208 
Patient  
Carer/friend/relative of a patient 
Other: member of staff (3) / hospital 
volunteer (4) / visitor (3) / participating in 
research (1) 
Not disclosed 
135 
48 
11 
 
 
13 
65.4 
23.1 
5.3 
 
 
6.3 
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10.2.1 Primary outcome:  Attitude to the use of a modified consent 
procedure  
Respondents’ attitudes to the use of the example research study (the study 
scenario) were measured at three different points during the questionnaire; 
‘Attitude 1’, was determined directly after the scenario had been presented in the 
introduction, ‘Attitude 2’ after a justification for using such a study design and 
‘Attitude 3’ after more information about the study and further justifications had 
been given.   
 
 
Figure 10.1.  Attitudes toward the acceptability of the study scenario 
measured at 3 points during the questionnaire 
 
Figure 10.1 graphically represents the acceptability of the study scenario at the 
three different points during the questionnaire.  By the time of ‘Attitude 3’, opinion 
was strongly polarised with the majority of participants indicating that they felt the 
study scenario was acceptable.  The median attitude score at Attitude 3 was 9 (IQ, 
7, 9).  
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Table 10.3 displays the median scores when the same responses were 
categorised as ‘unacceptable’, ‘acceptable’ or ‘no opinion’ at the three different 
points.  The majority of respondents felt that the study scenario was acceptable 
when measured at Attitude 3.  Of the 15.7% of participants that responded that the 
study scenario was unacceptable at Attitude 3 on the VAS, when using a 
dichotomised ‘yes/no’ response option which asked specifically if the study should 
not be carried out by researchers (appendix 19, question 2, option c), only (4%) of 
respondents (n=9) agreed. 
 
Table 10.3 Categorised responses of attitudes to the use of the study 
scenario 
 
 
10.2.2 Secondary outcomes  
10.2.2.1 Changes in Attitude 
As shown in Figure 10.1 and Table 10.4, when attitude towards the acceptability of 
the study scenario was measured initially (Attitude 1), most respondents felt the 
study was unacceptable.  When attitude was measured again (Attitude 2), opinion 
became more divided but more strongly favoured being acceptable.  The final 
measure of opinion (Attitude 3) found that the majority of respondents felt the 
study was acceptable.  Table 10.4 shows the median attitude score reported at the 
three measured points and compared them for statistical significance; the opinion 
Categorised 
opinion from 
VAS scale 
Attitude 1 
Initial response to 
scenario 
 
n (%) 
n = 202 
Attitude 2 
Reactivity bias 
described 
 
n (%) 
n = 202 
Attitude 3 
Final response 
following justification 
  
n (%) 
n = 204 
1 – 4 
Unacceptable 
106 (52.5) 60 (29.7) 32 (15.7) 
5 
No opinion  
7 (3.5) 8 (4.0) 10 (4.9) 
6 – 9 
Acceptable  
89 (44.1) 134 (66.3) 162 (79.4) 
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of the study scenario became more acceptable when a justification was given and 
this change in opinion was statistically significant. 
 
Table 10.4  Attitude scores reported at the three measure points 
 
The cross tabulation in Table 10.5 revealed that of the 202 respondents that 
responded to all 3 ‘attitude questions’, 57% (n=114) did not change their opinion 
between ‘Attitude 1 and 3’, 14% maintained that study was unacceptable and 43% 
maintained that the study was acceptable.  Seventy-two respondents (36%) did 
change their opinion between ‘Attitude 1 and 3’; 35% changed their opinion from 
being unacceptable at’ Attitude 1’ to acceptable at ‘Attitude 3’ and only 1% felt the 
study scenario was initially acceptable but unacceptable at ‘Attitude 3’.  
 
Table 10.5  Change in opinion between Attitude 1 and Attitude 3 using 
categorised responses. 
 
 
Attitude 3 
 
  
Unacceptable No opinion Acceptable Total 
Attitude 
1 
 
Unacceptable 28 7 70 105 
No opinion 1 1 5 7 
Acceptable 2 2 86 90 
Total 31 10 160 202 
 
 
 
Median 
(IQ range) 
Related samples Wilcoxon signed rank 
Attitude 1  
and 2 
Attitude 2  
and 3 
Attitude 1  
and 3 
Attitude 1 
n=203 
3.0 
(1.0, 8.0) 
P <0.001 P<0.001 P<0.001 
Attitude 2 
n=203 
7.0 
(3.0, 9.0) 
Attitude 3 
n=205 
9.0 
(7.0, 9.0) 
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Further analyses were carried out to establish if any specific factors influenced 
respondent change of opinion with respect to the study scenario from ‘Attitude 1’ 
to ‘Attitude 3’ as shown in Table 10.6.  Statistically significant factors from the 
multivariate model revealed that respondents who had previously taken part in 
research were more likely to change their opinion regarding the acceptability of the 
scenario once a justification had been given. 
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Table 10.6  Factors that may influence a change in opinion relating to 
acceptability of the study scenario 
 Did opinion of the 
acceptability of the 
scenario change? 
Unadjusted Selected 
Predictor No  Yes (%) 
OR 
(95% CI) 
p-value 
OR 
(95% CI) 
p-value 
Gender of respondent 
Female 71 34 (32.4) 
1.747 
(0.98, 3.13) 
0.060 
1.428 
(0.76, 2.70) 
0.273 
Male 49 41 (45.6) 1    
Age of respondent 
64 years and under 54 23 (29.9) 1  1  
65 years and over 65 52 (44.4) 
1.878 
(1.02, 3.45) 
0.043 
1.592 
(0.82, 3.10) 
0.171 
Reason the respondent was visiting hospital at time of collecting questionnaire 
A patient 80 52 (39.4) 
1.202 
(0.63, 2.30) 
0.576   
A carer/friend/relative/other  37 20 (35.1) 1    
Glaucoma status of the respondent 
Has glaucoma 19 14 (42.4) 
1.179 
(055, 2.51) 
0.670   
Does not have glaucoma 104 65 (38.5) 1    
Would feel that ensuring the research project does not cause risks to participants would Is 
important 
Yes 107 62 (36.7) 1    
No 15 13 (46.4) 
1.496 
(0.67, 3.35) 
0.328   
Would feel that participants should be told the real reason for the research project upon 
completion 
Yes 89 61 (40.7) 
1.616 
(0.80, 3.27) 
0.182   
No 33 14 (29.8) 1    
The respondent feels that the research project described in the scenario should not  
be carried out 
Yes 6 3 (33.3)     
No 116 72 (38.3) 
1.241 
(0.30, 5.12) 
0.765   
If respondent had taken part in the study scenario they would have no concerns 
Yes 39 30 (43.5) 
1.314 
(0.73, 2.38) 
0.368   
No 82 48 (36.9) 1    
If respondent had taken part in the study scenario they may have been initially concerned, but 
not once explained 
Yes 55 35 (38.9) 1    
No 66 43 (39.4) 
1.024 
(0.58, 1.81) 
0.936   
If respondent had taken part in the study scenario they would feel they had not be treated with 
respect 
Yes 28 15 (39.4) 1    
No 93 63 (40.4) 
1.265 
(0.63, 2.56) 
0.513   
If respondent had taken part in the study scenario they feel it would break the rapport with 
their doctor 
Yes 10 9 (47.4) 
1.448 
(0.56, 3.74 
0.445   
No 111  69 (38.3) 1    
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 Did opinion of the 
acceptability of the 
scenario change? 
Unadjusted Selected 
Predictor No  Yes (%) 
OR 
(95% CI) 
p-value 
OR 
(95% CI) 
p-value 
 
If respondent had taken part in the study scenario they would not trust doctors or researchers 
in the future  
Yes 6 2 (25.0) 1    
No 115 76 (39.8) 
1.983 
(0.39, 10.8) 
0.409   
If respondent had taken part in the study scenario they may consider whether they would take 
part in research again 
Yes 17 13 (43.3) 
1.224 
(0.62, 1.22) 
0.615   
No 104 65 (38.5) 1    
Has the respondent taken part in health research before? 
Yes 25 27 (51.9) 
2.237 
(1.12,4.09) 
0.022 
1.937 
(0.95, 3.95) 
0.069 
No 91 46 (33.6) 1  1  
If the respondent had taken part in research was this experience interesting? 
Yes 20 18 (47.4) 1    
No 6 8 (57.1) 
1.481 
(0.431, 5.10) 
0.533   
If the respondent had taken part in research were they given enough information about the 
research? 
Yes 19 15 (45.7) 1    
No 7 10 (58.8) 
1.696 
(0.53, 5.48) 
0.377   
If the respondent had taken part in research did they value the experience? 
Yes 21 19 (47.5) 
1 
 
   
No 5 7 (58.3) 
1.547 
(0.42, 5.70) 
0.512   
Would the respondent take part in research if asked in the future?  
Yes 50 41 (45.1) 
1.511 
(0.85, 2.68) 
0.157   
No / Would depend 70 38 (35.2) 1    
Would the respondent be concerned that their details may be shared with other people if they 
took part in research? 
Yes 40 19 (32.2) 1    
No 81 60 (42.6) 
1.559 
(0.82,2.96) 
0.174   
Would the respondent be concerned that your doctor might keep information from them if they 
took part in research? 
Yes 50 28 (35.9) 1    
No 71 51 (41.8) 
1.283 
(0.71, 2.31) 
0.405   
Would the respondent have any concerns about health risks if they took part in research? 
Yes 50 23 (31.5) 1    
No 71 56 (44.1) 
1.715 
(0.94, 3.14) 
0.081 
1.108 
(0.49, 2.50) 
0.805 
Would the respondent have any concerns about taking part research?  
Yes 85 41 (32.5)     
No 36 37 (50.7) 1    
* Using forward selection 
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10.2.2.2 Attitudes of patients who attend a glaucoma clinic  
To determine if attitudes differed between respondents who have a greater 
awareness of glaucoma treatment and those that did not, the attitudes of 
respondents who reported previously or currently attending a glaucoma clinic were 
analysed separately.  The median attitude scores are displayed in Table 10.7 and 
showed that use of the study scenario was more acceptable at Attitude 3 which 
was statistically significant, there having been an initial statistically significant 
difference of acceptability between Attitude 1 and 2.  
 
Table 10.7  Median attitude score of respondents who attend a glaucoma 
clinic, reported at each of three attitude measurement points and compared 
for statistical significance.  
 
 
Table 10.8 displays the attitudes from the respondents classified as ‘the general 
public’ compared to ‘patients that had attended a glaucoma clinic’.  There was a 
statistically significant difference at ‘Attitude 3’, which showed that members of the 
general public found the study scenario slightly more acceptable than patients who 
had attended a glaucoma clinic. 
  
 
Median 
(IQ range) 
Related samples Wilcoxon Signed Rank 
Attitude 1 and 
2 
Attitude 2 and 
3 
Attitude 1 and 
3 
Attitude 1 
n=33 
4.0 
(1.0, 9.0) 
p = 0.007 p = 0.076 p = 0.008 Attitude 2 
n=33 
7.0 
(3.0, 9.0) 
Attitude 3 
n=34 
8.0 
(5.0, 9.0) 
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Table 10.8  Median score of attitude compared between respondents who 
‘attend a glaucoma clinic’ or are ’members of the public’. 
 
 
10.2.2.3 Factors which may influence attitudes  
Logistical regression analysis was used to examine if there were other factors that 
might have affected the likelihood that respondents would react differently to the 
acceptability of the study scenario.  Table 10.9 presents the factors that were 
entered into a univariate model, from which statistically significant factors were 
selected to be entered into the multivariate model.  The study scenario appeared 
to be more acceptable to respondents if they had been told the real reason for the 
study retrospectively and by those who considered themselves to be a 
carer/relative and therefore not ‘a patient with glaucoma’ at the time of completing 
the questionnaire. 
 
 
Median  (IQ range) Independent 
Samples Mann- 
Whitney U 
Patients with 
Glaucoma 
General Public 
Attitude 1 
4.0 
(1.0, 9.0) n=33 
3.0 
(1.0, 8.0) n=170 
p = 0.760 
Attitude 2 
7.0 
(3.0, 9.0) n=33 
7.0 
(4.0, 9.0) n=170 
p = 0.872 
Attitude 3 
8.0 
(5.0, 9.0) n=34 
9.0 
(7.0, 9.0) n=171 
p = 0.043 
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Table 10.9 Factors that might influence acceptability of the study scenario  
 Was the study 
scenario considered 
acceptable  
Unadjusted Selected* 
Factor No  Yes (%) 
OR 
(95% CI) 
p-value 
OR 
(95% CI) 
p-value 
Gender of respondent 
Female 21 88 (80.7) 1    
Male 18 72 (80.0) 
1.048 
(0.52, 2.12) 
0.897   
Age of respondent 
64 years and under 19 60 (75.9) 1    
65 years and over 20 99 (83.2) 
1.567 
(0.77, 3.17) 
0.211   
Reason the respondent was visiting hospital at time of collecting questionnaire 
A patient 34 101 (74.8) 1    
A carer/friend/relative/other  3 55 (94.8) 
6.172 
(1.81, 21.02) 
0.004 
4.082 
(1.11, 15.05) 
0.035 
Glaucoma status of the respondent 
Has glaucoma 9 25 (73.5) 1    
Does not have glaucoma 33 138 (80.7) 
1.505 
(0.64, 3.53) 
0.346   
Of the respondents who have glaucoma how often the glaucoma clinic is attended 
One to two years 5 12 (70.6) 
1.200 
(0.25, 5.89) 
0.822   
More than once a year 4 8 (66.7) 1    
Does the respondent currently use or ever used eye drops for glaucoma? 
Yes 7 21 (75.0) 1    
No  2 8 (80.0) 
1.333 
(0.23, 7.83) 
0.750   
Of the respondents who have glaucoma do they feel their appointments at a glaucoma clinic are 
satisfactory 
Yes 9 26 (74.3) 
1.444 
(0.12, 17.90 
0.775   
No opinion 1 2 (66.7) 1    
Would feel that ensuring the research project does not cause risks to participants is important 
Yes 31 143 (82.2) 
2.563 
(1.08, 6.09) 
0.033 
1.896 
(0.57, 6.36) 
0.300 
No 10 18 (64.3) 1    
Would feel that participants should be told the real reason for the research project upon 
completion 
Yes 24 131 (84.5) 
3.093 
(1.48, 6.46) 
0.003 
2.398 
(0.92, 6.22) 
0.072 
No 17 30 (63.8) 1    
If respondent had taken part in the study scenario they would have no concerns 
Yes 6 64 (91.4) 
3.918 
(1.56, 9.83) 
0.004 
2.028 
(0.52, 7.97) 
0.311 
No 36 98 (73.1) 1    
If respondent had taken part in the study scenario they may have been initially concerned, but not 
once explained 
Yes 11 83 (88.3) 
2.961 
(1.39, 6.29) 
0.005 
1.590 
(0.47, 5.38) 
0.456 
No 31 79 (71.8) 1    
If respondent had taken part in the study scenario they would feel they had not be treated with 
respect 
Yes 23 23 (50.0) 1    
No 19 139 (88.0) 
7.316 
(3.45, 15.50) 
<0.001 
2.331 
(0.59, 9.16) 
0.225 
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 Was the study 
scenario considered 
acceptable  
Unadjusted Selected* 
Factor No  Yes (%) 
OR 
(95% CI) 
p-value 
OR 
(95% CI) 
p-value 
 
If respondent had taken part in the study scenario they feel it would break the rapport with 
their doctor 
Yes 10 12 (54.5) 1    
No 32 150 (82.4) 
3.906 
(1.55, 9.82) 
0.004 
1.308 
(0.37, 4.68) 
0.680 
If respondent had taken part in the study scenario they would not trust doctors or researchers in 
the future  
Yes 7 2 (22.2) 1    
No 35 160 (82.1) 
16.000 
(3.19, 80.32) 
0.001 
3.906 
(0.62, 24.65) 
0.147 
If respondent had taken part in the study scenario they may consider whether they would take 
part in research again 
Yes 15 15 (50.0) 1    
No 27 147 (84.5) 
5.444 
(2.39, 12.42) 
<0.001 
1.028 
(0.41, 2.59) 
0.223 
Has the respondent taken part in health research before? 
Yes 10 43 (81.1) 1    
No 26 113 (81.3) 
1.011 
(0.45, 2.27) 
0.979   
If the respondent had taken part in research was this experience interesting? 
Yes 7 33 (82.5) 
1.414 
(0.31, 6.51) 
0.656   
No 3 10 (76.9) 1    
If the respondent had taken part in research were they given enough information? 
Yes 7 30 (81.1) 1    
No 3 13 (81.3) 
1.011 
(0.23, 4.54) 
0.988   
If the respondent had taken part in research did they value the experience? 
Yes 8 34 (81.0) 1    
No 2 9 (81.8) 
1.059 
(0.19, 5.88) 
0.948   
Would the respondent take part in research if asked in the future?  
Yes 14 81 (85.3) 
2.025 
(0.99, 4.13) 
0.052 
1.028 
(0.41, 2.59) 
0.953 
No / Would depend 28 80 (74.1) 1    
Would the respondent be concerned that their details may be shared with other people if they 
took part in research? 
Yes 12 50 (80.6) 
1.116 
(0.53, 2.36) 
0.774   
No 30 112 (78.9) 1    
Would the respondent be concerned that your doctor might keep information from them if they 
took part in research? 
Yes 22 58 (72.5) 1    
No 20 104 (83.9) 
1.972 
(0.99, 3.92) 
0.052 
0.947 
(0.36, 2.50) 
0.912 
Would the respondent have any concerns about health risks if they took part in research? 
Yes 14 62 (81.6) 
1.240 
(0.61, 2.54) 
0.556   
No 28 100 (78.1) 1    
Would the respondent have any concerns about taking part research?  
Yes 12 62 (83.8) 
1.566 
(0.75, 3.28) 
0.236   
No 30 99 (76.7) 1    
10.2.2.4 Supplementary opinions 
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If they had taken part in any type of research study, the majority of respondents 
reported that they would expect to be told if there were any possible risks 
associated with participation (96.5%, 195 of responses).  A significant minority 
(30%, n=62) were concerned that personal details might be shared with other 
people, 40% (n=82) thought that their doctor/researcher might keep important 
information about their health from them and 37% (n=76) thought that there could 
be a risk to their health and wellbeing.  
When considering specific participation in the study scenario, 86% (n=173) of 
respondents felt that it was important to ensure that the study did not cause ‘risk’ 
to participants and 76% (n=154) felt that participants should be informed of the 
real reason for the research upon completion of the study.   
From 204 responses, the majority of participants (81%) felt that if they had 
participated in the study scenario they would not have been concerned or, at least 
would not have been concerned after the reason for the study had been explained 
to them.  Only 23% reported that they may have felt that they had not been treated 
with respect by their doctor or the researcher who had kept the information from 
them; 11% felt that it may break their rapport with their doctor or the researcher 
that had kept the information from them, 4% felt that they would not trust doctors 
or researchers in the future and 15% reported that they might consider not taking 
part in research again.   
Respondents were invited to give any other feedback relating to the use of the 
study scenario.  Three responses were positive towards the study scenario:  
 “Anything that furthers medical science is very welcome.” 
 “I would feel pleased that I had taken part in a worthwhile project.”  
 “I consider research into the condition is invaluable.”  
 
Three comments helped define when such a study may not be acceptable:  
 “As long as I wasn’t in any danger or at risk.”  
 “It would depend if the doctor was going to gain financially from the 
research.”  
 “I would ask a solicitor if I could sue if my ID had been disclosed.” 
 
One response was negative towards the use of the study scenario: 
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 “I would feel that the doctor/researcher had felt that their cause more 
important than patients right to knowledge.”  
 
10.2.2.5 Previous experience of research 
Only 26% (n=54) of respondents had previously taken part in research and 28% 
(n=15) of those had participated in more than one study.  The majority of 
participants had valued their experiences of taking part in research (78%) and 
found it interesting (74.1%) and had received enough information about the study 
in which they had participated (69%).  Participants’ past experiences of research 
and intention to take part in research did not have any effect on attitudes towards 
the use of the study scenario as discovered by the logistic regression analysis 
summarised in Table 10.8.   
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10.3 Discussion  
The majority of respondents felt that the study scenario was acceptable to some 
degree or had no opinion either way.  Only a small minority felt that a glaucoma 
related adherence study with modified consent should not be carried out at all.   
With respect to withholding information from participants, respondents felt it was 
important to ensure that there were no risks associated with this and that 
participants should be told the real reason for the study on completion of their 
participation.  If respondents had taken part in the study themselves, most would 
not have felt concerned about their participation, or indicated that at least once the 
reasons for the study had been explained to them, they would not have been 
concerned.   
Only a minority of respondents reported that they might have felt they had not 
been treated with respect by their doctor, or that their rapport with their doctor may 
have been broken if they had taken part in the study.  The broken trust with their 
doctor or researcher would make them consider whether they would take part in 
research again in the future.  For respondents who might have had such negative 
opinions, providing a way of contacting the researcher via telephone, email or 
letter, might have provided an opportunity for concerns to be discussed sensitively 
on a one-to-one basis in order to minimise the potential harmful effects described.  
Overall, respondents felt that informing participants retrospectively and taking 
consent after study completion increased acceptability of the study design.  
Furthermore, assessment of attitudes towards the study scenario at three different 
time points during the questionnaire gave clear evidence as to how disseminating 
information about the study and the justification for using such a study design, 
changed opinion of study acceptability.  Thus, providing information that positively 
validates the justification for the study might help participants to accept the use of 
a modified consent method and reduce the potential negative responses to having 
taken part in study without giving prior consent.  
Whilst generally a study to investigate reactivity effects in measuring glaucoma 
therapy adherence with a modified consent process appeared acceptable to the 
majority of respondents, there were those who held reservations about the use of 
such a method.  Members of the public found the study scenario slightly more 
acceptable than patients who had or were attending a glaucoma clinic; it could be 
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considered that members of the public are not so concerned with use of eye drops 
or participating in research compared to patients who have first-hand experience 
of these issues and where such matters are of greater concern to them.  In 
conclusion, however, questionnaire development and subsequent usage, 
highlighted what design aspects should be incorporated into such a study with a 
modified consent method in order to meet the needs of different individuals.  
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10.4 Methodological Critique 
The study had a good response rate and missing data was minimal which 
suggested that the advice from the literature and think aloud piloting maximised 
the design of the questionnaire to increase the response rate and completion of all 
questions adequately.   
Use of a study scenario that mimicked the potential design of the planned future 
study worked well to set the scene and form a base on which the justification for 
using retrospective consent methods could be explained to respondents.  A good 
response rate and minimal missing data evidenced that the study scenario and 
justification was understood by respondents of the questionnaire, assuming that 
respondents would have failed to complete the questionnaire if they had not 
understood it.   
Using a mix of ‘patients with glaucoma’ and ‘the general public’ showed that there 
were differences in attitude between the two groups and incorporating opinions 
was important in widening the breadth of opinions sought.  Asking respondents to 
give basic demographic details, previous experiences of research and ophthalmic 
care enabled confirmation that there was a mix of respondents, providing the 
ability to examine several factors that might have influenced attitudes to the study 
scenario.  The fact that the majority of respondents were over 65 years of age was 
considered appropriate for a glaucoma related study, since the condition is very 
age-related. 
The VAS was successful in eliciting responses and overcoming the problems 
identified in the piloting stages of the questionnaire when using a categorical, 
dichotomised (yes/no) answer had resulted in missing data.  
The initial concerns about how order effects, or introducing information into the 
questionnaire to give relevance and context to the questions, might bias answers 
was well founded since attitudes did change over the course of the questionnaire; 
the methodology used allowed for control of these effects reducing the introduction 
of any unintentional bias.  
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10.5  Conclusion 
This present section investigated the reasons for, and public opinion of, using a 
modified consent method.  Review of the literature suggested that whilst in some 
cases deception is necessary, its use can cause distress and harm to participants 
and they might become cynical of research activities.  
Focus group and PPIRes involvement helped inform the design of a questionnaire 
that was thoroughly validated and piloted before use in a wide consultation with 
patients and members of the public accessing an NHS facility.  
The findings from this exploration of patient and public opinion corroborated, at 
least to some extent, the guidance and evidence gathered from the 2009 ethical 
debate exercise undertaken by the NHS National Research Ethics Service 
(NRES)274 confirmed that deception should only be used when no other research 
method would suffice and that research would have a high probability of 
subsequent advances.   
Following the wide consultation that was undertaken to ensure that a project 
requiring modified consent was appropriate, a research project was designed to 
investigate the magnitude of reactivity effects in assessing glaucoma therapy 
adherence, which would minimise harm to participants and follow NRES guidance.  
Furthermore, it was felt that an application via NRES for ethical approval could be 
confidently made since the design was founded by evidence and suggestions for 
additional safeguarding procedures.  It was determined that participants should be 
fully briefed at the end of the study as to the reason for the study.  It was 
determined that the ethical review process itself would likely give further 
reassurances to participants, since the focus group findings suggested that 
participants of research trust the ethical review process.  As is standard good 
clinical practice, participants in the planned future study were set to be free to 
withdraw their data should they disagree with their participation in the study and 
were to have the opportunity to discuss their participation with the research team 
should further information or concerns need to be discussed.   
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Section 4. The React Study; using 
a modified consent 
procedure to observe 
reactivity effects 
 
Presentations resulting from this section: 
Cate H, Broadway DC, and Bhattacharya D. Investigating 
assessment reactivity bias. (Poster) UK Society of Behavioural 
Medicine, Manchester, 2012.  
Cate H, Broadway DC, and Bhattacharya D. Exploring Reactivity 
Bias: The (haw) Thorny Issue! Investigating assessment reactivity bias 
(Oral) School of Pharmacy Research Colloquium, 2015. Winner of 
Best Oral Presentation.  
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Chapter 11. The React Study 
11.1 Introduction  
Evidence from the NAGS qualitative follow-up study described in Section 2 
indicated that study reactivity effects might have altered the measured study 
findings.  Monitoring adherence behaviour, including mere measurement effects 
originating from completing questionnaires, are thought to activate messages 
and/or establish ideas to provide information that would not have been available to 
patients had they not taken part in the study.  In particular, the multiple methods 
used to measure adherence and gather participant opinion might also have 
changed usual behaviour in addition to the effects caused by participating in 
research.   
Thus, this final section describes the React study, a study designed to measure 
changes in adherence to medication behaviour when individuals participated in 
research and were aware that their adherence was being observed, in an attempt 
to quantify the magnitude of any reactivity effects.  As the methods describe, the 
TDA was used to simulate the effect of measuring adherence just as in NAGS.  
The ‘participation in research’, as a factor, was replicated by a consent process 
which used a participant information leaflet replicating that used in NAGS which 
explained that participants would have their adherence monitored using the TDA.  
A questionnaire was used to simulate mere measurement effects.   
The React study was designed to replicate NAGS as closely as possible.  
However, soon after the conception of the React study, latanoprost became the 
first line treatment for POAG at NNUH instead of travoprost; Xalatan (the trade 
name for latanoprost) was coming off patent and therefore generic latanoprost 
became available at a much lower cost and had to be prescribed in the NNUH Eye 
Department.  Therefore, it was not possible to recruit patients that were treatment 
naïve and about to commence treatment as was the case in NAGS.  Instead 
patients on established travoprost were recruited.   
A previous study comparing adherence measured by a MEMS bottle with patient 
self-reported adherence evaluated using a VAS, concluded that because patients 
were aware that their adherence was being monitored by the MEMS bottle, there 
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was a potential for their adherence and their estimations of adherence to be 
influenced.94  Thus, collecting self-report data using the 4-item Morisky self-report 
tool would not only ensure that consistency was maintained by using the same 
questions as in the NAGS questionnaire, but would also enable a comparison of 
how awareness of monitoring adherence might affect patient self-report when 
patients are masked and un-masked to the presence of adherence monitoring. 
The NAGS questionnaire also used SIMS to establish the potential barriers to use 
of medication.  However, the NAGS qualitative focus group study found that SIMS 
was not well received and many responses were left blank, since participants did 
not feel that the questions were relevant to problems experienced by eye drop 
users as described in paragraph 4.3.2.4.  Therefore, a new tool was sought to 
replace SIMS to ensure that the questionnaire emulated the same length and type 
of questioning used in NAGS.  The Identification of Medication Adherence Barriers 
(IMAB) questionnaire is a 30-item questionnaire designed to gauge attitude and 
decision-making processes in adherence behaviour.  Originally designed to 
assess barriers to adherence to medication for the prevention of cardiovascular 
disease, statements are given to a respondent to assess attitudes in 10 behaviour 
domains; ‘knowledge’, ‘skills’, ‘memory attention and decision making processes’, 
‘social influences’, ‘environmental constraints’, ‘emotions’, motivation and goals’, 
‘goal conflicts’, ‘beliefs about capabilities’ and ‘beliefs about consequences’.275, 276  
Patients are asked to complete the questionnaire by responding to each statement 
using a 5 point Likert scale ranging from ‘strongly agree’ to ‘strongly disagree’.  A 
response of ‘strongly agree’ for positively phrased statements would score 1 point 
and thus indicate a low barrier, whereas a response of ‘strongly disagree’ would 
score 5 points and indicate a high barrier to behaviour change.  For negatively 
phrased statements reverse scoring is used so that a response of ‘strongly agree’ 
scores 5 points and thus represent a high barrier to behaviour change.  Scores 
from the three statements for each behavioural domain are collated and used to 
calculate a mean score.  The process allows a researcher to clearly see which of 
the behavioural domains represents the highest barrier to adherence behaviour.  
Use of the IMAB in the React study not only fulfilled the need to replicate the 
NAGS study questionnaire as closely as possible, but had a further function of 
providing useful evidence for future intervention studies.  Identifying individual 
patient barriers would guide future studies to target individual needs and initiate 
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behaviour change that improves adherence.  It was considered that use of the 
IMAB questionnaire in a glaucomatous population where self-reported barriers that 
prevent good medication in conjunction with TDA measured non-adherence, would 
have the potential to establish if an association exists between measures.  An 
association between the measures of adherence could highlight the IMAB 
questionnaire as a useful tool for future glaucoma adherence studies and clinical 
practice.   
The design of the study required the use of a modified consent method that 
withheld information from participants.  Section 3 described the work undertaken 
to establish the acceptability of a modified consent method with patients and 
members of the public; the majority of which reported that this method would be 
acceptable.  The findings highlighted ways in which participants could be 
reassured and managed if any potential negative feelings did arise.   
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11.2 Method  
11.2.1 Study aims and objectives 
The aim of the React study was to observe the change in TDA measured 
adherence and self-reported adherence when individuals participated in research 
in which they were initially unaware and subsequently aware, that their adherence 
was being observed, during which they completed questionnaires that probed their 
attitude to adherence behaviour at completion of each phase of the study.  The 
difference in measured adherence determined the magnitude of reactivity effects.  
The React study also aimed to elicit patient-reported attitudes to adherence to 
travoprost and its association with measured non-adherence.   
The study objectives were to: 
A. Determine if there was a difference in adherence to travoprost when 
participants were un-aware and therefore masked to participation in the 
study, compared with that of the un-masked period, when participants had 
agreed to take part in a study in which their adherence was being 
monitored; Analysis A Figure 11.2.   
B. Examine if adherence to travoprost was an attributable factor for individuals 
declining participation in the un-masked phase; Analysis B Figure 11.2. 
C. Establish if there was a difference in self-reported non-adherence when 
participants were un-aware and therefore masked to participation in the 
study, compared with that of the un-masked period, when participants had 
agreed to take part in a study in which their adherence was being 
monitored.   
D. Establish if there was an agreement between self-reported non-adherence 
and TDA measured adherence in masked and un-masked phases.  
E. Establish if opinion of the TDA and perceived usefulness was an 
attributable factor for adherence to travoprost. 
F. Establish if opinion of the TDA and perceived usefulness was an 
attributable factor for individuals declining participation in either phase of 
the study. 
G. Examine if factors namely, previous problems with eye drops, or 
satisfaction with information received about diagnosis and eye drops, 
affected adherence with travoprost in the masked and un-masked phases.  
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H. Establish if the overall IMAB score or any specific behavioural domain had 
an association with non-adherence measured by the TDA in the masked 
and un-masked phases.   
I. Examine if age, gender and glaucoma diagnosis, were attributable factors 
for individuals declining participation in either phase of the study. 
 
11.2.2 Ethical approval 
The study received ethical approval from the Norfolk Research Ethics Committee, 
(appendix 20) and research governance approvals from the East Norfolk and 
Waveney Research Governance Committee (appendix 21).  
 
11.2.3 Setting, Participants and Recruitment  
Patients attending the glaucoma out-patient clinic at NNUH and Spire Hospital 
(Norwich) meeting the inclusion/exclusion criteria were invited to take part.   
Inclusion criteria  
- Treated glaucoma patients using travoprost, that, in the opinion of the 
clinician, was efficacious with no hypersensitivity or other unwanted side 
effects.* 
- Male or female ≥ 18 years of age. 
- Patients able to provide a signed informed consent. 
- Patients willing and with adequate ability to read and understand English. 
 
Exclusion criteria  
-  Patients whose drops were applied by care home staff / carers / home-
helpers. 
- Additional medication required for the treatment of glaucoma. 
- Patients who were previously participants in NAGS or the follow-up studies 
described in Chapter 5 and 7. 
 
*Of the participants from the NAGS study, 7% withdrew due to hypersensitivity or 
no effect to treatment.  By recruiting participants already using established 
treatment with travoprost the number of early withdrawals was expected to be 
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reduced significantly.  However, patients were withdrawn from the study if they 
stopped using travoprost for any reason during the study period.  
 
11.2.4 Identification and recruitment  
The flow diagram shown in Figure 11.1 shows the identification and recruitment 
phase, which was followed by the masked phase, intervention and un-masked 
study phase.  The consultant/primary care team identified eligible patients from 
NNUH and Spire hospital clinics.  The patient details were then passed to the 
specialist NNUH specialist glaucoma nurse.  The specialist glaucoma nurse 
approached the identified patients to ask if they would use the TDA for two months 
and then complete a questionnaire in order to give their feedback about the 
usefulness of the TDA using the The React study recruitment script (appendix 22).  
The patient was informed that their details would be recorded on the contact 
details form (appendix 23) so that the TDA and instruction leaflet (appendix 13) 
could initially be sent by post along with all further communication.  The identifying 
clinician/specialist nurse also gathered data about the patient on section B of the 
contact details form (appendix 23); date of birth, gender, and type of glaucoma 
diagnosed.  Those in contact with the patient specifically avoided using words 
such as ‘research’ and ‘a study’ or that the TDA measured adherence to ensure 
that the initial two-month period (56 days) remained a ‘masked phase’.   
When patients declined participation in the study, only section B of the data 
collection form (appendix 23) was completed to ensure that the data passed to the 
research team remained anonymous.  Date of birth, gender and type of glaucoma 
were used to determine if these variables were significantly different between 
those who took part in the study and those who declined.  
After one week, the patient was telephoned by the specialist glaucoma nurse, or a 
member of the primary care team, to confirm the use of the TDA and/or to resolve 
any problems relating to TDA usage.  If the patient had decided not to continue 
using the TDA after one week, a reply envelope was supplied by the primary care 
team so that the patient could return the TDA.   
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11.2.5 The study intervention  
The study intervention followed the initial two-month masked phase when patients 
were not aware that their adherence was being monitored or that they were 
participating in a study.  The intervention was designed to simulate the following 
factors:  
 Awareness of the participation in research study objectives - a patient 
information leaflet and formal consent process, together with discussion 
with the researcher.   
 Effect of measuring adherence – participants aware that the TDA measures 
adherence 
 Questionnaires - mere measurement effects.   
 
11.2.6 The masked phase 
Those patients who confirmed they were using the TDA at one week and were 
intending to continue use of the TDA were then considered to be enrolled into the 
masked phase for 56 days of monitoring.  A 56-day follow-up period was chosen 
to enable a long enough period for patients to become familiar with the TDA and 
enter a habitual routine of administering eye drops with the TDA whilst not 
extending the monitoring period for too long; NAGS found that when the 
monitoring period was extended beyond 56 days, data retrieval became less 
reliable, see Table 3.3 in Chapter 3.4.  
Upon completion of the masked phase (56 days of monitoring), individuals were 
sent Questionnaire 1, ‘A review of the Travalert Dosing Aid’ (appendix 24), in the 
post together with instructions to return their questionnaire and the TDA in a reply 
envelope provided using ‘end of review phase patient letter (appendix 25).  An 
administrator from the primary care team arranged postage of the questionnaires 
to ensure that patient details were kept anonymised from the researcher.  
Questionnaire 1 concluded by asking the patient if they would consider joining a 
research study which involved using the TDA for a further two months.  If the 
patient declined participation, a letter was sent to them to thank them for reviewing 
the TDA and to inform them that the data collected from their questionnaire and 
the TDA would be used for research purposes; however, they could opt out should 
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they prefer (appendix 26).  If patients declined use of their data, the TDA and 
questionnaire data collected was removed from the analysis.  In addition, patients 
were offered their TDA for future use if they had found that it was a useful aid for 
administering their eye drops.  
 
11.2.7 The un-masked phase  
For patients who were interested in taking part in the React study, a patient 
information sheet and consent form, with a cover letter, were sent a TDA with 
fresh batteries to avoid loss of data (appendix 27).  The cover letter asked for the 
consent form to be completed and returned in the postage reply envelope 
(appendix 28).  A one-week follow-up telephone call was made by the researcher 
to all individuals to ensured that, either they returned their consent form and had 
started using the TDA, or to resolve any issues about consenting to the study.  
The researcher ensure the participant understood that their adherence would be 
monitored by the TDA and that the data would be reviewed when they sent the 
TDA back to the research at the end of the 56-day monitoring period. 
After 56-days of monitoring in the un-masked phase the patient received 
Questionnaire 2, ‘Measuring patient use of travoprost’ (appendix 29), a reply 
envelope to return their TDA and a letter to thank them for taking part in the study 
(appendix 30).   
Receipt of the TDA and Questionnaire 2 by the researcher marked completion of 
the study.  A final letter was sent to them to thank them for taking part in the study 
and to inform them that the data collected from their questionnaire and the TDA in 
the initial review phase would be used for research purposes; however, they could 
opt out should they prefer (appendix 31).  Participants were contacted by 
telephone if they had not returned their final reply envelope.  If no contact was 
made and the data was not retrieved, the patient was considered ‘lost-to-follow-up’ 
but a letter was sent to thank them for their involvement in the study and to inform 
them that the data collected in the masked phase would be used as part of the 
study (appendix 5).  Participants were given the option to opt-out if they 
specifically requested to do so.   
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11.2.8 Travalert Dosing Aid  
The study used the TDA, which electronically stores the time, date and number of 
drops administered during the study period as described in 3.3.2.4.  The TDA had 
an alarm feature and visual cue window that displayed a ‘tear drop’ at a pre-set 
time to remind the user to administer a dose.  During NAGS the alarm feature was 
disabled and stickers were placed over the visual cue window so these features 
could not act as an adherence aid.  However, as many TDAs used in NAGS were 
returned with the stickers peeled off and the internal mechanism tampered with, it 
was felt better in the React study to leave the visual cue window clearly visable to 
all participants from the outset in order to reduce the desire for curious individuals 
to remove stickers and explore the internal mechanisms of the TDA.  Use of the 
electronic visual cue window also provided a justified reason for the TDA to have a 
battery comparment which operated the visual cue window, thus concealing the 
monitoring function of the TDA.  Therefore, in contrast to NAGS that covered the 
visual reminder with a sticker, the visual cue window was not covered and 
programmed to appear between 9 pm and 1 am; however, the alarm was 
deactivated as in NAGS.   
 
11.2.9 Questionnaires  
The questionnaires were given at two different time points; after the masked phase 
Questionnaire 1 called ‘The review of the Travalert Dosing Aid’ (appendix 23), and 
after the un-masked phase Questionnaire 2 called ‘Measuring patient use of 
travoprost’ (appendix 24).  Questionnaires were sent out in the post with a freepost 
envelope for participants to return to the researcher. 
MMAS: The Morisky Measure of Adherence Scale (MMAS)124 is a commonly used 
adherence self-report tool and previously used in NAGS, described in Chapter 
3.3.5.  The MMAS is composed of four yes/no questions (see appendix 8) about 
past medication use patterns.  Participants answering ‘yes’ to a question scored 1, 
thus scores ranged from 0-4; 0 indicating perfect adherence and 4 being non-
adherent.  Minor changes to the wording of the validated questionnaire were made 
in order to make MMAS relevant to use of eye drops. The questions can be 
reviewed in appendices 23 and 24, part B. 
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Usefulness of the TDA: Three ‘yes’, ‘no’ or ‘no difference’ questions were used 
so that participants could give their feedback about the use of the TDA; ‘Do you 
think the Travalert Dosing Aid… was easier to use than the bottle of eye drops 
alone?’, ‘…helped you remember using your eye drops?’, ‘…helped you apply 
your eye drops?’  The questions were chosen to gather further information about 
the perceived use of the TDA and the effect this might have had on adherence to 
medication.  The questions can be reviewed in appendices 23 and 24, part A.  
Satisfaction with use of eye drops and information: Three questions were 
used to assess satisfaction; 1) previous experience of problems using eye drops, 
2) satisfaction with information received about their diagnosis and 3) satisfaction 
with information received about their travoprost.  Positively phrased statements, 
scored 5 points for a response of ‘strongly agree’ and thus indicated a high 
satisfaction, whereas a response of ‘strongly disagree’ scored only 1 point.  
Negatively phrased statements used reverse scoring so that a response of 
‘strongly agree’ scored 1 point.  Findings from NAGS suggested that these topics 
might have had an effect on the adherence to travoprost.  The questions can be 
reviewed in appendices 23 and 24, page 4.  
IMAB: The IMAB questionnaire275 was modified for use with patients that had 
glaucoma and were using travoprost eye drops, by changing words referring to 
‘medication’ to ‘eye drops’ and ‘taking medication’ to ‘applying eye drops’.  Since 
the IMAB questionnaire was combined with other questions relating to the study 
objectives, the IMAB was shortened from 30 questions to 20, two rather than three 
from each of the 10 behaviour domains, to avoid respondent fatigue.  The 20 
questions were chosen to represent the most reported medication barriers from a 
glaucomatous population.  As described in Chapter 11.1 a positively phrased 
statement, scored 1 point for a response of ‘strongly agree’ and thus indicated a 
low barrier, whereas a response of ‘strongly disagree’ scored 5 points and 
indicated a high barrier to behaviour change.  Negatively phrased statements used 
the reverse scoring so that a response of ‘strongly agree’ scored 5 points and thus 
represented a high barrier to behaviour change.   
Assessment of face validity of the questionnaire was sought from the patient and 
public advisory group (PPIRes) and changes were made to the questionnaire 
following their recommendations.  
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Patient asked by their clinician or nurse specialist if they would like to try 
administering their eye drops using the TDA for two months. 
Patient agrees Patient disagrees 
Nurse specialist gives TDA to patient with instruction 
leaflet. 
 
Patient continues 
standard care 
Month 2 postal follow-up:  Patient returns 
questionnaire and TDA in reply envelope.  Patient 
asked to take part in 2 month study with TDA. 
 
Study information given and postal consent to take 
part in study and new TDA sent. 
 
After 1 week, nurse specialist telephones patient to 
check use of TDA. 
 
Patient declines study: 
Informed about how their 
‘review data’ will be used. 
TDA dispensed if 
required. 
 
Patient agrees, signed consent received. 
Patient declines study: 
Informed about how their 
‘review data’ will be used. 
TDA dispensed if 
required. 
After 1 week, participant telephoned to check use of TDA 
 
Month 2 postal follow-up – Participant returns questionnaire 
and TDA in reply envelope.   
 
Participant Informed about how their ‘review data’ will be 
used. Eyeot dosing aid dispensed if required 
 
If patient stopped use of 
TDA: patient continues 
standard care. 
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Figure 11.1.  Patient flow through ‘masked’, ‘intervention’ and ‘un-masked’ 
phases  
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11.2.10 Sample Size  
In an oral hygiene study,215 that compared the measured plaque build-up between 
a simulated experimental study group of patients compared to a control group, 
who were not aware that they were participating in a study, the experimental group 
were found to have 27% less plaque at a 6 month follow-up, than the control 
group.  Thus, the Hawthorne effect of participating in and fulfilling the requirements 
of a study, altered subject behaviour. 
Two previous glaucoma studies using TDAs to measure adherence can be used to 
estimate the monitoring effects of using the TDA; Rossi et al.47 and Okeke et al.93  
The Okeke et al. study masked participants to the fact that their adherence was 
being monitored for a duration of 12 months (n=196), whilst Rossi et al. monitored 
participants un-masked for 3 months (n=35).  The Okeke et al. 93 study had a 
mean adherence rate of 71%±24% and the Rossi et al. study47 77%±21% which 
suggested a 6% difference in measured adherence when comparing a masked 
and un-masked sample group.  However, the difference in measured adherence 
between the Okeke and Rossi sample groups may not be simply due to reactivity 
effects; different study methods, sample populations, sample sizes and duration of 
monitoring may affect measured adherence.   
Thus, without any evidence in the literature at the time of designing the React 
study, using the above studies for guidance only, ten percentage points was 
chosen to represent a reasonable assumption of expected change in behaviour 
due to the reactivity effects of study participation monitoring of adherence and 
mere measurement effects. 
Using data from NAGS, which used the same sample population as the proposed 
study, the difference between the mean adherence at month 2 (74.92%) and 
month 6 (78.47%) was 2.92 (SD 26.74).  Therefore, a sample of 56 participants 
with complete data from both masked and un-masked phases would give an 80% 
power to detect a 10 percentage point difference in adherence.   
During NAGS, 10% of participants did not complete the study and 25% of TDA 
data was missing.  Thus, an additional 20 participants would be recruited to allow 
for participants who might withdraw and for missing TDA data in the event of TDA 
failure.  Therefore, 76 participants were required to take part in both the masked 
and un-masked phases of the React study. 
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11.2.11 Outcome measures 
All the outcome measures were collected at two different time points; after the 
masked phase and after the un-masked phase.  
The percentage adherence score was calculated using the number of adherent 
doses recorded by the TDA divided by the expected number of doses for the 
monitoring period using the ‘adjusted adherence calculator’ described in Chapter 
3.3.4.  A dichotomised score was also calculated; the proportion of individuals with 
≥80% adherence measured by the TDA were dichotomised to the adherent group 
and those with less than <80% adherence were dichotomised to the non-adherent 
group.   
Secondary outcome measures were:  
 MMAS was dichotomised; participants who scored 0 were dichotomised to 
the adherent group, participants scoring 1-4 were dichotomised to the non-
adherent group.   
 Self-reported opinion of the usefulness of the TDA was coded into ‘yes’, ‘no’ 
or ‘no difference’ for each category; ‘ease of use’, ‘help to remember to 
apply eye drops’ and ‘help to administer eye drops’.  
 IMAB scores were collated as described in Chapter 11.1.  Each of the 10 
behavioural domains received a score out of 10, a higher score indicating a 
greater perceived barrier to use of travoprost.  The scores for each of the 
10 behavioural domains were collated to produce an overall score out of 
100.   
 Satisfaction with eye drops and information were calculated from participant 
responses using a scale of 1 to 5 to produce one overall ‘satisfaction score’.  
A higher score indicated a greater satisfaction with use of drops and 
provision of information.  
 
11.2.12 Statistical analysis 
Data were analysed using SPSS version 22.  Descriptive statistics were used to 
characterise the demographics of the study sample.  Histograms were visually 
checked to review the distribution of the data before deciding on the appropriate 
statistical analysis method. 
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The primary objective:  
Adherence measured by the TDA during the masked phase was compared with 
the un-masked phase.  The distribution of the primary outcome data were 
reviewed by visual inspection of the histograms and summary statistics reported 
accordingly.  The data in the masked and un-masked phases were skewed but the 
difference between the individual scores between the two groups was normally 
distributed.  Therefore, a paired t-test was used to test if the mean difference 
between the adherence scores from the masked and un-masked phases was 
zero. 
Secondary objectives: 
Opinion of the TDA and its effect on adherence:  Self-reported opinion of the 
TDA was compared with adherence measured by the TDA to establish if 
participants who found the TDA useful had improved adherence compared to 
those who did not find the TDA useful.  Adherence was described using median 
adherence scores and a Chi-squared test was used to compare the dichotomised 
adherence opinion of the TDA outcome measures.   
Individuals who declined participation: To determine if age, gender and type of 
glaucoma were attributable factors for the self-selected sample, individuals who 
declined to review the TDA (the masked phase) were compared with individuals 
who did agree to take part.  A Mann Whitney-U test for age was used as the data 
were from independent groups and not normally distributed, and a Chi-squared 
test was used to test for independence between gender and glaucoma diagnosis.  
In the same way, individuals who had taken part in the masked phase but declined 
participation in the un-masked phase were compared with those who did take part 
in the study phase for age, gender and glaucoma diagnosis.  In addition, to 
determine if good adherence measured by the TDA was an attributable factor for 
individuals choosing to participate in the ‘un-masked phase,’ the mean average 
TDA score for the sample who declined to participate in the un-masked phase was 
compared to the sample who did participate in the un-masked phase using a 
Student’s t-test.  To establish if opinion of the usefulness of the TDA was an 
attributable factor in individuals choosing to participate in the ‘un-masked study’ a 
Chi-squared test was used to test for independence in each of the three categories 
of self-reported opinion of the usefulness of the TDA.  
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Self-reported adherence: Agreement between the MMAS self-reported 
adherence and dichotomised adherence measured by the TDA was measured 
using a Cohen's kappa test.  Cohen’s kappa measures inter-rater agreement when 
rating the same object using categorical data and as such established the 
agreement between the two different methods of measuring adherence for the 
same individual.  The masked and un-masked phase samples were analysed 
separately to compare any difference between phases.   
Responses to the MMAS measure of self-reported adherence in the masked 
phase and un-masked phase were measured using a Cohen’s kappa test of 
agreement. 
Satisfaction with use of eye drops and information:  The satisfaction with 
travoprost and information score was correlated with TDA measured adherence 
using a Spearman’s rank correlation test, since the correlation was non-linear.  
The masked and un-masked phases were analysed separately and then 
compared to establish if there was an association between satisfaction and 
adherence.  
Self-reported barriers to adherence:  The self-reported barriers to use of 
medication using the total IMAB score, as well as each behaviour domain score 
was correlated to mean percentage adherence measured by the TDA in the 
masked phase and un-masked phase using a Spearman’s rank correlation test, 
since the correlation was non-linear.  
Demographics and glaucoma diagnosis: date of birth was used to calculate age 
at the time of entering the study, gender was dichotomised to either male or 
female and diagnosis was categorised to either glaucoma suspect, ocular 
hypertension or primary open angle glaucoma as determined from the patient 
hospital records.  
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11.3 Results 
11.3.1 Recruitment 
The recruitment period was two years; the first eligible patient was enrolled into 
the masked phase on the 8th January 2014 and the final patient on the 22nd 
December 2015.  At the end of the recruitment period, only 60 participants were 
recruited to the un-masked phase resulting in 51 individuals with complete paired 
data for both the masked and un-masked phases.  Therefore, the planned sample 
size had not been achieved.  Thus, an interim analysis is reported in this Chapter 
and recruitment continues in order to achieve the planned study sample of 76 
participants.   
Figure 11.2 details the number of patients accepting and declining participation in 
the masked and un-masked study phases and the data attrition rate.  Patients 
from the masked phase were all given the option of declining use of their data 
during the retrospective consent procedure.  No concerns were raised and no 
patients declined the use of their TDA data.  
Objective I: Table 11.1 describes the demographics of the populations that took 
part in the masked phase and un-masked phase.  Age, gender and type of 
glaucoma were compared between those who refused to take part in the masked 
phase and those who declined to participate in the un-masked phase.  Of the 161 
patients who agreed to use the TDA in the masked phase compared to those who 
refused, there were no statistically significant differences.  Of the 110 patients who 
completed the masked phase, only 60 took agreed to participate in the un-masked 
phase; there were no statistically significant differences.   
Patients refused to use the TDA in the ‘review’, and therefore the masked phase, 
because they were already happy with their current routine and use of drops and 
did not need/want a dosing aid (n = 27), or because they had other health issues 
that demanded their attention (n = 9).  Some people did not want to give a reason 
(n = 12), were going on holiday for the period of the masked phase (n = 2), or did 
not like the idea of using a device (n = 3).  Reasons for patients refusing to 
participate in the un-masked phase was not collected as recruitment was by 
written communication and could not be elicited.   
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Table 11.1  The demographics of the populations that refused to take part 
in the React study or took part in the masked and/or un-masked phases.  The 
statistical differences between those who refused to take part in the masked 
phase and those who declined to participate in the study (and therefore the 
un-masked phase) are shown.  
 
Refused  
(n=53) 
Difference 
between those 
who refused 
and those who 
participated in 
masked phase 
 
Masked 
Phase  
(n=161) 
Difference 
between those 
who took part in 
masked phase 
but declined un-
masked phase 
 
Un-
Masked 
Phase 
(n=60) 
Gender: 
Male 
26  
(49.1%) 
p =0.529 
71 
(45.3%) 
p=0.854 
27 
(45.0%) 
Age: 
Years (Mean) 
76.02  
(SD 9.6) 
p=0.216  
74.39  
(SD 9.5) 
p=0.190 
75.7  
(SD 9.7) 
Type of 
glaucoma: 
 
p=0.307 
 
p=0.172 
 
POAG 
35  
(66.0%) 
89 
(55.3%) 
27 
(45.0%) 
GS 
10  
(18.9%) 
33 
(20.5%) 
15 
(25.0%) 
OH 
8  
(15.1%) 
39 
(24.2%) 
18 
(30.0%) 
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Figure 11.2. Study recruitment flow chart and data attrition; includes details 
of analyses undertaken A-C   
Approached 
n = 232
Took part in review 
phase
n = 161 (69%)
Completed masked phase
n = 110 (68%)
(Masked TDA data: n=104)
Recruited to un-masked 
phase
n = 60 (54%)
(Masked TDA data: n=57)
Lost to follow-up
n = 2 (3%)
Completed un-masked  
phase
n =58 (97%)
(Un-masked TDA data: n=53)
TDA failure
n = 5 (9%)
Declined un-masked 
phase
n = 50 (46%)
(Masked TDA data: n=47)
TDA failure
n = 6 (6%)
Lost to follow-up
n = 7 (4%)
Stopped using TDA 
after one week 
n = 44 (27%)
Refused  n = 53 (23%)
Not eligible n = 18 
(7.8%)
Analyses undertaken with TDA data:  
Analysis A:       
Primary outcome - 
Paired data from 
masked Vs un-masked 
Analysis B:      
Declined Vs 
participated in un-
masked phase 
Analysis C:  
Completed masked 
phase only Vs un-
masked phase 
Declined 
retrospective 
consent request   
n=0 
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11.3.2 Monitoring period 
The monitoring period was 56-days in both phases; masked and un-masked.  
Participants were advised when to stop using their TDA and return it in the reply 
envelope provided.  Some participants stopped using the TDA before the 56-days 
was reached and some continued using the TDA for longer.  Thus, the period of 
monitoring time captured by the TDA in the masked phase was a mean of 71 days 
ranging from 49 to 96 days; 6 participants stopped using their TDA before they 
reached the planned 56 day monitoring period.   
The un-masked phase had a mean follow-up period of 71 days ranging from 43 to 
100 days.  Four participants stopped using their TDA before they reached the 56 
day monitoring period; 1 patient stopped at 43 days because they underwent 
cataract surgery and no longer required travoprost eye drops, 1 participant 
advised that they had dropped their TDA and it had subsequently stopped 
working. 
 
11.3.3 Measured adherence  
The mean adherence measured by the TDA during the masked phase was 59.5% 
(SD, 36.5) and the median was 75.2% (IQR 19.3, 91.4) (n=104).  The mean 
adherence measured by the TDA during the un-masked phase was 82.8% (SD, 
21.0) and the median was 91.8% (IQR, 76.5, 96.9) (n=53).  The proportion of 
individuals dichotomised to ≥80% adherence measured by the TDA in the masked 
phase was 50 (48.1%) and 37 (69.8%) in the un-masked phase (See Figure 11.5).  
Histograms are shown in Figure 11.3 showing the distribution of the adherence in 
both masked and unmasked phases; on visual inspection, there appeared to be 
more adherent individuals in the un-masked phase compared to the masked 
phase.   
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Figure 11.3  Histograms of TDA measured adherence for patients in the 
masked phase and participants in the un-masked phase  
 
11.3.4 Primary outcome  
Objective A (paragraph11.2.1) was achieved by using a matched pairs Students t-
test with patients who had complete TDA data from both the masked and un-
masked phase (Figure 11.2, Analysis A); mean adherence in the masked phase 
was 78.1% (SD, 22.2) and the un-masked phase was 82.2% (SD, 21.3) with a 
mean difference of 4.2% (CI, -2.5, 10.8), a difference that did not reach statistical 
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significance (p=0.214, n=51).  The results are also shown in Figure 11.5.  Such a 
result would lead to not rejecting the null hypothesis, thus implying that there was 
no difference in adherence behaviour when participants were masked or un-
masked.  However, as the histogram in Figure 11.4 showed that the majority of 
individuals had an increase in their adherence when examined visually. 
 
 
Figure 11.4   Histogram of difference in TDA measured adherence between 
the paired data for the masked and un-masked phases 
  
0
5
10
15
20
25
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
F
re
q
u
e
n
c
y
Difference between masked and un-masked adherence
 296 
 
 
 
 
 
 
Figure 11.5 Percentage adherence calculated from TDA data are presented 
to identify the data used for Analysis A, B and C  
Approached 
n = 232
Took part in review 
phase
n = 161 (69%)
Completed masked phase
Masked TDA data: n=104
59.5% (SD, 36.5)
Recruited to un-masked 
phase
Masked TDA data: n=57
77.5% (SD, 22.3)
Completed un-masked  
phase
Un-masked TDA data: n=53
82.3% (SD, 21.0)
Declined un-masked 
phase
Masked TDA data: n=47
37.8% (SD, 38.3)
Analysis A:                
4.2% (CI, -2.5, 10.8) 
p=0.214, n=51      
Analysis B:          
39.7% (CI, 27.7, 51.7)  
P<0.001 
Analysis C:  45.0% 
(CI, 32.4, 57.6) 
p<0.001 
78.1% (SD, 22.2) 
n=51         
(paired data) 
 
82.2% (SD, 21.3) 
n=51         
(paired data) 
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Objective B (paragraph 11.2.1): TDA measured adherence for those who declined 
participation in the un-masked phase was significantly different to those who did 
participate in the un-masked phase (Figure 11.2, Analysis B); mean adherence for 
the group that declined participation was 37.8% (SD 38.3, n=47) and those 
agreeing to participate was 77.5% (SD 22.3, n=57) a mean difference of 39.7%(CI 
27.7, 51.7, p<0.001) (See Figure 11.5).  Therefore, participants with lower 
adherence measured by the TDA were less likely to participate in the un-masked 
study phase. 
The reported primary outcome analysis matched the adherence score for 
individuals who had taken part in the masked phase with their adherence score in 
the un-masked phase; participants who declined participation in the un-masked 
phase, therefore, did not have an un-masked adherence score and were missing 
from the paired t-test analysis.  Thus, participants with low adherence scores were 
not included in the final analysis, which may have biased the un-masked sample.  
In addition, as there is a ceiling effect on measured adherence (adherence cannot 
be better than 100%), the final analysis was based upon on data with reduced 
variation.   
An unplanned analysis was undertaken to compare the mean of the masked 
sample group with the mean of the un-masked sample group (Figure 11.2, 
Analysis C) in an un-paired, before and after intervention, between group analysis.  
However, the two groups were not independent samples as the individuals who 
had participated in the un-masked phase had taken part in the masked phase 
prior.  Therefore, the adherence scores of individuals who participated in the un-
masked phase were removed from the masked-phase group mean score.  The 
mean adherence of individuals who had only taken part in the masked phase 
37.8% (SD 38.3, n=47) were compared to participants that had participated in the 
un-masked phase (82.8%, SD 21.0, n=53); the mean adherence of the between-
group (non-paired) analysis found a statistically significant difference of 45.0% (CI, 
32.4, 57.6), p<0.001 (See Figure 11.5).   
 
11.3.5 Self-reported adherence  
In the masked phase, the MMAS self-report tool found 89 participants (81.7%) and 
42 participants (71.2%) in the un-masked phase to be adherent; less participants 
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reported being adherent with MMAS in the un-masked phase.  Table 11.2 
compares the paired self-reported adherence data for individuals who took part in 
the masked and un-masked phases (Objective C, paragraph 11.2.1); the majority 
did not alter their self-reported adherence when in the masked phase compared to 
the un-masked phase and had a moderate Kappa agreement (k= 0.466, p <0.001, 
n=55).   
 
Table 11.2  Comparison of dichotomised MMAS scores using paired data 
for individuals with MMAS data in the masked phase and un-masked phase 
(n=55).  Percentages are calculated for the masked phase. 
MMAS 
Masked phase 
Agreement 
(Kappa) 
Adherent 
n (%) 
Non-adherent 
n (%) 
Total  
Un-masked 
phase 
Adherent 
36 
(81.8%) 
3 
(27.3%) 
39 
(k= 0.466,  
p <0.001). 
Non-
adherent 
8 
(18.2) 
8 
(72.7%) 
16 
Total 44 11 
 
55 
 
However, Table 11.3 shows adherence measured with the TDA and MMAS.  In 
the masked phase most participants reported being adherent with MMAS and 
there was poor Kappa agreement (k=-0.065, p=0.003, n=101).  In the un-masked 
phase there was slightly more agreement than in the masked phase but this was 
still poor and not statistically significant (k=0.007, p=0.835, n=51) (Objective D, 
paragraph 11.2.1). 
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Table 11.3 Comparison of dichotomised MMAS and TDA scores for 
individuals in the masked phase and the un-masked phase.  Percentages are 
calculated for MMAS. 
 
Masked phase Un-masked phase 
MMAS MMAS 
Adherent 
n (%) 
Non-
adherent 
n (%) 
Total 
Adherent 
n (%) 
Non-
adherent 
n (%) 
Total 
TDA 
Adherent 46 
(56.8) 
4 
(20.0) 
50 
26  
(68.4) 
10 
(71.4) 
36 
Non-
adherent 
35 
(43.2) 
16 
(80.0) 
51 
11  
(31.6) 
4 
(28.6) 
15 
Total 
81 20 
 
101 37 14 
 
51 
 
 
11.3.6  Perceived usefulness of the TDA 
Objective E (paragraph 11.2): Table 11.4 details participant reported opinion of the 
usefulness of the TDA compared with TDA measured adherence; participants 
were less adherent if they had not found the TDA easier to use than the bottle 
alone, helped remember to use eye drops or helped apply eye drops.  
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Table 11.4   Perceived usefulness of TDA use compared with adherence and 
participation in the un-masked study. 
 
Adherence 
Median (IQR) 
Dichotomised 
Adherent (%) 
Chi-
squared 
p-value 
Was easier to use than the bottle 
alone (n = 55) 
83.8  
(60.0, 93.7) 
34 (61.8) 
0.002 
Was not easier to use than the 
bottle alone (n = 38) 
19.5  
(3.5, 83.8) 
10 (26.3) 
Made no difference (n = 8) 
84.4  
(30.4, 95.4) 
5 (62.5) 
    
Helped to remember to use eye 
drops (n = 31) 
83.7  
(75,0, 91.4) 
21 (67.7) 
0.018 
Did not help to remember to use 
eye drops (n = 41) 
28.6  
(3.6, 89.0) 
14 (34.1) 
Made no difference (n = 28) 
79.1  
(36.7, 94.4) 
14 (50.0) 
    
Helped to apply eye drops  
(n = 54) 
86.2  
(71.0, 93.4) 
36 (66.7) 
0.001 Did not help to apply eye drops  
(n = 34) 
19.5  
(3.6, 81.1) 
9 (26.5) 
Made no difference  
(n = 13) 
59.7  
(18.7, 91.6) 
5 (38.5) 
 
Objective F (paragraph 11.2.1): Perceived usefulness of the TDA was compared 
with individuals’ decision to take part in the un-masked phase.  Table 11.5 shows 
that individuals that found using the TDA easier than using drops from the bottle 
alone, or helped them to remember to use their drops or helped them to apply their 
eye drops were more likely to take part in the un-masked phase.  The TDA was 
considered to be least useful at helping individuals remember to use eye drops 
compared to making use of drops easier or helping to apply eye drops. 
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Table 11.5   Perceived usefulness of TDA compared with participation in the 
un-masked study. 
 Number of participants that took part  
in un-masked phase 
No (%) Yes (%) p-value 
Was easier  10 (17.5) 47 (82.5) 
< 0.001 Was not easier  33 (78.6) 9 (21.4) 
No difference  8 (72.7) 3 (27.3) 
    
Helped to remember drops  5 (16.1) 26 (83.9) 
<0.001 
 
Did not help to remember 
drops  
29 (65.9) 15 (34.1) 
No difference  15 (46.9) 17 (53.1) 
    
Helped to apply drops  12 (21.1) 45 (78.9) 
<0.001 Did not help to apply drops  30 (78.9) 8 (21.1) 
No difference  8 (57.1) 6 (42.9) 
 
11.3.7  Satisfaction with information about eye drops and glaucoma 
Objective G (paragraph 11.2.1): Most participants rated high satisfaction with 
information received about their eye drops and glaucoma; out of maximum score 
of 15, 20 (18.5%) participants scored 8 to 11, 88 (81.5%) participants from 12 to 
15; improved satisfaction was not correlated with improved adherence in either the 
masked phase (r=0.078, p=0.438) or the un-masked phase (r=0.050, p=0.725). 
 
11.3.8  IMAB  
Objective H (paragraph 11.2.1):  The mean IMAB score for the masked group was 
34.9 (SD, 7.5) and for the un-masked 32.4 (SD, 7.75) out of a possible score of 
100.  There was a significant weak positive correlation in the masked phase with 
adherence measured by the TDA, (r=0.230, p=0.042), and a very weak negative 
correlation in the un-masked phase but this was not statistically significant, (r= -
0.029, p=0.848).  Table 11.6 displays the scores for the individual behavioural 
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domains in the masked phase.  Beliefs about capabilities presented the greatest 
reported barrier but this was not associated with increased non-adherence. 
 
Table 11.6  IMAB scores for individual behavioural domains and correlation 
with adherence in the masked phase 
 
Behavioural domains: 
IMAB score 
 (SD) 
Correlation with 
adherence  
(p-value) 
Knowledge 2.8 (1.0) 
0.098 (0.328) 
n=102 
Skills 2.9 (0.9) 
0.095 (0.342) 
n=102 
Memory, attention and 
decision making processes 
3.2 (1.3) 
0.090 (0.381) 
n=96 
Social Influences 3.4 (1.3) 
-0.007 (0.941) 
n=100 
Environmental constraints 3.5 (1.2) 
0.082 (0.428) 
n=96 
Emotions 3.5 (1.4) 
-0.109 (0.278) 
n=100 
Motivation and goals 2.8 (1.0) 
0.089 (0.376) 
n=101 
Goal conflicts 3.0 (1.1) 
0.132 (0.187) 
n=96 
Beliefs about capabilities 4.4 (1.5) 
0.178 (0.084) 
n=96 
Beliefs about consequences 3.4 (1.3) 
0.143 (0.164) 
n=96 
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11.4 Discussion  
The React study found no difference in measured adherence in individuals who 
had taken part in the masked and un-masked study phases suggesting that 
awareness of study participation and observation of adherence did not cause any 
significant reactivity effects.  However, the evidence confirms the presence of a 
reactivity effect at least to some magnitude and the interim results suggest a 10% 
difference in adherence between the masked and un-masked group may be 
possible if the planned sample of 76 participants is reached when the study 
concludes.  Furthermore, participants with lower measured adherence were less 
likely to participate in the un-masked phase.  Thus, non-adherent participants were 
missing from the un-masked sample group.  If a greater number of non-adherent 
individuals did continue into the masked phase, then the reactivity effect could 
have been larger; the mean adherence for the group of participants who took part 
in the un-masked phase was 45% higher than the mean adherence for the group 
that only took part in the masked phase.   
However, TDA measured adherence was generally higher in patients that felt the 
TDA made using eye drops easier than the bottle alone, easier to remember 
and/or easier to apply.  When patients preferred using the TDA, they might have 
been more likely to continue administering eye drops with the TDA and 
consequently good adherence was recorded.  In contrast, those who did not feel 
any benefit from using the TDA and chose to stop daily administration of eye drops 
using the TDA (either for the duration of the study or just occasionally, as the 
bottle of eye drops can be removed and re-inserted easily from the TDA), daily 
administration of eye drops was not recorded by the TDA resulting in a lower 
overall TDA adherence score.  Further, participants not using the TDA on a daily 
basis may have been disincentivised to participate in the un-masked study phase 
compared to patients who felt the TDA had been useful and therefore willing to 
take part in the un-masked study phase.  Arguably, the cause of the TDA 
measured non-adherence between the two groups may, therefore, have been due 
to preference for use of the TDA rather than any reactivity effects.    
Whilst patients had been asked to use the TDA for the purposes of aiding 
adherence, they had not been given any specific instructions to use it 
unconditionally for the duration of the 56-day review period in case they were 
alerted to the presence of the monitoring capacity of the TDA.  In an attempt to try 
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and ascertain if patients were likely to stop using their TDA prematurely, patients 
were contacted one week after the TDA was issued to discuss any problems with 
use of the TDA to try and resolve them with the patient or give the option of 
discontinuing with use.  Therefore, those patients remaining in the sample should 
have been those who had chosen to use the TDA and recorded missed doses 
would have been due to non-adherence rather than discontinuation of use of the 
TDA.  Extrapolating results from the TDA has always been contentious, since the 
measure is only an indication of the intention to use eye drops rather than 
indisputable evidence that an eye drop was or was not applied as discussed in 
Paragraph 1.2.6.1. 
The MMAS self-reported adherence found that majority of patients did not change 
their opinion of self-reported adherence when they were aware that their 
adherence was being monitored.  MMAS had poor agreement with adherence 
measured by the TDA in both the masked and un-masked phase which may 
indicate that patients were adherent but did not use their TDA on a daily basis.  
However, these results are in keeping with previous findings that patient self-report 
is unreliable.  Furthermore, the MMAS tool may not be sensitive enough to detect 
the potentially subtle changes in patients own perception of their adherence 
behaviour.  There was greater agreement between the TDA and MMAS 
adherence scores in the un-masked phase; however, since adherence measured 
by the TDA was found to be higher in the un-masked phase because there were 
more adherent individuals than in the masked group the potential bias could have 
caused the greater measured agreement.   
Previous satisfaction with use of eye drops and information received about 
glaucoma diagnosis did not improve adherence in the sample.  The IMAB results 
found ‘beliefs about capabilities’ was the behavioural domain with the highest 
reported barrier to use of travoprost, but this, and the overall scores, were not 
correlated with increased non-adherence.  From these preliminary findings there 
was no evidence to suggest that the IMAB could detect non-adherent patients, but 
use of the full 30-question IMAB with patients using multiple-doses of eye drops 
would be necessary to fully establish the usefulness of the tool within a 
glaucomatous population.   
Recruitment of patients, who had already taken part in the masked phase, into the 
un-masked phase was only 54%, which was surprisingly low given that NAGS 
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recruited 87% of approached patients.  The low recruitment into the un-masked 
phase taken together with those who declined to take part in the initial masked 
phase culminated in only 26% of the 232 patients initially approached participating 
in the un-masked phase.  The reason for the low recruitment is difficult to 
establish; NAGS recruited treatment naïve patients who may have been 
encouraged to participate because they were offered support to administer their 
eye drops with the TDA at a time when they may have felt more challenged by the 
concept of applying eye drops.  Thus, comparing the recruitment rate between 
NAGS and the React study may not be a fair comparison.  Whilst the use of 
travoprost was essential to the design of the study in order that the bottles fitted 
the TDA, the solution was to amend the inclusion criteria to include patients who 
were already on established treatment with travoprost.  One of the benefits of 
including individuals on established treatment was the reduction in the number of 
individuals that withdrew due to lack of efficacy or side effects to treatment, in 
comparison to NAGS.  However, patient behaviour in the React study may have 
been altered; experienced eye drop users might have been more self-confident 
with use of medication both in terms of their routine and administration technique 
and, therefore, not so amenable to accepting support with a dosing aid and/or not 
willing to change their habitual behaviour of using eye drops from the bottle alone.  
Once recruited, the majority of patients who participated were all successfully 
engaged with the study requirements, as was demonstrated by the low data 
attrition rate.   
Age, gender and diagnosis of either POAG, OH, GS were not significantly different 
between those who declined participation in either the masked or un-masked 
phases and therefore, the sample group were not biased by these factors.  The 
majority of those who declined participating in the masked phase either did not 
give a reason for declining or did not wish to use the TDA.  Those who did 
participate may have been more motivated, prepared to have their adherence 
monitored or willing to engage in research.  Further, the patient perceived 
usefulness of the TDA was found to improve adherence in the sample; together 
with so few participants continuing into the masked phase, both these factors 
suggest that the final masked sample were more motivated and adherent 
individuals caused by a self-selecting sample bias.  Use of a crossover design was 
beneficial because confounding covariates are reduced as each participant acts as 
their own control and are, therefore, statistically efficient, requiring fewer subjects 
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than non-crossover designed studies.  However, in the React study this could 
have introduced the self-selecting bias.  Arguably an RCT with a masked and un-
masked arm may have eliminated these factors.  Although a much larger sample 
size might have been required for an RCT, given that only approximately one 
quarter of participants agreed to participate in the un-masked phase, to date over 
200 patients have been approached to take part in the masked phase which may 
be equivalent to the amount of participants that might be required for a between 
group analysis RCT.  Order effects of crossover studies can also introduce 
practice fatigue or learning effects; participants in the un-masked phase may have 
become familiar with the TDA and found it easier to use over time in comparison to 
the un-masked phase.  Thus, improvement in adherence may be associated with 
ease of use of the TDA, rather than any other type of reactivity effect.  Conversely, 
participants may have become over familiar or tired of using the TDA thus 
negatively influencing their level of adherence.  
Without implicitly stating that patients must use the TDA for a certain length of time 
and therefore alerting them to the fact that the TDA was measuring their 
adherence during the monitoring phase, not all participants used the TDA for the 
full 56-day monitoring period required to ensure consistency.  In the masked 
phase when the participants were aware that the TDA was monitoring adherence it 
was possible to expressly ask the participant to use the TDA for at least 56-days.  
Due to technical problems with the TDA or when individuals changed treatment, 
some data was still missing.  However, this only affected a small number of 
participants in both groups and their monitoring period was cut short by just under 
a week which was not felt to significantly bias the results.  The decision to leave 
the tear drop cue panel visible on the TDA rather than covering it with a label as in 
NAGS was successful and successfully masked the monitoring properties of the 
TDA to remain concealed from patients.  Furthermore, less React study 
participants tampered with the devices and removed the battery when compared 
to those in NAGS.   
The aim to recruit 76 participants to the React masked was not reached.  As 
described, due to changes in the prescribing of travoprost at NNUH since the 
conception of the study fewer patients were using travoprost at the time of 
recruitment, thus hampering our ability to recruit enough participants in the one 
year recruitment period.  Recruiting individuals from Spire hospital in an attempt to 
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boost recruitment by increasing the pool of potentially available participants 
certainly helped increase the numbers, but a further source of eligible participants 
would have been beneficial.  The React study continues to recruit participants and 
when the required sample size is reached the final analysis can be completed.  
The major value of using a masked monitoring design was to maintain usual 
behaviour patterns that might otherwise be interrupted by awareness of being 
observed.  The React study found evidence that such behaviour changes exist, 
but the reactivity effect and adherence to medication remains notoriously difficult 
to measure.  The problems encountered using the TDA continues to prevent 
conclusive findings from being extrapolated from the data.  Future studies need an 
objective measure of adherence to eye drops such that all different bottles fit the 
monitoring device to enable both treatment naïve and established eye drop users 
on multiple dosing regimens to participate in such observational studies.  Remote 
electronic monitoring devices may also enable a totally new interface for 
adherence research in the future as information could be fed back instantly to the 
researcher enabling an early alert when participants stop using their eye drops 
and assess the behaviour patterns at the point it occurs, rather than 
retrospectively scrutinising old data; this would overcome the problem of patients 
underreporting non-adherence and forgetting the true reasons for their non-
adherence.  If such technology were to become available a new set of challenges 
would exist to examine the ethical practicalities and how this type of monitoring in 
itself would affect adherence behaviour.   
Since the retrospective consent method did not give rise to any reported concerns 
from patients/participants and no-one asked for their data to be withheld from the 
analysis, future studies may consider using a modified consent method to ensure 
that individuals who are likely to decline participation in research are still included 
in the sample, and to overcome the known change in behaviour caused by 
reactivity effects.   
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Section 5. Closing summary 
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Chapter 12.  Final discussion and future work 
12.1 Final discussion  
The introduction in Section 1 of this thesis discussed the importance of good 
adherence to medication in patients with glaucoma and ocular hypertension.  The 
evidence suggested that patients using glaucoma medication were lacking the 
support and education required to be adherent to their medication regimens.  
Thus, the Norwich Adherence Glaucoma Study (NAGS) described in Section 2 
was designed to address the research gap by providing an intervention intended to 
both target beliefs about use of medication and provide tailored education in order 
to elicit adherent behaviour.  NAGS hypothesised that additional education and 
advice about glaucoma using a Behaviour Change Counselling intervention would 
improve adherence with glaucoma medication when compared to standard care.   
However, the NAGS RCT described in Chapter 3 did not establish improvement in 
adherence to medication.  The NAGS study results revealed that the magnitude of 
non-adherence amongst the population studied was less than expected; the 
majority of participants in both arms of the study had very good adherence.  In 
addition to the apparent failure of the intervention, the NAGS results also indicated 
that, adherence to glaucoma medication in the population studied, might not be 
such a significant problem as previously suggested.   
 
12.2.1 Providing patient information and support 
However, from the participants’ perspective the NAGS intervention was reported to 
provide a valuable source of information and support when additional help and 
reassurance were required.  Furthermore, participants in the intervention group 
ran out of eye drops less than those in the control group indicating the intervention 
was successful in informing patients to renew their prescription to obtain travoprost 
on a monthly basis.  The emergent testimonies reported in the User study in 
Chapter 4 unearthed evidence that participants in the NAGS control group 
required additional information compared to those who took part in the intervention 
group.  The User study findings indicated that standard care needed to be 
improved to ensure that patients would be adherent to their medication in the long-
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term, in addition to feeling informed and supported in their journey of glaucoma 
care.  The NICE medicine adherence guidelines state that non-adherence 
represents a fundamental limitation in the delivery of healthcare that is not caused 
by patients own failure alone.277  Therefore, it was not surprising that participants 
felt the NAGS intervention should be made available to all patients in the future.  
New initiatives have emerged since the design and implementation of NAGS 
providing useful resources that might complement NHS standard care and future 
interventions to improve adherence.  One such initiative was the Glaucoma Think 
Tank meeting held in 2011.278  In the meeting that was chaired by Professors 
Peter Shah, David (Ted) Garway-Heath and Peng Khaw and supported by the 
International Glaucoma Association, patients and professionals came together to 
encourage communication between the two representative groups.  By listening to 
the testimonies that described the journey of care directly from individuals with 
glaucoma, patients were given the opportunity to be able to influence future 
glaucoma care, research and education.  The discussions from the Think Tank 
meeting helped develop a ‘glaucoma passport’; a personal health record designed 
to help patients keep track of their glaucoma care and provide support if they 
experience difficulties, thus encouraging patient self-care.279   
 
12.2.2 Future interventions 
Hundreds of patients with glaucoma and members of the public have been 
involved in the research used to bring this thesis to completion.  Many individuals 
have informally given feedback or discussed their needs and ideas with the 
researchers throughout the period of study.  Together with the formal data 
collected and reported, a great deal of insight has been amassed around the 
complex topic of medication adherence, ranging from person-specific needs for 
glaucoma care to the wider methodological implications of adherence 
measurement, data collection and reporting.  The deeper level of detail and 
breadth of understanding brought to the subject has the potential to underpin and 
positively influence future intervention development.  However, further research is 
required to better understand: 
 the type of information that should be incorporated into interventions 
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 the method of delivering interventions, considering both patient preferences 
and cost implications 
 which healthcare professionals are best placed to deliver interventions  
 how often an intervention needs to be reinforced 
 if patients’ carers and/or family members need to be included in the 
intervention provision particularly with patients who need support from a 
wider network of carers. 
The User study results described in Chapter 4 and new advances in research, 
such as the work from the Think-Tank meeting278 or the behaviour change 
taxonomy,141 might be able to address some of these questions and provide 
guidance from which the foundations of future interventions can be designed.   
Patients in the NAGS intervention group reported in the User study that they did 
not feel they had received enough information about their own glaucoma 
diagnosis, prognosis and progression of disease.  One solution to ensure 
adequate provision of information might be to incorporate the glaucoma 
passport279 into a future intervention; should provision of standardised information 
fail to convey specific details tailored to the individual, the research passport could 
be a useful tool to involve patients in their own clinical reports, thus empowering 
them to ask questions.  On the downside, adherence motivating resources 
introduce additional costs; the cost of the glaucoma passport alone is £9.95 per 
booklet, a relatively expensive resource should all patients with glaucoma to be 
provided with a copy, such that evidence of the benefit to patient care would be 
required to justify the expenditure.   
Considering the feedback from the User study in Chapter 4, some simple changes 
in information provision could be implemented with relatively little cost which could 
address some of the concerns raised by users of the NNUH eye clinic.  The main 
issues highlighted were that NNUH eye clinic was felt to be very impersonal and 
left patients feeling that they were on a conveyer belt during their visits.  The issue 
appeared to be exacerbated when there were long waiting times for tests to be 
carried out and waiting to see the clinician.  Long waiting times, in combination 
with patients not understanding the significance of completing the assessments, 
was stated to lead to increased frustration and distress for some patients.  Thus, 
technicians and clinicians need to take greater care to always explain the reasons 
for requiring visual field tests and imaging of the optic. 
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Some patients reported that clinicians did not always introduce themselves which 
was particularly confusing when there were optometrists, specialist nurses, 
consultants and junior doctors working in the glaucoma service.  Some 
participants felt that a simple introduction would be more courteous and reassuring 
for them at the start of their consultation.  Interestingly, this is an issue that has 
already been brought to fore with the new NHS initiative “Hello my Name is…”.280 
Hospital staff are reminded to go back to basics and remember to introduce 
themselves; such behavior is thought to help build trust and make a vital human 
connection with patients.   
Better communication is required with patients in the NNUH eye clinic to overcome 
some of these reported obstacles.  Poster provision may also be a method that is 
relatively simple to implement and when repeatedly seen around the waiting 
areas, visually appealing posters might reinforce important educational messages 
and might be a simple way to impart information to improve patient perceptions 
and encourage better patient engagement both with patients and any carers who 
accompany patients to the clinic.  Further work is required to establish how 
patients absorb information and if posters would meet this need but issues that 
could be addressed by posters are:   
 Explain the use of visual field test and imaging, how they are used in clinical 
practice  
 Introduce each member of the glaucoma service team, with a picture 
together with their name and role in the clinic  
 Posters providing information about eye drops, administration techniques, 
their common side effects, and appropriate action should side-effects be 
experienced and tips on how to incorporate use of eye drops into a daily 
regimen.  
The User study reported that if patients were well informed about glaucoma and 
the necessity of using eye drops, individuals would be inclined to be more 
adherent.  Information provision, therefore, would have to be an important element 
of any future intervention.   
However, NAGS participants from both control and intervention groups reported 
accessing information from a variety of many different sources, including leaflets, 
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talking to friends and/or other patients with glaucoma, the internet and books.  
Thus, it is clear that information should be provided in many different forms in 
order to cater for the changing modes in which our society accesses sources of 
information and support networks; group-based sessions, digital applications and 
on-line resources and social media are extremely popular resources and are 
featuring in new behaviour change interventions.  Currently, elderly patients may 
not be confident with the internet, but future generations are likely to prefer such 
digital information.  In NAGS it was found that the majority of participants in the 
intervention group requested more information from their GSA each time they 
attended a follow-up appointment.  Thus, an intervention placed only at the point 
of treatment initiation may have provided insufficient support for patients.  When 
and how often information is provided and reinforced to patients with glaucoma is, 
therefore, also significant.  Integrating more information into standard care and 
giving patients choice in the type and level of engagement they require to support 
them through their journey of glaucoma care should certainly be a priority for any 
future intervention designed to improve adherence to glaucoma medication.  The 
Cromer hospital, which has a satellite clinic to NNUH, has started running group 
sessions to give information and support to patients with glaucoma.  An evaluation 
of these group sessions could provide useful information from which a complex 
intervention, incorporating a group-based intervention, as one element of a wider 
intervention-package could be developed. 
Since the NAGS intervention was established, the behaviour change taxonomy141 
has been formulated.  The new behaviour change taxonomy characterises the 
active content of behaviour change techniques known to produce effective 
interventions.  As new adherence related research emerges using the behaviour 
change taxonomy to define the mode of action with the theoretical construct has 
the potential to improve the design of future interventions making these more 
focused and effective. 
An important aspect of the NAGS intervention was the availability of a telephone 
helpline.  The majority of calls made to the telephone helpline were about the side-
effects of eye drops.  At present patients at NNUH may be left for days with an 
unsatisfactory outcome to their problems with eye drops, which may lead to a 
decrease in faith in eye drop use.  In contrast, for NAGS patients experiencing the 
intervention, the use of the help-line resulted in participants with drop queries 
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having these dealt with quickly and efficiently by the GSAs.  The NAGS results 
showed that satisfaction with the support service part of the intervention was high.  
Thus, a dedicated helpline for treatment side-effect enquiries may might reduce 
the costs of a glaucoma service by reducing the number of unnecessary eye 
casualty appointments and ensuring that patients receive a better standard of 
care.  The GSAs ran a glaucoma specific support service during NAGS using a 
mixed team of healthcare professionals.  However, the type of healthcare 
professional ideally suited to provide a glaucoma specific support services remains 
unknown.  Further research respect to support delivery is required.  For 
development of future potential adherence improving interventions, assessment of 
the individuals that deliver support is an aspect of intervention design that needs 
further consideration.   
A pharmacist-led telephone advice service has been reported to improve 
medication adherence in patients with long-term conditions on established 
medication.281  Furthermore, in the UK, pharmacists already undertake ‘Medication 
Use Reviews’ to target patients most likely to stray from their recommended 
medication regimens.  Not only are pharmacists’ experts on medicines, but they 
are considered to be the most accessible and most consulted health professionals 
with respect to medication use.  Thus, pharmacists may be ideally placed to tackle 
the issue of poor adherence with eye drops.  It was beyond the scope of the NICE 
medication adherence guidelines to make recommendations about which 
healthcare professionals would be best placed to deliver interventions to improve 
adherence, but this remains an important aspect for the design of future 
interventions and assessment of related cost effectiveness.  Unfortunately, the 
cost benefits of any novel intervention will only be evidenced if the intervention can 
be proven to improve adherence and therefore robust measures of adherence, 
which are not biased by reactivity effects, are required.    
Finally, whilst NAGS was purely focused on delivering support and information to 
the patient with glaucoma, the NICE medicines adherence guidelines advocate the 
need for patients to decide who should be involved in their care and for carers to 
also have access to appropriate levels of information and support.277  Future 
interventions need to ensure access to the wider support and care network that 
some patients desire and perhaps require to remain fully adherent to their 
medication(s).  
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12.2.2 Reactivity effects  
Although a variety of adherence measures were used in NAGS, the analysis in 
Chapter 3 highlighted the difficulties in collecting complete data for the full period 
of the 8-month study.187  The literature suggested that objective monitoring of 
adherence with MEMS was superior to subjective self-reporting of adherence.  
However, unpacking the user experiences of NAGS in the User study and a follow-
up study described in Chapter 5 identified that measuring adherence with the TDA 
might have caused a variety of reactivity effects that changed behaviour 
introducing an element of uncertainty regarding the conclusions drawn from the 
study.  The React study was designed to establish if awareness of adherence 
monitoring caused a statistically significant increase in adherence.  The React 
study required the use of a modified consent procedure, since to determine the 
magnitude of reactivity effects a proportion of ‘studied’ participants had to partake 
in the study unaware that they were being studied and hence without consent.  
Section 3 described the body of work undertaken to establish that patients and 
members of the public were largely in favour of using a retrospective consent 
method in a study that would measure changes in behaviour when individuals 
participated in research when unaware that their adherence behaviour was to be 
observed.  
Section 4 described and reported the results of the React study, which was 
designed to establish if awareness of adherence monitoring caused a statistically 
significant increase in adherence.  Whilst no final results can be reported yet, work 
continues in order to complete the React study.  However, an interim analysis of 
the React study data suggested that reactivity effects caused a change in 
adherence behaviour.  However, adding to the problems associated with 
adherence research and modified consent, patients with poor adherence 
measured by an electronic monitoring device were less likely to volunteer to 
participate in the research study, causing a bias in the sample population.   
The current overall findings from the thesis have suggested that measuring 
adherence is problematic and may itself have a significant role in behaviour 
change making an assessment of the true magnitude of non-adherence difficult to 
specify accurately.  In the future, more emphasis must be placed on controlling 
potential reactivity effects in research involving outcome variables that influenced 
by observation of participant behaviour.   
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12.2.3 Measuring adherence  
Self-report tools remain the easiest and, if accurate, the most cost-effective 
measure of adherence to administer and are likely, therefore, to remain a popular 
method for future research.  Unfortunately, the results presented in this thesis 
were not able to prove that currently used self-report measures of adherence were 
sufficiently robust to prove useful as a sole outcome measure of adherence for 
topical anti-glaucoma therapy.  However, refinement of the wording used and/or 
visual modifications could improve self-report tools to make them more reliable for 
the future, this requiring further evaluation.94  
Use of electronic dosing monitors such as MEMS may remain the best objective 
method of measuring adherence.  Unfortunately, since eye drop bottles are 
manufactured in different sizes, researchers have difficulty in utilising suitable 
electronic devices in to which all bottle types can fit.  Presently, since the TDA is 
no longer commercially available, the only devices available are MEMS whereby 
the bottle of eye drops is placed within the MEMS requiring the user to unscrew 
the MEMS cap to retrieve the bottle of eye drops, subsequently unscrewing the 
eye drop cap before administering the dose.  Thus, a “bottle within a bottle” 
method requires multiple extra steps that deviates from the usual administration 
procedure; the extra processes required have the potential to cause a reactivity 
effect.58  A device that fits all sized bottles would aid the creation of a system to 
measure adherence that could be used to monitor the adherence behaviour of 
patients on varying dosing regimens and different classes of topical medication.  
NAGS had to be limited to individuals using a once daily prostaglandin (travoprost) 
since the TDA electronic device was designed specifically for the Travatan® 
product.  Engagement with a wider range of patients including those with more 
advanced glaucoma requiring more aggressive treatment therapies and regimens 
would enable an understanding of the magnitude of non-adherence in a different 
glaucomatous population, one which arguably should require more attention due 
to the risk of more imminent sight-threatening progression.   
As technology advances, remote real-time streaming of patient medical data is 
becoming more common place.  In time, it might be possible to live-stream 
medication usage thus allowing researchers to collate patterns of adherence 
behaviour and react to real-time data.  Novel digital electronic technology could be 
integral to the design of future interventions that could tailor help, advice and 
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education based on medication use in real-time.  Remote monitoring could also 
resolve the issues of missing data found with current monitors that store data 
internally particularly in studies requiring a long period of follow-up such as was 
the case in NAGS when devices malfunctioned before data could be recovered.  
Remote monitoring would also resolve the problem encountered when participants 
fail to return devices, either mistakenly or deliberately when perhaps feeling too 
uncomfortable to return their monitoring device when knowing that their adherence 
had been sub-optimal.  
Using masked studies to ensure that patients are not aware that they are 
participating in research, or that their adherence is being observed, may have an 
important role to play in future studies that measures patient behaviour or 
satisfaction with information.  Thus, concealing the use of medication monitors 
would offer yet another advantage for researchers in their attempts to overcome 
the reactivity bias thought to be caused by monitoring and participation effects.  
The React study did not find any participants that declined use of their data 
collected prior to undergoing retrospective consent and no participants made 
contact with the researcher to discuss any concerns with respect to use of their 
data; an indication that the method was well received and raised no misgivings 
amongst those who took part as suggested by the consultation work undertaken 
and described in Section 3.   
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12.2 Recommendations for future work 
Maintaining a constant low eye pressure in many patients with glaucoma is 
deemed crucial; therefore 100% adherence is often considered the goal for 
patients using glaucoma medication.  Thus, persevering with the design of an 
intervention to improve adherence with anti-glaucoma medication remains an 
important objective.  The advancement in current glaucoma treatments such, as 
slow release medicated pellets inserted into the eye or laser treatments such as 
SLT, might in time reduce the need for daily administration of eye drops, or at least 
might provide a more reliable treatment method for those who struggle to be 
adherent with their daily glaucoma medication regimens.  However, recently 
introduced treatments for glaucoma are still in their infancy, require further long-
term assessment and robust health economic analyses.  
In the meantime, and considering the evidence presented in this discussion, the 
design of an intervention using a health economic analysis to establish the cost 
benefits of improving adherence to glaucoma medication and supporting patients 
through their journey of glaucoma care is warranted.  The study design and 
methods used to measure adherence also need further development in order to 
avoid introducing reactivity bias.  Thus, future work must first establish the 
acceptability of using a modified consent method.   
The Medical Research Council’s Framework for the development and evaluation 
of RCTs for complex interventions that improve health282 provides the guidance 
required to negotiate the challenges that arose from NAGS.  Using a stepwise 
approach, the active components of a complex intervention should first be 
identified and piloted in small scale studies which can also be used to identify an 
appropriate control group, outcome measures and estimates of recruitment before 
being incorporated into a definitive RCT.  With a robust RCT and evaluation of the 
real life effectiveness using observational studies, the relevance of the intervention 
in health care is likely to be established.282  
 
12.2.1 Detailed plan of future work 
Using the MRC Framework for the Development and Evaluation of Complex 
Interventions the following work needs to be undertaken:  
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Step 1: Theoretical phase 
The evidence ascertained through this thesis provides the basis of the theoretical 
and modelling steps required.    
Step 2: Phase 1 or modelling 
Key questions for further investigation:  
 Does the design of the intervention need further development?  
 What are the active components of the intervention? 
Proposed work:  
1.  Review the evidence gathered through NAGS evaluation data and User 
study.   
2. Re-model the intervention as required referring back to theoretical 
evidence.  Diagram the components such as nature, timing, frequency, 
duration of inputs and organisational arrangements. 
3. Carry out qualitative testing with focus groups and/or surveys if required to 
help define the active components and refine the intervention. 
Step 3: Phase II or Exploratory trial 
Key priorities for this phase and questions:  
 Refine the intervention  
 What is the best method for the RCT to avoid bias? 
 What is an appropriate control group? 
 What is an appropriate and reliable outcome measure? 
Proposed work: 
1. Pilot the intervention. Vary the different components to see what effect each 
has on the intervention and acceptability by participants. 
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2. Establish how to standardise the intervention by all providers determining 
which factors need to be controlled to ensure consistency whilst defining 
the acceptable limits to which practitioners can individualise the 
intervention.  Establish how evidence of any learning curve effect and how 
this can be monitored and fidelity ensured throughout an RCT. 
3.  Investigate the experiences of those who took part in the React study to 
establish participant acceptability of a retrospective consent method and 
define the recommendations for the methodology of future RCTs. 
4. Use the REACT study findings to define the expected reactivity effect and 
make adjustments to the outcome measures accordingly or pilot the use of 
a control group which does not reveal signs of a reactivity effect. 
5. Design and pilot a MEMs device that accurately records adherence data 
without causing a reactivity effect. 
Step 4: Phase III or main trial 
Using the information from steps 1 to 3, design and carry out an RCT to evaluate 
the complex intervention with sufficient power using a robust outcome measure.  
The study must minimise reactivity effects and incorporate the standard features of 
a well designed RCT many of which were used in NAGS. 
Step 5: Phase IV and long-term observation 
Replicate the findings of the intervention in uncontrolled settings and observe 
outcomes over a long-term period. 
 
Clearly, there is a vast amount of work still required before the exact formula for an 
intervention which can improve adherence and be cost effective, can be 
established.  Fortunately, the work commenced with NAGS together with the User 
and React studies has advanced our understanding of patient behaviour and how 
in the future we might establish robust methods for measuring adherence that 
does not elicit reactivity effects.  Only when adherence can be measured properly, 
can moves be made to prove the ideal way by which we could improve the 
adhernce of our patients with glaucoma.  
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